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Abstract 
Altered methylation and subsequent changes in gene expression have been implicated in several 
fibroses including lung however, the full extent and role of altered DNA methylation in fibrotic lung 
fibroblasts is unknown. Emerging evidence also suggests gender-specific methylation differences are 
common in disease and could elucidate why diseases characterised by pulmonary fibrosis including 
idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc) have a sex-biased prevalence. Using a 
genome-wide array-based approach, this thesis investigates differentially methylated and expressed 
genes in fibrotic compared to control lung fibroblasts, gender-specific methylation and expression 
differences and the effects of modulating DNA methylation using a DNA methyltransferase (DNMT) 
inhibitor, 5-Aza-2’deoxycytidine (5-Aza). Data show primary human IPF and SSc lung fibroblasts have 
multiple genes with altered DNA methylation and expression compared to control lung fibroblasts. 
Multiple biological processes were enriched in these genes, many of which are relevant to fibrosis 
including, transcriptional regulation, extracellular matrix (ECM) organisation, Wnt signalling and 
apoptosis. Using siRNA knockdown and collagen gel contraction assays, novel genes including 
Tenascin-XB (TNXB), which encodes the ECM glycoprotein Tenasicn-X (TNX), were identified as having 
potential functional significance in the pathogenesis of pulmonary fibrosis. Furthermore, multiple 
genes including TNXB had altered methylation and expression in IPF compared to SSc lung fibroblasts 
and may distinguish IPF from other diseases associated with pulmonary fibrosis. Multiple genes were 
identified with gender-specific differences in methylation and expression in lung fibroblasts. 
Interestingly, multiple genes with altered methylation in IPF males compared to control males were 
not the same genes with altered methylation in IPF females compared to control females, which may 
in part explain why IPF predominates in males. The final chapter of my thesis shows 5-Aza treatment 
alters the methylation and expression of multiple genes in primary human lung fibroblasts. Strong 
correlation between changes in methylation and changes in expression were identified suggesting 
DNA methylation can directly regulate the expression of multiple genes in lung fibroblasts. 
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 Introduction  
1.1. Anatomy and physiology of the normal lungs and airways 
The human lung consists of an intricate branching network of airways starting at the trachea which 
links the lungs to the nasopharyngeal space. The trachea extends downwards from the larynx to enter 
midway in the thorax and terminates into two main bronchi. The right bronchus is wider than the left 
and based on their relation to the left and right pulmonary arteries, the right main bronchus is 
eparterial (above the pulmonary artery) whereas the left main bronchus is hyparterial (below the 
pulmonary artery). The bronchi transition into bronchioles which then lead to the terminal 
bronchioles. Terminal bronchioles are the last non-alveoliated airways, beyond which are respiratory 
bronchioles. Respiratory bronchioles have a diameter of less than 0.5 mm and terminate in acini 
containing multiple clusters of alveoli surrounded by alveolar walls. These alveolar walls contain 
capillaries, alveolar epithelium, capillary endothelium and extracellular matrix. This forms the gas-
exchange region of the lung which contains approximately 300 million alveoli (Ochs et al, 2004) with 
a gas-exchange surface area between 40 and 80 m2. The main cell populations located within this gas-
exchange region include type I alveolar epithelial cells (AECIs), which form >90% of the gas-exchange 
surface area, type II alveolar epithelial cells (AECIIs), alveolar capillary endothelial cells and interstitial 
cells such as fibroblasts and macrophages (Figure 1.1.1) (Crapo et al, 1982).  
 
 
Figure 1.1.1. Anatomy of a normal lung. Right: basic anatomy of the lungs. Left: a normal alveolus. 
Type I alveolar epithelial cells interface with pulmonary capillaries facilitating efficient gas exchange. 
Type II alveolar epithelial cells also interface with pulmonary capillaries and are multifunctional cells 
which secrete pulmonary surfactant (important for pulmonary compliance, reducing surface tension 
and innate immunity) and multiple molecules involved in innate host defence. 
 
1.1.1. ECM in the normal lung 
The ECM is the non-cellular component present within all tissues and organs and is essential for tissue 
homeostasis and development. The physical, topological and biochemical composition of the ECM is 
tissue-specific and markedly heterogeneous (Frantz et al, 2010). In the lung the ECM forms the three-
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dimensional scaffold of the alveolar walls, composed of a layer of epithelial and endothelial cells, their 
basement membranes and a thin layer of interstitial space between unfused capillary endothelium 
and alveolar epithelium basement membranes (West and Mathieu-Costello, 1999) (Figure 1.1.1.1). 
The pulmonary interstitium provides the elastic recoil of the lung and its ECM, which is located 
between the thin and thick sides of the alveolar septum, is formed by and composed of multiple 
stromal cells including fibroblasts and multiple macromolecules including, collagens (Bradley et al, 
1974), elastin (Rucker and Dubick, 1984, Starcher, 1986, Mecham et al 1991), proteoglycans 
(Bensadoun et al, 1996) and glycoproteins (Bhattacharyya et al, 1975) (Figure 1.1.1.1). In total, 
approximately 300 proteins, multiple ECM-modifying enzymes and multiple ECM-binding growth 
factors make up the core matrisome for all ECMs which co-operate to assemble, maintain and remodel 
the ECM (Hynes and Naba, 2012).  
 
 
Figure 1.1.1.1. Alveoli and the pulmonary interstitium. The ECM is located between the alveolar 
epithelial basement membranes and the capillary endothelial basement membranes at the thick sides 
of the pulmonary interstitium or where gas exchange takes place (thin sides of the pulmonary 
interstitium). The ECM contains multiple proteins, growth factors and different interstitial cell types 
including, macrophages, natural killer (NK) cells and fibroblasts. 
 
1.1.2. ECM turnover in the lungs 
The ECM is a highly dynamic structure which undergoes rapid rates of synthesis and degradation. 
Collagens are continually synthesised and degraded throughout life (Laurent, 1982, McAnulty and 
Laurent, 1987). Peak synthesis occurs during the perinatal stage of development although collagen 
deposited in the lung increases during mammalian growth, with a forty-fold change in collagen 
content between birth and adulthood (Mays et al, 1989). Studies on rat and rabbit lungs have shown 
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lung collagen is subjected to a turnover rate of approximately 10% a day, which suggests small daily 
changes in ECM turnover can result in large changes to the composition of the ECM over a longer 
period of time (McAnulty and Laurent, 1987). Within the majority of tissues, collagens are the most 
abundant proteins found in the ECM. Elastins play a critical role in development of the respiratory 
system and function in the lung to support the expansion and recoil of the alveoli during breathing. 
There is minimal turnover of elastin in normal healthy lungs (Shapiro et al, 1990) however, aberrant 
expression of proteases such as metalloproteinases (MMPs) which can cleave elastin fibres, can result 
in an increased turnover of elastin and a loss of elasticity (Ashworth et al, 1999). MMPs also play 
important roles in multiple biological processes including apoptosis and angiogenesis which are 
essential for normal lung function and in modulating the activity of growth factors/receptors (Pardo 
and Selman, 2012).   
 
1.1.3. Functions of the ECM in the lung 
In the lung, a diverse array of ECM components including collagens, elastin, fibronectin, proteoglycans 
and glycoproteins support the physical, biochemical and biomechanical functions of the ECM. Under 
normal conditions these ECM components form a compliant meshwork which allows the lungs to 
function correctly. The pulmonary ECM provides a physical scaffold for cells, maintains tissue integrity 
and generates mechanical, tensile and compressive strength (Frantz et al, 2010). In addition to 
providing structural support, the ECM physically acts as a barrier and anchorage site for cells to adhere 
to and organise into functional units (Lu et al, 2012). The mechanical properties of the ECM are 
important for a number of cellular functions including cell proliferation, differentiation, survival and 
migration (Wells, 2008). The pulmonary ECM is also biologically active and can control cell behaviour 
by either binding molecules such as growth factors or adhesion molecules or by interacting with cell-
surface receptors to generate signal transduction and regulate gene expression (Frantz et al, 2010, 
Cox and Erler 2011, Kim et al, 2011). Cell-surface receptors belonging to the integrin family are the 
primary mechanosensors which form key cell-matrix communications and response to physical forces 
transmitted by surrounding ECM and neighbouring cells (Janoštiak et al, 2014). The ECM also 
sequesters multiple growth factors and cytokines, thus acting as a local 'reservoir ' that can be used 
rapidly if needed without the need for de-novo synthesis.  
 
1.1.4. The composition of the main ECM components 
1.1.4.1. Collagens  
The pulmonary interstitium is mainly comprised of the fibrous collagen type I and together with 
laminins, gives mechanical strength to the lungs (Frantz et al, 2010). Collagens are the most abundant 
proteins in the interstitial ECM and provide structural strength to all forms of extracellular matrices. 
They also regulate cell adhesion, cell migration, support chemotaxis and are important in tissue repair 
and development (Rozario and DeSimone, 2010). Collagens consist of three polypeptide alpha chains. 
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Each polypeptide chain contains the amino sequence Gly-x-y where 'X' and 'Y' are predominately 
proline and hydroxyproline respectively (van der Rest and Garrone, 1991) (Figure 1.1.4.1.1). It is via 
the Gly-x-y sequence that the three polypeptide chains bind via hydrogen bonds, forming triple 
helices. Collagens are initially synthesised as pro-collagens that require cleavage to become active. To 
date, 28 collagens have been identified which can be broadly divided into either fibrillar or non-fibrillar 
(Heino, 2007, Gordon and Hahn, 2010). Fibrillar collagens, of which 11 are known to exist, have 
structural and mechanical functions and can influence cell behaviour by serving as ligands for 
receptors and as a reservoir of growth factors (Huxley-Jones et al, 2007). I, II, III, XI are the major 
fibrillar collagens in ECM, all of which are found within the pulmonary interstitium. Types I and III are 
the most abundant collagens in the human lungs, totalling > 90% (Bateman et al, 1981, Kirk et al, 
1984). Non-fibrillar collagens such as type IV form intricate networks and are essential components of 
basement membranes together with laminins (Boute et al, 1996, Exposito et al, 2010). Fibroblasts 
transcribe and secrete the majority of interstitial collagen and can organise collagen fibres by exerting 
tension on the matrix (De Wever et al, 2008). Covalent cross-linking of collagen fibrils is essential for 
the normal mechanical properties of ECM, however increased cross-linking causes the stiffness of the 
ECM to increase. This changes the mechanical properties of the ECM which has been linked to a 
number of diseases including pulmonary fibrosis (Calderwood et al, 2012, Clarke et al, 2013).  
 
 
Figure 1.1.4.1.1. Structure of collagen. Collagens are composed of three polypeptide alpha chains 
each of which contain the Gly-X-Y motif. X and Y can be any amino acid although they are 
predominately proline and hydroxyproline. Multiple collagen fibres form a collagen fibril.  
 
1.1.4.2. Proteoglycans 
Of the ~300 proteins that make up the core matrisome, 36 are proteoglycans (Hynes and Naba, 2012). 
Proteoglycans are glycosylated proteins that can covalently attach to glycosaminoglycans (GAGs) 
(Yanagishita, 1993) which play important functional roles in regulating cell adhesion, migration and 
proliferation (Wight et al, 1992, Järveläinen et al, 2009). The addition of GAGs also gives proteoglycans 
buffering and hydrating properties (Hynes and Naba, 2012). Proteoglycans such as decorin, aggrecan, 
versican and perlecan are interspersed among collagen fibrils in different ECMs (Hynes and Naba, 
2012) and can directly interact with growth factors and cytokines such as TGFß. Other proteoglycans, 
which can be membrane bound, also interact with chemical signals and proteases and can function as 
co-receptors thus playing an important role in regulating their biological activity (Yu and Woessner et 
al, 2000, Ruiz et al, 2012). 
19 
 
Proteoglycans can be separated into different multiple families (Iozzo and Murdoch, 1996). The two 
main families are those which encompass proteoglycans containing leucine rich repeats (LRRs) and 
those that contain link and C-type lectin domains (hyalectans) (Hynes and Naba, 2012). Proteoglycans 
with LRRs can bind to multiple glycoproteins. For example, the GAG chain of decorin can bind to 
tenascin-X and mediate its interaction with collagen fibrils (Merline et al, 2009). Hyalectans include 
versican, aggrecan, brevican and neurocan, all of which can bind to hyaluronic acid (Hynes and Naba, 
2012) and play important roles in cell adhesion, migration and apoptosis (Wu et al, 2005).  
 
1.1.4.3. Glycoproteins  
Approximately 200 glycoproteins are associated with the matrisome with tenascins, laminins, 
fibronectins, thrombospondins and fibrillins being some of the most well studied (Hynes and Naba, 
2012). Glycoproteins represent a diverse group of proteins that are covalently bound to carbohydrate 
motifs. They have important functions which include maintaining cell structure, mediating cell 
adhesion, migration and can have enzymatic and inhibitory activity. Fibronectin is one of the most 
common protein domains in vertebrates (Alberts, 2002) and alternative splicing of fibronectin results 
in a variety of isoforms. The type III fibronectin repeat is the most common form which binds to 
integrins (Carr et al, 1997). Integrins are cell-surface heterodimeric receptors consisting of an alpha 
and beta glycoprotein subunit (Akiyama, 1996). They link the ECM with the the intracellular 
cytoskeleton (Plow et al, 2000) and are key mechanosensors, essential in cell signalling and can 
regulate multiple molecules such as transforming growth factor beta (TGFß) in response to feedback 
from the ECM (Munger et al, 1999, Shyy and Chien, 2002, Yang et al, 2007).  
 
1.2. The role of fibroblasts in the ECM 
The essential role fibroblasts play in maintaining ECM homeostasis by regulating ECM turnover is 
highlighted by their ability to secrete both MMPs which degrade the ECM and tissue inhibitors of 
metalloproteinases (TIMPs) which inhibit ECM degradation (Gomez et al, 1997). MMPs/TIMPs are also 
involved in the regulation of growth factors and cytokine/chemokine activity (Elkington and Friedland, 
2006, Wynn, 2007). Furthermore, each fibroblast is capable of secreting more than 5000 molecules of 
pro-collagen every minute in response to biochemical or mechanical stimuli (McAnulty et al, 1991, 
Lindahl et al, 2002). Fibroblasts are located in the majority of tissues that are associated with 
extracellular molecules and constitute the principle cellular component of connective tissue (Tarin 
and Croft, 1970). They are large, elongated, flat spindle-shaped cells and are characterised by their 
morphology, ability to adhere to plastic (in vitro) and expression of the intermediate filament 
associated protein vimentin in the absence of markers associated with other cell lineages (McAnulty, 
2007). Multiple ECM proteins including collagens, elastin, proteoglycans, tenascins, laminins and 
fibronectin, as well as a number of ECM-modifying enzymes including collagen cross-linking enzymes 
and ECM-degrading enzymes are synthesised by fibroblasts which are essential to numerous biological 
processes. These include wound healing and repair (Tomasek et al, 2002), regulation of inflammation, 
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angiogenesis, ECM synthesis and deposition and homeostatic regulation of the ECM (McAnulty 1991, 
McAnulty, 1995, McAnulty 2002, McAnulty, 2007) (Figure 1.2.1). 
 
 
Figure 1.2.1. Role of fibroblasts in the ECM. In would healing fibroblasts proliferate and chemotax to 
sites of injury to repair the damaged ECM. In inflammation fibroblasts secrete and respond to factors 
including cytokines and prostaglandins which facilitates immune cell recruitment. In angiogenesis, 
fibroblasts interact with endothelial cells to induce angiogenesis into tissues which are not accessible 
to existing blood vessels. 
 
1.2.1. Effect of cytokines on fibroblasts  
Multiple cytokines have activating or inhibitory effects on fibroblasts, many of which are produced by 
fibroblasts themselves (Scotton and Chambers, 2007, Maher et al, 2010). TGFß is the prototypic pro-
fibrotic cytokine which is produced by a variety of cells including fibroblasts and acts on fibroblasts 
and myofibroblasts to induce proliferation, differentiation, cell migration and matrix production 
(Scotton and Chambers, 2007). Platelet-derived growth factor (PDGF) is another pro-fibrotic cytokine 
produced by cells including platelets and macrophages which acts similarly to TGFß in context with 
inducing fibroblast proliferation, differentiation and ECM production (Scotton and Chambers, 2007). 
Whilst these cytokines are essential for facilitating numerous fibroblast functions (Scotton and 
Chambers, 2007) , persistent or overexpression can lead to fibrosis as seen in patients with  IPF or 
pulmonary fibrosis associated with systemic sclerosis (SSc-PF) (LeRoy et al, 1989, Yamane et al, 2002). 
Other pro-fibrotic factors including vascular endothelial growth factor (VEGF), which is overexpressed 
in SSc, may support fibrosis by causing vascular damage which consequently causes fibroblast 
activation (Kajihara et al, 2013). In contrast, the anti-fibrotic cytokine prostaglandin E2 (PGE2), which 
inhibits fibroblast proliferation, collagen production (McAnulty et al, 1997) and apoptosis of alveolar 
epithelial cells (AECs) (Maher et al, 2010) is decreased in IPF and SSc-PF, highlighting the importance 
of balancing the correct levels of pro-fibrotic and anti-fibrotic cytokines (Figure 1.2.1.1). 
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Figure 1.2.1.1. Effect of cytokines on fibroblasts. Anti-fibrotic cytokines including PGE2 can act to 
decrease fibroblast proliferation and their differentiation into myofibroblasts and increase their 
apoptosis. Other anti-fibrotic cytokines include: hepatocyte growth factor (HGF), interferon gamma 
(IFN-γ) and tumor necrosis factor alpha (TNF-α). Pro-fibrotic cytokines including TGFß and VEGF can 
activate multiple genes and increase fibroblast proliferation and differentiation. Other pro-fibrotic 
cytokines include: connective tissue growth factor (CTGF), interleukin-1 (IL-1) and interleukin-6 (IL-6). 
 
1.3. ECM in fibrosis 
Excessive collagen production and remodelling of the lung architecture is a consequence of altering 
the balance of fibroblast proliferation, apoptosis and the accumulation and breakdown of the ECM. 
Under fibrotic conditions such as those found in pulmonary fibrosis, the ECM changes in composition, 
severely affecting lung function (Figure 1.3.1).  
 
Figure 1.3.1. Normal ECM function and structure compared to fibrotic ECM. The ECM in the normal 
lung is compliant and has very little elastin turnover. In contrast, a fibrotic lung has a high turnover of 
elastin, increased cross-linking of collagen and other ECM components, dysregulated MMP/TIMP 
levels and altered composition of multiple ECM components which leads to an inelastic, non-
compliant, stiff matrix. 
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Type I and III collagens are elevated in IPF patients (Laurent et al, 1988) and dramatic increases in 
collagen synthesis have been observed in a number of animal models following treatment with 
bleomycin (Clark et al, 1982, Laurent and McAnulty et al, 1983, Decaris et al, 2014), suggesting that 
altered turnover of collagen contributes to pulmonary fibrosis. Furthermore, increased collagen cross-
linking which results in a stiff matrix has been associated with IPF and SSc (Kadler et al, 2007, Kadler 
et al, 2008, Olsen et al, 2011, Cox et al, 2013, Ho et al, 2014). Cross-linking is a biochemical process 
mediated by cross-linking enzymes including transglutaminases (TG) and lysyl-oxidases (LOX) which 
stabilise and allow correct assembly of ECM components (Kadler et al, 2007, Kadler et al, 2008). 
Transglutamase 2 (TG2), an enzyme responsible for cross-linking ECM components including collagen, 
elastin and fibronectin, can alter ECM properties by increasing its resistance to degradation (Olsen et 
al, 2011). Furthermore, lysyl-oxidase expression is increased after bleomycin-and irradiation-induced 
pulmonary fibrosis and is strongly associated with areas of fibrosis (Cox et al, 2013). Elastin gene 
expression is also increased in pulmonary fibrosis (Hoff et al, 1999), after bleomycin treatment in mice 
(Decaris et al, 2014) and in response to TGFß (Kähäri et al, 1992). Aberrant, disorganised elastin 
production and increased degradation is also associated with IPF (Laurent and Tetley, 1984, Kristensen 
et al, 2015).  In IPF and SSc-PF, a number of  MMPs and TIMPs are aberrantly expressed (Table 1.3.1) 
(Selman et al, 2000, Zuo et al, 2002, Henry et al, 2002, Pardo et al, 2005, Selman et al, 2006, McKeown 
et al, 2009, Konishi et al, 2009, Zhou et al, 2010). Furthermore, knockout MMP models confer 
protection against bleomycin-induced pulmonary fibrosis (McKleroy et al, 2013), suggesting the 
balance of MMP/TIMP expression is important in maintaining ECM function. Multiple glycoproteins 
also have altered expression in IPF and SSc including, thy-1 cell surface antigen (THY1) (Hagood et al, 
2005, Sanders et al, 2008), mucin 1 (MUC1) (Kohno et al, 1993, Yokoyama et al, 2006) and tenascin-C 
(TNC) (Kuhn and Mason, 1995) suggesting they may be important in the pathogenesis of these 
diseases.  
Tenascins are a family of large glycoproteins found in the ECM and are responsible for a variety of 
functions including maintaining ECM structure, cell signalling and cell adhesion modifications (Jones 
and Jones 2000). There are currently four tenascin family members; TNC, tenascin-R, tenascin-W and 
tenascin-X (TNX). TNC has been linked to IPF and SSc-PF (Kuhn and Mason, 1995, Hisatomi et al, 2009, 
Brissett et al, 2012, Estany et al, 2014). TNX is encoded by the TNXB gene and is the largest of all 
tenascins. TNX is believed to play an important role in regulating collagen fibrillogenesis (Minamitani 
et al, 2004) and can bind to a number of collagens including fibril-associated type XII and XIV collagens 
(Lethias et al, 2006), elastin (Egging et al, 2007) and decorin (Elefteriou et al, 2001). Deficiency of TNX 
is associated with hypermobility type Ehlers Danlos syndrome which is characterised by joint 
hypermobility and skin hyperextensibility (Burch et al, 1997, Mao et al, 2002, Zweers et al, 2003). TNX 
deficiency is also associated with reduced type I collagen deposition, reduced density of collagen fibrils 
(Mao et al, 2002), and disruption of the elastic fibre network (Burch et al, 1997). Furthermore, 
knockout models of TNXB have shown protection against cardiac fibrosis in rat models, mediated by 
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a decrease in TGFß and an increase in PPARγ (Jing et al, 2011) whereas increased levels of TNX are 
associated with increased matrix stiffness (Margaron et al, 2010) and fibrous tumours including 
mesothelioma (Yuan et al, 2009). A list of ECM components which have altered expression in IPF and 
SSc is shown in Table 1.3.1. 
ECM 
component 
Disease Expression Function 
COL1 IPF 
SSc 
Increased 
Increased 
Provides tensile strength. (Laurent et al, 1988). 
COL3 IPF 
SSc 
Increased 
Increased 
Provides tensile strength. (Laurent et al, 1988). 
Chitinase-3-
like protein 1 
(CHI3L1) 
IPF 
SSc 
Increased 
Increased 
Tissue remodelling and stimulates fibroblast proliferation 
(Recklies et al, 2002, Nordenbaek et al, 2005, Johansen et al, 
2005, Korthagen et al, 2011). 
Superoxide 
dismutase 3 
(SOD3) 
IPF 
SSc 
Increased 
Increased 
Involved in inflammatory responses (Gao et al, 2008, Laurila et 
al, 2009, Arcucci et al, 2011). 
Secreted  
protein, 
acidic, 
cysteine-rich 
(SPARC) 
IPF 
SSc 
Increased 
Increased 
Suppresses apoptosis of IPF fibroblasts (Zhou et al, 2002, Zhou 
et al, 2006, Chang et al, 2010). 
MUC1 IPF 
SSc 
Increased 
Increased 
Multiple functions including regulation of growth factors, 
inflammation and apoptosis (Kohno et al, 1993, Yamane et al, 
2000, Sato et al, 2000, Ohnishi et al, 2003, Yokoyama et al, 
2006, Nath and Mukherjee, 2014).   
TG2 IPF Increased Cross-links ECM (Olsen et al, 2011). 
LOX IPF Increased Cross-links ECM (Cox et al, 2013). 
TNC IPF 
SSc 
Increased 
Increased 
Cell adhesion, fibroblast migration (Trebaul et al, 2007, 
Brissett et al, 2012). 
MMP-1 IPF 
SSc 
Increased 
Decreased 
Processes cytokines, cell migration, cell growth, role unknown 
in IPF and SSc (Pardo et al, 2012, Herrera et al, 2013). 
MMP-2 IPF Increased Degrades matrix and non-matrix components (Pardo and 
Selman, 2006). 
MMP-3 IPF Increased May contribute to epithelial-mesenchymal transition (EMT) 
(Radisky et al, 2010, Yamashita et al, 2011) and endostatin 
release promoting alveolar epithelial cell apoptosis (Richter et 
al, 2009). 
MMP-7 IPF 
SSc 
Increased 
Increased 
Pro-fibrotic, may promote fibrosis via activation of latent TGFß 
(Pardo et al, 2005, Rosas et al, 2008). 
MMP-8 IPF Increased Migration of fibrocytes (Moeller et al, 2009, García-de-Alba et 
al, 2010). 
MMP-9 IPF Increased Regulates tissue turnover (Lemjabbar et al, 1999, Selman et al, 
2000, Suga et al, 2000). 
MMP-10 IPF 
SSc 
Increased 
Increased 
Unknown. 
MMP-12 IPF 
 
SSc 
Unknown 
 
Increased 
May promote fas-induced pulmonary fibrosis (Matute-Bello et 
al, 2007). Cleaves urokinase-type plasminogen activator 
receptor causing impaired endothelial cell proliferation, 
migration and angiogenesis (D'Alessio et al, 2004). 
TIMP-1,2,3 
and 4 
IPF 
 
SSc 
Increased 
 
Increased 
Regulates MMP activity and modulates cell functions including 
apoptosis and cell differentiation (Ramos et al, 2000, Selman 
et al, 2000, Ries et al, 2014). 
Table 1.3.1. ECM Components which have altered expression in IPF and SSc. Multiple collagens, 
cross-linking enzymes, glycoproteins, metalloproteinases and tissue inhibitors of metalloproteinases 
have altered expression in IPF and/or SSc. 
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1.4. Pulmonary fibrosis 
Pulmonary fibrosis (PF) is a pathological condition originating from aberrant repair mechanisms in 
response to acute or chronic lung injury. PF is characterised by progressive scarring of the lungs and 
excessive ECM deposition in the pulmonary interstitium. The pulmonary interstitium comprises 
alveolar septa surrounding the bronchial and vascular spaces which are critical areas within the lung 
where fibrosis exerts its devastating effects. Effacement of this intricate lung architecture by excessive 
production of ECM, mainly collagens, results in scarring and ultimately leads to decreased lung 
function, respiratory failure and subsequent death.  
Hamman and Rich are seen as the first people to describe pulmonary fibrosis although it has been 
argued that previous papers in Germany described a number of fibrotic lung diseases before them 
(Homolka, 1987). In the early 20th century pulmonary fibrosis was described in four patients who 
displayed rapidly progressive diffuse interstitial fibrosis of the lungs (Hamman and Rich, 1935, 
Hamman and Rich, 1944). It was later found that not all patients deteriorated as rapidly as Hammond 
and Rich had first described. This led to distinct types of pulmonary fibroses being described such as 
diffuse fibrosing alveolitis and idiopathic pulmonary fibrosis (Scadding et al, 1960, Scadding et al, 1967, 
Crystal et al, 1976). 
PF epitomises the end stages of many interstitial lung diseases (ILDs) which describe a diverse 
heterogeneous group of over 200 pulmonary disorders (Raghu and Brown, 2004). Similar radiological 
and clinical manifestations are common in ILDs although their aetiologies and pathophysiologies are 
distinct. ILD and PF often occur as secondary effects of other diseases including rheumatoid arthritis 
(RA) (Shiel and Prete, 1984), systemic lupus erythematosus (Eisenberg et al, 1973) and SSc (McCarthy 
et al, 1988, Wells et al, 1994) or from exposure to substances such as asbestos or silica dust (Khalil et 
al, 2007).  
The vast majority of ILDs have no known etiology and are sub-categorised as idiopathic interstitial 
pneumonias (IIPs), the most prevalent and deleterious being IPF (Amercian Thoracic Society/European 
Respiratory Society (ATS/ERS), 2002, Travis et al, 2013). Although sufficiently different to warrant 
designation as separate diseases, many IIPs share similar features. In 2002 the ATS/ERS categorised 
IIPs into seven groups based on histological, radiological and clinical characteristics (ATS/ERS 2002). 
Since then the classification of IIPs has been updated (Figure 1.4.1) (Travis et al, 2013). This revision 
of IIP classification includes, recognition that idiopathic NSIP is a distinct clinical entity, sub-divisions 
of IIPs into major, rare and unclassifiable and grouping major IIPs into either chronic fibrosing, 
smoking-related or acute/subacute (Travis et al, 2013).   
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Interstitial lung disease
Idiopathic interstitial pneumonias Known association with ILD
RareMajor
Unclassifiable
Granulomatous
- Sarcoidosis
- Chronic beryllium disease
- Hypersensitivity pneumonitis
Chronic fibrosing Acute/subacuteSmoking related
Idiopathic 
pleuroparenchymal 
fibroelastosis
Connective tissue diseases
- Systemic sclerosis
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Sjorgen’s syndrome
- Polymyositis
Occupational exposures
- Asbestosis 
- Berylliosis
- Silicosis
Drug-incuded
- Bleomycin
- Amiodarone
- Methotrexate
- Nitrofurantoin
Idiopathic 
pulmonary 
fibrosis
Nonspecific 
interstitial 
pneumonia
Desquamative 
interstitial 
pneumonia
Respiratory 
bronchiolitis-
ILD
Cryptogenic 
organising 
pneumonia
Acute 
interstitial 
pneumonia
Idiopathic 
lymphocytic 
pneumonia  
Figure 1.4.1. Classification of ILDs including the revised ATS/ERS classification of idiopathic interstitial pneumonias. (Adapted from Zibrak and Price, 2014). 
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1.4.1. IPF 
IPF is a chronic, progressive fibrotic lung disease which is largely unresponsive to any therapy and 
remains the most common and deleterious of all IIPs, accounting for 62% of all diagnosed IIP cases 
(Bjoraker et al, 1998). Manifestations of IPF include, breathlessness on exertion, dry cough and 
increasing dyspnoea, bibasilar inspiratory crackles and 50% of IPF patients develop thickening of their 
fingertips, termed ‘finger clubbing’ (Raghu et al, 2011). IPF is clinically characterised by progressive 
dyspnoea, dry cough, presence of sub-pleural honeycombing upon high-resolution computed 
tomography (HRCT) scanning and absence of any known causes of other ILDs (Table 1.4.1.1). IPF is 
also associated with a histological pattern of usual interstitial pneumonia (UIP) (Figure 1.4.1.1), 
although it is not uncommon for UIP and non-specific interstitial pneumonia (NSIP) to exist in different 
regions of IPF lung biopsies (Monaghan et al, 2004). UIP has the worst prognosis of all IIPs whereas 
NSIP has a slightly better prognosis and is seen more often in PF associated with connective tissue 
diseases such as SSc and RA (Wells et al, 1997, Nicholson and Wells, 2001, Bouros et al, 2002). UIP is 
characterised by abnormal proliferation of mesenchymal cells, honeycombing, co-existence of fibrotic 
regions with histologically normal lung, distortion of normal lung architecture and presence of 
fibroblastic foci. Fibroblastic foci are seen as a pathological hallmark characteristic of UIP thought to 
represent active sites of ongoing fibrogenesis where fibroblasts/myofibroblasts accumulate and 
contribute to excessive ECM production and collagen deposition (Kuhn and McDonald, 1991).  
 
Major Criteria  
Exclusion of other known causes of ILD such as certain drug toxicities, environmental exposures, 
and connective tissue diseases. 
Abnormal pulmonary function studies that include evidence of restriction (reduced vital capacity 
(VC), often with an increased forced expiratory volume in one second to forced vital capacity ratio 
(FEV1/FVC)) and impaired gas exchange (increased P(A-a)O2, decreased PaO2 with rest or exercise 
or decreased diffusing capacity of the lungs for carbon monoxide (DLCO). 
Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT scans. 
Transbronchial lung biopsy or bronchial alveolar lavage showing no features to support an 
alternative diagnosis. 
Minor criteria 
Age >50 years old. 
Insidious onset of otherwise unexplained dyspnoea on exertion. 
Duration of illness >3 months. 
Bibasilar, inspiratory crackles (dry type in quality). 
Table 1.4.1.1. Clinical criteria required for IPF diagnosis. VC; vital capacity, FEV1/FVC; forced 
expiratory volume in 1 second/forced vital capacity, P(A-a)O2; the alveolar-arterial oxygen difference, 
PaO2; partial pressure of oxygen in the arterial blood. (Taken and adapted from ATS, 2002). 
27 
 
 
Figure 1.4.1.1. The histology of normal and IPF lung tissue. A) Normal lung tissue. Alveoli are 
separated by a thin interstitium conducive to lung function. B) IPF lung tissue. Increased collagen (blue 
staining) content in the ECM causes a thick interstitium and results in the distortion of the normal lung 
architecture. Brown staining shows cell nuclei. 
 
1.4.2. SSc 
SSc is a complex, autoimmune, connective tissue disease, characterised by vascular abnormalities, 
excessive collagen production and extensive fibrosis of the skin and internal organs (Varga and 
Abraham, 2007). SSc vasculopathy consists of fibrointimal proliferation of small vessels and Raynaud's 
phenomenon, which describes cold-induced or stress-induced excessive reduction in blood flow to 
the extremities, due to vasospasm of small blood vessels (Lewis, 1929, Kahaleh, 2009. ILD occurs in 
approximately 75% of SSc patients (Bussone and Mouthon, 2011, Tan et al, 2011), including 
pulmonary arterial hypertension (PAH) and PF which are the leading causes of mortality (Steen and 
Medsger, 2007).  
The exact etiology of SSc is unknown although there is strong evidence that genetic factors, 
epigenetics and environmental exposures all play an important role (Varga and Abraham, 2007). 
Inflammation, diffuse endothelial damage, immune abnormalities, microvascular alterations and 
interstitial and perivascular fibrosis are all characteristic of SSc (Abraham and Varga, 2005, Varga and 
Abraham, 2007). Depending on the pattern of skin involvement (Varga and Abraham, 2007), SSc can 
be classified as either diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc (lcSSc). Patients with 
lcSSc outnumber those with dcSSc by 4.7:1 (Allcock et al, 2004). This classification also in part reflects 
the severity of SSc. DcSSc is associated with rapid, progressive skin fibrosis and systemic organ 
involvement (LeRoy et al, 1988, Steen and Medsger 2000, LeRoy and Medsger, 2001). Approximately 
20-30% of patients with dcSSc also have the presence of anti-topoisomerase antibodies (ATA) (Steen 
et al, 1988, Koenig et al, 2008). ATA antibodies are associated with increased mortality and risk of 
developing pulmonary fibrosis (Steen et al, 1988, Koenig et al, 2008). In contrast, patients with lcSSc 
tend to have a relatively better prognosis than dcSSc patients, unless PAH develops as a secondary 
complication (Steen and Medsger, 2003). LcSSc is characterised by slow progressive skin changes with 
varying degrees of internal organ involvement (Varga and Abraham, 2005). Approximately 70-80% of 
patients with lcSSc have anti-centromere antibodies (ACA) which increases the risk of developing PAH 
A B 
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(Nihtyanova and Denton, 2010). Both ATA and ACA auto antibodies are useful for diagnosing and 
classifying SSc patients as although both dcSSc and lcSSc can have ATA antibodies, it is very rare that 
dcSSc patients have ACA antibodies (Spencer-Green et al, 1997).  
 
1.5. Epidemiology of IPF and SSc 
IPF typically affects adults over the age of 40 (Raghu et al, 2011) with a tendency to affect males more 
than females (Iwai et al, 1994, Scott et al, 1990, Coultas et al, 1994, Mannino et al, 1996, Johnston et 
al, 1997, Gribbin et al, 2006, Han et al, 2008, Nalysnyk et al, 2012) and whilst still classed as a rare 
disease, the incidence rates are increasing (Raghu et al, 2006, Gribben et al, 2006, Olson et al, 2007, 
Navaratnam et al, 2011, Nalysnky et al, 2012), although this may be due to improvements in the earlier 
and more accurate diagnosis of IPF (Hutchingson et al, 2014). Approximately 66% of IPF patients are 
older than 60, with a mean age of diagnosis at 66 years (Navaratnam et al, 2011). Age of diagnosis is 
also a predictor of survival rate, as increased age is strongly associated with an increased risk of death 
(Raghu et al, 2011, Navaratnam et al, 2011). 
IPF predominates in males (Iwai et al, 1994, Scott et al, 1990, Coultas et al, 1994, Mannino et al, 1996, 
Johnston et al, 1997, Gribbin et al, 2006, Han et al, 2008, Nalysnyk et al, 2012) and may also progress 
faster in males resulting in decreased survival rates (Gribbin et al, 2006, Han et al, 2008). In contrast, 
it has been shown the mortality rate amongst women is increasing at a faster rate than in men (Olson 
et al, 2007), although this may potentially be due to changes in working environments or smoking 
habits (Ley and Collard, 2013). It has also been shown that race and ethnicity may play a role in 
susceptibility towards developing IPF although different studies have produced conflicting results 
(Olson et al, 2007, Swigris et al, 2012). Recent studies show greater and increasing mortality in white 
populations compared to other racial and ethnic groups (Olson 2007, Swigris et al, 2012). In contrast, 
a previous study has shown black and Hispanic populations have increased mortality compared to 
white populations (Lederer et al, 2006).  
IPF affects more than 15,000 people in the UK and more than 128,000 people in the USA (Raghu et al, 
2006, Navaratnam et al, 2011) with mean survival rates from the time of initial diagnosis dismal, at 
only 2-3 years (Gribben et al, 2006). In Europe, IPF prevalence ranges from 1.25-23.4 cases per 100,000 
population (Nalysnyk et al, 2012). In the UK alone an estimated 5000 people suffering from IPF will 
die each year, making IPF a substantial cause of mortality in the UK and a more prominent killer than 
most cancers including leukaemia and kidney cancer (Navaratnam et al, 2011). Currently it is 
estimated that between 28,000-65,000 people in Europe and 13,000-17,000 people in the USA will 
die from IPF (Hutchinson et al, 2014, Hutchinson et al, 2015).  
SSc typically affects people aged over 45 (Chifflot et al, 2008) and predominates in women (Mayes et 
al, 2003). The prevalence of SSc varies dramatically according to geographical location and the criteria 
used to diagnose SSc (Mayes et al, 2003, Chifflot et al, 2008). In European countries, such as France 
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(Le Guern et al, 2004) and Spain (Arias-Nuñezet al, 2008), the prevalence rate of SSc is estimated at 
158 and 277 cases per million, respectively. The prevalence of SSc in the West Midlands of the UK is 
estimated at 31 cases per million (Silman et al, 1988), whereas in Newcastle, UK, the prevalence is 
estimated at 88 cases per million (Allock et al, 2000). In different parts of America including South 
Carolina (Maricq et al, 1989), Michigan (Mayes et al, 2003) and Oklahoma (Arnett et al, 1996) the 
prevalence is estimated at 286, 276 and 658 cases per a million, respectively. In general, SSc 
prevalence is estimated at 50-300 cases per million (Chifflot et al, 2008). Approximately 6000 people 
in the UK suffer from SSc whereas in America, approximately 100,000 people suffer from SSc (Mayes 
et al, 2003).  
 
1.6. The pathogenesis of IPF and SSc 
Intensive research into the etiology of IPF and SSc has identified multiple exogenous agents, pathways, 
transcription factors and risk factors that are potentially pathogenic. However, the exact molecular 
and cellular mechanisms underlying both diseases remain unknown. Lack of efficacy using anti-
inflammatory drugs in IPF patients and deleterious effects of immunosuppressive therapy led some 
researchers to challenge the antecedental view of IPF being a chronic inflammatory lung disease 
(Selman et al, 2001, Raghu et al, 2006, Maher et al, 2007). IPF is now seen as a multifactorial disease 
caused by chronic epithelial injury with an impaired wound healing response resulting in fibrosis and 
inflammation with multiple pathways, cell types, genetic and epigenetic factors and the ECM all 
pathologically implicated (Selman et al, 2001, Chambers et al, 2003, Kinnula et al, 2005, Thannickal et 
al, 2006, Maher et al, 2007, O'Donoghue et al, 2012, Parker et al, 2014). SSc is a clinically 
heterogeneous disease and whilst genetic, epigenetic and environmental factors all influence SSc 
pathogenesis, the exact causes of SSc remain unknown (Kowal-Bielecka et al, 2009).  
Much of the current understanding of IPF and SSc has come from the use of animal models of fibrosis, 
the murine bleomycin model and its variations being the most prominent. However, the bleomycin 
model fails to epitomise the hallmark characteristics of IPF (Scotton and Chambers, 2010) and SSc 
(Lakos et al, 2004) and with so many different variations of the bleomycin model, including route of 
bleomycin administration, dosing and measurements of outcome, it makes any generated results 
difficult to compare in the literature (Scotton and Chambers, 2010). Although the bleomycin model 
and other animal models of fibrosis fail to fully recapitulate IPF and SSc phenotypes they have 
provided researchers with an insight into possible mechanisms underlying IPF and in other diseases 
where PF often occurs and with careful use can prove a valuable resource.  
The majority of people suffering from IPF experience a gradual worsening of their symptoms however, 
it has been estimated annually that 5-10% of IPF sufferers experience unexplainable rapid 
deteriorations, defined as acute exacerbations (Song et al, 2011, Collard et al, 2007). Differences in 
gene expression patterns between stable IPF and IPF with acute exacerbations has recently been 
reported, highlighting the protein cyclin–A2 (CCNA2) which is essential for controlling the cell cycle, 
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as being upregulated in IPF with acute exacerbations (Konishi et al, 2009). Recent work by Wootton 
et al suggests viral infections do not play a key role in acute exacerbations in IPF as in the majority of 
cases no viral infection was detected (Wootton et al, 2011). However, viral infections including 
Epstein-Barr virus (EBV) (Egan et al, 1995), hepatitis C (Ueda et al, 1992) and adenovirus (Kuwano et 
al, 1997) have all previously been implicated in IPF pathology. Furthermore, the number of studies 
associating viral signatures with IPF is growing (Moore and Moore, 2015), suggesting viral infections 
may play an important role in the pathogenesis of IPF.  
Increased presence of fibroblastic foci has proved one of the most reliable predictors of IPF outcome, 
with increased numbers of fibroblastic foci correlating with disease severity, a worsened prognosis 
and decreased survival time (King et al, 2001, Nicholson et al, 2002, Barlo et al, 2010). Proliferation of 
fibroblasts, their differentiation and secretion of ECM components are normal primary responses to 
tissue damage (Tomasek et al, 2002) however, progressive, increased ECM deposition and altered 
ECM turnover rates are hallmark characteristics of many pulmonary diseases including IPF (Laurent et 
al, 2008) and SSc (Sato et al, 2003). In SSc, fibroblasts from lung explants have a constitutively 
activated, myofibroblast-like phenotype resulting from circulating auto-antibodies, connective tissue 
growth factor (CTGF) and IL-6 in response to viral infections (Markiewicz et al, 2004, Abraham and 
Varga, 2005, Varga and Abraham, 2007, Cox and Erler, 2010). The environmental, genetic and 
epigenetic factors which may play a role in the pathogenesis of IPF and SSc are summarised in Figure 
1.6.1. The following sections will discuss each of these pathological mechanisms in more detail. 
 
 
Figure 1.6.1. Possible factors involved in the pathogenesis of IPF and SSc. Blue: factors associated 
with the pathogenesis of IPF. Red: factors associated with the pathogenesis of SSc. 
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1.6.1. Altered wound healing in fibrosis 
Normal wound healing is a dynamic process achieved by continuous overlapping and highly 
coordinated phases (Guo and DiPietro 2010). Optimal wound healing in human adults involves rapid 
haemostasis followed by inflammation, mesenchymal cell differentiation, angiogenesis, re-
epithelialisation over the wound surface and suitable synthesis, crosslinking and alignment of collagen 
to strengthen healing tissue (Gosain and DiPietro, 2004, Guo and DiPietro, 2010). Perturbations to any 
of these phases can result in impaired wound healing, which can subsequently lead to extensive tissue 
remodelling and the replacement of functional tissue with permanent scar tissue, as seen in 
pulmonary fibrosis (Chambers, 2008) (Figure 1.6.1.1). Apoptosis plays an important role in the normal 
wound healing process by removing excessive fibroblasts/myofibroblasts after wound repair 
(Desmoulière et al, 1997). Myofibroblasts express alpha smooth muscle actin (α-SMA) and in skin 
models of wound healing they apoptose after resolution, whereas in IPF, fibroblasts and 
myofibroblasts are more readily activated, secrete exaggerated amounts of ECM proteins and are 
resistant to apoptosis (Moodley et al, 2004, Thannickal et al, 2006,  Maher et al, 2007, Fattman et al, 
2008, Maher et al, 2010). In contrast, AECIIs (injury to which is thought to initiate IPF), have increased 
apoptosis in IPF lungs, with up to 80% shown to have ongoing apoptosis (Korfei et al, 2008). 
COX2/PGE2 deficiency has been shown to play an important role in apoptosis in IPF (Maher et al, 
2010). Reduced PGE2 causes increased sensitivity of AECs to Fas ligand-induced apoptosis whilst 
conversely inducing fibroblast resistance to apoptosis (Maher et al, 2010) and to date, remains the 
only mediator to adequately explain this apoptosis paradox. Increased expression of survivin, a 
member of the inhibitor of apoptosis protein family, has been linked with promoting apoptosis 
resistance in IPF fibroblasts (Sisson et al, 2012). IL-6 may also play an essential role in balancing 
AEC/fibroblast apoptosis as in IPF fibroblasts as IL-6 can induce the anti-apoptotic protein B-cell 
lymphoma 2 (BCL2) whereas in normal fibroblasts IL-6 can enhance apoptosis by inducing the pro-
apoptotic protein, BCL2-associated X protein (BAX) (Moodley et al, 2003). IPF fibroblasts also have 
increased proliferation and decreased apoptosis when they attach to polymerised collagen (Nho and 
Hergert, 2014) which can result from increased protein kinase B (AKT) activity via phosphatase and 
tensin homolog (PTEN) suppression (Nho and Hergert, 2014). In contrast, normal lung fibroblasts have 
decreased proliferation and increased apoptosis when they attach to polymerised collagen via 
suppression of the PI3K/AKT pathway as a result of increased PTEN activity (Nho and Hergert, 2014). 
Furthermore, SPARC, a matricellular protein that regulates tissue repair and wound healing, can 
increase ß-catenin which subsequently leads to an apoptosis-resistant phenotype in IPF fibroblasts 
(Chang et al, 2010). Other factors including TGFß (Hagimoto et al, 2002, Murray et al, 2011), found in 
inflammatory zone 1 (FIZZ1) (Liu et al, 2004, Chung et al, 2007), interleukin-1 beta (IL-1ß) (Zhang et al, 
1993) and TNFα (Frankel et al, 2006), have all been linked to regulating apoptosis, yet the exact 
mechanisms that cause increased AECII apoptosis and increased resistance of fibroblasts apoptosis, 
remains to be elucidated. 
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Figure 1.6.1.1. Normal wound healing compared to wound healing in pulmonary fibrosis. After injury 
to the epithelium, haemostasis occurs resulting in the formation of a fibrin clot. An influx of 
inflammatory cytokines and growth factors create a pro-fibrotic environment which stimulates 
fibroblast proliferation and migration towards the provisional matrix. Here, fibroblasts deposit ECM 
components including collagens and exert forces on the matrix which enables collagen reorganisation. 
TGFß causes fibroblasts to differentiate into myofibroblasts which together with fibroblasts secrete 
ECM components and proteases which breakdown ECM. The balance between ECM synthesis and 
degradation is essential for successful wound repair. Under normal conditions fibroblasts and 
myofibroblasts apoptose after wound closure however, under pathological conditions such as in 
pulmonary fibrosis, they persist (are less sensitive to apoptosis) and continue to remodel the matrix. 
In IPF, fibroblasts and myofibroblasts form fibroblastic foci which represent active areas of fibrosis. 
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1.6.2. The role of ECM stiffness in IPF and SSc  
ECM provides the physical scaffolding for cellular constituents, as well as being involved in the 
initiation of biochemical and biomechanical events required for tissue homeostasis (Frantz et al, 
2010). Daily turnover of ECM in the lung is >10% and small changes over time can result in changes in 
the ECM composition and fibrosis (McAnulty and Laurent, 1987, McAnulty et al, 1991). The 
composition of collagens, elastins and proteoglycans which is essential for maintaining normal lung 
function is perturbed in IPF (Bienkowski and Gotkin, 1995). In normal lungs, collagen accounts for 20% 
of dry lung weight and is composed of several different types in a location-specific and organised 
manner (McAnulty and Laurent, 1995). In IPF, collagen deposition is disorganised and both types I and 
III are associated with significantly altered turnover rates, resulting in abnormal structural remodelling 
of the lungs (Kirk et al, 1984). Increased production of ECM is central to the pathophysiology of IPF.  
Fibroblasts derived from fibrotic diseases such as IPF and SSc have an altered phenotype characterised 
by increased proliferation and differentiation which subsequently results in exaggerated amounts of 
ECM components being secreted (Tomasek et al, 2002, Varga and Abraham, 2007). This corresponds 
with an ECM which is stiff, inelastic and contains an altered composition of ECM components including 
MMPs/TIMPs, glycoproteins and collagens (see section 1.3, Table 1.3.1). Recently it has been shown 
that the ECM can drive fibroblast phenotype (Marinković et al, 2013, Blaauboer et al, 2013, Parker et 
al, 2014, Liu et al, 2015). Fibroblasts interact with multiple components of the ECM and interpret 
signals which control their function and fate (Halliday and Tomasek 1995). Increased matrix stiffness 
is associated with driving fibroblast activation and myofibroblast differentiation (Liu et al, 2010, Huang 
et al, 2012) and gene expression can be modulated by the stiffness of the ECM (Booth et al, 2012, 
Parker et al, 2014). Multiple genes which encode ECM proteins including collagens and laminins are 
activated in fibroblasts grown on a stiff ECM as found in IPF, regardless of whether they are derived 
from a healthy or diseased origin (Parker et al, 2014) suggesting mechanical signals strongly influence 
fibroblast function. This emerging evidence suggests that changes in the composition of the ECM are 
not just a consequence, but a cause of fibrosis. Current data suggests a positive feedback loop exists 
between the ECM and fibroblasts whereby the mechanical properties of the ECM can regulate 
fibroblast gene expression and fibroblast gene expression can regulate the ECM composition (Figure 
1.6.2.1).  
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Figure 1.6.2.1. Positive feedback between ECM and fibroblasts. Fibroblasts become activated by 
potentially multiple pathways and proliferate and differentiate into myofibroblasts, secreting 
exaggerated amounts of ECM components. This subsequently leads to an altered composition of ECM 
and changes in the mechanical properties of the ECM. The changes in the mechanical properties of 
the ECM (increased stiffness) are recognised by integrins (primary mechanosensors) which provide 
feedback signals to fibroblasts. This signalling further drives fibroblast proliferation/differentiation 
and may lead to altered gene expression.  
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1.6.3. Gastroesophageal reflux  
Diseases including IPF and SSc-PF have reduced lung compliance due to the altered composition of 
the ECM. This results in altered intrathoracic pressure which may predispose individuals with these 
diseases to gastroesophageal reflux (GER) (Raghu et al, 2006). GER occurs when protective 
mechanisms fail to prevent the reflux and aspiration of acidic and non-acidic products from the 
gastrointestinal tract. Although no cause and effect relationship between GER and pulmonary fibrosis 
has been shown, GER is common in IPF patients (Raghu et al, 2006) and approximately 90% of all SSc 
patients have some degree of gastrointestinal involvement (Turner et al, 1973, Szamosi et al, 2006) 
which significantly contributes to patient morbidity (Thoua et al, 2010). The pressure gradient 
between the abdomen and thorax is important in regulating gastroesophageal reflux. However, it is 
also possible that GER may be a secondary effect of pulmonary fibrosis, rather than a cause, as 
decreased lung compliance results in increased negative pleural pressure which potentially could 
result in the reflux of gastric products in the oesophagus (Raghu et al, 2006). 
Chronic microaspiration of gastric contents may also cause iterative injury to the alveolar epithelium 
which is believed to be important in the pathogenesis of both IPF and SSc-PF (Lee et al, 2010). 
Furthermore, a positive relationship between the degree of acid and non-acid reflux and extent of PF 
has been shown in SSc (Savarino et al, 2014). Interestingly, acid suppression treatment in IPF patients 
does not stop GER and more recently acid suppression treatment has been shown to increase non-
acidic reflux (Kilduff et al, 2014). The role of non-acid reflux in PF is poorly understood, however a 
rodent model of chronic aspiration has shown that lung injury can be caused by non-acidic gastric 
products (Downing et al, 2008). This suggests that increased non-acid reflux could potentially cause 
lung injury in patients with pulmonary fibrosis. Thus, the recommendation that the majority of 
patients with IPF and asymptomatic acid reflux should receive acid suppression therapy may be 
unsuitable, as the increase in non-acidic reflux induced by acid suppression may further cause lung 
injury (Kilduff et al, 2014). However, the exact role of acidic and non-acidic reflux in PF remains 
unknown.  
 
1.6.4. The role of environmental factors in IPF 
Multiple environmental factors including occupational (Ramage et al, 1988, Scott et al, 1990, Monso 
et al, 1990, Billings and Howard, 1994, Iwai et al, 1994, Hubbard et al, 1996, Baumgartner et al, 2000), 
infectious (Ueda et al, 1992, Egan et al, 1995, Kuwano et al, 1997) and non-occupational/non-
infectious (Baumgartner et al, 1997) have been linked to ILD, although none have been shown to 
consistently increase the risk of developing IPF (Figueroa et al, 2010). Furthermore, it is important to 
note that many of the studies suggesting a role for these factors in IPF were conducted before the 
2002 and 2013 IPF criteria guidelines and have subsequently been classified separately from IPF 
(ATS/ERS, 2002, Travis et al, 2013). Thus the exact cause/causes of IPF still remain unknown. 
Nonetheless, some of these factors may still play an important role and/or increase the risk of 
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developing IPF. For example, increased oxidative stress, which has been associated with IPF (MacNee, 
2005) can be caused by toxic activation of oxygen species via hard metal and cobalt interactions (Lison 
et al, 1996, Baumgartner et al, 2000). Increased oxidative stress can also be a consequence of smoking 
which has been linked to several ILDs and may promote disease progression (MacNee et al, 2005). 
However, the exact mechanisms by which smoking may contribute to ILD and whether smoking plays 
an important role in the pathogenesis of IPF remain unknown. The prevalence of tobacco use in IPF 
patients ranges between 41%-83% (Ryu et al, 2001, Oh et al, 2012) and smoking has been associated 
with increasing the risk of developing both sporadic IPF and familial PF (Baumgartner et al, 1997, 
Steele et al, 2005, Taskar and Coultas, 2006). However, perhaps surprisingly, smoking has been 
associated with increased survival in IPF patients who smoke compared to ex-smokers (King et al, 
2001). 
Viruses and bacteria have the capacity to cause repetitive lung injury by damaging AECs and by causing 
apoptosis (Molyneaux and Maher, 2013). Viral infections have previously been implicated in IPF 
pathology (Table 1.6.4.1) however, results from different studies are conflicting (Ueda et al, 1992, 
Irving et al, 1993, Molyneaux and Maher, 2013). Human herpes viruses (HHV) which includes EBV, 
CMV and HHV-7 may cause IPF by inducing endoplasmic stress and apoptosis in epithelial cells (Isler 
et al, 2005, Lawson et al, 2008), processes which have previously been implicated in the pathogenesis 
of IPF (Maher et al, 2010, Zhong et al, 2011, Tanjore et al, 2012). The role of bacteria is less well known 
in the pathogenesis of IPF although pathogens including Haemophilus, Streptococcus and 
Pseudomonas have been reported in broncheoalveolar lavage fluid (BAL) from IPF patients (Richter et 
al, 2009). Furthermore, progression of IPF has been associated with the presence of Staphylococcus 
and Streptococcus in a recent study looking at biomarkers and whether they can predict IPF disease 
course (Han et al, 2014). Understanding the role of the lung microbiome in the development and 
progression of IPF will help determine to what extent bacteria play a role in the pathogenesis of IPF. 
This could subsequently lead to the development of drugs targeting specific bacteria/microbial 
signatures to help prevent, reverse or inhibit negative features associated with IPF.    
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Environmental agent Role/findings in PF Citations 
Wood dust Accelerates lung function 
decline. 
(Iwai et al, 1994, Hubbard et 
al, 1996, Scott et al, 1990, 
Baumgartner, et al 2000, 
Jacobsen et al, 2008). 
Metal dust Associated with increased 
incidence and mortality.  
(Hubbard et al, 1996, Hubbard 
et al, 2000). 
Silica  Increased risk for developing 
ILD and potentially, IPF. 
(Monso et al, 1990, Taskar 
and Coultas, 2006). 
Sand/stone Increased risk for developing 
ILD and potentially IPF. 
(Taskar and Coultas, 2006). 
Solvents/chemical exposure Increased TGFß and increased 
risk for developing ILD and 
potentially, IPF. 
(Billings and Howard, 1994). 
Livestock/farming Increased risk for ILD and 
potentially, IPF. 
(Scott et al, 1990, Iwai et al, 
1994, Baumgartner et al, 
2000, Gustafson et al, 2007). 
Cobalt Increased risk for developing 
ILD and potentially IPF. 
(Zanelli et al, 1994, Lison et al, 
1996). 
Aluminium Increased risk for developing 
ILD and potentially, IPF. 
(Vallyathan et al, 1982, De 
Vuyst et al, 1986, Jederlinic et 
al, 1990). 
Lead Increased risk for developing 
ILD and potentially, IPF. 
(Figueroa et al, 1992) 
Diesel exhaust Induces fibrosis, increased 
number of inflammatory cells 
in sputa. 
(Hyde et al, 1985, Ädelroth et 
al, 2006). 
EBV Increased in IPF BAL, may 
cause ER stress and epithelial 
apoptosis. 
(Vergnon et al, 1984, Egan et 
al, 1995, Stewart et al, 1999, 
Kelly et al, 2002, Manika et al, 
2007, Calabrese et al, 2013), 
Hepatitis C Conflicting data, higher 
prevalence of Hepatitis C virus 
markers in IPF. 
(Ueda et al, 1992, Arase et al, 
2008). 
Transfusion transmitted viruses 
(TTVs) 
Found in IPF BAL during acute 
exacerbations. 
(Bando et al, 2008, Wootton 
et al, 2011). 
HHVs Potential role in initiation and 
progression of IPF. 
(Tang et al, 2003). 
Haemophilus Increased in IPF BAL. (Richter et al, 2009).  
Streptococcus Increased in IPF BAL. (Han et al, 2014). 
Pseudomonas Increased in IPF BAL. (Richter et al, 2009). 
Staphylococcus Increased in IPF. (Han et al, 2014). 
 
Table 1.6.4.1. Environmental agents potentially involved in the pathogenesis of IPF. Environmental 
agents including smoking, dust exposure and viruses/bacteria have recently been associated with 
increased risk of developing IPF however, no single agent to date has been identified as having a 
causative relationship with IPF.  
 
 
1.6.5. The role of environmental factors in SSc 
Multiple environmental factors have been linked to SSc. These include occupational (Bramwell, 1914, 
Erasmus, 1957, Rodnan et al, 1967, McCormic et al, 2010), infectious (Vaughan et al, 2000, Lunardi et 
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al, 2000, Ferri et al, 2002, Lundari et al, 2006) and non-occupational/non-infectious factors (Thompson 
et al, 2002, Hudson et al, 2011) (Table 1.6.5.1). However, due to many of the studies consisting of 
relatively small sample numbers, it has often been difficult to determine the degree of risk an 
environmental factor has towards SSc development. Silica dust was one of the first environmental 
factors linked with SSc via studying workers with occupations involving high silica exposure such as 
stonemasonry (Bramwell, 1914), gold mining (Erasmus, 1957) and coal mining (Rodnan et al, 1967). A 
review analysing studies published between 1949-2009 found a significant association between silica 
exposure and development of SSc (McCormic et al, 2010). Although there were a number of 
limitations in the study, the strength of the association between silica and SSc appeared stronger in 
males than females, which may be due to increased exposure to silica in males (McCormic et al, 2010). 
The exact mechanisms by which silica dust may cause SSc are unknown, however, the adjuvant effect 
silica displays on antibody production highlights silica's biological plausibility (Uber et al, 1982, Parks 
et al, 2002). Furthermore, mice develop exacerbated autoimmunity and PF following treatment with 
crystalline silica (Brown et al, 2004). Solvents (Aryal et al, 2001) and epoxy resins (Yamakage et al, 
1980) have also been linked with increased risk of developing SSc.  
Multiple bacterial and viral infectious agents have been linked to fibrotic and autoimmune diseases 
(Leroy, 1996, White et al, 1996, Ferri et al, 2002) and there is mounting evidence suggesting bacterial 
and viral infectious agents contribute to the development of SSc, potentially via inducing signalling 
pathways leading to aberrant expression of genes including TGFß (Farina et al, 2014). CMV has been 
implicated in SSc in several studies (Vaughan et al, 2000, Lunardi et al, 2000, Ferri et al, 2002. Lundari 
et al, 2006) and may cause apoptosis of endothelial cells which is a characteristic of SSc (Vaughan et 
al, 2000, Lunardi et al, 2000, Ferri et al, 2002). Furthermore, CMV may also increase apoptosis of 
macrophages (Pandey and LeRoy, 1998) which play important roles in tissue homeostasis (Mosser and 
Edwards, 2008) and activation of CTGF which can drive fibroblast activation and increase fibrosis 
(Inkinen et al, 2005). Another virus, parvovirus B19 (Ferri et al, 2002, Zakrzewska et al, 2009) and the 
bacteria, helicobacter pylori (Yazawa et al, 1998, Kalabay et al, 2002, Radić et al, 2011) have also been 
implicated in the pathogenesis of SSc. 
Non-occupational risk factors such as smoking (Hudson et al, 2011), and alcohol (Thompson et al, 
2002) have also been linked to SSc. Smoking causes vascular damage (Powell et al, 1998) thus likely 
contributes to the vasculopathy seen in SSc. Smoking does not increase the risk of developing SSc but 
does impact on disease severity (Hudson et al, 2011) and reduces overall survival rates (Hissaria et al, 
2011). Overall the impact of a single environmental factor on the development of SSc is likely to be 
modest, based on large populations exposed to many of the environmental agents associated with 
SSc, who do not develop SSc (Broen et al, 2014). Nonetheless, multiple environmental agents may 
contribute to the development of SSc in people who are genetically and/or epigenetically predisposed.  
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Environmental agent Role/findings in SSc Citations 
Silica dust May cause epigenetic modifications. McCormic et al, 2010. 
Vinyl chloride Associated with increased risk of SSc.  Ostlere et al, 1992, Nietert and 
Silver, 2000. 
Solvents Associated with increased risk of SSc.  Aryal et al, 2001   
EBV Induces aberrant innate immune 
response. 
Farina et al, 2014. 
CMV Increased CMV antibodies, may cause 
endothelial apoptosis.  
Pandey and LeRoy, 1998, 
Vaughan et al, 2000, Lunardi et 
al, 2000, Ferri et al, 2002, 
Lundari et al, 2006, Namboodiri 
et al, 2006.  
Helicobacter pylori Increased prevalence, may play a role 
in oesophageal dysfunction.  
Yazawa et al, 1998, Kalabay et 
al, 2002, Radić et a, 2011. 
Table 1.6.5.1. Environmental factors associated with SSc.  
 
1.6.6. The role of genetic factors in IPF 
The variability amongst individuals exposed to fibrogenic agents and the development of fibrosis 
together with evidence from mouse models, where inbred mice have shown different responses to 
fibrogenic agents has previously led to the belief that genetic factors may play a key role in the 
pathogenesis of IPF. Although genetic mutations have been associated with IPF (Table 1.6.6.1), no 
single gene has been causally linked to the disease, which may not be surprising due to the 
heterogeneity often observed between different IPF populations. 
IPF generally occurs sporadically however, in rare cases IPF can occur in a familial form (FIPF). This 
inherited form of IPF is clinically identical to sporadic IPF (Marshall et al, 2000). FIPF studies have 
provided some of the most compelling evidence that genetic factors play a role in the pathogenesis 
of IPF (Steele et al, 2005). FIPF is diagnosed when two or more family members have an IIP (Loyd, 
2003, Steele et al, 2005) accounting for an estimated 0.5-3.7% of all IPF cases (Lawson and Loyd, 2006), 
although recent estimates suggest up to 20% of all IPF cases may be familial (Garcia-Sancho et al, 
2011). Linkage analysis and candidate gene approaches have identified four genes, telomere reverse 
transcriptase (TERT) (Armanios et al, 2007, Tsakiri et al, 2007), telomere RNA component (TERC) 
(Armanios et al, 2007, Tsakiri et al, 2007), surfactant protein C (SFTPC) (Nogee et al, 2001) and 
surfactant protein A2 (SFTPA2) (Wang et al, 2009) which are associated with FIPF. Mutations in the 
TERT gene are apparent in 18% of kindreds with FIPF and 3% in sporadic IPF cases (Armanios et al, 
2007, Tsakiri et al, 2007, Cronkhite et al, 2008, Diaz de Leon et al, 2010). TERT or TERC mutations which 
cause telomere shortening, dramatically increase susceptibility to adult-onset IPF (Tsakiri et al, 2007). 
In sporadic IPF, short telomeres are common in a number of cell types including AECs, lymphocytes 
and granulocytes (Alder et al, 2008) suggesting telomere dysfunction may frequently occur in fibrotic 
lung disease. Furthermore, smoking is strongly associated with familial IP (Steele et al, 2005) and can 
cause shortening of telomere length (Morlá et al, 2006). Telomere length is also influenced by 
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oxidative stress (Von Zglinicki, 2002) which has been linked with PF (Mastruzzo et al, 2002, Kinnula et 
al, 2005, Cheresh et al, 2013) and thus, may explain why lung disease is a common phenotype of 
telomere shortening.  
SFTPC and SFTPA2 mutations are known to causes endoplasmic reticulum (ER) stress (Mulugeta et al, 
2005, Maitra et al, 2010) which has been strongly associated with a number of diseases including FIPF 
and sporadic IPF (Lawson et al, 2011, Tanjore et al, 2012, Kropski et al, 2013). Mutations in the gene 
ATP-binding cassette sub-family A member 3 (ABCA3) have also been identified in children and older 
patients with chronic ILD (Doan et al, 2008, Young et al, 2008, Campo et al, 2014) and some of these 
mutations cause an increase in ER stress (Weichert et al, 2011). ER stress has been linked with 
increased AECII cell death (Mulugeta et al, 2005, Lawson et al, 2008), and generation of a pro-fibrotic 
AEC phenotype via EMT (Zhong et al, 2011, Tanjore et al, 2011) which may explain how ER stress 
contributes to PF.  
A recent genome-wide linkage study of IPF patients identified a single nucleotide polymorphism (SNP) 
in the promoter region of the gene mucin 5B (MUC5B) as being associated with the development of 
FIP and sporadic IPF (Seibold et al, 2011). MUC5B produces the main gel-forming mucin in mucus 
which functions to provide lubrication, hydrate epithelium and act as a barrier against pathogens and 
noxious substances (Bansil and Turner, 2006). Therefore, defective production of mucin may enhance 
susceptibility to environmental cues which may be involved in the pathogenesis of fibrosis. Genome-
wide associated studies (GWAS) have confirmed linkage studies and have also identified a number of 
genes which are associated with increased susceptibility of developing IPF (Mushiroda et al, 2008, 
Fingerlin et al, 2013, Noth et al, 2013). A number of these genes are involved in host defence, cell-cell 
adhesion and DNA repair (Fingerlin et al, 2013). Rare mutations in other genes including IL-1RN which 
encodes the interleukin1 receptor antagonist (IL-1RA) and TGFß1 have also been associated with 
increasing susceptibility to IPF (Whyte et al, 2000, Hutyrová et al, 2002, Xaubet et al, 2003, Riha et al, 
2004, Barlo et al, 2011, Korthagen et al, 2012, Son et al, 2013). 
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Gene Role of gene/effect of mutation Reference 
TERT  Telomere shortening Armanios et al, 2007 
TERC Telomere shortening Armanios et al, 2007 
SFTPC ER stress Kropski et al, 2013 
SFTPA2 ER stress Kropski et al, 2013 
ABCA3 ER stress Campo et al, 2014 
MUC5B Defective mucin  production Seibold et al, 2011 
IL-1RN Imbalance of IL1Ra/IL1b Barlo et al, 2011 
TGFB1 May affect disease progression  Xaubet et al, 2003 
Toll interacting protein 
(TOLLIP) 
Inhibitory adaptor protein Noth et al, 2013 
Signal peptide peptidase 
like 2C (SPPL2C) 
Unknown Noth et al, 2013 
Desmoplakin (DSP) Involved in integrity of lung epithelia Fingerlin et al, 2013 
Dipeptidyl-peptidase 9 
(DPP9) 
Involved in integrity of lung epithelia Fingerlin et al, 2013 
Family with sequence 
similarity 13 member A 
(FAM13A) 
Signal transduction responsive to 
hypoxia 
Fingerlin et al, 2013 
ATPase, class VI, type 11A 
(ATP11A) 
Encodes an integral membrane ATPase Fingerlin et al, 2013 
Oligonucleotide-binding 
fold containing 1 (OBFC1) 
Associated with telomere length Fingerlin et al, 2013 
Table 1.6.6.1. Genetic factors associated with FIPF/IPF. 
 
 
1.6.7. The role of genetic factors in SSc 
Multiple GWAS studies have reported an association of a number of human leukocyte antigen (HLA) 
and  non-HLA genes with SSc susceptibility and/or disease severity (Lambert et al, 2000, Gilchrist et 
al, 2001, Sato et al, 2004, Gladman et al, 2005, Fonseca et al, 2006, Radstake et al, 2010, Allanore et 
al, 2011, López-Isac, 2014) (Table 1.6.7.1). The low prevalence of SSc means there is a lack of multiplex 
families and monozygotic twins with the disease (Assassi and Tan, 2005), although the strongest risk 
factor for developing SSc is a family history of the disease (Englert et al, 1999, Arnett et al, 2001). 
Compared to the general population, there is a 15-19 fold increase in risk of developing SSc if a sibling 
has SSc and a 13-15 fold increase in risk of developing SSc for other first-degree relatives (Arnett et al, 
2001). Although this appears a large increase in risk it only equates to a 0.026% absolute risk of 
developing SSc in the general population and just 1.6% in first-degree relatives (Arnett et al, 2001). 
The prevalence rate of SSc in twins is approximately 4.7% (4.2% in monozygotic; 5.6% in dizygotic) 
(Feghall-Bostwick et al, 2003). Interestingly only two pairs of twins in this study (one monozygotic and 
one dizygotic) were concordant for SSc (Feghall-Bostwick et al, 2003). Although many twins in this 
study were below the typical age on SSc onset, it highlights that genetics are not solely responsible for 
causing SSc. 
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Genes Reference 
TGFß Varga and Pasche, 2009 
B-cell scaffold protein with Ankyrin repeats 1 (BANK1) Dieudé et al, 2009, Rueda et al, 2010 
Chromosome 8 open reading frame 13 B-cell signal 
transducer (C8orf13-BLK) 
Gourth et al, 2010, Coustet et al, 2011 
TNFAIP3 interacting protein 1 (TNIP1) Allanore et al, 2011 
Psoriasis susceptibility 1 candidate 1 (PSORS1C1) Allanore et al, 2011 
Ras homolog gene family, member B (RHOB) Allanore et al, 2011 
PPARG López-Isac, 2014 
CTGF Fonseca et al, 2007 
IL-1ß Mattuzzi et al, 2007 
Interferon regulatory factor 5 (IRF5) Dieudé et al, 2009, Ito et al, 2009, 
Radstake et al, 2010, Sharif et al, 2012 
Signal transducer and activator of transcription 4 
(STAT4) 
Gourh et al, 2009, Tsuchiya et al, 2009, 
Radstake et al, 2010, Yi et al, 2013 
T-box 21 (TBX21) Gourh et al, 2009 
Tumor necrosis factor superfamily member 4 (TNFSF4) Gourh et al, 2010, Bossini-Castillo et 
al, 2010 
Nitric oxide synthase 3 (NOS3) Fatini et al, 2006 
Monocyte chemoattractant protein-1 (MCP-1) Karrer et al, 2005 
Interleukin 23 receptor (IL-23R) Agarwal et al, 2009 
Interleukin 2 (IL-2) Mattuzzi et al, 2007 
Table 1.6.7.1. Genetic factors associated with SSc. 
 
 
1.7. Epigenetic mechanisms and their role in pulmonary fibrosis 
The word 'epigenetics' was first used to link developmental biology with genetics (Holiday, 2006). 
Epigenetics is now defined as the study of heritable changes in gene expression that cannot be 
attributed to changes in the DNA sequence. Types of epigenetic mechanisms include, DNA 
methylation, histone modifications (acetylation, phosphorylation and methylation) and non-coding 
RNAs (microRNAs, siRNAs and piRNAs). All these mechanisms function together to modulate 
chromatin structure and thus regulate gene transcription. Mounting evidence suggests defective 
epigenetic mechanisms contribute to a variety of complex diseases including cancers (Ngalamika et 
al, 2012, Jiang et al, 2013), autoimmune diseases (Quintero-Ronderos and Montoya-Ortiz, 2012) and 
fibrotic diseases (Sanders et al, 2012, Rabinovich et al, 2012, Komatsu et al, 2012, Tampe and Zeisberg, 
2013, Zhao et al, 2013, Yang et al, 2014,). Data regarding the role of epigenetic regulatory mechanisms 
in IPF and SSc including DNA methylation (Sander et al, 2012, Rabinovich et al, 2012, Huang et al, 2014, 
Yang et al, 2014), microRNAs (Pandit et al, 2010) and histone modifications (Huang et al, 2013) is still 
in its infancy. However, a number of genes that are potentially regulated epigenetically have been 
identified and are likely to play a role in the pathogenesis of IPF and SSc. 
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1.7.1. MicroRNAs and their role in fibrosis 
MicroRNAs (miRs) are endogenous, small, non-coding RNAs approximately 21 nucleotides in length. 
They are evolutionarily conserved and are responsible for mRNA cleavage, transcriptional repression 
and mRNA destabilisation (Ciechomska et al, 2014). MiRs also play an important role in regulating cell 
proliferation, differentiation, tissue repair and tissue development (Hwang and Mendell, 2006). There 
are approximately 1900 miRs currently identified in humans (Kozomara and Griffiths-Jones, 2011), 
each of which is expressed in a tissue-type and cell-type specific manner and has multiple gene targets 
(Bartel, 2004, Friedman et al, 2009). In a fibrosis context, several key pro-fibrotic molecules are 
regulated by multiple miRs (Duisters et al, 2009, Mann et al, 2010, Zhu et al, 2013) as well as multiple 
ECM proteins (Muth et al, 2010, Maurer et al, 2010, Cushing et al, 2011) and signalling pathways, 
including TGFß/CTGF (Leask and Abraham, 2006). TGFß is a profibrotic cytokine and a central mediator 
in fibrosis (Leask and Abraham, 2004). It can induce CTGF, which can in turn feedback to enhance TGFß 
signalling as well as induce multiple other pro-fibrotic mediators including VEGF, Wnts and integrins 
(Leask and Abraham, 2006).  To date, ten miRs are known to regulate TGFß/CTGF signalling (Vettori et 
al, 2012) including miR-18a, miR-19a and miR-19b, which have been shown to regulate CTGF in liver 
and cardiac fibrosis (Kodama et al, 2011, van Almen et al, 2011) and miR-133 and miR-30c which can 
regulate CTGF in cardiac fibrosis (Duisters et al, 2009). Other studies have shown the miR-200 family 
may play both direct and indirect roles in fibrogenesis by regulating TGFß2 expression (Wang et al, 
2011) and by regulating EMT which could potentially play an important role in fibrosis (Gregory et al, 
2008, Wang et al, 2011). However, controversy surrounds the role of EMT in PF as there is evidence 
suggesting multiple stromal cell populations contribute to PF without evidence for EMT (Rock et al, 
2011). 
 
1.7.2. Role of miRs in IPF and SSc 
There is limited data regarding the role of miRs in IPF, however a recent study suggested that 
compared to control lung tissue, 10% of all miRs have significantly altered expression in IPF lung tissue 
(Table 1.7.2.1) (Pandit et al, 2010, Pandit et al, 2011). The miR-17-92 cluster which encodes 6 miRs 
(miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1) has also been associated with IPF 
(Dakhlallah et al, 2013). MiR-17-92 is down-regulated in IPF lung tissue and miR-19b and miR-20a 
decrease in proportion to disease severity (Dakhlallah et al, 2013). The down-regulation of these miRs 
also correlates with increased expression of VEGF, CTGF, granulocyte macrophage colony-stimulating 
factor (GM-CSF), thrombospondin 1 (TSP-1) and TGFß which have all previously been associated with 
IPF (Voelkel et al, 2006), (Allen et al, 1999, Pan et al, 2001, Allen et al, 2001, Kono et al, 2011), (Moore 
et al, 2000), (Ide et al, 2008), (Khalil et al, 1991). Interestingly, the miR-17-92 cluster is methylated and 
a number of miRs from this cluster appear to be directly regulated by DNA methyltransferase 1 
(DNMT1) (Dakhlallah et al, 2013).  
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miR Tissue Expression in IPF Pro-/anti-fibrotic Reference 
Let-7d Lung Down-regulated Anti Pandit et al, 2010 
miR-21 Lung Up-regulated Pro Liu et al, 2010, Li et al, 
2013. 
miR-154 Lung fibroblasts Up-regulated Pro Milosevic et al, 2012.  
miR-29 Lung, lung 
fibroblasts 
Down-regulated Anti Cushing et al, 2011 
miR-26a Lung  Down-regulated Anti Liang et al, 2014 
miR-17-92 
cluster 
Lung, lung 
fibroblasts 
Down-regulated Anti Dakhlallah et al, 2013 
miR-199a-5p Fibroblasts Up-regulated Pro Lino Cardenas et al, 2013. 
Table 1.7.2.1. Dysregulated miRs in IPF. Which tissue the specified miR was studied in, miR expression 
compared to control groups and whether the miR is associated with being pro- or anti-fibrotic is 
shown.  
 
 
Multiple pro-fibrotic and anti-fibrotic miRs are also dysregulated in SSc skin (Li et al, 2012, Zhu et al, 
2012) and fibroblasts cultured ex vivo (Honda et al, 2012), compared to healthy controls (Table 
1.7.2.2). Subsequent studies have shown miRs may play an integral role in the pathogenesis of SSc by 
modulating multiple fibrosis-related genes including collagens, MMPs and integrins (Broen et al, 
2014).  
 
miR Tissue Expression in SSc Pro/anti-fibrotic Reference 
miR-30b Serum, Skin Down-regulated Anti Tanaka et al, 2013 
Let-7a Serum, Skin 
fibroblasts 
Down-regulated Anti Makino et al, 2013 
miR-29a/b/c Skin Down-regulated Anti Bhattacharyya et al, 
2013, Ciechomska et al, 
2014 
Let-7g Skin Up-regulated Unknown Li et al, 2012 
miR-142-3p Serum Up-regulated Unknown Makino et al, 2012 
miR-129-5p Skin fibroblasts Down-regulated Anti Nakashima et al, 2012 
miR-150 Skin fibroblasts Down-regulated Anti Honda et al, 2013 
miR-196a Skin fibroblasts Down-regulated Anti Honda et al, 2012, Honda 
et al, 2013, Wang et al, 
2013, Makino et al, 2013. 
miR-145 Skin Down-regulated Unknown Li et al, 2012, Zhu et al, 
2012. 
miR-125b Skin Down-regulated Unknown Li et al, 2012, Zhu et al, 
2012. 
miR-92a Skin fibroblasts, 
serum 
Up-regulated Pro Sing et al, 2012 
miR-206 Skin Down-regulated Unknown Li et al, 2012, Zhu et al, 
2012. 
miR-21 Skin fibroblasts, 
Skin 
Up-regulated Pro Zhu et al, 2013 
miR-7 Skin fibroblasts, 
skin 
Up-regulated Anti Kajihara et al, 2012 
Table 1.7.2.2. Dysregulated miRs in SSc. Which tissue the specified miR was studied in, miR expression 
compared to controls and whether the miR is associated with being pro- or anti-fibrotic is shown.  
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1.7.3. The role of DNA methylation  
DNA methylation is an epigenetic modification essential for maintaining genomic stability, specifying 
cell fate, genomic imprinting (Li et al, 1993),  X-chromosome inactivation and stabilisation (Heard et 
al, 1997, Sado et al, 2000), protection against retroviruses and transposons (Walsh et al, 1999 and 
regulating gene expression (Bird, 2002). The first suggestion that DNA methylation could have an 
important biological function was in 1969 by Griffith and Mahler. In 1975, two independent papers by 
Riggs and Holliday and Pugh, suggested changes in DNA methylation could directly activate or silence 
gene expression and could be inherited through somatic cell divisions (Bird, 1978). 
Cytosine nucleotides can be methylated at the fifth position on their pyrimidine ring which was first 
described in 1948 (Hotchkiss, 1948). Methylation occurs via DNA methyltransferase (DNMT) enzymes 
which use s-adenosyl-L-methionine (SAM) as a methyl donor to covalently attach a methyl group at 
this position (Adams and Burdon, 1982) (Figure 1.7.3.1). Cytosine nucleotides which directly precede 
guanine nucleotides are known as CpG dinucleotides (where 'p' represents the phosphate bond 
between cytosine and guanine). DNA methylation occurs almost exclusively in the symmetrical CG 
context and affects approximately 70-80% of all CpGs (Ehrlich et al, 1982, Bird et al, 1985). Non-CpG 
methylation can occur in rare circumstances but its function is unknown (Ramsahoye et al, 2000, 
Haines et al, 2001, Dodge et al, 2002, Ziller et al, 2011). 
 
H CH3
DNMT
SAM SAH 
Cytosine 5-methylcytosine
 
Figure 1.7.3.1. Cytosine conversion to 5-methylcytosine. A methyl group from S-adenosyl-L-
methionine (SAM) is transferred to cytosine at the fifth position of its pyrimidine ring via DNA 
methyltransferase (DNMT) enzymes. This forms 5-methylcytosine and S-adenosyl-L-homocysteine 
(SAH). 
 
 
Increased methylation is strongly associated with the formation of heterochromatin and 
transcriptional silencing (Keshet et al, 1986, Reik et al, 2001). Methylated cytosine, referred to as 5-
methylcytosine (5-mC), is found in approximately 1.5% of genomic DNA (Lister et al, 2009) and acts as 
a ligand for methyl-binding proteins (MBPs). There are currently 15 defined MBPs all of which contain 
a methyl-binding domain that exclusively binds to methylated CpGs (mCpGs) (Parry and Clarke 2011). 
The binding of MBPs to mCpGs causes recruitment of transcriptional repressors, HDACs and 
chromatin-modifying complexes which induce the formation of heterochromatin, a tightly packed 
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form of chromatin. These mechanisms cause transcription to be repressed resulting in gene silencing 
(Fuks, 2005) (Figure 1.7.3.2). CpG frequency in the human genome occurs less frequently than 
expected by random chance as methylcytosine has the ability to spontaneously deaminate to thymine 
(Bird, 1980). However, small genomic regions (approximately 1kb long) which contain a multitude of 
CpG dinucleotides in GC-rich regions exist and are predominantly unmethylated (Antequera and Bird, 
1993). These regions are termed CpG islands (CGIs), and are located in approximately 70% of all gene 
promoters (Saxonov et al, 2006). Although promoter-associated CGIs tend to be unmethylated, in 
specific tissues or during development, a differential methylated state may be adopted (Li, 2002, Song 
et al, 2005).  
 
Figure 1.7.3.2. Diagram of how methylation reduces gene expression. Unmethylated cytosine and 
acetylated histones are associated with transcriptional activity. Acetylation of histones allows 
chromatin to be loosely packed. Once cytosine becomes methylated, methyl-binding proteins (MBPs) 
can bind and recruit histone deacetylases (HDACs). HDACs remove the acetyl groups which induces 
the formation of densely packed chromatin (heterochromatin). This physically blocks transcription 
factors binding to receptors and is most commonly associated with repressed gene transcription.  
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1.7.4. Location of CpG methylation 
CGIs usually remain unmethylated to facilitate transcription, whereas increased methylation within 
some CGIs can block transcription (Deaton and Bird, 2011). Increased methylation of the gene body is 
believed to block aberrant transcription from within the gene, thus functioning to avoid the 
production of truncated forms of the protein although multiple studies have shown that for some 
genes, intragenic methylation correlates with increased transcription (Zilberman et al, 2007, Rauch et 
al, 2009, Kulis et al, 2013). Research into the role of DNA methylation in regulating gene expression 
has predominantly focused on CpG methylation with emphasis on CGIs located in promoter regions 
of genes. CGI methylation in promoter regions has been strongly linked to gene silencing in numerous 
pathologies (Esteller and Herman, 2001, Egger et al, 2004, Robertson, 2005), although the role of 
methylation in CGIs distal to promoter regions and its ability to regulate transcription is poorly 
understood (Illingworth et al, 2010).  
CGIs that are located remotely from defined promoter regions have been coined 'orphan CGIs' and 
are more readily methylated than CGIs within promoter regions (Illingworth et al, 2010). Orphan CGIs 
have the characteristics of functional promoters suggesting they can regulate gene expression and 
may be associated with novel transcripts that have a regulatory role (Illingworth et al, 2010). DNA 
methylation outside CGIs could be equally as important in regulating transcriptional activity (Irizarry 
et al, 2009). Irizarry et al recently demonstrated the majority (76%) of methylation in human colon 
cancer cells occurred at areas a short distance away from CGIs, coined 'CpG shores' (Irizarry et al, 
2009). These regions exist up to 2kb away from a CGI and have been shown to strongly correlate with 
gene expression (Irizarry et al, 2009). Flanking CpG island shores are CpG shelves which occur 2kb-4kb 
away from CGIs (Irizarry et al, 2009). CpGs located further than 4kb away from a CGI are said to be 
located in open sea regions (Figure 1.7.4.1). To what effect DNA methylation has on gene expression 
at CGIs, shores, shelves and open sea regions in IPF and other fibrotic diseases remains unknown. 
  
 
Figure 1.7.4.1. The different regions of a gene in which CpG methylation can occur. CpG shore regions 
(up to 2kb away) flank CpG islands. CpG shelf regions (up to 2kb away) flank CpG shores. Open sea 
regions are further than 4kb away from CpG islands.  
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1.7.5. The role of DNA methyltransferases  
As previously mentioned, DNMTs catalyse the formation of 5-mC by transferring a methyl group from 
S-adenosyl-L-methionine to the C5 position of cytosine residues. DNMT1, 2, 3A, 3B and 3L are the 
main DNMTs that belong to the DNMT family, although only DNMT1, DNMT3A and DNMT3B have 
methyltransferase activity. The first DNMT to be biochemically characterised was DNMT1 and is 
considered the primary maintenance DNA methyltransferase. The primary function of DNMT1 is to 
methylate newly synthesised DNA during the S phase of the cell cycle (Bird, 2007). DNMT1 recognises 
and has preference for hemimethylated DNA (methylated on one strand) rather than unmethylated 
DNA which stops previously unmethylated CpGs becoming methylated during DNA replication, thus 
maintaining methylation patterns during DNA replication (Okano et al, 1999, Bestor, 2000, Jones and 
Baylin, 2007). DNMT1 was originally believed to be the sole DNMT responsible for maintenance 
methylation, however, more recently it has been shown that DNMT3A and DNMT3B also play an 
important role (Liang et al, 2002, Chen et al, 2003, Jeong et al, 2009). DNMT1 may also act as a de 
novo methylase at sites of homologous recombination repair (Cuozzo et al, 2007) and can interact 
with HDACs (Fuks et al, 2000, Rountree et al, 2000, Fuks et al, 2001), other DNMTs, MBPs (Kimura and 
Shiota, 2003) and genes including ubiquiting-like with PHD and ring finger domains 1 (UHRF1) (Qian 
et al, 2008), proliferating cell nuclear antigen (PCNA) (Chuang et al, 1997) and DNA methyltransferase 
1-associated protein 1 (DMAP1) (Rountree et al, 2000).  
Like DNMT1, DNMT3A and DNMT3B are essential for embryonic development (Okano et al, 1999). 
DNMT3A and DNMT3B are the catalytically active DNMTs in the DNMT3 family. DNMT3L is 
catalytically inactive due to the mutation of specific catalytic residues (Pacaud et al, 2014). However, 
DNMT3L is an important co-factor for DNMT3A and DNMT3B which enhances de novo methylation 
and has recently be shown to interact with multiple transcription factors (Pacaud et al, 2014). The 
interaction of DNMT3L with specific transcription factors allows DNMT3A and DNMT3B to interact at 
specific sites on these genes, which are otherwise inaccessible (Pacaud et al, 2014). DNMT3A and 
DNMT3B are considered de novo DNMTs that are essential for the establishment of DNA methylation 
patterns during mammalian development and in germ cells (Okano et al, 1999). They do not show any 
preference for hemimethylated or unmethylated DNA (Okano et al 1999) and whilst both are de novo 
methylases, they also have important functions in maintenance methylation (Liang et al, 2002, Chen 
et al, 2003, Jeong et al, 2009). DNMT2 (renamed TRDMT1) plays an important role in catalysing 
cytosine methylation in RNA substrates (Goll et al, 2006), methylation of tRNAs (Schaefer et al, 2010) 
and RNA-mediated epigenetic heredity (Kiani et al, 2013). However, the exact biological functions of 
DNMT2/TRDMT1 remain poorly understood (Figure 1.7.5.1).  
 
 
 
49 
 
Catalytically active 
DNA DNMTs 
Maintenance
methylation
De novo
methylation
RNA
methylation
Methylation of 
hemimethylated 
cytosines during 
replication
Methylation
During embryonic 
development
Methylation of 
RNA substrates/
tRNAs
DNMT1 DNMT3a DNMT3b
DNMT2
(TRDMT1)
Catalytically inactive 
DNA DNMTs 
Co-factor for de novo
methylation
DNMT3L
Important for 
facilitating de 
novo methylation 
and germ cell 
development 
RNA 
methyltransferase
 
Figure 1.7.5.1. The role of different DNMTs. DNMT1 acts primarily to maintain genomic methylation 
patterns although it can also act as a de novo methyltransferase. DNMT3A and DNMT3B are primarily 
de novo methyltransferases but can also play a role in maintenance of DNA methylation. DNMT3L is 
a co-factor for DNMT3A and DNMT3B and can direct both DNMT3A and DNMT3B to specific sites in 
multiple transcription factors. DNMT2/TRDMT1 catalyses cytosine methylation in RNA substrates and 
tRNAs. 
 
 
1.7.6. DNA demethylation  
Although DNA methylation is relatively stable, as compared to histone marks, loss of methylation and 
DNA demethylation have been observed in a number of different biological contexts (Kohli and Zhang, 
2013). DNA demethylation can be active or passive. Passive DNA demethylation requires DNA 
replication and occurs by successive rounds of DNA replication in the absence of the required DNA 
methylation machinery such as DNMTs or SAM (Kohli and Zhang, 2013). Active demethylation does 
not require DNA replication to remove 5-mC. Instead, enzymes belonging to the ten-eleven 
translocation (TET) family oxidise 5-mC to form 5-hydroxymethylcytosine (5-hmC) (Tahiliani et al, 
2009, Ito et al, 2010). 5-hmC represents a key intermediate in active demethylation and can be further 
oxidised to form 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) (Ito et al, 2011, He et al, 2011). 
These oxidised bases are removed by thymine DNA glycosylase-triggered base excision repair (TDG-
BER) to reform unmethylated cytosine (Zhu, 2009, He et al, 2011, Kohli and Zhang, 2013) (Figure 
1.7.6.1). Interestingly, deletion of TDG does not affect demethylation in zygotes, suggesting other 
mechanisms exist for removing oxidised substituents (Guo et al, 2014). It has been suggested that 
DNMTs could theoretically function in demethylation by promoting the removal of oxidised 
substituents at the 5-C position of the pyrimidine ring although this has not been experimentally 
confirmed (Kohli and Zhang, 2013). 
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Nucleotide-based DNMT inhibitors such as 5-Aza-2’-deoxycytidine (5-Aza) can also act to cause 
demethylation in a DNA replication-dependant manner. 5-Aza is a chemical analogue of cytosine and 
can incorporate itself into DNA and bind to DNA methyltransferase enzymes which inhibits their 
activity (Christman, 2002). It has also been suggested that HDAC inhibitors can indirectly reverse CpG 
methylation by inhibiting ERK signalling which causes down-regulation of DNMT1 (Sarkar et al, 2011). 
Cytosine methylation is therefore reversible by either biochemical or biological manipulation and 
represents an attractive and exciting prospect for treating diseases in which aberrant DNA 
methylation plays an important pathological role.  
 
 
Figure 1.7.6.1. Active demethylation by TET enzymes TDG-triggered base excision repair. Cytosine 
(5-C) is converted to 5-methylcytosine (5-mC) by DNMTs. 5-mC is then converted to 5-
hydroxymethylcytosine (5-hmC) by TET enzymes. 5-hmC can be converted by iterative oxidation to 5-
formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) which can both be converted back to 
unmethylated cytosine by thymine DNA glycosylase-triggered base excision repair (TDG-BER). 
(Redrawn and adapted from Kohil and Zhang, 2013). 
 
 
51 
 
1.7.7. Modulation of DNA methylation 
Factors including drugs (Christman, 2002, Nielsen et al, 2009), alcohol (Garro et al, 1991, Tao et al, 
2011, Philibert et al, 2013), nutrition (Dominguez-Salas et al, 2014), age (Teschdorff et al, 2010, Bell 
et al 2012, Jung and Pfeifer, 2015), gender (Boks et al, 2009, Zhang et al, 2011, Tapp et al, 2013), 
smoking (Breitling et al, 2011, Lee and Pausova, 2013) and stress (Roth et al, 2009) can all influence 
and modulate methylation and as research continues to advance, this list is likely to become much 
larger (Figure 1.7.7.1). Alcohol can induce DNA methylation changes in sperm (Ouko et al, 2009), 
embryos (Garro et al, 1991, Wolff et al, 1998) and the brain (Otero et al, 2012) and can also disrupt 
enzymes (such as DNMTs) involved in methionine metabolism (Barak et al, 1987, Garro et al, 1991, 
Barak et al, 1993, Halsted et al, 1996, Lu et al, 2000). Methionine is a precursor to SAM which acts as 
a methyl donor in multiple reactions and plays an essential role in DNA methylation, thus changes to 
methionine metabolism can directly affect SAM-dependent methylation reactions. Alcohol may 
reduce absorption of folate which is also a key component of the methionine-homocysteine cycle 
(Halsted et al, 2002). There is strong evidence that folic acid is important in epigenetic programming 
(Steegers-Theunissen et al, 2009, Akchiche et al, 2012, Guéant et al, 2013) and maternal nutrition at 
conception has been associated with epigenetic alterations (Dominguez-Salas et al, 2014).   
Cigarette smoke can modulate DNMT1 expression (Lee and Pausova, 2013) and induce hypoxia, which 
in turn leads to hypoxia-induced factor 1A (HIF-1A)-dependent up-regulation of methionine 
adenosyltransferase 2A (Suter et al, 2011). This enzyme is involved in the synthesis of SAM (Liu et al, 
2011), thus smoking reduces methyl group availability. Cigarette smoke also contains carcinogens 
such as arsenic, chromium and nitrosamines which cause double-stranded breaks in DNA (Huang et 
al, 2012). DNMT1 is recruited to these repair sites (Mortusewicz et al, 2005) and can methylate 
adjacent CpGs (Cuozzo et al, 2007). A number of studies have identified smoke-related changes in 
DNA methylation (Breitling et al, 2011, Monick et al, 2012, Shenker et al, 2012, Sun et al, 2013, Besingi 
and Johansson, 2014, Dogan et al, 2014, Harlid et al, 2014, Elliott et al, 2014, Guida et al, 2015) and 
studies on women who smoke during pregnancy have shown genome-wide (Suter et al, 2011) and 
gene-specific (Maccani et al, 2013) changes in methylation. Furthermore, a recent study has shown 
that some CpGs can revert back to methylation states typical of non-smokers after smoking cessation, 
whereas other CpG sites remain differentially methylated even after more than 35 years smoking 
cessation (Guida et al, 2015).  
Aging has been associated with altered methylation in multiple species (Vanyushin et al, 1973, Wilson 
et al, 1987, Richardson, 2003) and multiple studies have shown genes and genomic regions which 
either get hypermethylated or hypomethylated with age (Teschdorff et al, 2010, Bell et al, 2012). 
Global hypomethylation has been reported in old age (Fuke et al, 2004, Fraga and Esteller, 2007, Heyn 
et al, 2012) although CpG islands tend to gain methylation with age (Calvanese et al, 2009). It has also 
been shown that some CpGs have a linear change in methylation with age (Hannum et al, 2013), 
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however, it is unknown how epigenetic modifications including DNA methylation are regulated during 
aging.  
 
 
Figure 1.7.7.1. Factors which modulate DNA methylation. DNA can be influenced by multiple factors 
including, diet, lifestyle, drugs, stress, age and sex.  
 
 
1.7.8. Differences in male and female methylation 
As previously mentioned, DNA methylation plays an important role in genomic imprinting and X-
chromosome inactivation. Genomic imprinting is a mechanism which determines the expression of a 
gene based on its parent of origin (Sharp et al, 2011). Either the paternal or maternal allele is 
hypermethylated which leads to monoallelic expression (Sharp et al, 2011). The epigenetic marks of 
imprinted genes are established in the male or female germline and maintained after fertilisation and 
during development (Kelsey et al, 2007, Ideraabdullah et al, 2008). Genomic imprinting is essential for 
multiple processes including foetal development and somatic differentiation (Reik et al, 2003).  
X-chromosome inactivation is a mechanism that equalises the expression of sex-linked genes between 
males and females (Lyon, 1962) and results in silencing the majority of genes on one of the two X-
chromosomes in each somatic cell of females (Carrel and Willard, 2005, Sharp et al, 2011). It has been 
shown that methylation profiles of human active and inactive X-chromosomes exist between males 
and females (Sharp et al, 2011). Furthermore, the majority of CpG sites on X-chromosomes in primates 
such as great apes show increased methylation in females compared to males which is consistent with 
the role of methylation in X-inactivation (Hernando-Herraez et al, 2013).  
In the context of healthy individuals, it has previously been shown that male and female cells have 
different methylation patterns (Sarter et al, 2005, Liu et al, 2010, Hall et al, 2014), however, the effects 
of sex on genome-wide DNA methylation is poorly understood. Liu et al, (2010) studied the effects of 
sex on genome-wide methylation using saliva from humans and showed that the influence of sex on 
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methylation was CpG site-specific (Liu et al, 2010). Xu et al, showed sex-specific methylome profiles 
in the human prefrontal cortex (Xu et al, 2014). For some genes sex has been shown to be as strong 
an indicator of methylation as age (Sartar et al, 2005). It has also been shown that age as well as sex 
affects DNMT3B expression in human liver samples (Xiao et al, 2008). Females have significantly higher 
expression of DNMT3B which could in turn, influence global DNA methylation levels (Xiao et al, 2008). 
During early human embryo development, genome-wide methylation in male pronuclei is decreased 
compared to female pronuclei, at the end of the zygotic stage (Guo et al, 2014). Furthermore, human 
male foetuses show decreased methylation of multiple immune response genes compared to females 
(Flanagan, 2014). In mice, primordial germ cells have different methylation patterns in males and 
females during development (Kobayashi et al, 2013). Furthermore, multiple genes in mouse hybrid 
strains have altered methylation between males and females (Orozco et al, 2014).  
In a disease context, it is often the case that one sex has a greater predisposition or tendency to be 
affected by a specific disease such as in IPF, which affects males more than females (Scott et al, 1990, 
Iwai et al, 1994, Coultas et al, 1994, Mannino et al, 1996, Johnston et al, 1997, Gribbin et al, 2006, Han 
et al, 2008, Nalysnyk et al, 2012) and SSc, which affects more females than males (Varga and Abraham, 
2007). In many cases gene expression profiles are different between healthy and diseased patients. 
Genetic factors alone cannot explain these differences suggesting a role for epigenetic mechanisms 
such as DNA methylation, which has been shown in diseases such as familial breast cancer (Pinto et 
al, 2013) however, there are very few studies highlighting the role of methylation in sex-biased 
diseases.  
 
1.7.9. Role of DNA methylation in disease 
Defective DNA methylation in mammals is embryonic lethal highlighting its biological importance (Li 
et al, 1992, Okano et al, 1999). Mounting evidence suggests that DNA methylation has an important 
regulatory role in a growing number of diseases. In 1983 it was first demonstrated that genomes of 
cancer cells were hypomethylated compared to healthy cells (Feinberg and Vogelstein, 1983, Feinberg 
and Tycko, 2004). Aberrant DNA methylation is now associated with multiple different cancers (Ting 
et al, 2006) including ovarian (Ahluwalia et al, 2001) colon (Nakamura and Takenaga, 1998) and lung 
(Esteller et al, 2001, Zöchbauer-Müller et al, 2002). Aberrant DNA methylation has also been linked to 
a number of neurodegenerative diseases including Alzheimer's disease (Siegmund et al, 2007, 
Mastroeni et al, 2009, Sung et al, 2011, Chouliaras et al, 2013), Parkinson's disease (Jowaed et al, 2010, 
Matsumoto et al, 2010) and Huntington's disease (Thomas et al, 2013) and autoimmune diseases 
including systemic lupus erythematosus (Lu et al, 2002, Lu et al, 2007, Javierre et al, 2010), RA (Kim et 
al, 1996, Fu et al, 2011), multiple sclerosis (Mastronardi et al, 2007) and SSc (Wang et al, 2006, Jüngel 
et al, 2011) and fibrotic diseases including liver fibrosis (Komatsu et al, 2012), kidney fibrosis (Bechtel 
et al, 2010) and IPF (Sanders et al, 2012, Rabinovich et al, 2012, Huang et al, 2014, Yang et al, 2014).  
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Aberrant expression of DNMTs are also associated with disease. Loss of imprinting and aberrant X-
chromosome inactivation are common manifestations with mutations or loss of expression of DNMT1 
(Li et al, 1993). Neurodegenerative diseases (Desplats et al, 2011, Klein et al, 2011, Winklemann et al, 
2012), cancers (Vogelstein et al, 2013) and a number of genetic disorders have also been associated 
with aberrant expression of DNMT1 (Robertson, 2005, Feinberg, 2007). Mutations in the DNMT3B 
gene cause a rare autosomal disease called immunodeficiency, centromere instability, facial 
abnormalities syndrome (Okano et al, 1999, Hansen et al, 1999). Mutations in DNMT3B has also been 
associated with hypomethylation of multiple X-linked genes (Li, 2002) and increased expression of 
DNMT3B has been linked to ischemic heart disease (Watson et al, 2014). Increased expression of both 
de novo DNMTs (DNMT3A and DNMT3B) has also been shown in IPF lung tissue (Sanders et al, 2012) 
which may have an effect on expression and methylation patterns in IPF, however they do not appear 
to affect global DNA methylation levels (Sanders et al, 2012). 
 
1.7.10. The role of DNA methylation in IPF  
The role of DNA methylation in the pathogenesis of IPF is poorly understood. Currently, three studies 
exist looking at global DNA methylation in human lung tissue (Sanders et al, 2012, Rabinovich et al, 
2012, Yang et al, 2014). These studies have shown multiple genes in IPF with altered methylation, 
some of which inversely correlate with gene expression (Sanders et al, 2012 and Rabinovich et al, 
2012, Yang et al, 2014). However, lung tissue contains multiple distinct cell types, thus making it 
impossible to determine cell-specific changes in methylation. The use of lung tissue could also 
potentially cause over or under estimation of methylation changes due to the multiple different cell 
types. Only one study exists that looks at global DNA methylation levels in fibroblasts (Huang et al, 
2014). This study identified multiple genes that have altered methylation in IPF lung fibroblasts but 
was unable to accurately determine what effect the observed changes in DNA methylation had on 
gene expression as they did not use expression data from the same cell lines (Huang et al, 2014). Other 
studies have focused on gene-specific DNA methylation in IPF lung fibroblasts and have provided 
evidence that DNA methylation in promoter regions of genes can directly regulate their expression. 
These genes include THY-1 (Sanders et al, 2008, Robinson et al, 2012), Prostaglandin E receptor 2 
(PTGER2) (Huang et al, 2010), P14 alternative reading frame (P14ARF) (Cisneros et al, 2012) and miR-
17-92 (Dakhlallah et al, 2013) all of which have hypermethylation which corresponds with reduced 
gene expression (Table 1.7.10.1).  
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Gene Tissue Methylation  Expression  Reference 
THY1 Lung fibroblasts Hypermethylated Decreased Sanders et al, (2008) 
P14ARF Lung fibroblasts Hypermethylated Decreased Cisneros et al, (2012) 
PTGER2 Lung fibroblasts Hypermethylated Decreased Huang et al, (2010) 
miR-17-92 Lung tissue  
Lung fibroblasts 
Hypermethylated Decreased Dakhlallah et al, (2013) 
Multiple Lung fibroblasts Hyper and hypo 
methylation 
Increased and 
decreased 
Huang et al, (2014) 
Cyclin-dependent 
kinase 4 inhibitor B 
(CDKN2B) 
Lung fibroblasts Hypermethylated Decreased Huang et al, (2014) 
Caspase recruitment 
domain family, 
member 10 (CARD10) 
Lung fibroblasts Hypermethylated Decreased Huang et al, (2014) 
O-6-methylguanine-
DNA 
methyltransferase 
(MGMT) 
Lung fibroblasts Hypomethylated Increased Huang et al, (2014) 
Multiple Lung tissue Hyper and hypo 
methylation 
Increased and 
decreased 
Sander et al, (2012), 
Rabinovich et al, (2012), 
Yang et al, (2014) 
Table 1.7.10.1. Summary of DNA methylation alterations in IPF. The name of the genes studied, the 
source of tissue/cell used, and the methylation/expression state compared with controls is shown.  
 
 
1.7.11. The role of DNA methylation in SSc  
In peripheral blood mononuclear cells derived from SSc patients, DNA methylation patterns of genes 
on the X chromosome are different in monozygotic twins which has been proposed to affect 
susceptibility to SSc (Selmi et al, 2012). Global DNA methylation levels are decreased in SSc CD4+ T 
cells and a number genes have increased expression (Lei et al, 2009, Lian et al, 2012, Jiang et al, 2012) 
(Table 1.7.11.1). In contrast, skin fibroblasts show global hypermethylation and decreased expression 
of DNMT1, Methyl-CpG binding domain protein 1 (MBD1) and Methyl-CpG binding protein 2 (MeCP2) 
(Wang et al, 2006). Furthermore, FLI1 (Wang et al, 2006) and two Wnt antagonists: Dickkopf-related 
protein 1 (DKK1) and Secreted frizzled-related protein 1 (SFRP1) (Dees et al, 2013) are 
hypermethylated and correlate with decreased expression. Treatment with a DNMT inhibitor (5-Aza) 
restores expression of DKK1 and SFRP1, inhibits Wnt signalling and ameliorates experimental fibrosis 
(Dees et al, 2014) suggesting DNA methylation plays an important role in Wnt signalling in SSc. Bone 
morphogenetic protein receptor type II (BMPR2), a gene with important functions in vascular cell 
proliferation and apoptosis has been shown to be hypermethylated and have decreased expression in 
microvascular endothelial cells (MVECs) (Wang et al, 2013). This could explain the increased apoptosis 
of MVECs in SSc which is seen in all affected organs (Sgonc et al, 1996). In the context of pulmonary 
fibrosis associated with SSc, to the author's knowledge, there are no studies examining DNA 
methylation from SSc-PF lung tissue or lung fibroblasts at a gene-specific or global level.    
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Gene Tissue Methylation  Expression  Reference 
Cluster of differentiation 
40 ligand (CD40LG) 
CD4+ T-cells Hypomethylated Increased Lian et al, (2012) 
Cluster of differentiation 
70 (CD70) 
CD4+ T-cells Hypomethylated Increased Jiang et al, (2012) 
DNMT1 
MBD3 
MBD4 
CD4+ T-cells 
CD4+ T-cells 
CD4+ T-cells 
Hypomethylated 
Hypomethylated 
Hypomethylated 
Increased 
Increased 
Increased 
Lei et al, (2009) 
Lei et al, (2009) 
Lei et al, (2009) 
DNMT1 
MBD1 
MeCP2 
Skin fibroblasts 
Skin fibroblasts 
Skin fibroblasts 
Hypermethylated 
Hypermethylated 
Hypermethylated 
Decreased 
Decreased 
Decreased 
Wang et al, (2006) 
Wang et al, (2006) 
Wang et al, (2006) 
FLI1 Skin fibroblasts Hypermethylated Decreased Wang et al, (2006) 
DKK1 
 
SFRP1 
Skin fibroblasts PBMCs 
Skin fibroblasts PBMCs 
Hypermethylated 
 
Hypermethylated 
Decreased 
 
Decreased 
Dees et al, (2013) 
 
Dees et al, (2013) 
BMPR2 MVECs Hypermethylated Decreased Wang et al, (2013) 
Table 1.7.11.1. Summary of DNA methylation alterations in SSc. The name of the genes studied, the 
source of tissue/cell used, and the methylation/expression state compared with controls is shown. 
 
 
1.8. IPF therapeutic options 
The lack of an effective therapy in IPF is a consequence of not knowing the etiology of IPF. Previous 
studies have tested numerous drugs aimed towards treating IPF, none of which have elicited a 
consistent, beneficial response in IPF patients. These unsuccessful treatments include anti-
inflammatory agents (Nagai et al, 1999, Flaherty et al, 2001, Richeldi et al, 2003, Collard et al, 2004), 
anti-coagulants (Noth et al, 2012), endothelin receptor antagonists (King et al, 2008, Jackson et al, 
2010, King et al, 2011, Costabel et al, 2011) and anti-fibrotics (King et al, 2009). A number of drug trials 
have reported no beneficial outcome, worsening of disease or have even been stopped due to 
increased mortality (Raghu et al, 2011, Raghu et al, 2012).  
Currently, pirfenidone is the only drug approved for the treatment of IPF and has acceptable 
tolerability in clinical trials (Noble et al, 2011). Pirfenidone has anti-inflammatory and antioxidant 
properties that inhibit TGFß in vitro (Walter et al, 2006) and in animal models of fibrosis, pirfenidone 
has been shown to inhibit TGFß mRNA and TGFß-stimulated collagen production (Di Sario et al, 2002, 
Oku et al, 2008). In IPF patients, pirfenidone is associated with reduced fibroblast proliferation 
(Schaefer et al, 2011), improved progression-free survival (Spagnolo et al, 2010) and a reduction in 
acute exacerbations of IPF (Azuma et al, 2005), although side-effects including dermatological, 
gastrointestinal and neurological symptoms are common (Noble et al, 2011, Cottin, 2013, Jenkins et 
al, 2013). Nintedanib, a small molecule tyrosine kinase inhibitor which targets growth factor receptors 
(PDGF, VEGF and FGF) associated with IPF (Hilberg et al, 2008, Richeldi et al, 2011) was recently shown 
to significantly reduce the annual decline in forced vital capacity (FVC) in IPF patients enlisted on a 
phase III trial (INPULSIS) compared to placebo (Richeldi et al, 2014). Pirfenidone is the first drug to 
offer some benefits to patients with IPF and nintedanib may soon be available however, with the 
exception of lung transplants, no treatment to date exists that can reverse or prevent IPF. 
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1.8.1. SSc-PF therapeutic options 
The majority of SSc-PF cases are characterised by a NSIP histopathological pattern (King, 2005) which 
is associated with a better prognosis compared to UIP, the characteristic histopathological pattern of 
IPF (Monaghan et al, 2004). However, as with IPF, the treatment of SSc-PF is not well established. A 
number of drugs including corticosteroids, anti-fibrosing agents and immunosuppressive agents have 
been proposed for treating SSc-PF (Bussone and Mouthon, 2011). Corticosteroids, which have anti-
inflammatory, immunosuppressive and anti-fibrosing properties, are recommended (at a low dose) 
for SSc patients with severe or worsening interstitial lung disease (Wells and Hirani, 2008), however 
the efficacy of corticosteroids in SSc-PF are unknown and high doses are associated with scleroderma 
renal crisis (Trang et al, 2012). Immunosuppressive agents such as cyclophosphamide which suppress 
lymphokine production are widely used in the treatment of SSc-PF however, multiple studies have 
shown no long-term benefits of cyclophosphamide compared to placebos (Hoyles et al, 2006, Tashkin 
et al, 2007, Nannini et al, 2008). That said, cyclophosphamide combined with azathioprine (another 
immunosuppressive drug) may be beneficial by stabilising or improving lung function in worsening 
cases of SSc-PF (Paone et al, 2007, Bérezné et al, 2008). Anti-fibrotic agents including D-Penicilliamine, 
IFN-γ and IFNα have all failed to provide a beneficial effect in patients with SSc (Grassegger et al, 1998, 
Black et al, 1999, Clements et al, 1999), thus no anti-fibrotic therapy currently exists. Two recent 
studies by Udwadia et al and Miura et al examining 1 and 5 patients with SSc-PF (respectively) suggest 
pirfenidone may provide some beneficial effects including improved lung function and increased vital 
capacity (Miura et al, 2014, Udwadia et al, 2015). Currently a phase II trial (LOTUSS) is examining the 
safety and tolerability of pirfenidone in patients with SSc-PF and studies examining other promising 
drugs including imatinib, dazatinib, rituximab and mycophenolate mofeti are ongoing, however to 
date, there is no effective ‘gold standard’ treatment currently recommended for patients with SSc-PF 
(Bussone and Mouthon et al, 2011).  
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1.9. Summary and Hypothesis 
This thesis will investigate the role of DNA methylation in fibrotic lung fibroblasts derived from 
patients with either IPF or SSc-PF. PF often occurs in patients with SSc and although SSc-PF and IPF are 
distinct diseases, they share some overlapping clinical similarities including reduced FVC and dypsnea 
on exertion (Herzog et al, 2014). PF is a pathological condition originating from aberrant repair 
mechanisms in response to acute or chronic lung injury, characterised by progressive scarring of the 
lungs and excessive ECM deposition in the pulmonary interstitium and often occurs at the end-stages 
of many interstitial lung diseases. Fibroblasts and myofibroblasts are the key effector cells of 
fibrogenesis in which multiple genes have been identified as being aberrantly expressed. DNA 
methylation is one of many epigenetic mechanisms that play a key role in gene regulation.  
Recent evidence has identified a number of genes in IPF lung fibroblasts and SSc fibroblasts, as having 
altered methylation which correlate to gene expression, however the full extent and role of DNA 
methylation in IPF and SSc-PF remains unknown. This is the first study to date to examine genome-
wide methylation in lung fibroblasts derived from SSc patients and the first study to examine the 
effects of DNA methylation of gene expression in the same lung fibroblasts derived from IPF patients.  
A number of genes have altered methylation which correspond to altered gene expression in IPF lung 
fibroblasts (Sanders et al, 2008) and many of these encode glycoproteins. Genes of particular interest 
are the tenascins which have important functions during wound healing, however, their role in fibrosis 
and wound healing and how they are regulated is poorly understood. TNC has recently been shown 
to have increased expression in IPF (Estany et al, 2014) and SSc-PF (Brissett et al, 2012, Inoue et al, 
2013) and is upregulated in response to TGFß (Estany et al, 2014). Furthermore aberrant expression 
of TNXB (the gene which encodes the protein TNX) plays an important pathogenic role in diseases 
such as cardiac fibrosis (Jing et al, 2011), Ehlers-Danlos syndrome (Burch et al, 1997, Mao et al, 2002, 
Zweers et al, 2003) and mesothelioma (Yuan et al, 2009). TNX can also associate with different 
collagen types and has the potential to activate latent TGFß (Alcaraz et al, 2014), the pro-fibrotic 
cytokine universally linked with fibrosis (Leask and Abraham, 2004). Furthermore, TNXB expression 
has been linked with DNA methylation, therefore the regulation and role of TNX in IPF and other 
fibrotic diseases including SSc-PF warrant further investigation.  
 
This thesis will address the following hypothesis: 
Aberrant DNA methylation in fibrotic lung fibroblasts derived from patient with IPF or SSc-PF is 
responsible for altering the expression of multiple genes which may contribute to the development 
of pulmonary fibrosis. 
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The aims of this thesis are to: 
 
 Identify genes with altered methylation/expression in IPF and SSc compared to control lung 
fibroblasts.  
 
 Identify overlapping and distinct genes between IPF and SSc lung fibroblasts which have 
altered methylation/expression compared to control lung fibroblasts.  
 
 Correlate DNA methylation and gene expression data to identify genes potentially regulated 
directly by methylation. 
 
 Identified biological processes enriched in genes with altered methylation/expression in IPF 
and SSc compared to control lung fibroblasts. 
 
 Determine whether sex has an influence on methylation and/or expression of genes. 
 
 Determine the effect of DNMT inhibition, using the demethylating agent, 5-Aza-2’-
deoxycytidine, on methylation/expression of genes in control, IPF and SSc lung fibroblasts.  
 
 Elucidate the role of DNA methylation in TNXB gene regulation and the role of TNX in IPF. 
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 Materials and methods 
2.1. General plastic-and glass-ware and chemicals  
All chemicals used were of analytical grade. Water used for the preparation of buffers was distilled 
and deionised using a Millipore water purification system (Millipore Ltd, UK). Plastic-and glass-ware 
included sterile tissue culture flasks, plates, disposable pipettes (Nunc, Denmark), Falcon tubes 
(Sigma, UK) and Poly-L-Lysine slides (VWR International, USA). Trypsin-EDTA (Fisher Scientific, USA), 
penicillin, streptomycin, foetal calf serum, Dulbecco's modified Eagle’s medium (Life Technologies, 
UK), amphotericin B (Sigma, UK), NF-H2O (Ambion, USA), BSA (Bioline, USA), Agarose (Merick, 
Germany), 96-well plates (Thermo Scientific, USA), 0.2ml PCR tubes (Starlab, UK), eppendorfs 
(Sarstedt, Germany), RNaseZAP (Sigma, UK), TRIzol (Invitrogen, UK), SYBR (Eurogentec, Belgium), q-
Script cDNA supermix (Quanta Biosciences, USA), EZ-DNA methylation-Gold kit (Zymo Research, USA), 
mineral oil, (Sigma, UK), 10x PCR buffer (Applied Biosystems, USA), magnesium chloride (Applied 
Biosystems, USA), QIA purification kit, (Qiagen, Germany), Opti-MEM (Life Technologies, UK), ethanol 
(VWR International, France), chloroform (Sigma, UK).  
 
2.2. Reagents, inhibitors and antibodies 
INTERFERin (Polyplus Transfection, USA), HEPES buffer (Sigma, USA), saponin (Sigma, USA), 5-Aza-2'-
deoxycytidine (5-Aza) (Sigma, UK), polyclonal rabbit anti-TNXB, (ab111270) (AbCam, UK), goat-anti-
rabbit IgG HRP, (P0448) (Dako, Denmark), TNXB, (AM16708) and non-targeting control siRNA, 
(AM4390846) (Ambion, USA), DNA HyperLadder (Bioline, USA), rat tail type I collagen, (A1048301) 
(Invitrogen, UK). 
 
2.3. Tissue culture 
2.3.1. Isolation of lung fibroblasts 
Fibrotic primary human lung fibroblast cell lines were derived from either IPF or SSc-PF lung explants. 
The SSc-PF cell lines were a kind gift from Professor David Abraham at the Centre for Rheumatology 
and Connective Tissue Diseases, UCL, UK, and are referred to throughtout the methods and results 
sections of this thesis as ‘SSc lung fibroblasts’. Primary human control lung fibroblasts were derived 
from histologically normal areas of lung parenchyma distal to tumour mass in lung cancer patients. All 
tissues were obtained with patient consent and approved for use by the relevant research ethics 
committee. Sections (1mm3) cut from lung biopsies were placed ~1cm apart on cell culture Petri dishes 
with 2ml of Dulbecco's modified Eagle's medium (Life Technologies, UK) supplemented with 10% (v/v) 
foetal calf serum (Life Technologies, UK), penicillin (100U/ml) (Life Technologies, UK), streptomycin 
(100µg/ml), L-glutamine (4mM) (Life Technologies, UK) and 2.5µg/ml amphotericin B (Sigma, UK). 
Cells were incubated at 37oC in a humidified atmosphere of air containing 10% CO2. Once cells had 
attached, a further 8ml of culture medium was added (drop wise). Culture medium was replaced with 
fresh medium one day after isolation and 200µl of amphotericin B was added (drop-wise) every 48 
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hours. Medium was changed every seven days. Static cultures of cells were maintained in T175cm2 
plastic culture flasks at 37oC in a humidified atmosphere of air containing 10% CO2. Cells were 
passaged using trypsin-EDTA upon reaching 80% confluence and characterised by their morphology, 
their expression of several markers including α-smooth muscle actin and vimentin and their ability to 
secrete collagens in the presence of TGFß.  
 
2.3.2. Cell culture 
For all studies, IPF, SSc and control lung fibroblasts were used at passage ≤8 to ensure cells did not 
undergo senescence. Cells were routinely plated in T175cm2 tissue culture flasks in Dulbecco's 
modified Eagle's medium supplemented with 10% (v/v) foetal calf serum, penicillin (100U/ml), 
streptomycin (100µg/ml) and L-glutamine (4mM). Cell cultures were maintained in T175cm2 plastic 
culture flasks at 37oC in a humidified atmosphere of air containing 10% CO2. Upon reaching 80% 
confluence cells were split. Medium was removed and cells were washed twice to remove any 
residual FCS. 2ml of trypsin-EDTA was added to each T175cm2 flask, ensuring the whole flask’s 
surface area was covered and incubated at 37oC for approximately 2 minutes. Supplemented DMEM 
(23ml) was then added to each flask to neutralise the trypsin-EDTA and transferred to a sterile 50ml 
falcon tube. Cells were gently centrifuged at 200g for 5minutes. The supernatant was removed, 
leaving the cell pellet. Cells were reconstituted in 10ml of supplemented DMEM and counted using a 
ScepterTM 2.0 handheld cell counter, (C85360) with 60µm tips (PHCC60050) (Millipore, UK). Cells 
were then split into new T175cm2 flasks.  
For Illumina microarray studies, 500,000 lung fibroblasts were counted using a ScepterTM 2.0 
handheld cell counter, (C85360) and seeded in T175cm2 flasks at 10% confluence 24 hours before 
treatment with or without 5-Aza-2'-deoxycytidine (5-Aza) (Sigma, UK). 1µM of 5-Aza was added to 
the culture medium and replaced at 24 hour intervals until the cells were confluent (≥  1 week, to 
ensure a minimum of 3 population doublings). Cells were then harvested for total RNA (TRIzol) or 
DNA (Nucleon) extraction. This was conducted by Dr. I.C. Evans. The number, gender and the mean 
age ± the standard deviation of the lung fibroblasts analysed using Illumina microarrays were as 
follows: IPF, n=5, aged 66.6 ±8 years, 2 male; SSc, n=7, aged 51.7 ±3.7 years, 1 male; and control, 
n=6, aged 58.3 ±14.5 years, 2 male (Table 2.3.2.1). 
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Fibroblast cell lines Gender Age 
Non-fibrotic controls   
C1 F 69 
C2 F 73 
C3 F 33 
C4 M 55 
C5 M 66 
C6 F 54 
IPF   
IPF1 F 61 
IPF2 M 58 
IPF3 M 77 
IPF4 F 73 
IPF5 F 64 
SSc-PF   
SSc1 M 47 
SSc2 F 56 
SSc3 F 49 
SSc4 F 53 
SSc5 F 56 
SSc6 F 48 
SSc7 F 53 
Table 2.3.2.1. Demographic data of lung fibroblast cell lines. This table shows the gender and age of 
all lung fibroblasts used in the methylation and expression microarray studies. IPF, n=5, aged 66.6 ±8 
years, 2 male; SSc, n=7, aged 51.7 ±3.7 years, 1 male; and control, n=6, aged 58.3 ±14.5 years, 2 male. 
 
2.4. RNA extraction 
All equipment was cleaned with RNaseZAP (Sigma, USA) prior to use and nuclease-free pipette tips 
were used (Continental Lab Products, UK) to minimise RNA degradation. TRIzol (Invitrogen, UK) was 
used to isolate RNA from primary lung fibroblasts. TRIzol is a monophasic solution of phenol and 
guanidinium isothiocyanate which solubilises biological material and denatures protein whilst 
maintaining RNA integrity (Rio et al, 2010). To isolate RNA, TRIzol was added to primary lung fibroblast 
cell cultures and incubated for 5 minutes at room temperature to ensure complete dissociation of 
nucleo-protein complexes. Chloroform (200µl per/ml of TRIzol reagent) was added to each sample 
and vortexed for 10 seconds followed by an incubation period of 5 minutes at room temperature to 
allow separation of the upper aqueous phase and a lower organic layer. Samples were then 
centrifuged at 16000g for 15 minutes at 4oC. The upper clear layer containing approximately 250µl 
RNA was pipetted into a new tube. An equal amount of 2-propanol (250µl) was added to each sample 
and incubated for 10 minutes at room temperature to precipitate the RNA. Samples were then 
centrifuged at 16000g for 15 minutes at 4oC. Supernatant was discarded leaving the pellet. Ethanol 
80%/1ml (VWR Chemical, UK) was added to each sample, vortexed for 10 seconds and centrifuged at 
16000g for 10 minutes at 4oC. Supernatant was removed leaving the pellet which was left to air dry. 
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Once dried, samples were re-suspended in 12.5µl of nuclease-free H2O (NF-H2O) (Ambion, USA). 10X 
buffer (1.5µl) and 1µl DNase-1 enzyme (Ambion, USA) was added to each tube, vortexed for 10 
seconds, pulse spun and incubated for 20 minutes at 37oC. Inactivation buffer (2µl) was then added 
to each tube and incubated for 5 minutes at room temperature. Samples were centrifuged at 16000g 
for 3 minutes and the supernatant placed into a new tube.  
The extracted RNA was quantified by measuring the 260nm wavelength absorbance reading (A260), 
using a NanoDrop Bioanalyzer ND1000 (NanoDrop, UK). The A260 reading represents the wavelength 
of maximum absorption of light by RNA and a reading of 1.0 is equivalent to 40µg/ml. The purity of 
RNA was determined by measuring the A260/A280 ratios where a ratio of ~2.0 is considered pure. As 
RNA has a maximum absorption of A260, any absorption at the 280nm wavelength could indicate the 
presence of non-RNA material such as protein. RNA with a 260/280 ratio between 1.8-2.2 was 
considered acceptable for use in experiments. For studies utilising the Illumina HT12v4 BeadChip 
expression microarray, 1µg of RNA was sent for analysis.  
 
2.5. DNA extraction 
A Nucleon blood and cell culture (BACC2) DNA extraction kit (Amersham, UK) was used to harvest DNA 
from the same primary lung fibroblast cell cultures used for the gene expression microarray. Following 
the manufacturer’s protocol, lung fibroblasts were trypsinised, counted using a ScepterTM 2.0 
handheld cell counter, (C85360) with 60µm tips (PHCC60050) (Millipore, UK) and centrifuged in 15ml 
falcon tubes at 4OC for 5 minutes. For 1x 106 cells, 250µl of reagent A was added for 5 minutes followed 
by centrifuging at 1300g for 5 minutes. Supernatant was discarded and 500µl of reagent B was added 
to each sample and vortexed gently. To remove proteins, 125µl of sodium perchlorate solution was 
added to each tube and inverted several times. DNA was extracted by adding 500µl of chloroform 
(Sigma, UK) followed by inverting the tube several times. Nucleon resin (75µl) was then added (which 
covalently binds proteins and traps proteinaceous material allowing the recovery of high quality DNA) 
followed by centrifuging at 1300g for 3 minutes. DNA was precipitated by transferring the upper phase 
into a new tube and adding ~ 2x the volume of ethanol to each sample. The DNA was centrifuged at 
4000g for 5 minutes and supernatant discarded, followed by washing the DNA in 2ml of 70% ethanol 
and re-centrifuging. The DNA pellet was then air-dried and re-dissolved in NF-H20 (Ambion, USA).  
The quantity of the DNA was determined using a Quant-iTTM Picogreen kit (Invitrogen, UK). Deionised 
water pre-treated with 0.1% diethyl pyrocarbonate (DEPC) for 12 hours at 37oC was autoclaved for 15 
minutes and used to dilute a 20X Tris-EDTA (TE) stock solution to form a 1XTE solution. The Quant-
iTTM Picogreen kit was warmed to room temperature and diluted 1:200 in the 1XTE buffer. A standard 
curve was prepared by diluting 100µg of the lambda DNA standard 50-fold in 1XTE to make a 2µg/ml 
working solution. DNA samples were diluted in the picogreen solution and incubated at room 
temperature for 5 minutes. Fluorescent readings were measured using a florescent plate reader and 
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compared to the standard curve to determine their concentrations. DNA samples with an A260/280 
ratio of 1.8-2.1 were considered acceptable for experimental use. This was conducted by Dr. I.C Evans. 
2.5.1. Bisulfite conversion of genomic DNA 
For the Illumina Infinium HumanMethylation450 BeadChip microarray, 500ng of each genomic DNA 
sample was sent to Cambridge Genomic Services (CGS, UK) to be bisulfite converted using an EZ DNA 
Methylation-GoldTM Kit (Zymo Research, USA). For validation studies, the same DNA was bisulfite 
converted in-house. The manufacturer’s protocol was followed which essentially involved adding a CT 
conversion reagent to the DNA and thermal cycling at 98oC for 10 minutes and then at 64oC for 2.5 
hours, followed by 4oC until further processing. DNA from the lung fibroblast sample was then added 
to a binding buffer and centrifuged at ≥ 10000g for 30 seconds. Flow through was discarded. Wash 
buffer was added and centrifuged at ≥ 10000g for 30 seconds. Samples were incubated in 
desulphonation buffer at room temperature for 20 minutes and then centrifuged at ≥ 10000g for 30 
seconds. Wash buffer was added and centrifuged at >10000g for 30 seconds. Elution buffer was then 
added and centrifuged at ≥ 10000g for 30 seconds to elute the DNA. Bisulfite converted DNA was 
analysed by an Illumina Infinium HumanMethylation450 BeadChip microarray and specific regions of 
the TNXB gene were bisulfite sequenced to validate the array (see section 2.11). Figure 2.5.1.1 shows 
how bisulfite conversion only affects unmethylated cytosines. 
 
Figure 2.5.1.1. Bisulfite conversion of genomic DNA. Bisulfite conversion results in unmethylated 
cytosines being converted to uracil. Subsequent PCR amplification results in thymine in the place of 
where the original unmethylated cytosines were. Methylated cytosine residues remain unaffected.  
 
2.6. Illumina microarrays 
The Illumina Infinium HumanMethylation450 BeadChip methylation microarray (Illumina, USA) and 
the Illumina Infinium HT 12v4 BeadChip expression microarray (Illumina, USA) were used to analyse 
genome-wide methylation and expression in primary human lung fibroblasts derived from IPF (n=5), 
SSc (n=7) and control (n=6) lung. Both these microarrays employ Illumina’s BeadArray technology 
which consists of 3µm silica beads, each of which is covered in multiple copies of a probe (a specific 
50-mer (50 nucleotides in length) oligonucleotide that acts as the capture sequence). The beads are 
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uniformly distributed (~5.7µm), randomly assembled into microwells and held in place by Van der 
Waals force and hydrostatic interaction with the walls of the well. 
 
2.6.1. Illumina Infinium HT 12v4 BeadChip microarray 
The Illumina Infinium HT 12v4 BeadChip expression (Illumina, USA) simultaneously profiles 47231 
transcripts and known splice variants from the RefSeq database release 38. Oligonucleotide (50-mer ) 
probes on the HT12v4 expression microarray are specific to each gene and immobilised to beads, with 
approximately 30 beads per a probe on the array. Each probe is designed using a multi-step algorithm 
to optimise parameters including self-complementarity for hairpin structure prediction, melting 
temperature for hybridisation uniformity, distance from 3’ end of transcript and lack of similarity to 
other genes. A 29-mer address sequence on each probe helps identify the location of each bead and 
validates the hybridisation process for each bead on the array. Each nucleotide is biotin-labelled and 
streptavidin-Cy3 is used to detect for downstream analysis (Figure 2.6.1.1).  
 
 
Figure 2.6.1.1. Gene expression profiling Illumina bead design. Thousands of oligomers (one shown 
for simplicity) are attached to a single bead. The address sequence is used to identify the 
oligonucleotide after it has been deposited on the array. (Figure adapted and redrawn from 
http://www.illumina.com/technology/beadarray-technology/direct-hybridization-assay.html). 
 
2.6.2. Illumina Infinium HumanMethylation450 BeadChip microarray 
The Illumina Infinium HumanMethylation450 BeadChip microarray (Illumina, USA) is the successor to 
the Illumina Infinium HumanMethylation 27k BeadChip microarray (Illumina, USA) and interrogates 
methylation at 482421 CpG sites across the genome, including 90% of the CpGs covered by the 27k 
array (Bibikova et al, 2011, Sandoval et al, 2011). 99% of all RefSeq genes with an average of 17 
CpGs/gene and 96% of all known CpG islands are covered. Furthermore, regions flanking CpGs islands 
including shore, shelf and open sea are also covered, representing genome-wide coverage. The 450k 
array uses two types of probe to detect methylation; Infinium type I probes which use two probes per 
a CpG to detect methylation (one specifically to hybridise to methylated DNA and the other to 
specifically hybridise to unmethylated DNA) and Infinium type II probes which use just one probe per 
a CpG locus. Type I probes are both in the same colour channel. The % of methylation (Beta-value) at 
any given CpG is calculated by comparing the intensities from the two different probes in the same 
colour channel (beta=M/ (U+M). Type II probes utilise either green or red dye colours to distinguish 
between methylated or unmethylated CpGs. The beta-value is calculated by comparing the two 
colours at the same CpG locus (beta= green (M)/ (red (U) + green (M)). Each probe is 50-mer 
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oligonucleotide, attached to a bead and replicated multiple times on the array. This means the 
methylation status of each CpG can be analysed thousands of times on a single run (Figure 2.6.2.1).  
 
 
Figure 2.6.2.1. Type I and Type II Infinium probes used in the 450k array. Type I probes use two 
probes (one unmethylated, one methylated) to detect methylation at a CpG using the same colour 
channel. Type II probes use one probe to detect methylation at a CpG using either green (for 
methylated) or red (for unmethylated). (Adapted and redrawn from 
http://www.illumina.com/technology/beadarray-technology/infinium-methylation-assay.html).   
 
2.6.3. Normalisation of the Illumina Infinium HT 12v4 BeadChip array 
Data from the Illumina Infinium HT 12v4 BeadChip expression (Illumina, USA) was normalised and 
subjected to quality control by Cambridge Genomic Services (CGS, UK). The lumi R package (Du et al, 
2008) was used to determine if a gene was significantly (P<0.01) expressed above the background as 
defined by the negative control probes. For any given probe to pass selection, it must have been 
detected in at least one sample (P<0.01 in Lumi). Normalisation of the HT12v4 array was done in two 
steps: first the data was transformed using variance stabilisation to stabilise the variance of larger 
intensities and reduce the number of false-positive results (Lin et al, 2008) followed by quantile 
normalisation to reduce background noise using the R package Lumi (Du et al, 2008). A basic analysis 
was performed by Cambridge Genomic Services (CGS, UK), using the limma R package (Smyth et al, 
2004, which included calculating the fold-changes in expression between different groups, the 
number of probes detected in each sample and false-discovery P values.  
 
2.6.4. Normalisation of the Illumina Infinium HumanMethylation 450 array 
The Illumina Infinium HumanMethylation 450 BeadChip array was normalised and subjected to quality 
control by Cambridge Genomic Services (CGS, UK). Raw data was obtained using Genome Studio 
software (Illumina, USA) and processed using the lumi R package to correct for colour bias present on 
the array due to different dyes used on the array. To correct this bias, Infinium type I and type II probes 
and both colour channels were separated and smooth quantile normalsation was applied. After this 
correction, both channels and probe types were combined and quantile normalisation was performed 
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using the lumi R package (Du et al, 2008). Beta-values were then calculated and probes demonstrating 
p values >0.01 removed. 
 
2.6.5. Filtering non-specific probes and probes covering a SNP 
Several studies have identified non-specific probes on the Illumina Infinium HumanMethylation450 
BeadChip microarray as well as more SNPs which cover CpGs in addition to the ones already 
documented on the array (Price et al, 2013, Chen et al, 2013). I matched a list of all non-specific probes 
(41937) identified by Price et al was to our data. Price et al followed a protocol developed by Chen et 
al, 2011 for the 27k array to determine non-specific probes on the 450k array. Essentially, the basic 
local alignment search tool-like analysis tool (BLAT) (Kent, 2002) was used to align the 50 nucleotide 
probe sequences to four different versions of the hg19 draft sequence genome. These included a fully 
unmethylated ‘bisulfite-treated’ genome (where all Cs were converted to Ts), a fully methylated 
‘bisulfite-treated’ genome (where only non-CpG Cs converted to Ts) and both the above versions on 
the reverse complement sequence (Price et al, 2013). For a probe to be considered non-specific, the 
following criteria had to be met: at least 90% identity over the aligned region (calculated by the 
dividing the number of matching bases by the span of the sequence match), at least 40/50 base pairs 
matching, no gaps (to avoid the potential of compromising the hybridisation between probes and 
cross-reactive sequences) and the 50th nucleotide (where the probe hybridises to the target CpG) had 
to align (Chen et al, 2011, Price et al, 2013). All non-specific probes were removed as they have the 
potential to hybridise to multiple genomic locations and thus could measure methylation at multiple 
CpG sites. Any CpG site which was covered by a SNP was also removed to avoid potentially assessing 
genotype rather than methylation differences. This left 324973 probes on the array. 
 
2.6.6. Statistical analysis of the Illumina Infinium HT 12v4 BeadChip array 
Due to a small sample size and heterogeneity that exists between IPF samples (Martinez et al, 2005, 
Habiel and Hogaboam, 2014, DePianto et al, 2015), very few genes reached statistical significance in 
the expression analysis using a false-discovery rate P value of <0.05. To minimise the number of false 
negative and false-positive results and in order not to miss true positive results, a threshold number 
of misclassifications (TNoM) score of ≤1 with a p value <0.05 was used. TNoM is a threshold-based 
method that separates class values (ie. control compared to IPF) to determine if a gene’s expression 
is above or below a given threshold. This was calculated by listing each cell lines’ expression value in 
ascending order and then setting a threshold (Figure 2.6.6.1). The TNoM score represents the 
minimum number of misclassifications possible (Bon-Dor et al, 2000). 
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Figure 2.6.6.1. TNoM definition. Control (n=6) and IPF (n=5) gene expression values listed in ascending 
order. Four IPF values are above the threshold, 1 is below the threshold representing a 
misclassification. Therefore in the above example, the minimum number of misclassifications = 1.  
 
2.6.7. Statistical analysis of the Illumina Infinium HumanMethylation 450 array 
Due to a small sample size and heterogeneity that exists between IPF samples (Martinez et al, 2005, 
Habiel and Hogaboam, 2014, DePianto et al, 2015), very few genes reached statistical significance in 
the methylation analyses using an false-discovery rate P value of <0.05. This has previously been 
shown in another IPF study using the smaller Illumina 27K microarray (Huang et al, 2014). To minimise 
the number of false negative and false positive results and in order to not miss true positive results, a 
delta-beta (Δβ) of ≥0.136 (≥13.6%) change in methylation with a non-stringent p value of <0.05 was 
used as a statistical cut-off based on previous studies utilising Illumina microarrays which show a 
P<0.05 and 13.6% change in methylation can detect differences with 95% confidence (Bibikova et al, 
2009, Lokk et al, 2012).  
 
2.7. Bioinformatics analysis of microarray data 
2.7.1. Data visualisation  
The R 3.2.0 (x64bit) statistical program and associated packages (including ggplot2 (Wickham, 2009), 
VennDiagram (Chen and Boutros, 2011), and RColorBrewer) and Microsoft Excel were used for 
visualising and analysing Illumina microarray data. Using R, I developed scripts which analysed Illumina 
microarray data saved in comma delimited file format (.csv). After installing and loading in the 
appropriate R package, .csv files were loaded and read into R. The scripts were then applied to the 
data and all images exported as .png files unless otherwise stated. Histogram scripts were used to 
analyse the distribution of genome-wide methylation and expression (Figure 2.7.1.1). For methylation 
and expression distribution, class boundaries (binwidth) were set at 0.05 (5% methylation) and 0.5 
respectively. Scatter plots (Figure 2.7.1.2), correlation (Figure 2.7.1.3) and bar graph (Figure 2.7.1.4) 
scripts were used to determine the distribution of CpG methylation in relation to CpG location, 
chromosomal location and for correlation between CpG methylation and gene expression. Weighted 
Venn diagram scripts were used to determine the number of distinct and overlapping genes which 
had altered methylation/expression (Figure 2.7.1.5). Heatmap/cluster scripts were used to determine 
clustering of cell lines (Figure 2.7.1.6).  
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Figure 2.7.1.1. Colour-coded script used for the generation of histograms using R 3.2.0. Blue: loads 
the required package into R console. Green: reads in the file to be used for analysis and gives it a 
simple label of ‘A’. Orange: creates the plot based on the values in ‘column 1’, sets each histogram 
border at 0.05 (representing 5% methylation), outlines each bar in black and fills it with a choice of 
colour and sets a limit on the plot size. In this example xlim is set at ‘1’ (100% methylation with each 
bar representing 5% methylation intervals) and ylim at 50000 (representing the maximum frequency 
of CpGs within each bar). Red: the histogram created using ‘column1’ is further categorised by ‘column 
X’ (I.e, frequency of CpGs with altered methylation, based on location). Purple: customises the plot 
visuals including the x-axis and y-axis labels, their size and their colour. All figures in bold text can be 
changed without affecting the script. 
 
Figure 2.7.1.2. Colour-coded script used for the generation of scatter plots using R 3.2.0. Blue: loads 
the required package into R console. Green: reads in the file to be used for analysis and gives it a 
simple label of ‘A’. Orange: creates the plot based on the values in ‘column 1’ and ‘column 2’. Defines 
them to be coloured based on values given in ‘column X’. Sets a limit on the plot size (in this example 
xlim and ylim are set for beta values of 0 (0% methylation) and 1 (100% methylation). Red: sets the 
colours of ‘column 1’ and ‘column 2’. Purple: customises the plot visuals including the x-axis and y-
axis labels, their size and their colour. All figures in bold text can be changed without affecting the 
script. 
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Figure 2.7.1.3. Colour-coded script used for the generation of correlation plots using R 3.2.0. Blue: 
loads the required package into R console. Green: reads in the file to be used for analysis and gives it 
a simple label of ‘A’. Orange: creates the plot based on the values in ‘gene1expression’ and 
‘gene1methylation’ and colours each point based on ‘celline’. Red: creates a regression line and 
shades regions indicating 95% confidence intervals, colours each ‘celline’ a different colour. Purple: 
customises the plot visuals including the x-axis and y-axis labels, their size and their colour. All figures 
in bold text can be changed without affecting the script. 
 
 
Figure 2.7.1.4. Colour-coded script used for the generation of bar graphs used in the location of CpG 
methylation using R 3.2.0. Blue: loads the required package into R console. Green: loads the file into 
a table in R. Orange: ‘x’ sets the number of colours and ‘colour’, the colours to be used in the bar 
graph. Red: sets position of text and margins. Purple: customises the plot visuals including size of text, 
name and location of labels and positioning. All figures in bold text can be changed without affecting 
the script. 
 
 
Figure 2.7.1.5. Colour-coded script used for the generation of weighted Venn diagrams using R 3.2.0. 
Blue: loads the required package into R console. Green: creates the Venn diagram based on values 
entered at x, y and z. Orange: creates the image as a .tiff file and sets the width, height and resolution 
of image. Red: colours the Venn diagram in based on ‘colour1’ and ‘colour2’. Purple: customises the 
plot visuals including size of text, font, location of labels and transparency. All figures in bold text can 
be changed without affecting the script. 
71 
 
 
Figure 2.7.1.6. Colour-coded script used for the generation of heatmap plots using R 3.2.0. Blue: 
loaded the required package into R console. Green: reads the file into R and converts it into a table. 
Orange: converts the table into a data frame and then into a matrix. Red: creates the heatmap and 
manually colours the heatmap base on low (colour1) to high (colour 4) values. 
 
2.7.2. Enrichment and network analysis 
The online tool, BioMart (Smedley et al, 2015) in Ensembl (Cunningham et al, 2015) was used to 
extract data from the Ensembl 81 database in order to map all genes with their respective protein 
family domains (PFAMs). Using the gene list containing genes with significantly altered methylation 
(Δβ ≥ 0.136; P<0.05) in IPF compared to control lung fibroblasts as an example, each gene within the 
list was compared with the full list of genes in Microsoft Excel 2013 using the Excel formula 
“=NOT(ISNA(VLOOKUP(X1,$Y:$Y,1,FALSE)))”, where ‘X’ represented the gene of interest within a given 
list and ‘$Y:$Y’ represented the full list of genes and their corresponding PFAMs. This formula returned 
a value of ‘TRUE’ if the gene was identified or ‘FALSE’ if the gene was not in the gene list. All values 
returning FALSE were filtered leaving the genes with significantly altered methylation in IPF compared 
to control lung fibroblasts and the PFAMs they were associated with. The genes were then given 
different values based on whether they had CpGs with increased, decreased or both increased and 
decreased methylation compared to control lung fibroblasts for later use in network visualisation. This 
was done using the Excel formula “=IFERROR(INDEX($X:$X,MATCH(Y,$Z:$Z,0)),"")”, where ‘$X:$X’ 
represents the gene list, ‘Y’ represents the specific gene, and $Z:$Z’ represents the specific value. The 
domain centric gene ontology (dcGO) database (Fang and Gough, 2013) was used to find biological 
processes enriched in PFAMs containing genes with significantly altered methylation/expression. A 
false discovery rate (FDR) threshold p value <0.01 was used as a cut-off. All levels of granularity (highly 
general, general, specific and highly specific) were included.  
The network integration and visualisation analysis tool, Cytoscape v3.2.1 (Shannon et al, 2003) was 
used to visualise networks of genes which shared specific PFAMs and groups of PFAMs enriched in 
specific biological processes. Genes and their corresponding PFAMs were imported into Cytoscape as 
nodes. The list of values indicating the direction of methylation change was imported into cytoscape 
and assigned to the nodes. VizMapper in Cytoscape was used to colour-code each node based on the 
direction of methylation. Genes which also had a change in expression were annotated using the 
import custom graphics option within VizMapper. Genecodis 3 web enrichment tool (Carmona-Saez 
et al, 2007, Nogales-Cadenas et al, 2009, Tabas-Madrid et al, 2012) was used to determine GO 
biological processes enriched in genes with significantly altered methylation/expression. The 
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hypergeometric statistical test was used with the Benjamini and Hochberg FDR p value correction test. 
Enriched biological processes with a corrected hypergeometric P value <0.05 were considered 
statistically significant.  
 
2.7.3. Protein-protein interactions and KEGG pathway analysis 
The STRING v10 database (www.string-db.org) was used to analyse protein-protein interaction 
networks and how genes with altered methylation and/or expression potentially interacted with each 
other (Szklarczyk et al, 2015). Specific gene lists of interest were entered as ‘user payload’ datasets. 
Each gene was assigned a hexadecimal colour which represented the direction of change to 
methylation and/or expression. The analysis was run using the default parameters which were set to 
confidence score ≥0.400 with all active prediction methods selected.  
For visualisation of pathways, KEGG pathways were downloaded as .kgml files from 
http://www.genome.jp/kegg/pathway.html and read into cytoscape using the Cytoscape plugin, 
KEGGscape (Nishida et al, 2014). Attribute tables were downloaded into .csv files and read using Excel. 
These files were then modified to include all genes associated in the pathway with altered methylation 
and/or expression by using the rest.kegg.jp/list/ function to convert all HSA KEGG IDs to gene symbols. 
The files were then uploaded as tables and merged to the appropriate cytoscape KEGG pathway. The 
pathway was then visually enhanced to show genes with altered methylation and/or expression using 
the VizMapper tool within Cytoscape. 
 
2.8. RT-PCR and real-time qRT-PCR validation of microarray data 
2.8.1. cDNA synthesis 
To validate the expression microarray, cDNA was prepared by reverse transcription of RNA. All 
components were placed on ice. RNA (1µg) was made up to a volume of 16µl with NF-H2O (Ambion, 
USA) in a 0.2ml PCR tube (Starlabs, UK). A master-mix containing 4µl of q-Script cDNA SuperMix (5X 
reaction buffer containing optimised concentrations of, MgCl2, dNTPs, primers, RNase inhibitor 
protein, qScript reverse transcriptase and stabilisers) (Quanta Biosciences, USA) was then added. RT-
PCR was performed using a tetrad PTC-225, Peltier Thermal cycler, (Global Medical Instrumentation, 
USA) with cycle conditions set to: 25oC  for 5 minutes, 42oC for 30 minutes, 85oC for 5 minutes and 
held at 4oC. After completion of cDNA synthesis the product was diluted 1:4 with NF-H2O (Ambion, 
USA) and divided into aliquots which were immediately frozen at -20oC for future analysis by qPCR.  
 
2.8.2. Primer design 
All primers were designed using Primer Blast software. The primer design parameters were set as 
follows: product size 80-180bp (to ensure efficient amplification), maximum temperature melting 
difference 1oC, primer pair separated by at least 1 intron (when possible, to allow differentiation 
between amplification of cDNA and potential genomic DNA by melting curve analysis), primer size 18-
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25 nucleotides long (to provide practical annealing temperatures), primer GC % >50%, melting 
temperature 58oC-62oC, maximum poly-X 3 (when possible, to avoid inappropriate hybridisation), 
maximum self and pair complementarity at 4.0 and maximum 3' self and pair complementarity at 2.0 
(when possible) and when possible, primers at the 3’ end ended with GC (to enhance annealing of the 
end that is extended). All primers were produced by Invitrogen Life Sciences, UK. Tris-EDTA (100µl) 
was added to solubilise each primer, followed by vortexing and centrifugation. Primers were then 
quantified using a NanoDrop Bioanalyzer ND1000 (NanoDrop, UK) and made to 100µM with Tris-
EDTA. For optimisation, primers were made to 800nM and 400nM in NF-H2O (Ambion, USA). A 1:2 
cDNA dilution series was performed to check primer efficiency. Primer efficiency was determined by 
plotting the known concentrations of the dilution series with their corresponding Ct value. The Ct value 
represents the cycle number at which the fluorescent signal of the reaction crosses the threshold. 
From the standard curve, the correlation coeffiecient and slope of the log-linear phase of the 
amplification were calculated. Only primers with an R2 ≥0.9 and a slope between -3.58 and -3.10 (close 
to 90%-100% efficiency) were used. 100% efficiency meant the template doubled after each thermal 
cycle during exponential amplification. A list of primers used in qRT-PCR is shown in Table 2.8.2.1. 
 
Gene  Forward primer Reverse primer 
IL8 5'-GGACCACACTGCGCCAACACA-3' 5'TCTCCACAACCCTCTGCACCCA-3' 
CADM1 5'-AGTACAGTATAAGCCTCAAGTGC-3' 5'-CCCAAGTTACCATCACAGGC-3' 
TNXB 5'-GAGGGAGACTTCCCTGTCCTGCC-3' 5'ACCAGGAGAACCAGGCTGGAGG-3' 
PPARγ 5'-AGGCGAGGGCGATCTTGACAG-3' 5'-GATGCGGATCGCCACCTCTTT-3' 
EIF1AY 5'-AGCTCTGGGTTTGTGAATAGC-3' 5'-ACTTGTGGCACTGCAATTTGA-3' 
MMP10 5’-GCTCGCCCAGTTCCGCCTTT-3’ 5’-GCAGGATCACACTTGGCTGGCA-3’ 
MMP12 5’-CACTTCTTGGGTCTGAAAGTGA-3’ 5’-GAGGTGCGTGCATCATCTC-3’ 
TGFβ 5’-AGAGCAGAAGGAGGACCAGT-3’ 5’- CGGAAGTCAGAGAGTGAGGC-3’ 
DCN 5’-GGAATAATAAGACACGCCCTGA-3’ 5’-AGATGCTGCTTTCTCCCTCT-3’ 
COL6A3 5’-TTGCTCTGCCCTCAGCG-3’ 5’-AGCGGTTCACTTGCTATTTCTTT-3’ 
COL12A1 5’-GCTACCTCTCCCTGTTGCCG-3’ 5’-CACTCCATCCCTTCTGCCTCAA-3’ 
HPRT 5’-TGACACTGGCAAAACAATGCA-3’ 5’-GGTCCTTTTCACCAGCAAGCT-3’ 
YWHAZ Primerdesign Ltd (reference gene assay) Primerdesign Ltd (reference gene assay) 
EIF4A2 Primerdesign Ltd (reference gene assay) Primerdesign Ltd (reference gene assay) 
Table 2.8.2.1. Primers used for qRT-PCR. Interleukin 8 (IL8), Cell adhesion molecule 1 (CADM1), 
Tenascin XB (TNXB), Peroxisome proliferator-activated receptor gamma (PPARγ), Eukaryotic 
translation initiation factor 1A, Y-linked (EIF1AY), Matrix metallopeptidase 10 (MMP10), Matrix 
metallopeptidase 12 (MMP12), Transforming growth factor beta (TGFß), Decorin (DCN), Collagen, 
type VI, alpha 3 (COL6A3), Collagen, type XII, alpha 1 (COL12A1), Hypoxanthine-guanine 
phosophoribosyltransferase (HRPT), Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide (YWHAZ), Eukaryotic translation initiation factor 4A, isoform 2 
(EIF1AY).  
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2.8.3. qRT-PCR 
All qRT-PCR was performed using an Eppendorf Realplex 4 Mastercycler (Eppendorf, Germany). 
Master-mixes for 10µl qPCR reactions consisting of 5µl SYBR green mix (Eurogentec, Belgium), 2µl NF-
H2O (Ambion, USA) and 1µl of forward/reverse primers at a final concentration of 800nM were made 
on ice and 8µl was added to each well of a 96-well plate (Thermo Scientific, USA). cDNA (2µl at a 
concentration of 12.5ng/µl) was then added to each well, the plate was sealed, vortexed for 30 
seconds and centrifuged at 1100g for 2 minutes. The qPCR cycling conditions were as follows: 95oC for 
5 minutes (activation of SYBR green), followed by 40 cycles of denaturing at 95oC for 15 seconds, 
annealing at 62oC for 45 seconds and extension at 72oC for 15 seconds. Melting curve analysis was 
used to confirm the specificity of the PCR product.  
 
2.8.4. Statistical analysis of qRT-PCR 
A geNorm 12 housekeeping reference gene kit (Primerdesign, UK), was used to normalise qPCR data. 
The geNorm algorithm was applied to determine the best housekeeping reference genes to normalise 
qRT-PCR data to by ranking each reference gene in order of stability of expression using the geNorm 
software provided. The geometric mean of three housekeeping genes; Tyrosine 3-
Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, Zeta (YWHAZ), Eukaryotic 
Translation Initiation Factor 4A2 (EIF4A2) and Hypoxanthine Phosphoribosyltransferase (HPRT) were 
chosen as they were the most stable across different samples. The fold-changes in mRNA expression 
were calculated using the standard ΔΔCt method (Livak and Schmittgen, 2001). ΔCt values were 
calculated using the formula Ct (gene)-Ct (geometric mean of 3 housekeeping genes). ΔΔCt values were 
calculated using the formula ΔCt (gene) - ΔCt (average basal gene). Fold-changes were calculated using 
the standard 2-ΔΔCt methods. Statistical analyses were performed on the ΔCt values using GraphPad 
PRISM 6 software (GraphPad Software, USA). A Student’s t-test was used to detect significant 
differences between two different groups. One-way analysis of variance with a Tukey’s post hoc or 
two-way analysis with a Bonferroni post hoc test was used to compare multiple groups. A p value of 
<0.05 was considered to be statistically significant. 
 
2.9. Histological analysis 
2.9.1. Slide preparation 
Formalin-fixed, paraffin-embedded sections of lung tissue derived from in-house archival banks 
obtained with patient consent and ethical approval for use in research, were placed on a cold plate 
(Tissue Tek III) (Sakura, USA) before 3µm lung sections were cut and adhered to Poly-L-lysine slides 
(VWR International, USA). All slides were left overnight to dry at room temperature. Slides were then 
secured in a cassette allowing lung sections to be dewaxed in xylene, rehydrated in decreasing 
concentrations of ethanol (100%, 70% and 30%) and washed in PBS.  
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2.9.2. Antigen retrieval  
To determine the best method for detecting TNXB, three different antigen unmasking techniques 
were tested: no antigen retrieval using 1x Tris Buffered Saline (1xTBS), microwaving lung sections in 
10mM citrate buffer, pH6.0 (2 x 10 minutes), and incubation with 0.05% saponin (Sigma, USA) at room 
temperature for 30 minutes. Slides were washed in 1xTBS for 2 x 5 minutes and then incubated at 
room temperature for 30 minutes with 3% hydrogen peroxide to block endogenous peroxidase. Slides 
were then washed in 1xTBS for 2 x 5 minutes and incubated for 20 minutes at room temperature with 
2-3 drops of horse serum block (ImmPRESS reagent kit) (Vector Laboratories, UK). Different 
concentrations of primary antibodies were made in 1%BSA/TBS to determine optimum conditions. 
Slides were incubated at 4oC overnight in a humidified chamber.  Slides were washed in 1xTBS (2 x 5 
minutes). ImmPRESS reagent anti-rabbit IgG peroxidase (Vector Laboratories) was added to slides and 
incubated at room temperature for 30 minutes. Slides were washed in 1xTBS (2 x 5 minutes) and 
incubated at room temperature for 3 minutes with ImmPACT NovaRED peroxidase (Vector 
Laboratories). Slides were then rinsed with H2O, counterstained with haematoxylin and sealed with 
coverslips. Lung tissue sections were then visualised and analysed using a Nanozoomer (Hamamatsu, 
Japan) and NanoZoomer Digital Pathology Virtual Slide Viewer software (Hamamatsu, Japan). Saponin 
and no antigen retrieval methods showed similar staining and 5µg/ml of primary antibody was 
determined suitable to use (Figure 2.9.2.1). After optimisation, no antigen retrieval and staining with 
5ug/ml antibody were used for all IHC experiments. 
 
Figure 2.9.2.1. Immunohistochemical staining of TNXB in human lung using no antigen retrieval. 
Histological sections of human IPF lung specimens stained with: A) 20µg/ml IgG isotype control, B) 
20µg/ml TNXB, C) 10µg/ml TNXB, D) 5µg/ml TNXB. At the highest concentration (20µg/ml), TNXB 
staining was very strong. Very weak staining was observed using an IgG isotype control at a 20µg/ml 
concentration. To avoid high background staining a 5µg/ml concentration of anti-TNXB was chosen. 
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2.10. siRNA transfection 
IPF and control primary human lung fibroblasts were transfected using INTERFERin (Polyplus 
Transfection, USA) following the manufacturer’s protocol. Ambion siRNA targeting TNXB was 
reconstituted to 20µM stocks in NF-H20 (Ambion, USA). A range of concentrations (1µM, 5µM 10µM 
and 20µM) were tested to optimise TNXB knockdown, with 10µM being the most efficient. Cells at 
passage ≤ 8 were seeded in a 24-well plate at 25,000 cells per well at 30-50% confluence and left 
overnight. The following day 6 pmoles of TNXB siRNA (Ambion, USA) or negative control siRNA 
(Ambion, USA) was diluted in 100µl of Opti-MEM (Life Technologies, USA). INTERFERin (3µl) (Polyplus 
Transfection, USA) was added to the siRNA duplexes and immediately vortexed for 10 seconds. To 
allow transfection complexes to form between siRNA duplexes and INTERFERin, the mix was incubated 
for 10 minutes at room temperature. Fresh pre-warmed DMEM (0.5ml) was added to each well with 
100µl of transfection mix resulting in siRNA duplexes at 10nM per a well. The 24-well plates were 
incubated at 37oC for 24 hours and 48 hours. Cells were lysed using TRIzol reagent (Invitrogen, UK). 
RNA was isolated as previously described and analysed by qRT-PCR.  
 
2.10.1. Collagen gel contraction assays 
Collagen gel contraction assays are frequently used to study cell-mediated reorganisation and 
contraction of ECM (Vernon and Gooden, 2002) and are regarded as an in vitro model of wound 
contraction. Type I collagen is used as it easily polymerises to form a fibrillary network (Vernon and 
Gooden, 2002). When fibroblasts are transferred into collagen gels, they are able to reorganise the 
collagen fibres and subsequently contract the collagen gel (Bell et al, 1979). The collagen gels used to 
examine lung fibroblast-mediated collagen gel contraction were based on a previous study using 
fibroblasts (Tingstrom et al, 1992). Plates (24-wells) were coated with 1ml of 2% BSA in PBS overnight 
at 37oC and then washed PBS (3 x 1 minute) to stop cells attaching. Neutral collagen solution was 
prepared by mixing DMEM, 0.2 HEPES buffer (pH 8.0) (Sigma, UK), and 3mg/ml rat tail type I collagen, 
A1048301 (Invitrogen, UK) on ice in a 5:1:4 ratio (by volume), resulting in a collagen gel solution with 
the final concentration of 1.2mg/ml collagen. Primary human lung fibroblasts derived from IPF and 
control lung were used at passages ≤8. Cells were cultured on 6-well plates, harvested at confluency 
and resuspended in DMEM (Life Technologies, UK) at 0.5x106 cells/ml. Primary human lung fibroblasts 
(100,000 cells) in 200µl DMEM were slowly added to the collagen gel solution. Collagen solution 
containing lung fibroblasts (1ml) was slowly added into each pre-coated well. Collagen was left for 
30mins to polymerise and 1ml of DMEM was added to each well. Using a sterile needle, collagen gels 
were detached from the side of the well to ensure gels were ‘free floating’ in media.  
For collagen gel assays examining the effects of TNXB knockdown, cells were treated with 10nM TNXB 
siRNA (Ambion, USA) or 10nM non-targeting negative control siRNA (Ambion, USA) and incubated at 
37oC for 48 hours, after which they were trypsinised and resuspended in fresh DMEM before being 
added to the collagen gels. Photos of collagen gels were taken at every 24 hour time-point for 72 
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hours. Image J v1.46r (Schneider et al, 2012) was used to measure gel contraction by subtracting the 
circumference of the collagen gel at a set time-point from the original gel circumference. Statistical 
analyses were performed using GraphPad PRISM 6 software (GraphPad Software, USA). A Student’s t-
test was used to detect significant differences between two different groups. One-way analysis of 
variance with a Tukey’s post hoc or 2-way analysis with a Bonferroni post hoc test was used to 
compare multiple groups. A p value of <0.05 was considered to be statistically significant. 
 
2.11. Bisulfite sequencing of the TNXB gene 
2.11.1. Bisulfite primers for TNXB sequencing 
DNA was bisulfite converted in-house using an EZ DNA Methylation-GoldTM Kit (Zymo Research, USA) 
as previously described in section 2.5.1. TNXB bisulfite primers were designed using Methyl Primer 
Express v1.0 (Applied Biosystems, USA), Primer Blast (http://blast.ncbi.nlm.nih.gov/) and Primer3 
software (Rozen and Skaletsky, 2000). Melting temperatures were increased by increasing the length 
of primers. For unbiased amplification, no more than 1 CpG dinucleotide was included in a primer. 
The TNXB bisulfite primers used for the CpG island in exon 3 were; forward primer, 5'-
TTTGAGAAGTTTGTTYGGTATATATA-3', reverse primer, 5'-CTAAAACTTACCTCTCCCCTC-3' and exon 10;  
forward primer, 5’-GGGAAGGTTGGGAGTTAGTAG-3’, reverse primer, 5’-ACAACAACAACAAAACCAAC-
3’. 
 
2.11.2. RT-PCR and PCR purification 
RT-PCR was performed using a tetrad PTC-225, Peltier Thermal cycler (Global Medical 
Instrumentation, USA). For the TNXB bisulfite primers, a master-mix was prepared on ice, containing 
all reagents except the bisulfite-converted DNA. The final volume of each PCR reaction was 45µl, 
containing; 4.5µl of 10xPCR buffer (Applied Biosystems, USA), 3.6µl of magnesium chloride (25mM) 
(Applied Biosystems, USA), 2.25µl of both forward and reverse primers, 29.55µl of NF-H2O (Ambion, 
USA), 0.9µl of dNTP (10mM) (Applied Biosystems, USA) and 0.45µl of Taq (Applied Biosystems, USA). 
1.5µl of DNA was then added, vortexed and 20µl of mineral oil (Sigma, USA) was added to prevent any 
evaporation. PCR cycling conditions were used based on the primer melting temperatures and the 
PCR product length and were as follows: 94oC for 5 minutes, followed by 10 cycles of 94oC for 
20seconds, touchdown from 60oC to 50oC (-1 degree/cycle) for 20 seconds and 72oC for 30 seconds, 
followed by 35 cycles of 94oC for 30 seconds, 62oC for 30 seconds, 72oC for 7.5 minutes and 25oC for 
30 seconds (extention times were longer than normal as uracil decreased the rate of DNA 
polymerisation) (Darst et al, 2011). Afterwards samples were held at 4oC until storage.  
TNXB PCR products were resolved on a 1% agarose gel made with 1xTBE buffer (1g of agarose/100ml 
1xTBE), containing 3µl of a 10000X stock solution of GelRed (Biotium, UK). After the gel had set, the 
gel was covered with 1xTBE buffer. A 5x DNA loading buffer (Bioline, UK) was added to each DNA 
sample and a molecular weight maker, HyperLadder (Bioline, UK), was then added to the first lane 
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followed by each DNA sample. The 1% agarose gel was run at 80v for 1.5 hours. DNA bands were 
observed using a Syngene GeneGenuis imagining system (Syngene, UK). A QIAquick PCR purification 
kit (Qiagen, Germay) was used to purify the TNXB PCR product. Buffer was added to the sample and 
centrifuged at ≥ 10000g for 30 seconds to bind DNA. Flow through was discarded and buffer was 
added to wash DNA. DNA was then eluted by adding 50µl of 10mM Tris-Cl, pH 8.5 and centrifuging at 
≥ 10000g for 1 minute.  
 
2.11.3. Bisulfite sequencing analysis 
Bisulfite-converted DNA samples were sent to the Wolfson Institute for Biomedical Research (UCL, 
UK) for DNA sequencing. Template (10µl per a reaction) was provided in 1.5ml Eppendorf tubes at a 
concentration of ~4ng/µl. Custom primers were provided at a concentration of 5pmole/µl as 
requested. Analysis of methylation was performed using Sequence Scanner 2 software (Applied 
Biosystems, USA). The methylation percentage at each CpG site was determined by measuring the 
area of the C and T peaks using ImageJ software (Abramoff et al, 2004, Erfurth et al, 2006). Data was 
normalised to area measurements of C peaks from non-methylated cytosine nucleotides. 
 
2.12. General statistical analysis 
All analysis for methylation data is presented as the mean values ± the S.E.M unless otherwise stated. 
All analysis for expression data is presented as the geometric mean ± 95 confidence intervals (CI) 
unless otherwise stated. Statistical analyses were performed using GraphPad PRISM 6 software 
(GraphPad Software, USA). A Student’s t-test was used to detect significant differences between two 
different groups. One-way analysis of variance with a Tukey’s post hoc or 2-way analysis with a 
Bonferroni post hoc test was used to compare multiple groups. A p value of <0.05 was considered to 
be statistically significant. 
 
 
 
 
 
 
 
 
 
 
79 
 
 DNA methylation in lung fibroblasts and its role in pulmonary fibrosis 
3.1. Introduction 
Aberrant DNA methylation of multiple cell types has been implicated in a number of different fibrotic 
diseases including liver fibrosis (Komatsu et al. 2012), kidney fibrosis (Bechtel et al, 2010), IPF (Sanders 
et al, 2012, Rabinovich et al, 2012) and SSc (Wang et al, 2006). Genes including THY1 (Sanders et al, 
2008), PTGER2 (Huang et al, 2010), P14ARF (Cisneros et al, 2012) and miR-17-92 (Dakhlallah et al, 
2013) have all previously been identified as having altered methylation in IPF compared to control 
lung fibroblasts. Multiple genes including DNMT1, MBD1, MeCP2, FLI1 (Wang et al, 2006), DKK1 and 
SFRP1 (Dees et al, 2013) have altered methylation in SSc compared to control skin fibroblasts however, 
there have been no studies that examine methylation of lung fibroblasts in SSc-PF patients. 
Throughout the following result sections, all figures and text with ‘SSc’ refer to patients with SSc-PF 
as stated in section 2.3.1. 
Approximately 70% of all genes have CpG islands (CGIs) in their promoter regions (Saxonov et al, 2006) 
and aberrant methylation of CpGs located in CGIs has previously been linked to numerous diseases 
including IPF and SSc (Sanders et al, 2008, Wang et al, 2006). However, DNA methylation outside CGIs 
could be equally as important in regulating transcriptional activity (Irizarry et al, 2009). CpG 
methylation in shore regions (which flank CpG islands and can be located up to 2kb away) and shelf 
regions (which flank shore regions and can be up to 4kb away from the CpG island), may play an 
important role in disease but the role of methylation in these locations remains poorly understood 
(Irizarry et al, 2009). CpGs located beyond shelf regions are denoted as being in 'open sea' regions and 
their importance also remains poorly understood.  
The primary aims of the following experiments were to determine: 
 Methylation and expression profiles of primary human lung fibroblasts derived from IPF and 
SSc-PF patients compared with control lung fibroblasts. 
 The number and location of CpGs with altered methylation in IPF and SSc-PF compared to 
control lung fibroblasts and compared to each other. 
 Overlapping and distinct CpGs with altered methylation in IPF and SSc-PF compared to 
control lung fibroblasts. 
 Biological processes enriched in differentially methylated/expressed genes.  
 How differentially methylated/expressed genes could potentially interact with each other in 
pathways relevant to fibrosis.  
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3.2. Genome-wide distribution of DNA methylation in lung fibroblasts 
After filtering out non-specific probes and probes which covered a SNP, 324973 CpGs remained on 
the array. The average methylation value (ß value) of each CpG in control (n=6), IPF (n=5) and SSc 
(n=7) lung fibroblasts identified a bimodal distribution of CpG methylation on autosomes, with the 
highest frequency of CpGs having low methylation (0-15%) and high methylation (80-90%) (Figure 
3.2.1). The X-Chromosome also had a bimodal distribution but CpGs were more partially methylated 
with the highest frequencies of CpGs having 25-35% and 75-80% methylation (Figure 3.2.1).  
 
 
Figure 3.2.1. Distribution of CpG methylation across the genome in autosomes and the X-
chromosome. Each bar represents the number of CpGs within each boundary. The β value represents 
the level of methylation (0= unmethylated, 1= methylated). Red: Control (n=6), blue: IPF (n=5) and 
yellow: SSc (n=7) lung fibroblasts.  
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A high frequency of CpGs with low (0-15%) methylation were located in CGIs within 1.5kb of their 
corresponding genes transcription start site (TSS) (Figure 3.2.2). This confirms previous data which 
showed hypomethylated CpG sites are more commonly found in CpG islands and within 1.5kb of the 
TSS of a gene (Jones, 2012, Wagner et al, 2014). In contrast, CpGs located in islands further than 1.5kb 
away from their corresponding genes TSS showed a bimodal pattern of methylation with the highest 
frequencies of CpGs occurring at 0-15% and 80-85% methylation (Figure 3.2.2).  
CpGs in north and south shore regions within 1.5kb of their corresponding genes TSS had higher 
frequencies of CpGs with low methylation compared to CpGs in north and south shore regions further 
than 1.5kb away from their corresponding genes TSS (Figure 3.2.3). In north and south shelves, CpGs 
within and further than 1.5kb of their genes corresponding TSS had the highest frequency of CpGs 
with high (85-90%) methylation. CpGs in open sea regions within 1.5kb of their corresponding genes 
TSS had a bimodal distribution of CpG methylation, with the highest frequencies of CpGs having 10-
15% and 85-90% methylation. The majority of CpGs in open sea regions further than 1.5kb away from 
their corresponding genes TSS had high (85-90%) methylation (Figure 3.2.3).   
 
 
Figure 3.2.2. Distribution of CpG methylation across the genome in CpG islands in relation to the 
distance from the corresponding gene’s transcription start site (TSS). Each bar represents the 
number of CpGs within each boundary. The β value represents the level of methylation (0= 
unmethylated, 1= methylated). Red: Control (n=6), blue: IPF (n=5) and yellow: SSc (n=7) lung 
fibroblasts.  
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Figure 3.2.3. Distribution of CpG methylation across the genome in shore, shelf and open sea regions 
in relation to the distance from the corresponding gene’s TSS. Each bar represents the number of 
CpGs within each boundary. The β value represents the level of methylation (0= unmethylated, 1= 
methylated). Red: Control (n=6), blue: IPF (n=5) and yellow: SSc (n=7).  
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3.3. Microarray analysis of differentially methylated genes in IPF and SSc compared 
to control primary human lung fibroblasts 
Multiple CpGs were identified as having significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF 
and SSc compared to control lung fibroblasts. The distribution of these CpGs showed a partially 
methylated pattern of methylation in control and IPF lung fibroblasts with the highest frequency of 
CpGs having 45-65% methylation in IPF compared to 60-80% in control lung fibroblasts (Figure 3.3.1). 
The distribution of CpG methylation showed SSc also had a partially methylated pattern of 
methylation (Figure 3.3.2) with the highest frequency of CpGs having 35-65% methylation in SSc 
compared to 20-55% in control lung fibroblasts.  
 
 
Figure 3.3.1. Distribution of CpGs which had altered methylation in IPF compared to control lung 
fibroblasts. Each bar represents the number of CpGs within each boundary which had significantly 
altered methylation (Δβ ≥ 0.136; P<0.05) in IPF (n=5) compared to control (n=6) lung fibroblasts. The 
β value represents the level of methylation (0= unmethylated, 1= methylated). Red: Control (n=6), 
blue: IPF (n=5).  
 
 
Figure 3.3.2. Distribution of CpGs which had significantly altered methylation in SSc compared to 
control lung fibroblasts. Each bar represents the number of CpGs within each boundary which had 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) in SSc (n=7) compared to control (n=6) lung 
fibroblasts. The β value represents the level of methylation (0= unmethylated, 1= methylated). Red: 
Control (n=6), yellow: SSc (n=7).  
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7153 CpGs corresponding to 4563 genes in IPF and 8392 CpGs corresponding to 5294 genes in SSc had 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) compared to control lung fibroblasts. The 
average methylation of each CpG with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF 
compared to control and SSc compared to control lung fibroblasts is shown in (Figure 3.3.3). 4908 
CpGs (69%) of the 7153 significantly differentially methylated (Δβ ≥ 0.136; P<0.05) CpGs in IPF 
compared to control lung fibroblasts, had significantly decreased methylation (Δβ ≥ 0.136; P<0.05). 
This represented a predominance of CpGs with decreased methylation in IPF lung fibroblasts (Table 
3.3.1). Conversely in SSc lung fibroblasts, 5609 (67%) of the 8392 significantly differentially methylated 
(Δβ ≥ 0.136; P<0.05) CpGs in SSc compared to control lung fibroblasts, had significantly increased 
methylation (Δβ ≥ 0.136; P<0.05). This represented a predominance of CpGs with increased 
methylation in SSc lung fibroblasts (Table 3.3.1). 
 
 
Figure 3.3.3. Scatter plots of CpGs with significantly altered methylation in IPF and SSc compared to 
control lung fibroblasts. Scatter plots show the average methylation in IPF (n=5) compared to control 
(n=6) and SSc (n=7) compared to control (n=6) lung fibroblasts. Each dot represents a CpG with either 
a P<0.05; Δβ< 0.136 (<13.6% change in methylation) (●) or a Δβ ≥ 0.136; P<0.05 (≥ 13.6% change in 
methylation) (●). 
 
Fibroblast 
source 
CpG sites with increased 
methylation 
CpG sites with decreased 
methylation 
Total number of 
CpG sites 
IPF 2245 4908 7153 
SSc 5609 2783 8392 
Table 3.3.1. Number of CpG with altered methylation in IPF/SSc compared to control lung 
fibroblasts. The number of CpG sites which had significantly altered methylation (Δβ ≥ 0.136; P<0.05) 
in IPF (n=5) and SSc (n=7) compared to control (n=6) lung fibroblasts.  
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Hierarchical cluster analysis on the 7153 CpGs which had significantly altered methylation (Δβ ≥ 0.136; 
P<0.05) in IPF compared to control lung fibroblasts identified IPF cell lines cluster together (Figure 
3.3.4). Hierarchical cluster analysis on the 8392 CpGs which had significantly altered methylation (Δβ 
≥ 0.136; P<0.05) in SSc compared to control lung fibroblasts identified all SSc cell lines clustered 
together, however, control cell line 6 had a similar methylation profile to SSc cell lines (Figure 3.3.4). 
The top ten CpGs with the greatest increased and decreased methylation in IPF and SSc compared to 
control lung fibroblasts are shown in Table 3.3.2 and Table 3.3.3. 
 
 
Figure 3.3.4. Hierarchical clustering based on CpGs with altered methylation in IPF and SSc 
compared to control lung fibroblasts. Heat-maps show CpGs with significantly altered (Δβ ≥ 0.136; 
P<0.05) methylation (n=7153) in IPF (n=5) and (n=8392) in SSc (n=7) compared to control (n=6) lung 
fibroblasts. Light blue represents low methylation, yellow represents high methylation with respect 
to each CpG across all cell lines.  
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Top 10 CpGs with increased methylation in IPF compared to control lung fibroblasts 
TSS Gene name Symbol Chr Location P value Δβ 
2585 Forkhead box P1 FOXP1 3 N_Shelf 0.001472 0.44837 
1188 Wingless-type MMTV integration 
site family, member 5A 
WNT5A 3 N_Shore 0.002809 0.42303 
2221 Proteasome assembly chaperone 3 PSMG3 7 N_Shelf 0.01675 0.40959 
3187 Zinc finger protein, multitype 2 ZFPM2 8 S_Shelf 0.007444 0.40484 
17980 Forkhead box P1 FOXP1 3 Open_sea 0.002096 0.4022 
46045 Long intergenic non-protein coding 
RNA 284 
LINC0284 13 Open_sea 0.000222 0.39743 
3958 Synaptopodin 2 SYNPO2 4 Open_sea 0.042721 0.39036 
40713 Collagen, type IV, alpha 2 COL4A2 13 Open_sea 0.003676 0.3892 
56446 AX748239 AX748239 8 Island 0.021265 0.38691 
70596 Homolog of rat pragma of Rnd2 SGK223 8 Open_sea 0.005544 0.38075 
Top 10 CpGs with decreased methylation in IPF compared to control lung fibroblasts 
-291 Bone morphogenetic protein 4 BMP4 14 S_Shore 0.002545 -0.497547 
285961 Chromosome 22 open reading 
frame 34 
C22orf34 22 Island 0.005924 -0.459054 
13 Chromosome 19 open reading 
frame 59 
C19orf59 19 N_Shelf 0.000128 -0.455819 
354 Sidekick cell adhesion molecule 1 SDK1 7 Open_sea 0.002093 -0.430344 
-52 Ret finger protein-like 2 RFPL2 22 Open_sea 0.010819 -0.430104 
-24273 AL832737 AL832737 6 S_Shore 0.008077 -0.420629 
1160 Ankyrin repeat and SOCS box 
containing 2 
ASB2 14 Island 0.026261 -0.419376 
-99424 AK126852 AK126852 16 Island 0.007678 -0.414982 
-2411 Frizzled class receptor 7 FZD7 2 N_Shore 0.030301 -0.412765 
-470 Estrogen receptor 1 ESR1 6 N_Shelf 9.69E-05 -0.40573 
Table 3.3.2. Top 10 most differentially methylated CpGs with increased and decreased methylation 
in IPF compared to control lung fibroblasts. The distance in base pairs (bp) the CpG is from its 
corresponding genes transcription start site (TSS), the gene which the CpG corresponds to, which 
chromosome the gene is on, the location of where the CpG is in relation to CpG islands, and the 
average difference in methylation (Δβ) between control (n=6) and IPF (n=5) is shown.  
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Top 10 CpGs with increased methylation in SSc compared to control lung fibroblasts 
TSS Gene name Symbol Chr Location P value Δβ 
-388 Solute carrier family 37 member 
2 
SLC37A2 11 N_Shore 0.000514 0.49385 
34647 Long intergenic non-protein 
coding RNA 523 
LINC00523 14 Open_sea 0.001112 0.46801 
-125 Solute carrier family 25 member 
2 
SLC25A2 5 Island 0.000472 0.44709 
-8091 Dihydrouridine synthase 3-like DUS3L 19 Island 0.000307 0.42738 
-99840 PR domain zinc finger protein 1 PRDM1 6 Island 0.000194 0.42273 
9846 BC061632 BC061632 3 Open_sea 0.005037 0.41355 
3098 LIM homeobox 4 LHX4 1 Island 0.000138 0.41105 
20098 Testis specific protein, Y-linked 1 TSPY1 Y Island 0.002806 0.40858 
8078 Collagen, type IV, alpha 1 COL4A1 13 Open_sea 7.46E-05 0.4011 
-2049 Neuroligin 4, Y-linked NLGN4Y Y N_Shelf 0.002027 0.40061 
Top 10 CpGs with decreased methylation in SSc compared to control lung fibroblasts 
201986 LOC286083 LOC286083 8 Island 0.000301 -0.403498 
-10189 Chromosome 10 open reading 
frame 11 
C10orf11 10 Open_sea 0.002153 -0.394424 
64108 Rabphilin 3A-like RPH3AL 17 N_Shore 0.000114 -0.391314 
-1325 Peptidylprolyl isomerase A 
(cyclophilin A)-like 4A 
PPIAL4A 1 Open_sea 0.000155 -0.36739 
54267 BC039356 BC039356 1 Open_sea 0.001861 -0.357374 
6930 Coiled-coil domain containing 
102B 
CCDC102B 18 Open_sea 0.006385 -0.356484 
30437 Semaphorin 3E SEMA3E 7 Open_sea 0.000939 -0.351348 
190871 AK126491 AK126491 10 Open_sea 0.003145 -0.335878 
8377 Cat eye syndrome chromosome 
region, candidate 1 
CECR1 22 Open_sea 0.001681 -0.329455 
-202 MX dynamin like GTPase 2 MX2 21 Open_sea 0.000812 -0.324892 
Table 3.3.3. Top 10 most differentially methylated CpGs with increased and decreased methylation 
in SSc compared to control lung fibroblasts. The distance in base pairs (bp) the CpG is from its 
corresponding genes transcription start site (TSS), the gene which the CpG corresponds to, which 
chromosome the gene is on, the location of where the CpG is in relation to CpG islands, and the 
average difference in methylation (Δβ) between control (n=6) and SSc (n=7) is shown. 
 
3.3.1. Overlapping differentially methylated CpGs and genes in IPF and SSc 
compared to control primary human lung fibroblasts 
Multiple genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) had CpGs which overlapped 
between IPF and SSc lung fibroblasts. Of the 2245 CpG sites which had increased methylation in IPF 
compared to control lung fibroblasts, 729 (33%) were the same CpG sites which had increased 
methylation in SSc compared to control lung fibroblasts. These 2245 CpG sites with increased 
methylation in IPF compared to control lung fibroblasts corresponded to 1767 genes of which 983 
(55%) were the same genes with increased methylation in SSc compared to control lung fibroblasts 
(Figure 3.3.1.1). Of the 2783 CpG sites which had decreased methylation in SSc compared to control 
lung fibroblasts, 735 (26%) were the same CpG sites which had decreased methylation in IPF compared 
to control lung fibroblasts. These 2783 CpGs with decreased methylation in SSc compared to control 
lung fibroblasts corresponded to 2109 genes of which 942 (45%) were the same genes with decreased 
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methylation in IPF compared to control lung fibroblasts (Figure 3.3.1.1). These data suggest there are 
multiple common differentially methylated CpGs and genes in IPF and SSc compared to control lung 
fibroblasts (Figure 3.3.1.2). Furthermore, more genes overlap in IPF and SSc compared to CpGs, 
suggesting that for some genes, different CpGs of the same genes are affected. However, many 
differentially methylated CpGs and genes were distinct to either IPF or SSc (Figure 3.3.1.3) which may 
in part explain the phenotypic differences of each disease. 
 
 
Figure 3.3.1.1. Overlapping and distinct CpGs/genes in IPF and SSc compared to controls. Number of 
distinct and overlapping CpGs and their corresponding genes which had significantly altered 
methylation (Δβ ≥ 0.136; P<0.05) in IPF (n=5) and SSc (n=7) compared to control (n=6) lung fibroblasts. 
 
.  
Figure 3.3.1.2. Overlapping CpGs which have altered methylation in both IPF and SSc compared to 
control lung fibroblasts. Examples of genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) 
in IPF and/or SSc compared to control lung fibroblasts. ● Control (n=6), ▲  IPF (n=5), ■ SSc (n=7). Each 
point represents a different cell line. Data presented as the mean ± the SEM. One-way ANOVA was 
performed with Tukey’s post hoc test for statistical analysis.  
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Figure 3.3.1.3. Distinct CpGs which have altered methylation in IPF or SSc compared to control lung 
fibroblasts. Examples of genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF or SSc 
compared to control lung fibroblasts. ● Control (n=6), ▲  IPF (n=5), ■ SSc (n=7). Each point represents 
a different cell line. Data presented as the mean ± the SEM. One-way ANOVA was performed with 
Tukey’s post hoc test for statistical analysis. Differentially methylated CpGs and genes in IPF compared 
to SSc primary human lung fibroblasts. 
 
3.4. Differentially methylated CpGs in IPF compared to SSc lung fibroblasts 
Multiple CpGs were identified as having significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF 
compared to SSc lung fibroblasts. The distribution of these CpGs showed that the majority had a 
partially methylated pattern of methylation which was skewed towards lower methylation in IPF 
compared to SSc lung fibroblasts (Figure 3.4.1). Open sea regions distal to a genes TSS had the highest 
frequency of CpGs with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc 
lung fibroblasts (Figure 3.4.2). There was a higher frequency of CpGs with low methylation (<30%) and 
a lower frequency of CpGs with high methylation (>80%) in IPF compared to SSc lung fibroblasts in all 
regions, which was most apparent in CpG islands within 1.5kb of a genes TSS (Figure 3.4.2).  
 
 
Figure 3.4.1. Distribution of CpGs which have altered methylation in IPF compared to SSc lung 
fibroblasts. Each bar represents the number of CpGs within each boundary with significantly altered 
methylation (Δβ ≥ 0.136; P<0.05) in IPF (n=5) compared to SSc (n=7) lung fibroblasts. The β value 
represents the level of methylation (0= unmethylated, 1= methylated).  
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Figure 3.4.2. Distribution of CpGs which had altered methylation in IPF compared to SSc lung 
fibroblasts in relation to their corresponding gene’s TSS. Each bar represents the number of CpGs 
within each boundary with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF (n=5) 
compared to SSc (n=7) lung fibroblasts. The β value represents the level of methylation (0= 
unmethylated, 1= methylated).  
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7827 CpGs corresponding to 5082 genes in IPF had significantly altered methylation (Δβ ≥ 0.136; 
P<0.05) compared to SSc lung fibroblasts. 2085 CpGs corresponding to 1701 genes had significantly 
increased methylation (Δβ ≥ 0.136; P<0.05) and 5742 CpGs corresponding to 3835 genes had 
significantly decreased methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc lung fibroblasts. 
Cluster analysis identified all IPF lung fibroblast cell lines clustered separately from all SSc lung 
fibroblast cell lines (Figure 3.4.3). Examples of CpGs and their corresponding genes which had 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc lung fibroblasts are 
shown in Figure 3.4.4. 
 
 
Figure 3.4.3. Hierarchical clustering based on CpGs with significantly altered methylation (Δβ ≥ 
0.136; P<0.05) in IPF compared to SSc lung fibroblasts. Heat-map shows the differentially methylated 
CpGs (n=7827) in IPF (n=5) and compared to SSc (n=7) lung fibroblasts. Light blue represents low 
methylation, yellow represents high methylation.  
 
 
Figure 3.4.4. CpGs which have decreased methylation in IPF compared to SSc lung fibroblasts. 
Examples of genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc 
lung fibroblasts. ▲ IPF (n=5), ■ SSc (n=7). Each point represents a different cell line. Data presented as 
the mean ± the SEM.  
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3.5. Location of differentially methylated CpGs in IPF and SSc compared to control 
primary human lung fibroblasts 
As previously discussed (see chapter 1: section 1.7.4), the location of CpG methylation in relation to 
CpG islands, shores, shelves and open sea regions may be important in regulating gene expression. 
The average methylation and location of the 7153 CpGs with significantly altered methylation (Δβ ≥ 
0.136; P<0.05) in IPF compared to control lung fibroblasts is shown in Figure 3.5.1. In order to 
determine whether any region was overrepresented, the observed (O) number of CpGs in each region 
were compared to the number of CpGs expected (E) in each region. North shore (O/E: 1.19), south 
shore (O/E: 1.18) and open sea (O/E: 1.46) regions had more than the expected number of CpGs with 
increased methylation in IPF compared to control lung fibroblasts whereas island (O/E: 0.27) regions 
had fewer CpG sites than expected. North shelf (O/E: 1.38), south shelf (O/E: 1.38) and open sea (O/E 
1.52) regions had more than the expected number of CpGs sites with decreased methylation in IPF 
compared to control lung fibroblasts whereas as island (O/E: 0.41) regions had fewer CpG sites than 
expected (Table 3.5.1). 
The average methylation and location of the 8392 CpGs with significantly altered methylation (Δβ ≥ 
0.136; P<0.05) in SSc compared to control lung fibroblasts is shown in Figure 3.5.2. North shore (O/E: 
1.20), south shore (O/E: 1.31) and open sea (O/E: 1.14) regions had more than the expected number 
of CpGs with increased methylation in SSc compared to control lung fibroblasts whereas island (O/E: 
0.74) regions had fewer CpG sites than expected. North shelf (O/E: 1.27), south shelf (O/E: 1.21) and 
open sea (O/E 1.78) regions had more than the expected number of CpGs sites with decreased 
methylation in IPF compared to control lung fibroblasts whereas island (O/E: 0.26) regions had fewer 
CpG sites than expected (Table 3.5.2). 
 
93 
 
           
Figure 3.5.1. CpGs with altered methylation in relation to CpG islands in IPF compared to control 
lung fibroblasts. Left: scatter plots showing the average methylation and the location of each CpG 
with a significant difference (P<0.05) in methylation between IPF (n=5) and control (n=6) lung 
fibroblasts. Each dot represents a CpG with either a Δβ< 0.136 (<13.6% change in methylation) (●) or 
a Δβ ≥ 0.136 (≥ 13.6% change in methylation) between IPF and control lung fibroblasts (●). Right: bar 
graphs showing the number of CpGs in different locations with significantly altered methylation (Δβ ≥ 
0.136; P<0.05) in IPF compared to control lung fibroblasts. 
 
Location Total no. 
of CpGs 
CpGs with increased methylation in 
IPF 
CpGs with decreased 
methylation in IPF 
Observed Expected O/E Observed Expected O/E 
Island 108197 313 747 0.42* 672 1634 0.41* 
N_Shelf 15598 96 108 0.89 324 236 1.38* 
N_Shore 43922 360 303 1.19* 616 663 0.93 
Open_sea 108961 1102 753 1.46* 2503 1646 1.52* 
S_Shelf 14040 94 97 0.97 293 212 1.38* 
S_Shore 34255 280 237 1.18* 500 517 0.97 
Total 324973       
Table 3.5.1. Observed to expected ratio (O/E) of the number of CpGs in each location with altered 
methylation in IPF compared to control lung fibroblasts. CpGs with significantly altered methylation 
(Δβ ≥ 0.136; P<0.05) in IPF (n=5) compared to control (n=6) lung fibroblasts. *= Chi-square value; 
P<0.05.  
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Figure 3.5.2. CpGs with altered methylation in relation to CpG islands in SSc compared to control 
lung fibroblasts. Left: scatter plots showing average methylation and the location of each CpG with a 
significant difference (P<0.05) in methylation between SSc (n=7) and control (n=6) lung fibroblasts. 
Each dot represents a CpG with either a Δβ< 0.136 (<13.6% change in methylation) (●) or a Δβ ≥ 0.136 
(≥ 13.6% change in methylation between IPF and control lung fibroblasts (●). Right: bar graphs 
showing the number of CpGs in different locations with significantly altered methylation (Δβ ≥ 0.136; 
P<0.05) in SSc compared to control lung fibroblasts. 
 
Location Total no. 
of CpGs 
CpGs with increased methylation in 
SSc 
CpGs with decreased 
methylation in SSc 
Observed Expected O/E Observed Expected O/E 
Island 108197 1383 1867 0.74* 238 927 0.26* 
N_Shelf 15598 209 269 0.78* 170 134 1.27* 
N_Shore 43922 912 758 1.20* 339 376 0.90 
Open_sea 108961 2152 1881 1.14* 1660 933 1.78* 
S_Shelf 14040 180 242 0.74* 146 120 1.21* 
S_Shore 34255 773 591 1.31* 230 293 0.78* 
Total 324973       
Table 3.5.2. Observed to expected ratio (O/E) of the number of CpGs in each location with altered 
methylation in SSc compared to control lung fibroblasts. CpGs with significantly altered methylation 
(Δβ ≥ 0.136; P<0.05) in SSc (n=7) compared to control (n=6) lung fibroblasts. *= Chi-square P<0.05.  
 
 
3.6. Location of differentially methylated CpGs in IPF compared to SSc primary 
human lung fibroblasts 
The average methylation and location of the 7827 CpGs with significantly altered methylation (Δβ ≥ 
0.136; P<0.05) in IPF compared to SSc lung fibroblasts is shown in Figure 3.6.1. North shelf (O/E: 1.36) 
and open sea (O/E: 1.91) regions had more than the expected number of CpGs with increased 
95 
 
methylation in IPF compared to SSc lung fibroblasts. The number of CpGs observed in island regions 
with increased methylation in IPF compared to SSc lung fibroblasts were fewer than expected (O/E: 
0.27). CpGs sites with decreased methylation in IPF compared to SSc lung fibroblasts were more 
abundant than expected in north shore (O/E: 1.22) and south shore (O/E: 1.20) regions. Island (O/E: 
0.88), north shelf (O/E: 0.89) and south shelf (O/E: 0.73 had fewer than expected CpG sites with 
decreased methylation in IPF compared to SSc lung fibroblasts (Table 3.6.1). 
 
       
Figure 3.6.1. CpGs with altered methylation in relation to CpG islands in IPF compared to SSc lung 
fibroblasts. Left: scatter plots showing average methylation and the location of each CpG with a 
significant difference (P<0.05) in methylation between IPF (n=5) and SSc (n=7) lung fibroblasts. Each 
dot represents a CpG with either a Δβ< 0.136 (<13.6% change in methylation) (●) or a Δβ ≥ 0.136 (≥ 
13.6% change in methylation (●).Right: bar graphs showing the number of CpGs in different locations 
with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc lung fibroblasts. 
 
Location Total no. 
of CpGs 
CpGs with increased methylation 
in IPF 
CpGs with decreased 
methylation in IPF 
Observed Expected O/E Observed Expected O/E 
Island 108197 190 694 0.27* 1679 1912 0.88 
N_Shelf 15598 136 100 1.36* 245 276 0.89 
N_Shore 43922 290 282 1.03 948 776 1.22* 
Open_sea 108961 1171 699 1.68* 1965 1925 1.02 
S_Shelf 14040 90 90 1.00 181 248 0.73* 
S_Shore 34255 208 220 0.95 724 605 1.20* 
Total 324973       
Table 3.6.1. Observed to expected ratio (O/E) of the number of CpGs in each location with altered 
methylation in IPF compared to SSc lung fibroblasts. CpGs with significantly altered methylation (Δβ 
≥ 0.136; P<0.05) in IPF (n=5) compared to SSc (n=7) lung fibroblasts. *= Chi-square P<0.05.  
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3.7. Bisulfite sequencing validation of the Illumina Infinium Human Methylation 
450 BeadChip microarray using TNXB. 
The Illumina Infinium 450k methylation microarray identified TNXB as having a large number of CpGs 
with significantly altered methylation (P<0.05), many of which had large (≥13.6%) changes. As 
previously discussed, TNXB belongs to the tenascin family of ECM which consists of four family 
members: TNXB, TNR, TNC, and TNW. The TNXB gene contains 44 exons and encodes a large (464kDa) 
ECM, TNX, which is involved in collagen deposition, matrix stiffness and cell adhesion. 
Hypomethylation of a CGI located in exon 3 (-931 from the TNXB TSS) of the TNXB gene has previously 
been shown to correlate with increased tenascin-X expression in muscle tissue (Rakyan et al, 2004), 
suggesting that methylation could be important for tenascin-X gene activity. SP1 and SP3 binding sites 
in the TNXB promoter region have also been suggested to be important in regulating TNXB 
transcription (Wijesuriya et al, 2002). Other regions such as enhancers or other CpGs may also be 
important but the mechanisms of TNXB regulation remain poorly understood and no studies to date 
have examined the methylation or expression of TNXB in IPF or SSc lung fibroblasts. 
 
To validate the Illumina Infinium 450k methylation microarray, bisulfite sequencing was performed 
on the TNXB gene. Microarray analysis identified 88 CpG sites in the TNXB gene with altered (P<0.05) 
methylation (14 increased, 74 decreased) in IPF compared to control lung fibroblasts (Figure 3.7.1). 
Ten of these CpGs had ≥ 13.6% increases in methylation, whilst 17 of these CpGs had ≥ 13.6% 
decreases in methylation. 151 CpG sites were identified as having altered (P<0.05) methylation (73 
increased, 78 decreased) in SSc compared to control lung fibroblasts (Figure 3.7.2). 38 of these CpGs 
had ≥ 13.6% increases in methylation, whilst only 3 of these CpGs had ≥ 13.6% decreases in 
methylation. These data suggest that TNXB has decreased methylation in IPF compared to control lung 
fibroblasts whereas SSc lung fibroblasts have increased methylation of TNXB. Furthermore, 139 CpGs 
were identified as having significantly (P<0.05) altered methylation (35 increased, 104 decreased) 
methylation in IPF compared to SSc lung fibroblasts (Figure 3.7.3). CpG sites with increased 
methylation (≥ 13.6%) in IPF compared with control lung fibroblasts were mainly located in a north 
shelf region flanking the CGI in exon 10. CpGs with decreased methylation (≥ 13.6%) were 
predominantly found in the open sea regions and in a south shelf region flanking the CGI in exon 10 
(Figure 3.7.4). Only 4 CpG sites had increased (≥ 13.6%) methylation in IPF compared to SSc lung 
fibroblasts, all of which were located in the north shore regions flanking the CGI located in intron 6 of 
the TNXB gene. CpG sites with increased methylation (≥ 13.6%) in SSc compared to control lung 
fibroblasts were mainly located in CGIs, north shelf regions and open sea regions (Figure 3.7.4). 
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Figure 3.7.1. Location of CpGs in the TNXB gene which have altered methylation in IPF compared to 
control lung fibroblasts. Each dot represents a different CpG which had significantly (P<0.05) altered 
methylation in IPF (n=5) compared to control (n=6) lung fibroblasts. ● CpGs with a Δβ ≤ 0.136 (≤13.6% 
change in methylation), ● CpGs with a Δβ ≥ 0.136 (≥ 13.6% change in methylation). The β value 
represents the level of methylation (0= unmethylated, 1= methylated). 
 
 
Figure 3.7.2. Location of CpGs in the TNXB gene which have altered methylation in SSc compared to 
control lung fibroblasts. Each dot represents a different CpG which had significantly (P<0.05) altered 
methylation in SSc (n=7) compared to control (n=6) lung fibroblasts. ● CpGs with a Δβ ≤ 0.136 (≤13.6% 
change in methylation), ● CpGs with a Δβ ≥ 0.136 (≥ 13.6% change in methylation). The β value 
represents the level of methylation (0= unmethylated, 1= methylated). 
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Figure 3.7.3. Location of CpGs in the TNXB gene which have altered methylation in IPF compared to 
SSc lung fibroblasts. Each dot represents a different CpG which had significantly (P<0.05) altered 
methylation in IPF (n=5) compared to SSc (n=7) lung fibroblasts. ● CpGs with a Δβ ≤ 0.136 (≤13.6% 
change in methylation), ● CpGs with a Δβ ≥ 0.136 (≥ 13.6% change in methylation). The β value 
represents the level of methylation (0= unmethylated, 1= methylated). 
 
 
The microarray identified 2 CpGs within the exon 3 CGI which contained significantly altered 
methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to control lung fibroblasts. In the exon 3 CGI, 14 
CpG sites had significantly increased methylation (Δβ ≥ 0.136; P<0.05) in SSc compared to control lung 
fibroblasts (Figure 3.7.4). A 349bp region within this CGI was bisulfite sequenced to validate the 
microarray data. This region included 7 CpGs which were identified on the microarray. Bisulfite 
sequencing showed the differences in methylation between control, IPF and SSc lung fibroblasts was 
in agreement with microarray data (Pearsons correlation: r=0.77), although these differences in 
methylation were generally smaller (Figure 3.7.5).  
 
 
Figure 3.7.4. Diagram of the TNXB gene. The location of 27 CpGs with significantly altered methylation 
(Δβ ≥ 0.136; P<0.05) in IPF (n=5) and 41 CpGs with significantly altered methylation (Δβ ≥ 0.136; 
P<0.05) in SSc (n=7) compared to control (n=6) lung fibroblasts. ▲  represents IPF CpGs, ■ represents 
SSc CpGs. 3 CGIs located in exon 3, intron 6 and exon 10 were identified by the microarray.  
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Figure 3.7.5. Validation of microarray data using bisulfite sequencing on 7 CpGs located in the exon 
3 CpG island. CpGs with a significant difference in methylation in IPF (blue; n=5) and/or SSc (yellow; 
n=7) compared to control (red; n=6) lung fibroblasts using, top; microarray data, bottom; bisulfite 
sequencing. Data presented as the mean ± S.E.M.  
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The CpG island in exon 10 had 5 CpG sites which were covered by the array, 1 of which had a significant 
(P<0.05) decrease in methylation in IPF compared to control lung fibroblasts. A 440bp region covering 
more CpGs than the array (19 CpGs) within this CGI was bisulfite sequenced to further explore changes 
in TNXB methylation in IPF lung fibroblasts. Seven of these CpGs had significantly (P<0.05) decreased 
methylation in IPF compared to control lung fibroblasts. Five of these CpGs also had significantly 
(P<0.05) decreased methylation in IPF compared to SSc lung fibroblasts (Figure 3.7.6). 
 
 
 
Figure 3.7.6. Bisulfite sequencing of CpGs located in the exon 10 CpG island. Seven CpGs with 
significantly (P<0.05) altered methylation in IPF (blue; n=5) compared to control (red; n=6) lung 
fibroblasts. Five of these CpGs also had significantly altered (P<0.05) methylation in IPF compared to 
SSc (yellow; n=7) lung fibroblasts. Data presented as the mean ± S.E.M. 
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3.8. Summary 
 Distribution of CpG methylation was bimodal in control, IPF and SSc-PF lung fibroblasts with 
the highest frequency of CpGs having 0-15% methylation and 80-90% methylation on 
autosomes and 25-35% and 75-80% on the X-chromosome.  
 
 CpG islands within 1.5kb of their corresponding gene’s TSS had a very high frequency of CpGs 
with 0-15% methylation whereas CGIs further than 1.5kb had a bimodal distribution of CpG 
methylation with the highest frequencies of CpGs having 0-15% and 80-85% methylation.  
 
 7153 and 8392 CpGs had significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF and SSc-
PF compared to control lung fibroblasts, respectively.  
 
 69% (4908) of the 7153 CpGs in IPF had decreased methylation compared to control lung 
fibroblasts.  
 
 67% (5609) of the 8392 CpG in SSc-PF had increased methylation compared to control lung 
fibroblasts.  
 
 Multiple CpGs and genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF 
and SSc-PF compared to control lung fibroblasts overlap including Wnt genes WNT10A and 
SFRP1 and novel genes potentially important in PF including, SDK1, SATB2, FOXS1 and GATA2, 
however multiple CpGs and genes are also distinct to each disease.  
 
 Open sea regions consistently had significantly (P<0.05) more than the expected number of 
CpGs whereas CGIs had less than the expected number of CpGs with increased and decreased 
methylation in IPF and SSc-PF compared to control lung fibroblasts. This suggests that altered 
methylation in open sea regions is common in IPF and SSc-PF and could potentially be 
important and overlooked by studies solely focusing on methylation of CpGs within promoter 
CGIs. 
 
 Bisulfite sequencing of the TNXB gene confirmed methylation microarray data and 
highlighted CpGs not on the array which also have significantly altered (P<0.05) methylation 
in IPF compared to control and SSc-PF lung fibroblasts. 
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3.9. Distribution of gene expression in lung fibroblasts and in IPF and SSc compared 
to control primary human lung fibroblasts 
Genome-wide distribution of gene expression in control (n=6), IPF (n=5) and SSc (n=7) lung fibroblasts 
identified the highest frequency of genes with a Log2 transformed normalised value <7.0 (Figure 
3.9.1). Genes below this level were judged as having low expression as genes with a log2 transformed 
normalised value were rarely detected. The highest frequency of genes with significantly altered 
expression (TNoM ≤1; P<0.05) in IPF and SSc compared to control lung fibroblasts were also those 
which had low expression (Log2 transformed normalised value <7.0) (Figure 3.9.2).  
 
 
Figure 3.9.1. Genome-wide distribution of gene expression in lung fibroblasts. Each bar represents 
the number of genes within each boundary. Red: Control (n=6), blue: IPF (n=5) and yellow: SSc (n=7) 
lung fibroblasts.  
 
 
Figure 3.9.2. Distribution of genes which had altered expression in IPF and SSc compared to control 
lung fibroblasts. Each bar represents the number of genes within each boundary which had 
significantly altered expression (TNoM ≤1; P<0.05) in IPF (n=5) or SSc (n=7) compared to control (n=6) 
lung fibroblasts. Red = control, blue = IPF and yellow = SSc lung fibroblasts.  
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3.10. Microarray analysis of differentially-expressed genes in IPF and SSc compared 
to control primary human lung fibroblasts 
The Illumina Human Expression array identified 568 genes (267 decreased, 301 increased) with altered 
expression (TNoM ≤1; P<0.05) in IPF and 688 genes (324 decreased, 364 increased) with altered 
expression (TNoM ≤1; P<0.05) in SSc compared to control lung fibroblasts. Ninety-six genes including 
WNT2B (Bayle et al, 2008) and PPARγ (Lakatos et al, 2007, López-Isac et al, 2014) which have 
previously been associated with fibrosis, had significantly altered expression (47 increased, 49 
decreased) in both IPF and SSc compared to control lung fibroblasts (Figure 3.10.1). The average 
expression for each gene which had significantly altered expression (TNoM ≤1; P<0.05) in IPF or SSc 
compared to control lung fibroblasts and which chromosomes the genes are located on is shown in 
Figure 3.10.2.  
 
 
 
 
Figure 3.10.1. The number of distinct and overlapping genes with altered expression in IPF and SSc 
compared with control lung fibroblasts. Genes with significantly altered expression (TNoM ≤1; 
P<0.05) in IPF (n=5) and SSc (n=7) compared to control (n=6) lung fibroblasts.  
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Figure 3.10.2. Gene expression in IPF and SSc compared to control lung fibroblasts. Top: shows the 
average expression of genes with significantly increased or decreased expression (TNoM ≤1; P<0.05) 
in IPF (n=5) compared with control (n=6) lung fibroblasts and which chromosome they are located on. 
Below: shows the average expression of genes with significantly increased or decreased expression 
(TNoM ≤1; P<0.05) in SSc (n=7) compared with control (n=6) lung fibroblasts and which chromosome 
they are located on. ● shows genes with a TNoM=0, ● shows genes with a TNoM=1.  
 
 
 
Genes previously shown to have altered expression in IPF including IL8, WNT2B, FBLN2, PPARγ, SEPP1, 
CXCL1 and CXCL6 all had significantly altered expression (TNoM ≤1; P<0.05) in IPF compared to control 
lung fibroblasts (Figure 3.10.3). Genes previously shown to have aberrant expression in SSc including 
S100A4 (Tomcik et al, 2014), NOTCH3 (Dees et al, 2011), IGFBP7 (Hsu et al, 2011), CCL13 (Yanaba et 
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al, 2010), IL7R (Grigoryev et al, 2008) and TIMP4 (Elias et al, 2008) all had significantly altered 
expression (TNoM ≤1; P<0.05) in SSc compared to control lung fibroblasts (Figure 3.10.4).  
 
 
Figure 3.10.3. Genes previously implicated in IPF which had altered expression compared to control 
lung fibroblasts. Genes which had significantly altered expression (TNoM ≤1; P<0.05) IPF (n=5) 
compared to control (n=6) lung fibroblasts. Data presented as the geometric mean fold-change 
relative to the average control ± 95% CI. Each data point represents a different cell line.  
 
 
 
Figure 3.10.4. Genes previously implicated in SSc which had altered expression compared to control 
lung fibroblasts. Genes which had significantly altered expression (TNoM ≤1; P<0.05) SSc (n=7) 
compared to control (n=6) lung fibroblasts. Data presented as the geometric mean fold-change 
relative to the average control ± 95% CI. Each data point represents a different cell line.  
 
 
Cluster analysis of the 568 and 688 differentially expressed genes in IPF and SSc respectively, clearly 
distinguished IPF and SSc from control lung fibroblasts however, there was some heterogeneity 
between cell lines (Figure 3.10.5). Although all control cell lines clustered together, control 6 had a 
gene expression profile that appeared intermediate between an SSc and a control. This was the 
same control which had a methylation profile which clustered with SSc cell lines (see section 3.3, 
figure 3.3.4). 
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                      Control v IPF                                                                                  Control v SSc 
                                
Figure 3.10.5. Hierarchical cluster analysis on differentially-expressed genes in IPF and SSc 
compared to control lung fibroblasts. Genes with significantly altered expression (TNoM ≤1; P<0.05) 
in IPF (n=5) and SSc (n=7) compared to control (n=6) lung fibroblasts. Light blue represents low 
expression, yellow represents high expression with respect to each gene across all cell lines.   
 
 
3.11. Differentially-expressed genes in IPF compared to SSc lung fibroblasts  
The highest frequency of genes with significantly altered expression (TNoM ≤1; P<0.05) in IPF 
compared to SSc lung fibroblasts were those which had a Log2 transformed normalised value <6.5 
(Figure 3.11.1). The Illumina Human Expression array identified 1117 genes (499 decreased, 618 
increased) with significantly altered expression (TNoM ≤1; P<0.05) in IPF compared to SSc lung 
fibroblasts (Figure 3.11.2). IPF and SSc cell lines clustered separately from each other (Figure 3.11.3) 
suggesting they may have distinct gene expression profiles. Examples of strongly differentially-
expressed genes in IPF compared to SSc lung fibroblasts, some of which have previously been linked 
to PF (Kohno, 1999, Königshoff et al, 2009, Ishikawa et al, 2012), are shown in Figure 3.11.4. 
 
Figure 3.11.1. Distribution of genes which had altered expression in IPF compared to SSc lung 
fibroblasts. Each bar represents the number of genes within each boundary which had significantly 
altered expression (TNoM ≤1; P<0.05) in IPF (n=5) compared to SSc (n=7) lung fibroblasts. Blue = IPF, 
orange = SSc lung fibroblasts.  
107 
 
 
Figure 3.11.2. Gene expression in IPF compared to SSc lung fibroblasts. Scatter graphs show the 
average expression of genes with significantly increased or decreased expression (TNoM ≤1; P<0.05) 
in IPF (n=5) compared with SSc (n=7) lung fibroblasts and which chromosome they are located on. ● 
Show genes with a TNoM=0, ● show genes with a TNoM=1.  
 
 
 
Figure 3.11.3. Hierarchical cluster analysis on differentially expressed genes in IPF compared to SSc 
lung fibroblasts. Genes (n=1117) with significantly altered expression (TNoM ≤1; P<0.05) in IPF (n=5) 
compared to SSc (n=7) lung fibroblasts. Light blue represents low expression, yellow represents high 
expression with respect to each gene across all cell lines.  
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Figure 3.11.4. Differences in gene expression in IPF compared to SSc lung fibroblasts. Genes which 
had significantly altered expression (TNoM ≤1; P<0.05) in IPF (n=5) compared to SSc (n=7) lung 
fibroblasts. Data presented as the geometric mean fold-change relative to the average IPF expression 
± 95% CI. Each data point represents a different cell line.  
 
 
3.12. qRT-PCR validation of the Illumina Infinium gene expression microarray 
Genes including Cell adhesion molecule 1 (CADM1), Eukaryotic Translation Initiation Factor 1A, Y-
Linked (EIF1AY) and IL8 were selected to validate the expression microarray based on all genes having 
significantly altered expression in IPF and/or SSc compared to control lung fibroblasts, which inversely 
correlated to methylation status according to microarray analysis. Other genes including 
metalloproteinases (MMP10, MMP12) which have been linked to fibrosis and can be activated by 
hypomethylation (Couillard et al, 2006) and TNXB, a gene identified which had multiple CpGs with 
significantly altered methylation in IPF and SSc compared to control (but was not detected on the 
expression array), were also analysed.  
 
qRT-PCR confirmed the microarray data by identifying similar significant differences in gene 
expression between IPF, SSc and control lung fibroblasts (Figure 3.12.1). qRT-PCR and microarray data 
strongly correlated for all genes (IL8: r=0.91, CADM1: r=0.74, EIF1AY: r=0.85). In general, microarray 
and qRT-PCR analysis of fold-changes in gene expression and variation between cell lines in control 
(n=6), IPF (n=5) and SSc (n=7) lung fibroblasts cell lines were consistent. TNXB, a gene which encodes 
the large 464kDa ECM glycoprotein, TNX, was of particular interest based on its previously described 
role in the ECM, disease and its interactions with other ECM proteins (see Chapter 1: section 1.3). 
Although a TNXB probe was on the Illumina expression microarray, it was not detected. qRT-PCR did 
detect TNXB and identified a significant increase in TNXB expression in IPF (n=5) compared to control 
(n=8) and SSc (n=8) lung fibroblasts. There was no significant difference (P=0.791) in TNXB gene 
expression between control and SSc lung fibroblasts (Figure 3.12.2).  
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Figure 3.12.1. Validation of microarray data using qRT-PCR. Comparison of gene expression data for 
3 genes; IL8, CADM1 and EIF1AY in control (n=6), IPF (n=5) and SSc (n=7) using microarray and qRT-
PCR data. Data presented as the geometric mean fold-change relative to the average control 
expression ± 95% confidence intervals. Each data point represents a different cell line.  
 
 
 
Figure 3.12.2. TNXB expression in lung fibroblasts. TNXB expression in control (n=8), IPF (n=5) and 
SSc (n=8) lung fibroblasts. Data presented as the geometric mean fold-change relative to the average 
basal control expression ± 95% confidence intervals. Each data point represents a different cell line.  
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3.12.1. Immunolocalisation of TNX in control, IPF and SSc lung tissue confirms qRT-
PCR 
Following confirmation of increased TNXB at the mRNA level in IPF compared to control and SSc lung 
fibroblasts, immunohistochemistry experiments were performed to determine the 
immunolocalisation of TNX in human control (n=7), IPF (n=6) and SSc (n=3) lung tissue. To optimise 
the concentration of the primary anti-TNX antibody, a dilution series was first performed on human 
lung tissue sections. Antibody at 5µg/ml showed strong staining of TNX. Specificity was confirmed 
using tissue sections incubated with serum only or with an IgG isotype control which showed no 
obvious staining. All IPF lung tissue sections showed strong staining for TNX in the ECM and fibroblasts, 
whereas control and SSc lung tissue section showed weak staining confirming that TNX is also 
increased in IPF lung (Figure 3.12.1.1). 
 
 
     Control   IPF           SSc 
 
Figure 3.12.1.1. TNX immunolocalisation in lung tissue. Representative histological sections showing 
TNX immunolocalisation in control (n=3), IPF (n=3) and SSc (n=3) lung tissue specimens. Brown staining 
depicts TNX. 20x original magnification. Scale bar = 400µm.  
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3.13. Summary 
 Multiple genes previously associated with IPF and/or SSc-PF, including PPARγ, IL8, CCL13, 
CXCL1, SEPP1, S100A4 and TIMP4, have significantly altered expression (TNoM ≤1; P<0.05) in 
IPF and SSc compared to control lung fibroblasts respectively. Multiple other genes identified 
with significantly altered expression (TNoM ≤1; P<0.05) in IPF and SSc-PF compared to control 
lung fibroblasts may be novel to fibrosis. 
 
 96 genes overlapped between IPF and SSc-PF suggesting multiple common genes are affected 
in both diseases. 
 
 1117 (618 increased, 499 decreased) genes had significantly altered expression (TNoM ≤1; 
P<0.05) in IPF compared to SSc-PF lung fibroblasts suggesting IPF and SSc-PF have a different 
expression pattern. 
 
 qRT-PCR gene expression strongly correlated with microarray expression.  
 
 TNXB expression was identified using qRT-PCR and had increased expression in IPF compared 
to control and SSc-PF lung fibroblasts.  
 
 IHC confirmed TNX expression in control, IPF and SSc-PF lung tissue.   
 
 Data suggest TNXB is a novel gene in IPF which may be regulated by methylation. 
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3.14. Correlation between methylation and gene expression in primary human lung 
fibroblasts 
3.14.1. Overview 
It remains unknown what change in methylation is sufficient to have a biological effect and whether 
the change in methylation is the same for all genes or cell types. For example, Yang et al, showed that 
8 CpGs on the Castor zinc finger 1 (CASZ1) gene, had on average a 3.5% change in methylation in IPF 
compared to control alveolar type II epithelial cells which corresponded with increased gene 
expression (Yang et al, 2014). Huang et al, showed that an average decrease of 6.9% over 28 CpGs of 
the gene Cyclin-dependent kinase 4 inhibitor B (CDKN2B) resulted in increased expression (Huang et 
al, 2014) whereas Sanders et al, showed that genes including Dimethylarginine 
dimethylaminohydrolase DDAH and Tumor protein p53-inducible nuclear protein 1 (TP53INP1) had 
large methylation differences (>20%) in IPF compared to control lung tissue which corresponded with 
altered expression (Sanders et al, 2012). Other studies with Illumina arrays have used a 13.6% cut as 
this can detect differences with 95% confidence (Bibikova et al, 2009, Lokk et al, 2012).  
 
DNA methylation is one of many epigenetic mechanisms which control transcriptional programmes, 
thus it is difficult to distinguish the direct effects from the indirect effects of methylation on gene 
expression. Direct effects of methylation on gene expression refer to CpGs belonging to a gene which, 
when altered, affect the expression of that gene. Indirect effects of methylation on gene expression 
can refer to genes which have been activated/deactivated by changes in their methylation, which in 
turn regulate other genes. A good example of this is the miR-17-92 cluster which has reduced 
expression due to promoter hypermethylation in IPF lung tissue and fibroblasts. This cluster can 
regulate DNMT1 expression which in turn can regulate methylation levels of multiple targets 
(Dakhalallah et al, 2013).  
 
To determine which CpGs in a gene may have a direct effect on that gene’s expression, CpG  
methylation and gene expression were correlated together using all 18 cells lines (control; n=6, IPF: 
n=5 and SSc: n=7). In the following section I show correlation between basal methylation and basal 
expression levels. In Chapter 6 I show the effects of 5-Aza and how small changes in methylation may 
correlate to large changes in expression.  
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3.14.2. Distribution of CpG methylation which correlated with gene expression  
Methylation of multiple CpGs strongly correlated (R2= ≥0.5; P<0.05) with expression of their 
corresponding gene in lung fibroblasts. These CpGs were mainly distributed in island regions within 
1.5kb of their corresponding genes TSS or in open sea regions further than 1.5kb from their 
corresponding genes TSS (Figure 3.14.2.1). The highest frequency of genes had low expression (Figure 
3.14.2.2).  
 
 
Figure 3.14.2.1. Distribution of CpG methylation of CpGs which correlated with expression of the 
genes. Top: distribution and location of CpGs within 1.5kb and bottom: further than 1.5kb of their 
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corresponding genes TSS, which had significant correlation between CpG methylation and expression 
in control (red; n=6), IPF (blue; n=5) and SSc (orange; n=7) lung fibroblasts.  
 
 
Figure 3.14.2.2. Distribution of genes which had expression levels which correlated with CpG 
methylation. Each bar represents the number of genes within each boundary. Red: Control (n=6), 
blue: IPF (n=5) and yellow: SSc (n=7) lung fibroblasts.  
 
 
3.14.3. Microarray analysis of CpG methylation which correlated to expression 
Methylation of 1088 CpGs (724 genes) correlated (R2= ≥0.5; P<0.05) with expression of their respective 
gene across all lung fibroblast cell lines (n=18). Of these CpGs, 585 (412 genes) negatively correlated 
and 503 (358 genes) positively correlated (R2= ≥0.5; P<0.05) with expression of their respective gene 
(Table 3.14.3.1). Methylation of 46 CpGs had both positive and negative correlation with expression, 
suggesting multiple locations of CpG methylation in the same gene may be important in regulating 
expression (Table 3.14.3.2). Examples of genes which had a significant correlation (R2= ≥0.5; P<0.05) 
between CpG methylation and gene expression are shown in Figure 3.14.3.1.  
 
 Positive correlation Negative correlation  Overlap Total  
CpGs 503 585  0 1088 
Genes 358 412  46 724 
Table 3.14.3.1. The number of CpGs/genes with methylation which correlated with gene expression. 
CpG methylation which significantly correlated (R2= ≥0.5; P<0.05) with expression in all 18 cell lines 
(control: n=6, IPF: n=5 and SSc: n=7).  
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Genes with both positive and negative correlation between methylation and expression  
ACVRL1 CDH13 FST MYOM2 PLAGL1 STX18 
ADAM15 CHST15 GPER NETO2 PPP3CA TANC1 
ADAMTS2 CLEC14A GSTT1 NLGN4Y PRKY TNFAIP8L3 
ALDH3A1 CPNE8 ICMT NPTX1 RAMP1 TRIM56 
ANO1 CRIPAK IL16 PAX8 RPS4Y1 ZFHX4 
C13orf15 DLL1 MACF1 PGM3 SAMD14 ZFY 
C1orf159 EIF1AY MAPRE1 PLA2G5 SASH1  
CA12 FAM13A MGMT PLAG1 SPON2  
Table 3.14.3.2. Genes with both positive and negative correlation. CpG methylation which 
significantly correlated (R2= ≥0.5; P<0.05) with expression in all 18 cell lines (control: n=6, IPF: n=5 and 
SSc: n=7). Full gene names can be found on appendice A. 
 
 
 
Figure 3.14.3.1. Scatter plots showing methylation of 4 CpGs which correlated with their respective 
gene expression level. Example of CpGs which significantly correlated (R2≥0.5, P<0.05) across all cell 
lines (n=18). The methylation level is shown by the beta-value (0= 0% methylated, 1= 100% 
methylated). The expression level is the log2 transformed normalised value. Shaded areas indicate 
95% confidence regions. ● Control (n=6), ● IPF (n=5), ● SSc (n=7).  
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Whilst 724 genes had a significant correlation (R2= ≥0.5; P<0.05) between CpG methylation and gene 
expression, there was no overall correlation between methylation and gene expression (R=-0.067). 
This was evident when plotting the beta-methylation values against the log2 transformed normalised 
expression values (Figure 3.14.3.2) and suggests that different levels of methylation at specific CpGs 
may be important in determining the level of expression rather than a ‘one rule that fits all’. 
 
 
Figure 3.14.3.2. The location of CpGs which correlated with their corresponding genes expression in 
lung fibroblasts. Top: CpGs within 1.5kb of their corresponding genes TSS, bottom: CpGs further than 
1.5kb from their corresponding genes TSS. Each dot represents a different CpG which significantly 
correlated (R2≥0.5; P<0.05) with gene expression in control (red; n=6), IPF (blue; n=6) and SSc (orange; 
n=7).  
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3.15. Differentially-methylated and expressed genes in IPF and SSc compared to 
control fibroblasts in which CpG methylation correlated with gene expression 
From 1088 CpGs (724) genes which had methylation which correlated with gene expression, 100 CpGs 
corresponding to 85 genes had significantly (P<0.05) altered methylation and 41 genes had 
significantly (P<0.05) altered expression in IPF compared to control lung fibroblasts. Of these genes, 
20 had both significantly altered methylation and expression in IPF compared to control lung 
fibroblasts (Table 3.15.1, Table 3.15.2 and Figure 3.15.1). 
 
CvIPF Expression (P<0.05) Methylation (P<0.05) Expression and methylation (P<0.05) 
CpGs N/A 75 25 
Genes 21 65 20 
Table 3.15.1. Genes/CpGs which correlated and had altered expression/methylation in IPF 
compared to control lung fibroblasts. Expression which significantly correlated with basal expression 
in all cell lines (n=18) where significant difference in expression and/or methylation were present 
between IPF (n=5) compared to control (n=6) lung fibroblasts.  
 
Gene symbol Gene name 
ACSS2 Acyl-coa synthetase short-chain family member 2 
ALDH4A1 Aldehyde dehydrogenase 4 family, member A1 
ATP5EP2 ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit 
pseudogene 2 
C1QTNF9B C1q and tumor necrosis factor related protein 9B 
DGAT1 Diacylglycerol O-acyltransferase 1 
FASTK Fas-activated serine/threonine kinase 
FBLN2 Fibulin 2 
FOXP1 Forkhead box P1 
GPC1 Glypican 1 
IGF2BP3 Insulin-like growth factor 2 mRNA binding protein 3 
ISLR Immunoglobulin superfamily containing leucine-rich repeat 
KLHL21 Kelch-like 21 
LPCAT2 Lysophosphatidylcholine acyltransferase 2 
MAPK8 Mitogen-activated protein kinase 8 
PDE9A Phosphodiesterase 9A 
PLA2G5 Phospholipase A2, group V 
PMP22 Peripheral myelin protein 22 
PRKD1 Protein kinase D1 
RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 
SESN3 Sestrin 3 
Table 3.15.2. List of gene names which correlated and had altered expression/methylation in IPF 
compared to control lung fibroblasts. Genes which had expression which significantly correlated with 
methylation in all cell lines (n=18), which also had significant differences in expression and/or 
methylation in IPF (n=5) compared to control (n=6) lung fibroblasts.  
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Figure 3.15.1. The number and location of the CpGs which had correlation between CpG methylation 
and expression which also had differences in methylation and/or expression in IPF/SSc compared 
to control lung fibroblasts. Top: IPF (n=5) compared to control (n=6) lung fibroblasts. Bottom: SSc 
(n=7) compared to control (n=6) lung fibroblasts. Delta-beta value: difference in methylation between 
IPF and control or SSc and control lung fibroblasts. Log2FC: the log2 fold-change in expression between 
IPF/SSc compared to control lung fibroblasts. Each dot represents a different CpG and its 
corresponding gene. Different coloured dots represent the following in IPF (top) or SSc (bottom) 
compared to controls: ● CpGs corresponding to genes with significantly altered methylation and 
expression ● CpGs corresponding to genes with significantly altered expression only ● CpGs 
corresponding to genes with significantly altered methylation only ● CpGs corresponding to genes 
which had no significant change in methylation or expression.  
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More genes in SSc reached the statistical threshold (P<0.05) likely due to male/female differences in 
IPF samples (see Chapter 5). Multiple (397) CpGs corresponding to 263 genes had significantly (P<0.05) 
altered methylation and 210 genes had significantly (P<0.05) altered expression in SSc compared to 
control lung fibroblasts. Of these genes, 154 had both significantly altered methylation and expression 
in SSc compared to control lung fibroblasts (Figure 3.15.1, Table 3.15.3 and Table 3.15.4).  
 
CvSSc Expression (P<0.05) Methylation (P<0.05) Expression and methylation (P<0.05) 
CpGs - 137 260 
Genes 56 109 154 
Table 3.15.3. Genes/CpGs which correlated and had altered expression/methylation in SSc 
compared to control lung fibroblasts. Basal expression which significantly correlated with basal 
expression in all cell lines (n=18) where significant differences in expression and/or methylation were 
present between SSc (n=7) compared to control (n=6) lung fibroblasts.  
 
Gene symbol Gene name 
ACACB Acetyl-coa carboxylase beta 
ACSS2 Acyl-coa synthetase short-chain family member 2  
ACVRL1 Activin A receptor type II-like 1 
ADAMTS2 ADAM metallopeptidase with thrombospondin type 1 motif, 2 
ADAMTSL1 ADAMTS-like 1  
AFF3 AF4/FMR2 family, member 3 
AMPH Amphiphysin 
ANO1 Anoctamin 1, calcium activated chloride channel 
ANTXR2 Anthrax toxin receptor 2 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 
ATP5EP2 ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit pseudogene 
2 
AUTS2 Autism susceptibility candidate 2 
C13orf15 Chromosome 13 open reading frame 15 
C13orf16 Chromosome 13 open reading frame 16 
CACNA1A Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
CCL11 Chemokine (C-C motif) ligand 11 
CD248 CD248 molecule, endosialin 
CD47 CD47 molecule 
CD9 CD9 molecule 
CHD1L Chromodomain helicase DNA binding protein 1-like 
CHERP Calcium homeostasis endoplasmic reticulum protein 
CHRNA1 Cholinergic receptor, nicotinic, alpha 1 
CHST15 Carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 
CLEC14A C-type lectin domain family 14, member A 
COL9A2 Collagen, type IX, alpha 2 
CPNE8 Copine VIII 
CPXM2 Carboxypeptidase X (M14 family), member 2 
CRLF1 Cytokine receptor-like factor 1 
CTNNA1 Catenin (cadherin-associated protein), alpha 1 
CTNNB1 Catenin (cadherin-associated protein), beta 1 
CYFIP2 Cytoplasmic FMR1 interacting protein 2 
CYTH3 Cytohesin 3 
DAB2 Disabled homolog 2, mitogen-responsive phosphoprotein 
DCTD Dcmp deaminase 
DGAT1 Diacylglycerol O-acyltransferase 1 
DOCK2 Dedicator of cytokinesis 2 
DRG2 Developmentally regulated GTP binding protein 2 
EFCAB4A EF-hand calcium binding domain 4A 
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EIF1AY Eukaryotic translation initiation factor 1A, Y-linked 
EPHB2 EPH receptor B2 
ERH Enhancer of rudimentary homolog 
F3 Coagulation factor III (thromboplastin, tissue factor) 
FAM105A Family with sequence similarity 105, member A 
FBLN2 Fibulin 2 
FNBP1L Formin binding protein 1-like 
FOXP1 Forkhead box P1 
FST Follistatin 
GFRA1 GDNF family receptor alpha 1 
GLDN Gliomedin 
GPC1 Glypican 1 
GPER G protein-coupled estrogen receptor 1 
GPNMB Glycoprotein (transmembrane) nmb 
GPR56 G protein-coupled receptor 56 
GSTM1 Glutathione S-transferase mu 1 
GTPBP4 GTP binding protein 4 
H19 H19, imprinted maternally expressed transcript (non-protein coding)  
HIATL1 Hippocampus abundant transcript-like 1 
HLA-DMA Major histocompatibility complex, class II, DM alpha 
HOXB6 Homeobox B6 
HOXC4 Homeobox C4 
ICAM2 Intercellular adhesion molecule 2 
ISLR Immunoglobulin superfamily containing leucine-rich repeat 
JUP Junction plakoglobin 
KCNMA1 Potassium large conductance calcium-activated channel, subfamily M, alpha 1 
KLHL21 Kelch-like 21 
LPCAT2 Lysophosphatidylcholine acyltransferase 2 
LRIG1 Leucine-rich repeats and immunoglobulin-like domains 1 
LRRN4CL LRRN4 C-terminal like 
MAGEC2 Melanoma antigen family C, 2 
MAPK8 Mitogen-activated protein kinase 8 
MAPKAP1 Mitogen-activated protein kinase associated protein 1 
MGMT O-6-methylguanine-DNA methyltransferase 
MRI1 Methylthioribose-1-phosphate isomerase homolog 
MRPS6 Mitochondrial ribosomal protein S6 
MSX1 Msh homeobox 1 
MYOM2 Myomesin (M-protein) 2 
NAPRT1 Nicotinate phosphoribosyltransferase domain containing 1 
NCAM2 Neural cell adhesion molecule 2 
NEDD9 Neural precursor cell expressed, developmentally down-regulated 9  
NETO2 Neuropilin (NRP) and tolloid (TLL)-like 2 
NFIB Nuclear factor I/B 
NLGN4Y Neuroligin 4, Y-linked 
NPTX1 Neuronal pentraxin I 
NTN1 Netrin 1 
NUMA1 Nuclear mitotic apparatus protein 1 
OLFM1 Olfactomedin 1 
OLFML1 Olfactomedin-like 1 
OPLAH 5-oxoprolinase (atp-hydrolysing 
OSBPL10 Oxysterol binding protein-like 10 
PAGE2B P antigen family, member 2B 
PAGE5 P antigen family, member 5  
PCBP3 Poly(rc) binding protein 3 
PCF11 PCF11, cleavage and polyadenylation factor subunit, homolog 
PGF Placental growth factor 
PGM3 Phosphoglucomutase 3 
PLA2G5 Phospholipase A2, group V 
PLAC9 Placenta-specific 9 
PLAG1 Pleiomorphic adenoma gene 1 
PLAGL1 Pleiomorphic adenoma gene-like 1 
PLXNB1 Plexin B1 
PMP22 Peripheral myelin protein 22 
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PPP2CB Protein phosphatase 2, catalytic subunit, beta isozyme 
PPP2R3A Protein phosphatase 2, regulatory subunit B, alpha 
PPP3CA Protein phosphatase 3, catalytic subunit, alpha isozyme 
PRDM8 PR domain containing 8 
PRKCZ Protein kinase C, zeta 
PRKY Protein kinase, y-linked, pseudogene 
PTPRH Protein tyrosine phosphatase, receptor type, H 
PUM1 Pumilio homolog 1 
RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 
REEP3 Receptor accessory protein 3 
RPL29 Ribosomal protein L29 
RPL34 Ribosomal protein L34 
RPS4Y1 Ribosomal protein S4, Y-linked 1 
RPS4Y2 Ribosomal protein S4, Y-linked 2 
S100A4 S100 calcium binding protein A4 
SARS Seryl-trna synthetase 
SASH1 SAM and SH3 domain containing 1 
SATB2 SATB homeobox 2 
SCARA3 Scavenger receptor class A, member 3 
SESN2 Sestrin 2 
SESN3 Sestrin 3 
SGCE Sarcoglycan, epsilon 
SGIP1 SH3-domain GRB2-like (endophilin) interacting protein 1 
SHANK2 SH3 and multiple ankyrin repeat domains 2 
SHANK3 SH3 and multiple ankyrin repeat domains 3 
SHISA3 Shisa homolog 3 
SP2 Sp2 transcription factor 
SPATA18 Spermatogenesis associated 18 homolog 
ST3GAL2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 
ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 
STK32B Serine/threonine kinase 32B 
SYTL2 Synaptotagmin-like 2 [Source:HGNC Symbol;Acc:15585] 
TECR Trans-2,3-enoyl-coa reductase 
TGFB2 Transforming growth factor, beta 2 
THBS1 Thrombospondin 1 
THSD4 Thrombospondin, type I, domain containing 4 
TIPARP TCDD-inducible poly(ADP-ribose) polymerase 
TMED1 Transmembrane emp24 protein transport domain containing 1 
TMEM26 Transmembrane protein 26 
TMTC1 Transmembrane and tetratricopeptide repeat containing 1 
TPM1 Tropomyosin 1 (alpha) 
TRAF3IP2 TRAF3 interacting protein 2 
TRIM56 Tripartite motif containing 56 
TSC22D1 TSC22 domain family, member 1 
TSC22D2 TSC22 domain family, member 2 
UBIAD1 Ubia prenyltransferase domain containing 1 
VGLL4 Vestigial like 4 
VPS11 Vacuolar protein sorting 11 homolog 
WDR25 WD repeat domain 25 
XRCC6BP1 XRCC6 binding protein 1 
YPEL1 Yippee-like 1 
ZFHX4 Zinc finger homeobox 4 
ZSCAN16 Zinc finger and SCAN domain containing 16 
 
Table 3.15.4. List of gene names which correlated and had altered expression/ methylation in SSc 
compared to control lung fibroblasts. Gene names of genes which had basal expression which 
significantly correlated with basal expression in all cell lines (n=18) where significant differences in 
expression and/or methylation were present between SSc (n=7) compared to control (n=6) lung 
fibroblasts.  
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Cluster analysis of the 20 genes which had significantly altered methylation which correlated with 
gene expression in IPF compared to control lung fibroblasts, identified heterogeneity between IPF and 
control samples. Methylation of control 6 clustered with IPF samples.  (Figure 3.15.2). In contrast, 
cluster analysis of the 154 genes which had CpG methylation that correlated with gene expression and 
had significantly altered methylation and expression in SSc compared to control lung fibroblasts 
identified less heterogeneity between SSc samples, although control 6 also clustered with SSc lung 
fibroblasts (Figure 3.15.3). 
 
Figure 3.15.2. Hierarchical cluster analysis of genes with altered methylation and expression in IPF 
compared to control lung fibroblasts. Heat maps show CpGs which had significantly altered (P<0.05) 
methylation in IPF (n=5) compared to control (n=6) lung fibroblasts and the genes which they 
corresponded to which also had significantly altered expression in IPF (n=5) compared to control (n=6) 
lung fibroblasts. Light blue represents low expression/methylation, yellow represents high 
expression/methylation with respect to each gene across all cell lines.  
 
Figure 3.15.3. Hierarchical cluster analysis of genes with altered methylation and expression in SSc 
compared to control lung fibroblasts. Heat maps show the methylation of CpGs which had 
significantly altered (P<0.05) methylation in IPF (n=5) compared to control (n=6) lung fibroblasts and 
the genes which they corresponded to which also had significantly altered expression in IPF (n=5) 
compared to control (n=6) lung fibroblasts. Light blue represents low expression/methylation, yellow 
represents high expression/methylation with respect to each gene across all cell lines.  
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3.16. Summary 
 Methylation of multiple CpGs strongly correlated (R2≥0.5; P<0.05) with their corresponding 
genes expression in human lung fibroblasts, identifying multiple novel genes potentially 
regulated directly by methylation. 
 
 No overall positive or inverse relationship between methylation and expression was found, 
suggesting that different levels of methylation affect genes to different extents. 
 
 Multiple genes had both negative and positive correlation of CpG methylation with gene 
expression, suggesting that some genes may have multiple CpGs which can directly regulate 
expression.  
 
 20 genes in IPF and 154 genes in SSc-PF which had significant (R2≥0.5; P<0.05) correlation 
between methylation and expression in all cell lines, had significantly altered methylation 
(P<0.05) and expression (P<0.05) compared to control lung fibroblasts, suggesting multiple 
novel genes involved in PF are potentially regulated directly by methylation in lung 
fibroblasts. 
 
 The number of genes identified as having CpG methylation correlating with their expression 
is likely to be largely underestimated due to probes which were not detected by the 
expression array as a potential result of high/low methylation levels completely silencing 
gene expression, other epigenetic mechanisms masking DNA methylation and CpGs not 
interrogated by the array. Further studies using bisulfite sequening/arrays which interrogate 
more CpGs are required to more accurately determine methylation and expression 
correlation. 
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 Network and functional analysis of genes with altered methylation and 
expression in IPF and SSc compared to control lung fibroblasts.  
4.1. Overview 
To determine which biological processes may be important and relevant in IPF and/or SSc, two main 
types of enrichment analyses were conducted; protein family (PFAM) domain-centric and gene-GO 
term enrichment analysis. PFAMs describe proteins grouped into families which are represented 
by multiple sequence alignments and hidden Markov models (HMMs), which are used to measure 
probability distributions over multiple observations (Finn et al, 2014). Protein domains are functional 
regions and genes which share common domains can be easily identified and mapped to their 
respective PFAM using the Ensembl genome database (see Chapter 2: section 2.7.2). PFAM domain-
centric analysis uses pre-defined protein-level GO annotations to determine if a specific biological 
process is enriched in a given list of PFAMs. It does this by determining whether there is a significantly 
greater number of PFAMs observed for a specific biological process compared to what would be 
expected by chance. Thus, the genes mapped to PFAMs which are associated with a specific biological 
process may not themselves be enriched in the biological process but the domains they share are. This 
allows the potential to identify genes which share domains but have not yet been associated with the 
specific biological process. 
Gene-GO term enrichment analysis compares genes from a given list to pre-defined gene lists 
associated with a specific biological process. Thus, gene-GO term enrichment analysis identifies 
enriched biological processes by determining, from a given list of genes, whether there is a 
significantly greater number of genes observed for a specific biological process compared to what 
would be expected by chance. Combining data from these two types of enrichment analyses makes it 
possible to identify genes associated with a biological process enriched in PFAMs and a biological 
processes enriched in specific genes with altered methylation/expression in IPF and SSc compared to 
control lung fibroblasts.  
PFAM enrichment was conducted using the dcGO: database of gene ontologies. Genes belonging to 
different PFAM groups which had altered methylation were analysed using Cytoscape 3.2.1 (see 
Chapter 2 section 2.7.2). The networks of genes linked to their respective PFAM domains generated 
by Cytoscape were too large to be viewed as a document, however, specific PFAMs and enriched 
biological processes could be visualised. The following chapter goes into detailed analysis of biological 
processes enriched in PFAMs containing genes with altered methylation and expression and biological 
processes enriched in genes with altered methylation and expression. 
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4.2. Biological processes enriched in PFAMs containing genes with altered 
methylation in IPF and SSc compared to control lung fibroblasts.  
Genes which had significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF and SSc compared to 
control lung fibroblasts mapped to 1328 and 1461 different PFAM domains, respectively. Multiple 
(633 and 611) biological processes were significantly (FDR P<0.01) enriched in these PFAMs in IPF and 
SSc compared to control lung fibroblasts, respectively. Of the 611 enriched biological processes in SSc, 
523 (86%) overlapped with IPF. Many of these biological processes have previously been associated 
with the pathobiology of pulmonary fibrosis including EMT, ECM organisation, apoptosis and Wnt 
signalling (Table 4.2.1). 
 
Control v IPF 
Biological process Specificity FDR Overlap 
PFAMs 
Total 
PFAMs 
ECM organization 2 4.36E-07 45 63 
Wnt receptor signalling pathway 2 1.93E-06 30 38 
Regulation of FGFR signalling pathway 3 1.27E-04 11 11 
Integrin-mediated signalling pathway 3 9.61E-04 14 17 
Tissue remodelling 3 1.36E-03 12 14 
Response to hypoxia 3 2.57E-03 28 45 
Induction of apoptosis by extracellular signals 3 3.56E-03 9 10 
Collagen fibril organization 3 5.28E-03 10 12 
Bile acid metabolic process 4 8.30E-03 6 6 
Blood vessel remodelling 4 8.30E-03 6 6 
EMT 3 8.78E-03 13 18 
Regulation of JAK-STAT cascade 3 8.78E-03 13 18 
Control v SSc 
Extracellular matrix organization 2 2.41e-10 52 63 
Immune response 2 1.41e-09 95 140 
Wnt receptor signalling pathway 2 8.73E-09 34 38 
Integrin-mediated signalling pathway 3 2.55e-06 17 17 
Response to hypoxia 3 8.43e-05 33 45 
Inflammatory response 3 1.42e-04 22 27 
Regulation of FGFR signalling pathway 3 3.32e-04 11 11 
Tissue remodelling 3 4.66e-04 13 14 
JAK-STAT cascade 3 9.26E-04 12 13 
Collagen fibril organization 3 1.84e-03 11 12 
Induction of apoptosis by extracellular signals 3 6.86e-03 9 10 
Table 4.2.1. Domain-centric enrichment of biological processes enriched in PFAMs associated with 
genes with altered methylation in IPF and SSc compared to control lung fibroblasts. Specificity = 
levels of granularity of a specific biological process (1=highly general, 2; general, 3; specific, 4; highly 
specific). FDR = false discovery rate (P<0.01). Overlap PFAMs = number of overlapping PFAMs 
associated with the biological process out of the total number of PFAMs in the input list. Total PFAMs 
= total number of PFAMs associated with the biological process.  
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Multiple PFAMs overlapped in biological processes such as ECM organisation and collagen fibril 
organisation. ECM, classed as a general biological process, was associated with 63 different PFAMs, of 
which 45 and 52 PFAMs contained genes which had significantly altered methylation (Δβ ≥ 0.136; 
P<0.05) in IPF and SSc compared to control lung fibroblasts, respectively. Collagen fibril organisation, 
classed as a specific biological process, was associated with 12 different PFAMs, all of which were 
associated with the broader gene ontology of ECM organisation. PFAMs (10 and 11) associated with 
collagen fibril organisation contained genes which had significantly altered methylation (Δβ ≥ 0.136; 
P<0.05) in IPF (Figure 4.2.1) and SSc (Figure 4.2.2) compared to control lung fibroblasts, respectively.  
 
 
Figure 4.2.1. Genes belonging to PFAMs associated with collagen fibril organisation which have 
altered methylation in IPF compared to control lung fibroblasts. Genes belonging to PFAMs (red 
boxes) which had significantly altered methylation (Δβ ≥0.136; P<0.05) in IPF (n=5) compared to 
control (n=6) lung fibroblasts. Coloured boxes represent direction of methylation, orange; genes with 
increased methylation, blue; genes with decreased methylation, green; genes with both increased and 
decreased methylation in IPF compared to control lung fibroblasts. Annotated boxes indicate genes 
with both significantly altered methylation (Δβ ≥0.136; P<0.05) and significantly altered expression 
(TNoM ≤1; P<0.05) in IPF compared to control lung fibroblasts. M= methylation, E= expression. Blue = 
decreased, orange = increased in IPF (n=5) relative to the average control lung fibroblast 
methylation/expression value.  
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Figure 4.2.2. Genes belonging to PFAMs associated with collagen fibril organisation which have 
altered methylation in SSc compared to control lung fibroblasts. Genes belonging to PFAMs (red 
boxes) which had significantly altered methylation (Δβ ≥0.136; P<0.05) in SSc (n=7) compared to 
control (n=6) lung fibroblasts. Coloured boxes represent direction of methylation, orange; genes with 
increased methylation, blue; genes with decreased methylation, green; genes with both increased and 
decreased methylation in SSc compared to control lung fibroblasts. Annotated boxes indicate genes 
with both significantly altered methylation (Δβ ≥0.136; P<0.05) and significantly altered expression 
(TNoM ≤1; P<0.05) in SSc compared to control lung fibroblasts. M= methylation, E= expression. Blue 
= decreased, orange = increased in SSc (n=7) relative to the average control lung fibroblast 
methylation/expression value. 
 
Gastroesophageal reflux has previously been associated with IPF and SSc (Chapter 1 section 1.6.3). 6 
PFAMs were associated with the bile acid metabolic process, (labelled as a highly specific process), all 
of which contained genes which had significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF 
compared to control lung fibroblasts. PF00067 describes proteins belonging to the cytochrome P450 
family (CYPs) which are major enzymes involved in drug metabolism and important for steroid (Nebert 
and Russell, 2002), arachidonic acid (Rifkind et al, 1995) and bile acid metabolism (Norlin and Wikvall, 
2007, Chiang, 2009). PF00104 describes proteins with a ligand-binding domain of nuclear hormone 
receptors. Nuclear receptors can directly bind DNA and regulate gene expression (Aranda and Pascual, 
2001), some of which can also regulate cytochrome P450 enzymes and function as metabolic sensors. 
Dysregulation of genes belonging to these PFAMs may therefore play an important role in IPF (Figure 
4.2.3). Although bile acid metabolic process did not reach the statistical significant cut off of P<0.01 
FDR in SSc compared to control lung fibroblasts, all 6 PFAMs had genes belonging to them which had 
altered methylation in SSc compared to control lung fibroblasts (Figure 4.2.4).  
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Figure 4.2.3. Genes belonging to PFAMs associated with bile acid metabolic process which have 
altered methylation in IPF compared to control lung fibroblasts. Genes belonging to PFAMs (red 
boxes) which had significantly altered methylation (Δβ ≥0.136; P<0.05) in IPF (n=5) compared to 
control (n=6) lung fibroblasts. Coloured boxes represent direction of methylation, orange; genes with 
increased methylation, blue; genes with decreased methylation, green; genes with both increased and 
decreased methylation in IPF compared to control lung fibroblasts. Annotated boxes indicate genes 
with both significantly altered methylation (Δβ ≥0.136; P<0.05) and significantly altered expression 
(TNoM ≤1; P<0.05) in IPF compared to control lung fibroblasts. M= methylation, E= expression. Blue = 
decreased relative to the average control lung fibroblast methylation/expression value. 
 
 
Figure 4.2.4. Genes belonging to PFAMs associated with bile acid metabolic process which have 
altered methylation in SSc compared to control lung fibroblasts. Genes belonging to PFAMs (red 
boxes) which had significantly altered methylation (Δβ ≥0.136; P<0.05) in SSc (n=7) compared to 
control (n=6) lung fibroblasts. Coloured boxes represent direction of methylation, orange; genes with 
increased methylation, blue; genes with decreased methylation, green; genes with both increased and 
decreased methylation in SSc compared to control lung fibroblasts. Boxes annotated with bar graphs 
indicate genes with both significantly altered methylation (Δβ ≥0.136; P<0.05) and significantly altered 
expression (TNoM ≤1; P<0.05) in SSc compared to control lung fibroblasts. Annotated boxes indicate 
genes with both significantly altered methylation (Δβ ≥0.136; P<0.05) and significantly altered 
expression (TNoM ≤1; P<0.05) in SSc compared to control lung fibroblasts. M= methylation, E= 
expression. Blue = decreased, orange = increased in SSc (n=7) relative to the average control lung 
fibroblast methylation/expression value. 
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Multiple PFAMs such as PF00096 were identified containing a large number of genes with significantly 
altered methylation (Δβ ≥0.136; P<0.05) in IPF and SSc compared to control lung fibroblasts (Figure 
4.2.5) PF00096 describes proteins which contain a C2H2 zinc-finger domain. Zinc-finger proteins play 
important roles in multiple biological processes including EMT (Savagner et al, 1997, Nieto, 2002, 
Lamouille et al, 2014). Multiple (91 and 88) significantly (P<0.01 FDR) enriched biological processes 
contained PF00096 in IPF and SSc compared to control lung fibroblasts, respectively. Many of these 
biological processes were broadly associated with cell changes such as cell morphogenesis, cell fate, 
mesenchyme development and pathways such as notch signalling and serine/threonine signalling 
which play important roles in regulating EMT (Larue and Bellacosa, 2005, Wang and Zhou, 2011).  
 
Figure 4.2.5. Zinc-finger C2H2 family (PF00096) containing multiple genes with altered methylation 
in IPF and SSc compared to control lung fibroblasts. Genes belonging to PFAMs (red boxes) which 
had significantly altered methylation (Δβ ≥0.136; P<0.05) in IPF (n=5) and/or SSc (n=7) compared to 
control (n=6) lung fibroblasts. Coloured boxes represent direction of methylation, orange; genes with 
increased methylation, blue; genes with decreased methylation, green; genes with both increased and 
decreased methylation in IPF/SSc compared to control lung fibroblasts. Annotated boxes indicate 
genes with both significantly altered methylation (Δβ ≥0.136; P<0.05) and significantly altered 
expression (TNoM ≤1; P<0.05) in IPF/SSc compared to control lung fibroblasts. M= methylation, E= 
expression. Blue = decreased, orange = increased in IPF (n=5) or SSc (n=7) relative to the average 
control lung fibroblast methylation/expression value.  
 
4.3. Biological processes enriched in PFAMs containing genes with altered 
expression in IPF and SSc compared to control lung fibroblasts. 
Genes which had significantly altered expression (TNoM ≤1; P<0.05) in IPF compared to control and 
SSc compared to control lung fibroblasts mapped to 419 and 527 different PFAM domains 
respectively. Multiple (676 and 767) biological processes were significantly (FDR P<0.01) enriched in 
these PFAMs in IPF and SSc compared to control lung fibroblast respectively. Of the 676 enriched 
biological processes in IPF, 534 (79%) overlapped with SSc. These included many biological processes 
previously implicated in IPF and/or SSc such as JAK-STAT signalling, ECM organisation, apoptosis, 
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interleukin-4 signalling, lung alveolus development and Wnt signalling (Table 4.3.1). The biological 
processes enriched in PFAMs which were shared between IPF and SSc often involved different genes 
belonging to the same PFAMs. This may indicate that similar processes are affected by different genes 
with altered methylation and/or expression in IPF and SSc. This is exemplified in the lung alveolus 
development process enriched in PFAMs where only 5 genes overlapped between IPF and SSc which 
had significantly altered expression compared to control lung fibroblasts (Figure 4.3.1). This 
observation could potentially have wide-ranging benefits in IPF and SSc such as acting as a method for 
disease phenotyping and a method for the identification of shared and distinct biomarkers. 
Control v IPF 
Biological process Specificity FDR Overlap 
PFAMs 
Total 
PFAMs 
Wnt receptor signalling pathway 2 2.33E-04 14 38 
Regulation of tissue remodelling 3 2.31e-03 4 5 
Positive regulation of tyrosine phosphorylation of 
Stat3 protein 
4 2.31E-03 4 5 
Positive regulation of epithelial cell proliferation 
involved in lung morphogenesis 
4 3.73e-03 3 3 
Interleukin-4 production 4 3.73e-03 3 3 
Lung alveolus development 3 4.26e-03 5 9 
ECM organization 2 4.64e-03 16 63 
Signal transduction involved in regulation of gene 
expression 
4 5.04e-03 4 6 
Bile acid metabolic process 4 5.04e-03 4 6 
Inflammatory response 3 5.84e-03 9 27 
Response to FGFR stimulus 3 6.88e-03 5 10 
Induction of apoptosis by extracellular signals 3 6.88e-03 5 10 
Chromatin silencing 3 9.28e-03 8 24 
Histone phosphorylation 3 9.55e-03 4 7 
RNA methylation 3 9.75E-03 6 15 
Control v SSc 
ECM organization 2 5.37e-12 34 63 
Wnt receptor signalling pathway 2 1.78E-04 16 38 
ECM disassembly 3 2.73e-04 5 5 
Induction of apoptosis by extracellular signals 3 4.55e-04 7 10 
Histone phosphorylation 3 2.88e-03 5 7 
JAK-STAT cascade 3 2.91E-03 7 13 
Positive regulation of anti-apoptosis 3 3.09e-03 6 10 
Chromatin silencing 3 3.19e-03 10 24 
Positive regulation of interleukin-4 production 4 4.75e-03 4 5 
Positive regulation of collagen biosynthetic process 4 6.33e-03 3 3 
Positive regulation of epithelial cell proliferation 
involved in lung morphogenesis 
4 6.33e-03 3 3 
TGFß receptor complex assembly 4 6.33e-03 3 3 
NK T cell differentiation 4 6.33E-03 3 3 
Interleukin-4 production 4 6.33e-03 3 3 
Lung alveolus development 3 9.72e-03 5 9 
Table 4.3.1. Domain-centric enrichment of biological processes enriched in PFAMs associated with 
genes with altered expression in IPF and SSc compared to control lung fibroblasts. Specificity = levels 
of granularity of a specific biological process (1=highly general, 2; general, 3; specific, 4; highly 
specific). FDR = false discovery rate (P<0.01). Overlap PFAMs = number of overlapping PFAMs 
associated with the biological process out of the total number of PFAMs in the input list. Total PFAMs 
= total number of PFAMs associated with the biological process.  
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Figure 4.3.1. Genes belonging to PFAMs associated with lung alveolar development which have 
altered expression in IPF/SSc compared to control lung fibroblasts. Genes which had significantly 
altered expression (TNoM ≤1; P<0.05) in IPF (n=5) and/or SSc (n=7) compared to control (n=6) lung 
fibroblasts. Colour boxes represent expression direction, orange; genes with increased expression, 
blue; genes with decreased expression in IPF/SSc compared to control lung fibroblasts. Annotated 
boxes indicate genes with both significantly altered methylation (Δβ ≥0.136; P<0.05) and significantly 
altered expression (TNoM ≤1; P<0.05) in IPF/SSc compared to control lung fibroblasts. M= 
methylation, E= expression. Blue = decreased, orange = increased in IPF (n=5) or SSc (n=7) relative to 
the average control lung fibroblast methylation/expression value.   
 
Multiple biological processes significantly (FDR P<0.05) enriched in PFAMs containing genes with 
significantly altered expression (TNoM ≤1; P<0.05) in IPF and SSc were the same biological processes 
enriched in PFAMs containing genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF 
and SSc compared to control lung fibroblasts. This adds further evidence that aberrantly 
methylated/expressed genes in IPF/SSc are associated with common and specific PFAMs and suggests 
a strong link between methylation and expression. Of the 676 biological processes enriched in PFAMs 
containing genes with altered expression, 445 (66%) were the same PFAMs which contained genes 
with altered methylation in IPF compared to control lung fibroblasts. Similarly, of the 767 biological 
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processes enriched in PFAMs containing genes with altered expression, 481 (63%) were the same 
biological processes enriched in PFAMs containing genes with altered methylation in SSc compared to 
control lung fibroblasts. Furthermore, PFAMs, such as PF00096, which contained multiple genes with 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF and SSc compared to control lung 
fibroblasts (Section 4.2, Figure 4.2.5) also had multiple genes with significantly altered expression 
(Figure 4.3.2), showing that multiple PFAMs contain genes with both altered methylation and 
expression. 
 
Figure 4.3.2. Genes associated with the C2H2 zinc finger domain (PF00096) which have altered 
expression in IPF and SSc compared to control lung fibroblasts. Genes which had significantly altered 
expression (TNoM ≤1; P<0.05) in IPF (n=5) and/or SSc (n=7) compared to control (n=6) lung fibroblasts. 
Colour boxes represent expression direction, orange; genes with increased expression, Blue; genes 
with decreased expression in IPF/SSc compared to control lung fibroblasts. Annotated boxes indicate 
genes with both significantly altered methylation (Δβ ≥0.136; P<0.05) and significantly altered 
expression (TNoM ≤1; P<0.05) in IPF/SSc compared to control lung fibroblasts. M= methylation, E= 
expression. Blue = decreased, orange = increased in IPF (n=5) or SSc (n=7) relative to the average 
control lung fibroblast methylation/expression value.   
 
 
4.4. Biological processes enriched in PFAMs containing genes with altered 
methylation in IPF compared to SSc lung fibroblasts.  
Genes which had significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc lung 
fibroblasts mapped to 1468 different PFAM domains. Multiple (601) biological processes were 
enriched in these PFAMs, including Wnt signalling, ECM organisation, epithelial cell differentiation and 
induction of apoptosis by extracellular signals (Table 4.4.1). Of these, 488 (81%)  biological processes 
were the same as those which were enriched in PFAMs containing genes with altered methylation in 
IPF and SSc compared to control lung fibroblasts (Figure 4.4.1). The identification of these processes 
adds further evidence that multiple pathways overlap between IPF and SSc which may involve both 
common and distinct genes in each disease. Furthermore, specific PFAMs associated with multiple 
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biological processes which may be relevant to pulmonary fibrosis but were not significantly enriched, 
including collagen fibril organisation and bile acid metabolic process, also contained multiple genes 
which had significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc lung 
fibroblasts (Figure 4.4.2). 
 
Biological process Specificity FDR Overlap 
PFAMs 
Total 
PFAMs 
Epithelial cell differentiation 2 6.05e-12 58 69 
ECM organization 2 2.02e-09 51 63 
Wnt receptor signalling pathway 2 6.81E-07 32 38 
Response to hypoxia 3 1.27e-06 36 45 
Regulation of histone modification 3 1.57e-06 23 25 
Chromatin remodelling 3 3.01e-04 24 31 
Trachea development 3 3.53e-04 11 11 
Tissue remodelling 3 5.03e-04 13 14 
Inflammatory response 3 7.17e-04 21 27 
Patterning of blood vessels 3 1.64e-03 9 9 
Cell aging 3 3.82e-03 15 19 
Regulation of FGFR signalling pathway 3 3.82e-03 10 11 
Response to virus 2 5.56e-03 29 45 
Regulation of respiratory gaseous exchange 3 6.90e-03 7 7 
Induction of apoptosis by extracellular signals 3 7.25e-03 9 10 
Table 4.4.1. Domain-centric enrichment of biological processes enriched in PFAMs associated with 
genes with altered methylation in IPF compared to SSc lung fibroblasts. Specificity = levels of 
granularity of a specific biological process (1=highly general, 2; general, 3; specific, 4; highly specific). 
FDR = false discovery rate (P<0.01). Overlap PFAMs = number of overlapping PFAMs associated with 
the biological process out of the total number of PFAMs in the input list. Total PFAMs = total number 
of PFAMs associated with the biological process. 
 
 
Figure 4.4.1. Number of distinct and overlapping biological processes enriched in PFAMs containing 
genes with altered methylation in IPF and SSc compared to each other and compared to control lung 
fibroblasts. Biological processes (488) were identified as being enriched in PFAMs containing genes 
with altered methylation in IPF and SSc compared to controls and IPF compared to SSc lung fibroblasts.  
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Figure 4.4.2. PFAMs associated with biological processes potentially relevant to pulmonary fibrosis. 
PF01421 ADAM and ADAMTS domain family and PF00067 cytochrome P450 domain family which, 
among other biological processes, are associated with collagen fibril organisation and bile metabolic 
process respectively. Collagen fibril organisation and bile acid metabolic process were not significantly 
enriched in PFAMs with altered methylation in  IPF compared to SSc lung fibroblasts but multiple genes 
belonging to PFAMs associated with these biological processes did have significantly altered 
methylation (Δβ ≥ 0.136; P<0.05). Coloured boxes represent direction of methylation, orange; genes 
with increased methylation, Blue; genes with decreased methylation, green; genes with both 
increased and decreased methylation in IPF compared to SSc lung fibroblasts. Annotated boxes 
indicate genes with both significantly altered methylation (Δβ ≥0.136; P<0.05) and significantly altered 
expression (TNoM ≤1; P<0.05) in IPF compared to SSc lung fibroblasts. M= methylation, E= expression. 
Blue = decreased, orange = increased in IPF (n=5) relative to the average SSc lung fibroblast 
methylation/expression value. 
 
4.5. Biological processes enriched in PFAMs containing genes with altered 
expression in IPF compared to SSc lung fibroblasts.  
Genes which had significantly altered expression in IPF compared to SSc lung fibroblasts mapped to 
765 PFAMs. Biological processes (636) including Wnt signalling, ECM organisation and bile acid 
metabolic process were enriched in these PFAMs (Table 4.5.1). Of these 636 enriched biological 
process, 447 (70%) overlapped with those enriched in PFAMs containing genes which had significantly 
altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc lung fibroblasts. These included 
response to hypoxia, Wnt signalling, ECM organisation, chromatin remodelling and induction of 
apoptosis by extracellular signals.  
As previously shown, multiple biological processes enriched in PFAMs containing genes with 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) and expression overlapped (66% and 63% 
respectively) between IPF and SSc compared to control lung fibroblasts and 70% overlapped between 
IPF and SSc lung fibroblasts. This shows that the multiple biological processes are commonly enriched 
in PFAMs containing genes with both significantly altered methylation and expression. Many of these 
genes have both significantly altered methylation (Δβ ≥ 0.136; P<0.05) and expression suggesting a 
direct effect of methylation on expression. For example the biological process ‘induction of apoptosis 
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by extracellular signals’ was associated with 10 PFAMs; 9 of these PFAMs contained 271 genes with 
altered methylation in IPF compared to SSc and 7 of these PFAMs contained 57 genes with altered 
expression in IPF compared to SSc lung fibroblasts (Figure 4.5.1). Twenty-two genes overlapped which 
had altered methylation and expression in IPF compared with SSc lung fibroblasts, suggesting multiple 
genes encoding proteins with functional domains associated with apoptosis could be directly 
regulated by methylation. 
Furthermore, biological processes such as Wnt signalling were enriched in PFAMs containing genes 
with significantly altered methylation (Δβ ≥ 0.136; P<0.05) and expression in both IPF and SSc 
compared to control lung fibroblasts and in PFAMs containing genes with significantly altered 
methylation (Δβ ≥ 0.136; P<0.05) and expression in IPF compared to SSc lung fibroblasts. This suggests 
that Wnt signalling may be different in both IPF and SSc compared to control but also different in IPF 
compared to SSc lung fibroblasts.  
Biological process Specificity FDR Overlap 
PFAMs 
Total 
PFAMs 
ECM organization 2 3.71e-13 42 63 
Response to hypoxia 3 4.82e-06 25 45 
Regulation of PI3K activity 3 4.80e-05 12 16 
Regulation of IL-2 production 3 5.11e-05 9 10 
Regulation of epithelial cell proliferation 
involved in lung morphogenesis 
3 4.70e-04 6 6 
Bile acid metabolic process 4 4.70e-04 6 6 
JAK-STAT cascade 3 1.20E-03 9 13 
Wnt receptor signalling pathway 2 1.38E-03 18 38 
Lung epithelium development 3 1.81e-03 7 9 
Collagen fibril organization 3 3.22e-03 8 12 
Induction of apoptosis by extracellular signals 3 4.18e-03 7 10 
Methylation 2 4.79e-03 30 83 
Collagen catabolic process 4 5.75e-03 4 4 
Chromatin remodelling 3 7.32e-03 14 31 
Regulation of viral reproduction 3 9.64e-03 8 14 
Table 4.5.1. Domain-centric enrichment of biological processes enriched in PFAMs associated with 
genes with altered expression in IPF compared to SSc lung fibroblasts. Specificity = levels of 
granularity of a specific biological process (1=highly general, 2; general, 3; specific, 4; highly specific). 
FDR = false discovery rate (P<0.01). Overlap PFAMs = number of overlapping PFAMs associated with 
the biological process out of the total number of PFAMs in the input list. Total PFAMs = total number 
of PFAMs associated with the biological process. 
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Figure 4.5.1. Genes belonging to PFAMs associated with induction of apoptosis by extracellular 
signals which have altered methylation and expression in IPF compared to SSc lung fibroblasts. 
Coloured boxes represent direction of methylation/expression, yellow; genes with increased 
methylation/expression, blue; genes with decreased methylation/expression, green; genes with both 
increased and decreased methylation in IPF compared to SSc lung fibroblasts. Annotated boxes 
indicate genes with both significantly altered methylation (Δβ ≥0.136; P<0.05) and significantly altered 
expression (TNoM ≤1; P<0.05) in IPF compared to SSc lung fibroblasts. M= methylation, E= expression. 
Blue = decreased, orange = increased in IPF (n=5) relative to the average SSc lung fibroblast 
methylation/expression value. 
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4.6. Functional analysis of differentially methylated and expressed genes in IPF and 
SSc compared to control lung fibroblasts 
As previously described, Genecodis 3 web analysis tool (Tabas-Madrid et al, 2012) was used to 
determine enriched functional groups and understand the biological meaning of the differentially 
methylated genes in IPF and SSc compared to control lung fibroblasts. Multiple biological processes 
(550 and 309) were significantly (FDR P<0.05) enriched in genes with significantly altered methylation 
(Δβ ≥ 0.136; P<0.05) in IPF and SSc compared to control lung fibroblasts, respectively. Of the 309 
enriched biological processes in SSc, 203 (66%) overlapped with IPF. These included apoptosis, Wnt 
signalling, blood coagulation, regulation of transcription, small GTPase-mediated signal transduction 
and ECM organisation (Table 4.6.1). Many of these processes have previously been implicated in the 
pathogenesis of pulmonary fibrosis (Morrisey, 2003, Chilosi et al, 2003, Königshoff et al, 2008, 
Chambers, 2008, Chambers and Scotton, 2012, Mercer et al, 2013). 
 
Multiple biological processes (31 and 17) were identified as being significantly (FDR P<0.05) enriched 
in genes that had significantly altered expression (TNoM ≤1; P<0.05) in IPF and SSc compared to 
control lung fibroblasts, respectively. These included apoptosis, regulation of transcription, gene 
expression and small GTPase-mediated signal transduction (Table 4.6.2). Only 4 biological processes 
overlapped between IPF and SSc. Wnt signalling, ECM organisation and lung development were not 
enriched in genes that were differentially expressed in IPF and SSc compared to control lung 
fibroblasts, however, there were specific genes which did have altered expression belonging to these 
processes. Furthermore, although these biological processes were not significantly enriched in genes 
with significantly altered expression (TNoM ≤1; P<0.05) in IPF and SSc, they were significantly (P<0.01) 
enriched in PFAMs containing genes with significantly altered expression (TNoM ≤1; P<0.05) (see 
section 4.3, Table 4.3.1).  
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Control v IPF 
Biological process (BP) Number of 
genes 
Total number of genes 
associated with the BP  
Hypergeometric P 
value 
Cell adhesion  170 556 4.53E-35 
Regulation of transcription 290 1609 4.00E-17 
Regulation of small GTPase 
mediated signal transduction  
54 172 2.99E-11 
Apoptotic process  122 594 1.86E-10 
Blood coagulation  96 457 1.02E-08 
ECM organization  25 73 5.68E-06 
Regulation of cell proliferation  30 101 1.01E-05 
Wnt receptor signalling pathway  31 110 2.03E-05 
Immune response  74 382 2.08E-05 
Negative regulation of BMP 
signalling pathway  
13 26 3.48E-05 
Wound healing  22 68 5.90E-05 
Response to glucocorticoid 
stimulus  
25 84 6.53E-05 
Inflammatory response  53 259 0.000113 
EMT  11 25 0.000667 
Lung development  21 75 0.000772 
Control v SSc 
Cell adhesion  199 556 9.13e-43 
Regulation of transcription 373 1609 3.20E-31 
Apoptotic process  159 594 7.65e-19 
Regulation of small GTPase 
mediated signal transduction  
70 172 3.60E-18 
Blood coagulation  125 457 1.87e-15 
Wnt receptor signalling pathway  42 110 9.31E-10 
Chromatin modification  65 224 4.14e-09 
Integrin-mediated signalling 
pathway  
31 70 4.95e-09 
ECM organization  29 73 3.47e-07 
Lung development  28 75 2.43e-06 
Chemotaxis  35 126 0.000102 
FGFR signalling pathway  25 78 0.00015 
Inflammatory response  58 259 0.000182 
Immune response  76 382 0.000604 
Pregnancy  19 72 0.013026 
Table 4.6.1. Functional analysis of differentially methylated genes in SSc compared to control lung 
fibroblasts. Multiple biological processes and pathways were identified which included genes with 
significantly increased or decreased (Δβ ≥ 0.136; P<0.05) methylation in IPF (n=5) and SSc (n=7) 
compared to control (n=6) lung fibroblasts. The number of genes associated with each biological 
process and the total number of genes that belong to each process is shown. The P-value was 
calculated using the hypergeometric distribution and corrected for multiple testing using the 
Benjamini-Hochberg FDR method. A smaller adjusted P-value correlated with greater gene 
enrichment.  
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Control v IPF 
Biological process Number of 
genes 
Total number of genes 
associated with the BP 
Hypergeometric P 
value 
Apoptotic process 28 594 2.57e-05 
Signal transduction 39 1176 0.000296 
Viral reproduction 15 329 0.008767 
Ubiquitin-dependent protein 
catabolic process 
10 150 0.009025 
Viral transcription 7 82 0.014664 
Gene expression 16 408 0.019243 
Small GTPase-mediated signal 
transduction 
13 312 0.028138 
Platelet activating factor 
biosynthetic process 
2 4 0.043839 
Negative regulation of cell 
proliferation 
13 341 0.047919 
Regulation of transcription, 
DNA-dependent 
38 1609 0.048648 
Control v SSc 
Pregnancy  10 72 0.000691 
Transport  29 604 0.000802 
Apoptotic process  12 156 0.009583 
Negative regulation of cell 
proliferation  
17 341 0.020969 
Signal transduction  39 1176 0.025865 
Translation  14 241 0.027217 
Copper ion transport  4 14 0.028483 
Regulation of transcription, 
DNA-dependent  
48 1609 0.031969 
Negative regulation of cell 
volume  
2 2 0.03632 
Microtubule cytoskeleton 
organization  
6 55 0.036543 
Table 4.6.2. Functional analysis of differentially expressed genes in IPF/SSc compared to control lung 
fibroblasts. Genes which had significantly altered expression (TNoM ≤1; P<0.05) in IPF (n=5) or SSc 
(n=7) compared to control (n=6) lung fibroblasts. The number of genes associated with each biological 
process and the total number of genes that belong to each process is shown. The P-value was 
calculated using the hypergeometric distribution and corrected for multiple testing using the 
Benjamini-Hochberg FDR method. A smaller adjusted P-value correlated with greater gene 
enrichment.  
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4.7. Functional analysis of differentially methylated and expressed genes in IPF 
compared to SSc lung fibroblasts 
Multiple (639) biological processes, many of which have previously been implicated in pulmonary 
fibrosis including apoptosis, Wnt signalling, blood coagulation, regulation of transcription, lung 
development and ECM organisation, were identified as being significantly (FDR P<0.05) enriched in 
genes that had significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc lung 
fibroblasts (Table 4.7.1). 
 
Biological process Number of 
genes 
Total number of genes 
associated with the BP 
Hypergeometric P value 
Multicellular organism 
development  
339 945 8.36e-78 
Regulation of transcription, DNA-
dependent  
367 1609 2.70E-31 
Cell adhesion  174 556 2.41e-30 
Blood coagulation  121 457 1.48e-14 
Regulation of small GTPase 
mediated signal transduction  
61 172 5.76E-13 
Apoptotic process  135 594 6.97e-11 
Platelet activation  60 234 1.03e-06 
Response to hypoxia  49 175 1.04e-06 
Lung development  27 75 5.75e-06 
Wnt receptor signalling pathway  33 110 2.66E-05 
ECM organization  25 73 4.02e-05 
Negative regulation of BMP 
signalling pathway  
13 26 0.000115 
Cellular response to TGFß 
stimulus  
11 24 0.001203 
Female pregnancy  20 72 0.004635 
DNA methylation  7 19 0.044627 
Table 4.7.1. Functional analysis of differentially methylated genes in IPF compared to SSc lung 
fibroblasts. Multiple biological processes and pathways identified which included genes with 
significantly increased or decreased (Δβ ≥ 0.136; P<0.05) methylation in IPF (n=5) compared to SSc 
(n=7) lung fibroblasts. The number of genes associated with each biological process and the total 
number of genes that belong to each process is shown. The P-value was calculated using the 
hypergeometric distribution and corrected for multiple testing using the Benjamini-Hochberg FDR 
method. A smaller adjusted P-value correlated with greater gene enrichment.  
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Multiple (45) biological processes were identified as being significantly (FDR P<0.05) enriched in genes 
which had significantly altered expression (TNoM ≤1; P<0.05) in IPF compared to SSc lung fibroblasts. 
O these biological processes, 19, including apoptosis, regulation of transcription, blood coagulation, 
TGFß signalling and small GTPase-mediated signal transduction, overlapped with those which were 
significantly (FDR P<0.05) enriched in genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) 
in IPF compared to SSc lung fibroblasts (Table 4.7.2).   
 
Biological process Number of genes 
(Methylation) 
Number of genes 
(expression) 
Total number of genes 
associated with the BP 
Placenta development  10 5 28 
Regulation of transcription, 
DNA-dependent  
367 78 1609 
Proteolysis  101 35 543 
Ubiquitin-dependent protein 
catabolic process  
31 15 150 
Transport  110 45 604 
Endocytosis  29 14 110 
Apoptotic process  135 41 594 
Mitosis  41 14 187 
Signal transduction  308 72 1176 
Small GTPase-mediated signal 
transduction  
80 25 312 
Nervous system development  137 29 410 
Axon guidance  115 20 307 
Pregnancy  20 10 72 
Blood coagulation  121 29 457 
Negative regulation of cell 
proliferation  
101 27 341 
Cellular nitrogen compound 
metabolic process  
48 18 200 
Intracellular signal transduction  83 26 303 
Negative regulation of 
apoptotic process  
79 20 272 
Cellular lipid metabolic process  30 13 128 
Table 4.7.2. Functional analysis of biological processes which contained differentially expressed 
genes which overlapped with biological processes containing differentially methylated genes in IPF 
compared to SSc lung fibroblasts. Nineteen overlapping biological processes which contained genes 
which had significantly altered expression (TNoM ≤1; P<0.05) and significantly altered methylation (Δβ 
≥0.136; P<0.05) in IPF (n=5) compared to SSc (n=7) lung fibroblasts.  The number of genes associated 
with each biological process and the total number of genes that belong to each process is shown. The 
P-value was calculated using the hypergeometric distribution and corrected for multiple testing using 
the Benjamini-Hochberg FDR method. A smaller adjusted P-value correlated with greater gene 
enrichment.  
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4.8. Summary 
 PFAM and gene-term enrichment analysis identified multiple biological processes enriched 
in genes with significantly altered methylation in IPF and/or SSc compared to control lung 
fibroblasts, many of which have previously been implicated in pulmonary fibrosis and many 
of which are novel which may be relevant to fibrosis.  
 
 Multiple biological processes enriched in genes with significantly altered methylation were 
the same as those enriched in genes with significantly altered expression in IPF and SSc 
compared to control lung fibroblasts. This suggests that methylation is important in 
regulating gene expression in pulmonary fibrosis.  
 
 Many of these biological processes were also significantly enriched in genes which had 
significantly altered methylation and/or expression in IPF compared to SSc lung fibroblasts. 
 
 Taken together this data suggests multiple common biological processes are enriched with 
genes which have altered methylation and expression in IPF and SSc compared to control 
lung fibroblasts, however, multiple genes are distinct to each disease.  
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4.9. Pathway analysis of differentially methylated and expressed genes in IPF and 
SSc compared to control lung fibroblasts  
GO term enrichment analysis identified multiple biological processes associated with the lung and/or 
fibrosis, including Wnt signalling, ECM organisation and lung development which were enriched in 
genes that were differentially methylated in both IPF and SSc compared to control lung fibroblasts. 
There were also multiple genes in commonly enriched processes that were distinct to each disease 
which was concurrent with data from the PFAM enrichment analysis. Biological processes including 
Wnt signalling, ECM organisation and lung development were not enriched in genes that were 
differentially expressed in IPF and SSc compared to control lung fibroblasts, potentially because the 
cut-off for inclusion was too stringent. However, there were specific genes which did have altered 
expression belonging to these processes. Furthermore, although these biological processes were not 
significantly enriched in genes with significantly altered expression in IPF and SSc, PFAMs containing 
genes with significantly altered expression were significantly enriched in these processes.  
Aberrant Wnt signalling has previously been implicated in a multitude of fibroses including IPF and SSc 
(Chilosi et al, 2003, Selman et al, 2008, Königshoff and Eickelberg, 2010, Lam and Gottardi, 2011). Β-
catenin is a downstream component of the Wnt signalling pathway and has been implicated in fibroses 
including SSc-PF where its expression is increased (Lam and Gottardi, 2011). Active β-catenin acts as 
a transcription coactivator for the transcription factors Lymphoid enhancer-binding factor 1 (LEF1)/ T-
cell factor 1 (TCF1) which mediate nuclear responses to Wnt signals (Eastman and Grosschedl, 1999). 
Glycogen synthase kinase 3β (GSK3β) can degrade β-catenin (Nakamura et al, 1998), however, the 
binding of Wnt ligands to low-density lipoprotein receptor-related protein (LRP)/Frizzled (FZD) 
receptors inhibits GSK3β which subsequently inhibits the phosphorylation and degradation of β-
catenin (Liu et al, 2002). Expression of Wnt-related genes including WNT5A, frizzled class receptor 2 
(FZD2) and frizzled class receptor 3 (FZD3) are increased in IPF (Königshoff et al, 2008, Vuga et al, 
2009). Expression of FZD2 and the Wnt target LEF1 are increased in SSc skin fibroblasts whereas Wnt 
antagonists DKK1, Dickkopf-related protein 2 (DKK2), SFRP1 and WNT inhibitory factor 1 (WIF1) all 
have decreased expression which has been associated with promoter methylation (Wei et al, 2012, 
Dees et al, 2013), however, the full extent and role of methylation in Wnt signalling in pulmonary 
fibrosis is unknown. 
GO term enrichment analysis identified the WNT receptor signalling pathway as being significantly 
enriched in 31 genes that were differentially methylated in IPF (P=2.03E-05) and 42 genes that were 
differentially methylated in SSc (P=9.31E-10) compared to control lung fibroblasts. Eighteen genes 
were the same in both IPF and SSc, 13 were distinct to IPF and 24 were distinct to SSc (Table 4.9.1). 
Whilst GO enrichment is a useful tool for finding enriched biological processes and potentially in the 
use of generating user-defined pathways, GO terms do not correspond directly with well-defined 
pathways such as KEGG pathways (Mao et al, 2005). For already well-defined pathways such as the 
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KEGG Wnt signalling pathway, KEGG enrichment was also used. KEGG enrichment identified 45 genes 
that were differentially methylated in IPF (P=1.835E-09) and 59 genes that were differentially 
methylated in SSc (P=1.56E-14) compared to control lung fibroblasts (Table 4.9.1).   
 
GO-term enrichment 
Differentially methylated genes in fibrotic lung fibroblasts involved in WNT signalling 
CALCOCO1 FBXW11 SFRP5 CSNK1D TNIK C1orf187 GSK3A TNKS 
CCDC88C GRK6 TLE3 CSNK1G3 WNT4 CSNK1G1 LRRFIP2 WIF1 
CCNY LEF1 WNT11 FAM123B WNT8A CTNNB1 MCC WISP1 
CD44 LRP5 WNT5A FBXW4 APC CYLD NDRG2 WNT10B 
CDK14 MITF BRD7 KREMEN2 ARL6 DRD2 RSPO2 WNT16 
CPZ NKD2 CELSR2 RNF146 BCL9 FZD6 TCF7L1 WNT7B 
DACT1 NXN CSNK1A1L SOSTDC1 BTRC GRK5 TLE2  
KEGG pathway enrichment 
Differentially methylated genes in fibrotic lung fibroblasts involved in WNT signalling 
AXIN2 FZD7 SFRP5 CSNK1A1L SMAD2 CTNNB1 PPP3CA WIF1 
CAMK2A LEF1 TBL1XR1 CUL1 WNT4 CTNNBIP1 PRICKLE1 WNT10B 
CAMK2B LRP5 TCF7L2 CXXC4 WNT7A DAAM2 PRKCG WNT16 
CAMK2G MAPK10 VANGL2 FZD9 WNT8A FOSL1 SIAH1 WNT6 
CSNK2A1 NFATC1 WNT10A PLCB1 WNT8B FZD1 SKP1 WNT7B 
CTBP2 NKD2 WNT11 PLCB2 APC FZD6 SMAD3  
DKK4 PRKCA WNT3 PPP2R5A BAMBI GPC4 SOST  
FBXW11 PRKCB WNT5A PPP2R5C BTRC JUN SOX17  
FZD10 SFRP1 WNT9A PRICKLE2 CACYBP NFATC2 TBL1Y  
FZD5 SFRP2 CCND3 SENP2 CREBBP PLCB3 TCF7L1  
Table 4.9.1. Differentially methylated genes in fibrotic compared to control lung fibroblasts involved 
in the Wnt signalling pathway as determined by GO-term and KEGG enrichment. Genes highlighted 
in red are differentially methylated in both IPF (n=5) and SSc (n=7) compared to control (n=6) lung 
fibroblasts. Genes specifically differentially methylated in IPF (n=5) or SSc (n=7) compared to control 
(n=6) lung fibroblasts are highlighted in blue and yellow respectively. Genes in bold text overlap 
between both enrichment analyses. Full gene names can be found on appendice B. 
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In IPF, multiple Wnts had significantly altered methylation compared to control lung fibroblasts, 
although WNT2B was the only Wnt which had significantly increased expression in IPF compared to 
control lung fibroblasts. Wnt ligand receptors LRP5 had significantly increased methylation and FZD4 
had significantly increased expression in IPF compared to control lung fibroblasts, however, no change 
in methylation or expression of GSK3β or CNNTB1 was observed. The Wnt target gene, LEF1, also had 
significantly increased methylation in IPF compared to control lung fibroblasts but no change in LEF1 
expression was observed. Secreted frizzled-related protein 5 (SFRP5), a Wnt signalling inhibitor 
(Stuckenholz et al, 2013), had significantly decreased methylation in IPF compared to control lung 
fibroblasts. In breast cancer cell lines/tissue, promoter methylation correlates with decreased 
expression (Veeck et al, 2008) suggesting SFRP5 expression can be regulated by methylation, however, 
no change in SFRP5 expression was observed in IPF compared to control lung fibroblasts. 
In SSc multiple Wnts also had significantly altered methylation compared to control lung fibroblasts, 
and like IPF, WNT2B was the only Wnt with significantly increased expression. In contrast with IPF, SSc 
lung fibroblasts had increased methylation of Wnt signalling inhibitors including SFRP5 and WIF1, 
compared to control lung fibroblasts. GSK3β expression was significantly increased in SSc compared 
to control lung fibroblasts. Downstream targets CNNTB1, LEF1 and Transcription factor 7 like 1 
(TCF7L1) all had significantly increased methylation in SSc compared to control lung fibroblasts but 
had no change in expression, suggesting that methylation of these genes does not directly regulate 
their expression.  
Using genes identified by GO term enrichment and KEGG enrichment analyses, known functional 
interactions between genes associated with Wnt signalling which had significantly altered methylation 
and/or expression in IPF and SSc compared to control lung fibroblasts were identified by STRING 10 
analysis and are shown in Figure 4.9.1 and Figure 4.9.3. These genes were mapped to the Wnt 
signalling KEGG pathway using cytoscape (see Chapter 2: section 2.7.2) to identify where they fit and 
how they potentially interact with other genes in the pathway (Figure 4.9.2 and Figure 4.9.4).  
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Figure 4.9.1. Protein-protein interactions of genes involved in Wnt signalling which have altered 
methylation and/or expression in IPF compared to control lung fibroblasts. Network analysis 
showing genes which interact with each other which have significantly altered methylation (Δβ 
≥0.136; P<0.05) in IPF (n=5) compared to control (n=6) lung fibroblasts. Predicted functional links are 
indicated by the colour of adjoining lines: each colour represents a different type of evidence. Blue; 
binding, green; activation, red; inhibition, yellow; expression, black; reaction, purple; catalyst, pink; 
post-translational modification, grey; co-mentioned in abstracts. Coloured nodes represent genes 
directly linked to the input list. Coloured circles around the nodes indicate direction of methylation 
and expression: yellow = genes with CpGs which had increased methylation, blue = genes with CpGs 
which had decreased methylation, green = genes with CpGs which had both increased and decreased 
methylation in IPF compared to control lung fibroblasts. Red = genes with significantly increased 
(TNoM ≤ 1; P<0.05) expression in IPF compared to control lung fibroblasts.  
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Figure 4.9.2. Genes associated with the KEGG pathway of Wnt signalling which have altered 
methylation and/or expression in IPF compared to control lung fibroblasts. Coloured nodes outlined 
in black represent genes with significantly altered methylation (Δβ ≥0.136; P<0.05) and in red 
represent genes with significantly altered expression (TNoM ≤ 1; P<0.05) in IPF compared to control 
lung fibroblasts. For methylation: yellow = genes with CpGs which had increased methylation, blue = 
genes with CpGs which had decreased methylation, green = genes with CpGs which had both 
increased and decreased methylation in IPF compared to control lung fibroblasts. For expression: 
yellow = genes which had increased expression in IPF compared to control lung fibroblasts. +P = 
phosphorylation, e = gene expression relationship, dotted lines = indirect effect on gene, purple boxes 
= joining pathways. 
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Figure 4.9.3. Protein-protein interactions of genes involved in Wnt signalling which have altered 
methylation and/or expression in SSc compared to control lung fibroblasts. Network analysis 
showing genes which interact with each other which have significantly altered methylation (Δβ 
≥0.136; P<0.05) in SSc (n=7) compared to control (n=6) lung fibroblasts. Predicted functional links are 
indicated by the colour of adjoining lines: each colour represents a different type of evidence. Blue; 
binding, green; activation, red; inhibition, yellow; expression, black; reaction, purple; catalyst, pink; 
post-translational modification, grey; co-mentioned in abstracts. Coloured nodes represent genes 
directly linked to the input list. Coloured circles around the nodes indicate direction of methylation 
and expression: yellow = genes with CpGs which had increased methylation, blue = genes with CpGs 
which had decreased methylation, green = genes with CpGs which had both increased and decreased 
methylation in SSc compared to control lung fibroblasts. Red = genes with significantly (TNoM ≤ 1; 
P<0.05) increased expression in SSc compared to control lung fibroblasts.  
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Figure 4.9.4. Genes associated with the KEGG pathway of Wnt signalling which have altered 
methylation and/or expression in SSc compared to control lung fibroblasts. Coloured nodes outlined 
in black represent genes with significantly altered methylation (Δβ ≥0.136; P<0.05) and in red 
represent genes with significantly altered expression (TNoM ≤ 1; P<0.05) in SSc compared to control 
lung fibroblasts. For methylation: yellow = genes with CpGs which had increased methylation, blue = 
genes with CpGs which had decreased methylation, green = genes with CpGs which had both 
increased and decreased methylation in SSc compared to control lung fibroblasts. For expression: 
yellow = genes which had increased expression in SSc compared to control lung fibroblasts. +P = 
phosphorylation, e = gene expression relationship, dotted lines = indirect effect on gene, purple boxes 
= joining pathways. 
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4.10. Pathway analysis of differentially methylated and expressed genes in IPF 
compared to SSc lung fibroblasts  
The WNT receptor signalling pathway was significantly enriched in 33 genes that were differentially 
methylated in IPF (P=2.66E-05) compared to SSc lung fibroblasts (Table 4.10.1).  
 
Differentially-methylated genes in IPF compared to SSc lung fibroblasts associated with Wnt signalling 
Symbol Name Symbol Name 
BCL9 B-cell CLL/lymphoma 9 NXN Nucleoredoxin 
CCDC88C Coiled-coil domain containing 88C PORCN Porcupine homolog  
CCNY Cyclin Y PYGO2 Pygopus homolog 2  
CELSR2 Cadherin, EGF LAG seven-pass G-type 
receptor 2  
SOSTDC1 Sclerostin domain containing 1 
CSNK1G1 Casein kinase 1, gamma 1 TCF7 Transcription factor 7 (T-cell specific, 
HMG-box) 
CTNNB1 Catenin (cadherin-associated 
protein), beta 1 
TCF7L1 Transcription factor 7-like 1 (T-cell 
specific, HMG-box) 
CYLD Cylindromatosis  TLE3 Transducin-like enhancer of split 3 
(E(sp1) homolog, Drosophila) 
DRD2 Dopamine receptor D2 TLE4 Transducin-like enhancer of split 4 
(E(sp1) homolog, Drosophila) 
DVL3 Dishevelled, dsh homolog 3  TNIK TRAF2 and NCK interacting kinase 
ETV2 Ets variant 2 WIF1 WNT inhibitory factor 1 
FAM123B Family with sequence similarity 123B WNT1 Wingless-type MMTV integration site 
family, member 1 
FBXW11 F-box and WD repeat domain 
containing 11 
WNT2 Wingless-type MMTV integration site 
family member 2 
FZD6 Frizzled homolog 6  WNT5A Wingless-type MMTV integration site 
family, member 5A 
GRK5 G protein-coupled receptor kinase 5 WNT5B Wingless-type MMTV integration site 
family, member 5B 
LRP5 Low density lipoprotein receptor-
related protein 5 
WNT7B Wingless-type MMTV integration site 
family, member 7B 
MCC Mutated in colorectal cancers WNT8A Wingless-type MMTV integration site 
family, member 8A 
NKD2 Naked cuticle homolog 2    
Table 4.10.1. Differentially-methylated genes in IPF compared to SSc lung fibroblasts associated 
with Wnt signalling. Genes associated with WNT signalling with significantly altered methylation (Δβ 
≥ 0.136; P<0.05) in IPF (n=5) compared to SSc (n=7) lung fibroblasts are shown.  
 
Genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc lung 
fibroblasts associated with Wnt signalling known to interact with each other are shown in Figure 
4.10.1. Compared to SSc; IPF lung fibroblasts had multiple Wnts including WNT1, WNT2, WNT5B, 
WNT7B and WNT8A which had significantly decreased methylation. Conversely, WNT5A had 
significantly increased methylation and significantly decreased expression. Although no Wnt genes 
had significantly increased expression, frizzled receptors FZD1 and FZD4 had significantly increased 
expression which could potentially facilitate greater Wnt binding. GSK3β expression was significantly 
decreased whereas CTNNB1 expression was significantly increased in IPF compared to SSc lung 
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fibroblasts (Figure 4.10.2). This is in agreement with previous evidence in Wnt literature showing the 
binding of Wnt ligands to FZD receptors leads to inhibition of GSK3β resulting in increased CTNNB1 
(Liu et al, 2002). Interestingly, CTNNB1 also had significantly altered methylation (Δβ ≥ 0.136; P<0.05) 
in IPF compared to SSc lung fibroblasts suggesting a potential direct link between methylation and 
expression. 
 
 
Figure 4.10.1. Protein-protein interactions of genes involved in Wnt signalling which have altered 
methylation and/or expression in IPF compared SSc lung fibroblasts. Network analysis showing 
genes which interact with each other which have significantly altered methylation (Δβ ≥0.136; P<0.05) 
in IPF (n=5) compared to SSc (n=7) lung fibroblasts. Predicted functional links are indicated by the 
colour of adjoining lines: each colour represents a different type of evidence. Blue; binding, green; 
activation, red; inhibition, yellow; expression, black; reaction, purple; catalyst, pink; post-translational 
modification, grey; co-mentioned in abstracts. Coloured nodes represent genes directly linked to the 
input list. Coloured circles around the nodes indicate direction of methylation and expression: yellow 
= genes with CpGs which had increased methylation, blue = genes with CpGs which had decreased 
methylation, green = genes with CpGs which had both increased and decreased methylation in IPF 
compared to SSc lung fibroblasts. Red = genes with increased (TNoM ≤ 1; P<0.05) expression, purple 
= genes with decreased (TNoM ≤ 1; P<0.05) expression in IPF compared to SSc lung fibroblasts.  
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Figure 4.10.2. Genes associated with the KEGG pathway of Wnt signalling which have altered 
methylation and/or expression in IPF compared to SSc lung fibroblasts. Coloured nodes outlined in 
black represent genes with significantly altered methylation (Δβ ≥0.136; P<0.05) and in red represent 
genes with significantly altered expression (TNoM ≤ 1; P<0.05) in IPF (n=5) compared to SSc (n=7) lung 
fibroblasts. For methylation: yellow = genes with CpGs which had increased methylation, blue = genes 
with CpGs which had decreased methylation, green = genes with CpGs which had both increased and 
decreased methylation in IPF compared to SSc lung fibroblasts. For expression: yellow = genes which 
had increased expression, blue = genes which had decreased expression in IPF compared to SSc lung 
fibroblasts. +P = phosphorylation, e = gene expression relationship, dotted lines = indirect effect on 
gene, purple boxes = joining pathways. 
 
4.11. Validation of functional analyses using TNXB 
As previously shown TNXB had multiple CpGs with significantly altered methylation in IPF and SSc 
compared to control lung fibroblasts as confirmed by microarray and bisulfite sequencing (see section 
3.7, Figure 3.7.5). TNXB expression was also significantly increased in IPF compared to SSc and control 
lung fibroblasts as confirmed by qRT-PCR and IHC (see section 3.12.1, Figure 3.12.2). Remodelling of 
the ECM involves multiple processes which include organisation and rearrangement of ECM 
components which can lead to matrix stiffening. TNX is known to play an important role in collagen 
deposition and in regulating collagen fibril density (Mao et al, 2002) and was associated with multiple 
biological processes including cell adhesion, signal transduction and actin cytoskeletal organisation. 
The ECM-receptor interaction and focal adhesion KEGG pathways were also enriched in TNXB, among 
other genes which had significantly altered methylation in IPF compared to control lung fibroblasts 
(Figure 4.11.1).  
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Figure 4.11.1. TNXB is associated with ECM-receptor interactions and focal adhesions KEGG 
pathways. Coloured nodes outlined in black represent genes with significantly altered methylation 
(Δβ ≥0.136; P<0.05) and in red represent genes with significantly altered expression in IPF (n=5) 
compared to control (n=6) lung fibroblasts. For methylation: yellow = genes with CpGs which had 
increased methylation, blue = genes with CpGs which had decreased methylation, green = genes with 
CpGs which had both increased and decreased methylation in IPF compared to control lung 
fibroblasts. For expression: yellow = genes which had increased expression. +P = phosphorylation, e = 
gene expression relationship, HA = Hyaluronic acid, dotted lines = indirect effect on gene, purple boxes 
= joining pathways. 
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Actin cytoskeletal organisation, which is strongly linked to cell contractility and focal adhesions, form 
mechanical links between cells and ECM and thus provide feedback loops to the ECM. To validate 
function analysis data, the role of TNXB in tissue contraction was determined using collagen gel 
contraction assays. Lung fibroblast-mediated collagen gel contraction was significantly (P<0.05) 
increased in IPF compared to control lung fibroblasts at 24, 48 and 72 hours (Figure 4.11.2) and TNXB 
knockdown significantly (P<0.05) decreased collagen gel contraction in all IPF lung fibroblast cell lines 
suggesting an important role for TNXB in tissue contractility (Figure 4.11.3) 
 
 
 
Figure 4.11.2. Lung fibroblast-mediated collagen gel contraction in control and IPF lung fibroblasts. 
Control ● (n=3) and IPF ▲ (n=4) lung fibroblast-mediated contraction of collagen gels was measured 
between 0-72 hours. Each point represents data from two replicate experiments for each individual 
primary lung fibroblast cell line. Data presented as the mean  SEM. Photographs show 1 control and 
1 IPF cell lines contracting collagen gels at 24, 48 and 72 hours.  
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Figure 4.11.3. Lung fibroblast-mediated collagen gel contraction in IPF lung fibroblasts after TNXB 
knockdown. TNXB was knocked down in IPF (n=4) lung fibroblast cell lines using TNXB siRNA. Lung 
fibroblasts-mediated contraction of collagen gels was measured between 0-72 hours. Each point 
represents data from two replicate experiments for each individual primary lung fibroblast cell line. ● 
= untreated, ■ = non-targeting siRNA and ▲ = TNXB siRNA. Data presented as the mean  SEM. One-
way ANOVA with Tukey’s post hoc test was performed for statistical analysis; *P<0.05, **P<0.01. Error 
bars not shown fall within the data point. 
 
 
TNXB can interact with multiple ECM components including collagens, integrins and proteoglycans 
and deficiency has previously been associated with increased PPARγ expression and decreased TGFß 
expression (Jing et al, 2011). To determine whether TNXB could regulate PPARγ and/or TGFß, IPF lung 
fibroblasts were treated with 10nM of a non-targeting control siRNA and a TNXB siRNA for 48 hours. 
TNXB was significantly (P=0.002) knocked down in IPF lung fibroblasts using TNXB siRNA compared 
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with non-targeting control siRNA, however, there was no significant change in PPARγ (P=0.854) or 
TGFß (P=0.255) expression (Figure 4.11.4). Expression of ECM-associated genes including collagens 
(COL6A3, COL12A1) and decorin (DCN) were also unchanged after TNXB knockdown (Figure 4.11.5).  
 
 
Figure 4.11.4. TNXB, PPARγ2 and TGFß1 expression after knockdown of TNXB. Quantitative PCR 
analysis of TNXB, PPARγ2 and TGFß1 after 48 hours using 10nM of TNXB siRNA and 10nM of a control 
non-targeting siRNA in IPF (n=5) fibroblasts. Data shown as the geometric mean of triplicate 
experiments with error bars showing ± 95% CIs. 
 
   
Figure 4.11.5. ECM-associated gene expression after knockdown of TNXB. Quantitative PCR analysis 
of COL6A3, COL12A1 and Decorin after 48 hours using 10nM of TNXB siRNA relative to a non-targeting 
siRNA in IPF (n=5) fibroblasts. Data shown as the geometric mean of triplicate experiments with error 
bars showing ± 95% CIs.  
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4.12. Summary 
 Combining multiple bioinformatics tools including STRING 10.0, Cytoscape 3.2.1 and R 
packages, helped identify how genes with significantly altered methylation and expression 
could potentially interact with each other. 
 
 Mapping genes with significantly altered methylation and/or expression onto KEGG 
pathways identified genes previously associated with fibrosis but not with altered 
methylation including Wnts, collagens, as well as novel genes not previously associated with 
IPF or SSc but associated with pathways which have been associated with fibrosis. These 
included, Wnt signalling including the genes, Small ubiquitin-related modifier 1 (SENP2), 
Nucleoside diphosphate kinase (NDK2) and C-terminal-binding protein 2 (CTBP2) and ECM-
interactions including the genes, TNXB and Thrombospondin 4 (THBS4).  
 
 PFAM and gene-term enrichment identified TNXB as being important in a number of 
processes including focal adhesion and actin cytoskeletal organisation both of which are 
important in regulating cell contractility. A model of cell-mediated extracellular matrix 
contraction using collagen gels showed IPF lung fibroblasts contracted collagen to a greater 
extent than control lung fibroblasts and knockdown of TNXB in IPF lung fibroblasts 
significantly reduced collagen gel contraction. 
 
 TNXB knockdown did not have a significant effect on PPARγ2 and TGFß1 expression, 
suggesting TNXB does not directly regulate these genes in lung fibroblasts. 
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 Differentially methylated genes in male compared to female lung 
fibroblasts 
5.1. Overview 
DNA methylation influences a number of cellular processes such as genomic imprinting (Nicholls et al, 
1989) and X-chromosome inactivation (Mohandas et al, 1981, Payer and Lee, 2008). Although sex-
differences across the epigenome remain poorly understood, during the course of my PhD it became 
apparent from the emerging literature that gender may influence methylation in multiple diseases. 
For example, Pinto et al, 2013 showed that in familial breast cancer, males had a different methylation 
and miRNA expression pattern compared to females. Furthermore, sex-specific differences in 
methylation can alter cell phenotypes (Hall et al, 2014) and sex-specific differences in methylation 
during brain development can affect multiple genes (Spiers et al, 2015). This has led to speculation 
that a number of neurological diseases with a sex-bias may be linked to altered methylation.  
 
There is unquestionable evidence that IPF predominates in males and SSc predominates in females, 
however, no study has reported global methylation differences between male and female lung 
fibroblasts or within the context of IPF lung fibroblasts. Therefore methylation differences between 
males and females may be important in determining disease outcome or could be used to target 
different therapeutic treatments in these sex-bias diseases.  
 
Using male (n=4) and female lung fibroblasts (n=7) derived from control (n=6, 2 male/4 female) and 
IPF (n=5, 2 male/3 female) lung fibroblasts, I show that multiple genes on autosomes and the X-
chromosome have CpGs with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in male compared 
to female lung fibroblasts. Much of the heterogeneity observed in control and IPF lung fibroblasts was 
accounted for by differences in methylation and expression between male and females. Furthermore, 
multiple biological processes enriched in genes with altered methylation in male compared to female 
lung fibroblasts were the same biological processes which were enriched in genes with altered 
methylation in IPF and SSc compared to control lung fibroblasts. This data suggests that multiple 
biological processes potentially involved in the pathogenesis of IPF are enriched in CpGs/genes with 
altered methylation in male compared to female lung fibroblasts.  
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5.2. Genome wide distribution of methylation in male and female lung fibroblasts 
Male (n=4) and female (n=7) lung fibroblasts had a similar genome-wide bimodal distribution of 
methylation patterns on all autosomes, with the highest frequencies of CpGs having 0-15% and 85-
90% methylation (Figure 5.2.1). This was also true for the X-chromosome in male lung fibroblasts, 
however, in female lung fibroblasts the CpG distribution on the X-chromosome showed a partially 
methylated methylation pattern with the highest frequency of CpGs having 40-50% methylation 
(Figure 5.2.1) which is consistent with X-chromosome inactivation. This partially methylated pattern 
of CpG methylation which was apparent in island, shore, shelf and open sea regions, within and 
beyond 1.5kb of their corresponding genes TSS (Figure 5.2.2). In male lung fibroblasts, island regions 
within 1.5kb of their corresponding genes TSS had a unimodal distribution of CpG methylation with 
the highest frequency of CpGs having low (0-20%) methylation. In contrast, there was a bimodal 
pattern of methylation for CpGs located in island regions further than 1.5kb away from their gene’s 
corresponding genes TSS in males (Figure 5.2.2) 
 
 
Figure 5.2.1. Distribution of CpG methylation in autosomes and the X-chromosome in male and 
female lung fibroblasts. Each bar represents the number of CpGs within each boundary. The β value 
represents the level of methylation (0= unmethylated, 1= methylated). Blue: male (n=4) and pink: 
female (n=7) lung fibroblasts.  
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Figure 5.2.2. CpG distribution of CpGs in relation to their corresponding genes TSS. CpGs which had 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) in male (n=4) compared to female (n=7) lung 
fibroblasts. The β value represents the level of methylation (0= unmethylated, 1= methylated).  
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5.3. Microarray analysis of differentially methylated genes in male compared to 
female lung fibroblasts 
The Illumina Infinium Human Methylation 450k BeadChip microarray identified multiple CpG sites 
with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in male (n=4) compared to female (n=7) 
lung fibroblasts. In male lung fibroblasts, 8979 CpGs corresponding to 4131 genes had significantly 
altered methylation (Δβ ≥ 0.136; P<0.05) compared to female lung fibroblasts. 50% were located on 
the X-chromosome, 49% on autosomes and 1% on the Y-chromosome. Of these 8979 CpGs, 2404 CpGs 
corresponding to 1730 genes had significantly increased methylation (Δβ ≥ 0.136; P<0.05) and 6575 
CpGs corresponding to 2928 genes had significantly decreased methylation (Δβ ≥ 0.136; P<0.05) in 
male compared to female lung fibroblasts (Figure 5.3.1). Examples of genes with significantly altered 
methylation (Δβ ≥ 0.136; P<0.05) in male compared to females lung fibroblasts are shown in Figure 
5.3.2. 
 
 
Figure 5.3.1. Number of CpGs/genes with altered methylation in male compared to female lung 
fibroblasts. CpGs/genes with significantly (Δβ ≥ 0.136; P<0.05) increased or decreased methylation in 
male (n=4) compared with female (n=7) lung fibroblasts.  
 
 
Figure 5.3.2. CpGs with altered methylation in male compared to female lung fibroblasts. Example 
of 4 CpGs/genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in male (n=4) compared 
to female (n=7) lung fibroblasts. Beta-value (β) indicates methylation. 0 = 0% methylated, 1= 100% 
methylated. Error bars represent the mean +-S.E.M.  
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The number of differentially methylated CpGs between male and female lung fibroblasts and where 
they are located in relation to CpG islands is shown in Figure 5.3.3. North shelf (O/E: 1.90) and south 
shelf (O/E: 1.91) regions had almost double the expected number of CpGs with increased methylation 
in male compared to female lung fibroblasts. North shore (O/E: 1.25) and south shore (O/E: 1.09) and 
open sea (O/E: 1.26) regions also had more than the expected number of CpGs with increased 
methylation in male compared to female lung fibroblasts. The number of CpGs observed in island 
regions with increased methylation in male compared to female lung fibroblasts were fewer than 
expected (O/E: 0.36). In contrast, CpGs sites with decreased methylation in males were more 
abundant than expected in island regions (O/E: 1.35) and fewer than expected in north shelf (O/E: 
0.61) and south shelf (O/E: 0.51) and open sea (O/E: 0.67) regions (Table 5.3.1). Cluster analysis clearly 
identified male lung fibroblast cell lines cluster separately from female lung fibroblast cell lines, 
independent of whether they were derived from IPF or control patients (Figure 5.3.4).  
 
 
               
Figure 5.3.3. CpGs with altered methylation in relation to CpG islands in male compared to female 
lung fibroblasts. Left: scatter plots showing the average methylation and the location of each CpG 
with a significant difference (P<0.05) in methylation between male (n=4) and female (n=7) lung 
fibroblasts. Each dot represents a CpG with either a Δβ< 0.136 (<13.6% change in methylation) (●) or 
a Δβ ≥ 0.136 (≥ 13.6% change in methylation) between male and female lung fibroblasts (●). Right: 
bar graphs showing the number of CpGs in different locations with significantly altered methylation 
(Δβ ≥ 0.136; P<0.05) in male compared to female lung fibroblasts.  
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Location Total no. 
of CpGs 
CpGs with increased methylation 
in males 
CpGs with decreased 
methylation in males 
Observed Expected O/E Observed Expected O/E 
Island 108197 288 800 0.36* 2904 2189 1.33* 
N_Shelf 15598 219 115 1.90* 193 316 0.61* 
N_Shore 43922 406 325 1.25* 1020 889 1.15* 
Open_sea 108961 1016 806 1.26* 1487 2205 0.67* 
S_Shelf 14040 198 104 1.91* 144 284 0.51* 
S_Shore 34255 277 253 1.09 827 693 1.19* 
Total 324973       
Table 5.3.1. Observed to expected ratio (O/E) of the number of CpGs in each location with altered 
methylation in male compared to female lung fibroblasts. CpGs with significantly altered methylation 
(Δβ ≥ 0.136; P<0.05) in male (n=4) compared to female (n=7) lung fibroblasts. *= Chi-square value; 
P<0.05.  
 
 
Figure 5.3.4. Hierarchical clustering based on CpGs with altered methylation in male compared to 
female lung fibroblasts. Heat-map showing the CpGs with significantly altered methylation (Δβ ≥ 
0.136; P<0.05) in male (n=4) compared to female (n=7) lung fibroblasts. Light blue represents low 
methylation, yellow represents high methylation.  
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5.4. Genome-wide distribution of gene expression in male and female lung 
fibroblasts 
The distribution of gene expression in male and female lung fibroblasts was similar with the highest 
frequency of genes having low expression (Figure 5.4.1). The highest frequency of genes with 
significantly altered expression (TNoM ≤1; P<0.05) in male compared to female lung fibroblasts had 
low expression (Figure 5.4.2).  
 
 
                    
Figure 5.4.1. Genome-wide distribution of gene expression in male and female lung fibroblasts. Each 
bar represents the number of genes within each boundary. Blue = male; pink = female lung fibroblasts.  
 
 
 
Figure 5.4.2. Distribution of genes which had altered expression in male compared to female lung 
fibroblasts. Each bar represents the number of genes within each boundary which had significantly 
altered expression (TNoM ≤1; P<0.05) in male (n=4) compared to female (n=7) lung fibroblasts. The 
raw value for expression is shown on the x-axis. Blue = male; pink = female lung fibroblasts.  
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5.5. Microarray analysis of differentially expressed genes in males compared to 
female primary human lung fibroblasts 
The Illumina Human Expression array identified 297 genes (137 increased, 160 decreased) with 
significantly altered expression (TNoM ≤1; P<0.05) in male compared to female lung fibroblasts. The 
average expression for each gene differentially expressed in male and female lung fibroblasts and 
which chromosomes the genes mapped to is shown in Figure 5.5.1. Examples of genes with large 
significant changes in expression (TNoM ≤1; P<0.05) in male compared to female lung fibroblasts are 
shown in Figure 5.5.2.  
 
Figure 5.5.1. Gene expression in male compared with female lung fibroblasts. Scatter graphs show 
the average expression of genes with significantly increased or decreased expression (TNoM ≤1; 
P<0.05) in male (n=4) compared with female (n=7) lung fibroblasts. Right: shows which chromosome 
each differentially expressed gene is on. ● Show genes with a TNoM=0, ● show genes with a TNoM=1.  
 
 
Figure 5.5.2. Genes with altered expression in male compared to female lung fibroblasts. Four 
examples of individual genes including MFF, LPXN, CCL7 and XIST which have significantly altered 
expression (TNoM ≤1; P<0.05) in male (n=4) compared to female (n=7) lung fibroblasts. Fold-changes 
are relative to the geometric mean of female gene expression. Error bars represent 95% confidence 
intervals.  
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Cluster analysis of the 297 differentially expressed genes clearly distinguished male from female lung 
fibroblasts irrespective of whether they were dervived from control or IPF lung fibroblasts. (Figure 
5.5.3). 
 
 
Figure 5.5.3. Cluster analysis showing the differentially expressed genes in male compared to female 
lung fibroblasts. Genes (n=297) with significantly altered expression (TNoM ≤1; P<0.05) in male (n=4) 
compared to female (n=7) lung fibroblasts. Light blue represents low expression, yellow represents 
high expression with respect to each gene across all cell lines.  
 
 
5.6. Differentially methylated CpGs in IPF males compared to control males and IPF 
females compared to control females 
As previously shown, IPF and SSc have multiple CpG sites which have altered methylation compared 
to control lung fibroblasts and multiple CpG sites have altered methylation in male compared to 
female lung fibroblasts. Differences in methylation of male and female lung fibroblasts could underlie 
sex differences in vulnerability of developing sex-biased diseases such as IPF or SSc and potentially 
underlie sex differences in vulnerabilities to drugs in order to treat such diseases. To explore whether 
these methylation difference exist between male and female IPF lung fibroblasts, male IPF lung 
fibroblasts were compared to male control lung fibroblasts and female IPF lung fibroblasts were 
compared to female control lung fibroblasts.  
Genome-wide distribution of CpG methylation in IPF males compared to control males was similar on 
autosomes and on the X-chromosome with both control and IPF lung fibroblasts displaying a bimodal 
distribution. However, the distribution of CpG methylation in male IPF compared with male control 
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lung fibroblasts was different on the Y-chromosome (Figure 5.6.1). Genome-wide distribution of CpG 
methylation in IPF female and control female was similar on autosomes and the X-chromosome, with 
the highest frequency of CpGs having low (0-15%) and (high 80-90%) methylation across autosomes 
and 40-50% methylation on the X-chromosome (Figure 5.6.2).  
 
 
Figure 5.6.1. Genome-wide distribution of CpGs on autosomes, the X-chromosome and the Y-
chromosome in IPF male and control male lung fibroblasts. Each bar represents the number of CpGs 
within each boundary. Average methylation values (β value) are shown for IPF male (n=2) and control 
male (n=2) lung fibroblasts.  
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Figure 5.6.2. Genome-wide distribution of CpGs on autosomes and the X-chromosome and in IPF 
female and control female lung fibroblasts. Each bar represents the number of CpGs within each 
boundary. Average methylation values (β value) are shown for IPF female (n=3) and control female 
(n=4) lung fibroblasts.  
 
 
5.7. Microarray analysis of differentially methylated genes in male IPF compared 
to male control and female IPF compared to female control primary human lung 
fibroblasts 
CpGs (4467) corresponding to 3493 genes had significantly altered methylation (Δβ ≥ 0.136; P<0.05) 
in male IPF compared to male control lung fibroblasts. Of these, 1823 CpGs corresponding to 1588 
genes had significantly increased methylation (Δβ ≥ 0.136; P<0.05) and 2644 CpGs corresponding to 
2147 genes had significantly decreased methylation (Δβ ≥ 0.136; P<0.05) in male IPF compared to 
male control lung fibroblasts (Figure 5.7.1). CpGs (5437) corresponding to 3853 genes had significantly 
altered methylation (Δβ ≥ 0.136; P<0.05) in female IPF compared to female control lung fibroblasts. 
Of these, 2302 CpGs corresponding to 1816 genes had significantly increased methylation (Δβ ≥ 0.136; 
P<0.05) and 3135 CpGs corresponding to 2331 genes had significantly decreased methylation (Δβ ≥ 
0.136; P<0.05) in female IPF compared to female control lung fibroblasts (Figure 5.7.1).  
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Figure 5.7.1. The number of distinct and overlapping CpGs/genes which have altered methylation 
in IPF male compared to control male and IPF female compared control female lung fibroblasts. 
CpGs/genes which have significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF male (n=2) 
compared to control male (n=2) and IPF female (n=3) compared to control female (n=4) lung 
fibroblasts.  
 
 
Of the 1823 CpG sites which had increased methylation in male IPF compared to male control lung 
fibroblasts, only 66 were the same CpG sites which had increased methylation in female IPF compared 
to female control lung fibroblasts. The 1823 CpG sites with increased methylation in male IPF 
compared to male control lung fibroblasts corresponded to 1588 genes of which 308 were the same 
genes with increased methylation in female IPF compared to female control lung fibroblasts. Of the 
2644 CpG sites which had decreased methylation in male IPF compared to male control lung 
fibroblasts, 126 were the same CpG sites which had decreased methylation in female IPF compared 
to female control lung fibroblasts. The 2644 CpG sites with decreased methylation in male IPF 
compared to male control lung fibroblasts corresponded to 2147 genes of which 572 were the same 
genes with decreased methylation in female IPF compared to female control lung fibroblasts. Very 
few CpGs and only 25% of genes overlapped suggesting that differences in CpG methylation between 
male IPF and male controls are not the same CpGs with differences between female IPF and female 
controls including multiple ECM associated gene (Figure 5.7.4). Representative genes are shown in 
Figure 5.7.2, Figure 5.7.3 and Figure 5.7.4. The number of differentially methylated CpGs between 
male IPF compared to male control and female IPF compared to female control lung fibroblasts and 
their location in relation to CpG islands is shown in Figure 5.7.5.  
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Figure 5.7.2. CpGs and their corresponding gene which had altered methylation in male IPF male 
compared to control male and in IPF female compared to control female lung fibroblasts. Statistical 
analysis performed using 1-way ANOVA analysis with Tukey’s multiple comparison test identified 
some CpGs which had significantly altered (P<0.05) methylation in IPF males (IM) (n=2) compared to 
control males (CM) (n=2) which also had significantly altered (P<0.05) methylation in IPF females (IF) 
(n=3) compared with control females (CF) (n=4). Error bars represent the mean ± S.E.M.  
 
 
 
Figure 5.7.3. CpGs and their corresponding genes which had altered methylation in IPF male 
compared to control male but not in IPF female compared to control female lung fibroblasts. 
Statistical analysis performed using 1-way ANOVA analysis with Tukey’s multiple comparison test 
identified multiple CpGs which had significantly altered (P<0.05) methylation in IPF males (IM) (n=2) 
compared to control males (CM) (n=2) and significantly altered (P<0.05) methylation in IPF males (IM) 
(n=2) compared with IPF females (IF) (n=3). Error bars represent the mean ± S.E.M.  
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Figure 5.7.4. CpGs and their corresponding genes which had altered methylation in IPF female 
compared to control female but not in IPF male compared to control male lung fibroblasts. Statistical 
analysis performed using 1-way ANOVA analysis with Tukey’s multiple comparison test identified 
multiple CpGs which had significantly altered (P<0.05) methylation in IPF females (IF) (n=3) compared 
to control females (CF) (n=4) and significantly altered (P<0.05) methylation in IPF females (IF) (n=3) 
compared with IPF males (IF) (n=2). Error bars represent the mean ± S.E.M.  
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Figure 5.7.5. CpGs with altered methylation in relation to CpG islands in IPF male compared to 
control male and IPF female compared to control female lung fibroblasts. Scatter plots show average 
methylation and the location of each CpG with a significant difference (P<0.05) in methylation 
between IPF male (n=2) compared to control male (n=2) and IPF female (n=3) compared to control 
female (n=4) lung fibroblasts. Each dot represents a CpG with either a Δβ< 0.136 (<13.6% change in 
methylation) (●) or a Δβ ≥ 0.136 (≥ 13.6% change in methylation (●). Bar graphs show the number of 
CpGs and their location in respect to CpG islands.  
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Shelf, open sea (more than expected) and islands (less than expected) had significantly different O/E 
ratios in the number of CpGs with decreased methylation in IPF male compared to control male (Table 
5.7.1) and IPF female compared control female (Table 5.7.2) lung fibroblasts. North shore, shelves, 
open sea (more than expected) and islands (less than expected) had significantly different O/E ratios 
(Chi2 = <0.05) in the number of CpGs with increased methylation in IPF male compared to control male 
whereas in IPF female compared control female lung fibroblasts, only island regions (less than 
expected) and open sea regions (more than expected) had significantly different O/E ratios (Chi2 
<0.05). 
 
Location Total no. 
of CpGs 
CpGs with increased 
methylation in IPF males 
CpGs with decreased methylation 
in IPF males 
Observed Expected O/E Observed Expected O/E 
Island 108197 257 607 0.42* 374 880 0.42* 
N_Shelf 15598 125 88 1.43* 196 127 1.54* 
N_Shore 43922 323 246 1.31* 372 357 1.04 
Open_sea 108961 792 611 1.30* 1273 887 1.44* 
S_Shelf 14040 103 79 1.31* 143 114 1.25* 
S_Shore 34255 223 192 1.16 286 279 1.03 
Total 324973       
Table 5.7.1. Observed to expected ratio (O/E) of the number of CpGs in each location with altered 
methylation in IPF male compared to control male lung fibroblasts. CpGs with significantly altered 
methylation (Δβ ≥ 0.136; P<0.05) in IPF male (n=2) compared to control male (n=2) lung fibroblasts. 
*= Chi-square P<0.05.  
 
Location Total no. 
of CpGs 
CpGs with increased 
methylation in IPF females 
CpGs with decreased methylation 
in IPF females 
Observed Expected O/E Observed Expected O/E 
Island 108197 376 766 0.49* 544 1044 0.52* 
N_Shelf 15598 89 110 0.81 218 150 1.45* 
N_Shore 43922 318 311 1.02 424 424 1.00 
Open_sea 108961 1170 772 1.52* 1443 1051 1.37* 
S_Shelf 14040 84 99 0.84 182 135 1.34* 
S_Shore 34255 265 243 1.09 324 330 0.98 
Total 324973       
Table 5.7.2. Observed to expected ratio (O/E) of the number of CpGs in each location with altered 
methylation in IPF female compared to control female lung fibroblasts. CpGs with significantly 
altered methylation (Δβ ≥ 0.136; P<0.05) in IPF female (n=3) compared to control female (n=4) lung 
fibroblasts. *= Chi-square P<0.05.  
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5.8. Comparing expression profiles of IPF males with control males  
As IPF affects males more than females and clear differences in gene expression were observed when 
comparing male with female lung fibroblasts, IPF males (n=2) were compared with control males (n=2) 
and IPF females (n=3) were compared with control females (n=4) in order to determine gene 
expression differences between IPF males and IPF females. Because of low N numbers in the male 
group, a TNoM of ≤1 and a large fold-change (≥2FC) instead of a P value <0.05 was used to find 
differentially expressed genes. 407 genes (204 decreased, 203 increased) had altered expression 
(TNoM ≤1; ≥2FC) in IPF male lung fibroblasts compared to control male lung fibroblasts. Seventy-five 
genes (28 decreased, 47 increased) had altered expression (TNoM ≤1; ≥2FC) in IPF female lung 
fibroblasts compared to control female lung fibroblasts. Interestingly, 5 genes located on the Y-
chromosome (Ribosomal protein S4, Y isoform 1 (RPS4Y1), Eukaryotic translation initiation factor 1A, 
Y-linked (EIF1AY), Taxilin gamma pseudogene, Y-linked, (CYorf15A), Neuroligin 4, Y-linked (NLGN4Y) 
and Jumonji/ARID domain-containing protein 1D (JARID1D) (a histone demethylase) all had large 
significant increases (≥2FC) in IPF male compared to control male lung fibroblasts and compared to 
IPF and control female lung fibroblasts (Figure 5.8.1).  
 
Multiple genes involved in interferon signalling were downregulated in male IPF compared to male 
control lung fibroblasts although these differences were not significant. Gene expression differences 
between fibroblasts of the same sex and origin appeared highly heterogeneous, unlike CpG 
methylation where fibroblasts of the same sex and origin were homogenous. Nonetheless, these data 
identified some genes which had large changes in expression and suggest that sex-differences in gene 
expression in patients with IPF may exist. Further studies using more cell lines should delineate the 
full extent of sex-specific differences in gene expression in IPF lung fibroblasts. 
 
 
Figure 5.8.1. Genes with altered expression in IPF male compared to control male lung fibroblasts 
located on the Y-chromosome. Five genes including RPS4Y1, EIF1AY, CYorf15A, NLGN4Y and JARID1D 
had significantly altered expression (TNoM ≤1; P<0.05) in IPF male (IM) (n=2) compared control to 
male (CM) (n=2), control female (CF) (n=4) and IPF female (IF) (n=3) lung fibroblasts. Data presented 
as the geometric mean fold changes relative to the average control male gene expression ± 95% 
confidence intervals.  
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5.9. Summary 
 Multiple genes have significantly altered methylation and/or expression in male compared 
to female lung fibroblasts. 
 
 49% of genes with significantly altered methylation in male compared to female lung 
fibroblasts were located on autosomes.  
 
 Only 192 CpGs (4.3%) with significantly altered methylation in IPF males compared to control 
males were the same CpG sites which had significantly altered methylation in IPF female 
compared to control female lung fibroblasts, suggesting changes to methylation in IPF occur 
at different CpGs in male compared to female lung fibroblasts.  
 
 880 genes (25.2%) with significantly altered methylation in IPF males overlapped with 
females, suggesting multiple genes are common between both sexes, however multiple 
genes were distinct to each sex, including multiple ECM associated genes and may underlie 
sex-specific susceptibilities towards developing pulmonary fibrosis.  
 
 Genes on the Y-chromosome including, RPS4Y1, EIF1AY, CYorf15A, NLGN4Y and JARID1D had 
large increases in expression in IPF male compared with control male lung fibroblasts, 
suggesting they may play an important role in male pulmonary fibrosis.  
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5.10. Biological processes enriched in PFAMs containing genes with altered 
methylation in male compared to female lung fibroblasts.  
As previously shown in section 5.3, multiple genes had significantly altered methylation (Δβ ≥ 0.136; 
P<0.05) in male (n=4) compared to female (n=7) lung fibroblasts. These genes mapped to 1663 
different PFAM domains. Biological processes (629) were significantly (FDR P<0.01) enriched in these 
PFAMs including EMT, ECM organisation, collagen fibril organisation, apoptosis, integrin signalling and 
Wnt signalling. Many of these biological processes have previously been associated with the 
pathobiology of pulmonary fibrosis and were also significantly enriched in PFAMs containing genes 
with significantly altered methylation in IPF/SSc compared to control lung fibroblasts (Table 5.10.1).  
For example, the biological process ‘collagen fibril organisation’ was significantly enriched in 11 out of 
12 PFAMs which contained 89 genes with significantly altered methylation in male compared to 
female lung fibroblasts and 10 out of 12 PFAMs which contained 134 genes with significantly altered 
methylation in IPF compared control lung fibroblasts. Of these genes, 55 overlapped (Figure 5.10.1). 
One of these genes, MUC5B, had decreased methylation in IPF compared to controls and in male 
compared to female lung fibroblasts. A MUC5B polymorphism has been linked to IPF (Seibold et al, 
2011) and aberrant methylation surrounding the polymorphism may play a role in increased MUC5B 
expression in IPF (Helling et al, 2015). These data could suggest that males and females have altered 
methylation of genes which are associated with multiple biological processes relevant to pulmonary 
fibrosis, which could in part, explain the sex-bias in IPF and SSc. Furthermore, biological processes 
including sex determination and pregnancy were identified as being enriched in genes with 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) in male compared to female lung fibroblasts, as 
one might expect, suggesting PFAM analysis is a suitable tool for determining enriched processes. 
Genes with significantly altered expression in male compared to female lung fibroblasts were 
associated with 286 PFAMs. Biological process (687) were significantly (FDR<0.01) enriched in these 
PFAMs including the toll receptor pathway, ECM organisation, apoptosis, Wnt signalling and 
methylation (Table 5.10.2). Of the biological processes enriched in PFAMs containing genes with 
significantly altered methylation, 441 (70%) overlapped with those enriched in PFAMs containing 
genes with significantly altered expression in male compared to female lung fibroblasts. These data 
suggest multiple biological processes relevant to pulmonary fibrosis are enriched in PFAMs containing 
genes which have significantly altered methylation in male compared with female lung fibroblasts and 
adds further evidence that differentially methylated/expressed genes are associated with common 
and specific PFAMs suggesting a strong link between methylation and expression. 
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Biological process Specificity FDR Overlap 
PFAMs 
Total 
PFAMs 
ECM organization 2 8.73e-09 47 63 
Wnt receptor signalling pathway 2 5.49E-06 29 38 
Integrin-mediated signalling pathway 3 9.00e-06 16 17 
Collagen fibril organization 3 6.09e-04 11 12 
Response to virus 2 6.34e-04 29 45 
Tissue remodelling 3 1.04e-03 12 14 
Regulation of FGFR signalling pathway 3 1.32e-03 10 11 
EMT 3 1.76e-03 14 18 
JAK-STAT cascade 3 2.07E-03 11 13 
Induction of apoptosis by extracellular signals 3 2.87e-03 9 10 
Sex determination 3 4.27e-03 15 21 
Blood vessel remodelling 4 7.17e-03 6 6 
Regulation of gene expression 4 7.17e-03 6 6 
Bile acid metabolic process 4 7.17e-03 6 6 
Cellular response to mechanical stimulus 3 8.49e-03 9 11 
Table 5.10.1. Domain-centric enrichment of biological processes enriched in PFAMs associated 
with genes with altered methylation in male compared to female lung fibroblasts. Specificity = 
levels of granularity of a specific biological process (1=highly general, 2; general, 3; specific, 4; highly 
specific). FDR = false discovery rate (P<0.01). Overlap PFAMs = number of overlapping PFAMs 
associated with the biological process out of the total number of PFAMs in the input list. Total 
PFAMs = total number of PFAMs associated with the biological process. 
 
Biological process Specificity FDR Overlap 
PFAMs 
Total 
PFAMs 
Regulation of JAK-STAT cascade 3 5.00E-07 10 18 
Respiratory system development 2 8.28e-07 21 82 
Epithelial cell differentiation 2 1.74e-05 17 69 
Integrin-mediated signalling pathway 3 2.64e-04 7 17 
Toll signalling pathway 3 3.89E-04 6 13 
Female pregnancy 3 4.49e-04 8 24 
Wnt receptor signalling pathway 2 6.05E-04 10 38 
Histone H3-K4 methylation 3 1.30E-03 5 11 
ECM organization 2 2.66e-03 12 63 
Methylation-dependent chromatin silencing 4 5.37e-03 3 5 
Response to FGFR stimulus 3 6.10e-03 4 10 
Induction of apoptosis by extracellular signals 3 6.10e-03 4 10 
Response to virus 2 6.12e-03 9 45 
Tissue homeostasis 3 8.69e-03 6 24 
Table 5.10.2. Domain-centric enrichment of biological processes enriched in PFAMs associated with 
genes with altered expression in male compared to female lung fibroblasts. Specificity = levels of 
granularity of a specific biological process (1=highly general, 2; general, 3; specific, 4; highly specific). 
FDR = false discovery rate (P<0.01). Overlap PFAMs = number of overlapping PFAMs associated with 
the biological process out of the total number of PFAMs in the input list. Total PFAMs = total number 
of PFAMs associated with the biological process. 
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Figure 5.10.1. Collagen fibril organisation enriched in PFAMs containing genes with altered 
methylation in male compared to female lung fibroblasts. Coloured boxes represent direction of 
methylation, yellow; genes with increased methylation, blue; genes with decreased methylation, 
green; genes with both increased and decreased methylation in male (n=4) compared to female (n=7) 
lung fibroblasts. Boxes with a red border indicate genes which also have significantly altered 
methylation (Δβ ≥0.136; P<0.05) in IPF (n=5) compared to control (n=6) lung fibroblasts.  
 
 
5.11. Biological processes enriched in PFAMs containing genes with altered 
methylation in IPF male compared to control male and IPF female compared to 
control female lung fibroblasts. 
In section 5.7, I showed male IPF lung fibroblasts had multiple CpGs/genes with significantly altered 
methylation and expression compared to male control lung fibroblasts many of which were not the 
same as the CpGs/genes which had significantly altered methylation and expression in female IPF lung 
fibroblasts compared to female lung fibroblasts. This potentially suggested that male and female IPF 
lung fibroblasts may have different methylation and expression patterns. As multiple biological 
processes enriched in PFAMs containing genes with significantly altered methylation in IPF compared 
to control and male compared to female lung fibroblasts overlapped, IPF lung fibroblasts were 
compared to control lung fibroblasts based on gender. This analysis was done to elucidate whether 
biological processes enriched with PFAMs/genes which had significant differences in 
methylation/expression in male IPF compared to male control lung fibroblasts were similar to 
enriched biological processes in female IPF compared to female control lung fibroblasts. 
As previously shown in section 5.7, 3493 and 3853 genes had significantly altered methylation (Δβ ≥ 
0.136; P<0.05) in male IPF (n=2) compared to male control (n=2) and female IPF (n=3) compared to 
female control (n=4) lung fibroblasts, respectively. These genes mapped to 1529 and 1559 different 
PFAM domains respectively. In males, 662 biological processes were significantly (FDR P<0.01) 
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enriched in PFAMs containing genes with significantly altered methylation in male IPF compared to 
male control lung fibroblasts including EMT, ECM organisation, apoptosis, integrin signalling and Wnt 
signalling (Table 5.11.1). Similarly in females, 673 biological processes were significantly (FDR P<0.01) 
enriched in PFAMs containing genes with significantly altered methylation in female IPF compared to 
female control lung fibroblasts including EMT, ECM organisation, collagen fibril organisation, 
apoptosis, integrin signalling and Wnt signalling (Table 5.11.2).  
Biological process Specificity FDR Overlap 
PFAMs 
Total 
PFAMs 
ECM organization 2 1.72e-07 43 63 
Sex determination 3 7.05e-05 17 21 
Wnt receptor signalling pathway 2 8.14E-04 24 38 
JAK-STAT cascade 3 9.80E-04 11 13 
Induction of apoptosis by extracellular signals 3 1.53e-03 9 10 
Integrin-mediated signalling pathway 3 1.53e-03 13 17 
Detection of virus 3 4.63e-03 6 6 
Bile acid metabolic process 4 4.63e-03 6 6 
Methylation 2 6.15e-03 41 83 
EMT 3 7.71e-03 7 18 
Lung morphogenesis 3 9.82e-03 8 10 
Tissue homeostasis 3 9.82e-03 15 24 
Table 5.11.1. Domain-centric enrichment of biological processes enriched in PFAMs associated with 
genes with altered expression in male IPF compared to male control lung fibroblasts. Specificity = 
levels of granularity of a specific biological process (1=highly general, 2; general, 3; specific, 4; highly 
specific). FDR = false discovery rate (P<0.01). Overlap PFAMs = number of overlapping PFAMs 
associated with the biological process out of the total number of PFAMs in the input list. Total PFAMs 
= total number of PFAMs associated with the biological process. 
 
Biological process Specificity FDR Overlap 
PFAMs 
Total 
PFAMs 
Sex differentiation 2 1.08E-12 58 75 
ECM organization 2 5.94E-07 43 63 
Integrin-mediated signalling pathway 3 4.33E-06 16 17 
Wnt receptor signalling pathway 2 9.32E-06 28 38 
Collagen fibril organization 3 3.91E-04 11 12 
Induction of apoptosis by extracellular signals 3 2.03E-03 9 10 
EMT 3 4.62E-03 13 18 
Regulation of JAK-STAT cascade 3 4.62E-03 13 18 
Pregnancy 3 4.95E-03 16 24 
Bile acid metabolic process 4 5.59E-03 6 6 
Methylation 2 7.13E-03 42 83 
Table 5.11.2. Domain-centric enrichment of biological processes enriched in PFAMs associated with 
genes with altered expression in female IPF compared to female control lung fibroblasts. Specificity 
= levels of granularity of a specific biological process (1=highly general, 2; general, 3; specific, 4; highly 
specific). FDR = false discovery rate (P<0.01). Overlap PFAMs = number of overlapping PFAMs 
associated with the biological process out of the total number of PFAMs in the input list. Total PFAMs 
= total number of PFAMs associated with the biological process. 
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Of biological processes enriched in PFAMs containing genes with significantly altered methylation in 
male IPF compared to male control fibroblasts, 548 (83%) were the same biological processes enriched 
in PFAMs containing genes with significantly altered methylation in female IPF compared to female 
control lung fibroblasts. Interestingly, biological processes distinct to males, enriched in PFAMs 
containing genes with significantly altered methylation in male IPF compared to male control 
fibroblasts included some relating to viruses/bacteria, whereas enriched biological processes distinct 
to females included response to hexose, response to corticosteroid stimulus and ER stress (Table 
5.11.3).  
  Distinct to males 
Biological process Specificity FDR Overlap 
PFAMs 
Total 
PFAMs 
Response to virus 2 2.70e-03 26 45 
Detection of virus 3 4.63e-03 6 6 
Regulation of IL2 production 3 1.07e-04 10 10 
Response to TNF 3 1.08e-04 12 13 
Positive regulation of ERK1 and ERK2 cascade 3 6.55E-04 10 11 
Actinobacterium-type cell wall biogenesis 3 1.53E-03 9 10 
Regulation of circadian rhythm 3 3.07e-03 12 16 
Proteoglycan metabolic process 3 3.27e-03 13 18 
Superoxide metabolic process 3 3.27e-03 13 18 
Fatty acid biosynthetic process 3 5.61e-03 22 38 
Lipopolysaccharide-mediated signaling pathway 3 5.90e-03 11 15 
Hormone biosynthetic process 3 5.90e-03 11 15 
  Distinct to females 
Biological process Specificity FDR Overlap 
PFAMs 
Total 
PFAMs 
Insulin receptor signaling pathway 3 2.34e-05 12 12 
Response to hexose stimulus 3 8.67e-05 16 19 
Phosphatidylinositol-3-phosphate biosynthetic 
process 3 8.95e-04 10 11 
Mammary gland morphogenesis 3 2.31e-03 7 7 
Cell aging 3 2.40e-03 14 19 
Rho protein signal transduction 3 3.73E-03 11 14 
Female genitalia development 3 4.54e-03 8 9 
PDGF receptor signaling pathway 3 4.54e-03 8 9 
Regulation of ph 3 4.85E-03 14 20 
Response to corticosteroid stimulus 3 6.01e-03 9 11 
Chromatin remodeling 3 7.25e-03 19 31 
Response to ER stress 3 8.07e-03 17 27 
Table 5.11.3.Domain-centric enrichment of biological processes distinct to males or females. 
Domain-centric enrichment of biological processes distinct to males (top) or females (bottom) 
enriched in PFAMs associated with genes with altered expression compared to respective control lung 
fibroblasts and Specificity = levels of granularity of a specific biological process (1=highly general, 2; 
general, 3; specific, 4; highly specific). FDR = false discovery rate (P<0.01). Overlap PFAMs = number 
of overlapping PFAMs associated with the biological process out of the total number of PFAMs in the 
input list. Total PFAMs = total number of PFAMs associated with the biological process. 
181 
 
Furthermore, as shown in section 5.7 multiple genes which had different methylation in male IPF 
compared to male control were not the same genes which had had different methylation in female 
IPF compared to female control lung fibroblasts.  This was also apparent from the PFAM enrichment 
analysis. Bile acid metabolic process was significantly enriched in PFAMs containing 26 genes with 
significantly altered methylation in male IPF compared to male control lung fibroblasts and 30 genes 
with significantly altered methylation in female IPF compared to female control lung fibroblasts. Only 
9 of these genes overlapped (Figure 5.11.1).  
IPF males compared to control males 
 
IPF females compared to control females 
 
Figure 5.11.1. Bile acid metabolic process enriched in PFAMs containing genes with altered 
methylation in IPF male compared to control male and IPF female compared to control female lung 
fibroblasts. Coloured boxes represent direction of methylation, yellow; genes with increased 
methylation, blue; genes with decreased methylation, green; genes with both increased and 
decreased methylation in male IPF (n=2) compared to male control (n=2) or female IPF (n=3) 
compared to female control (n=4) lung fibroblasts. Boxes with a red border represent overlapping 
genes which also had significantly altered expression (TNoM ≤1; ≥2FC). 
 
In another example, the biological process ‘induction of apoptosis by extracellular signals’ was 
significantly enriched in PFAMs containing 193 genes with significantly altered methylation in male 
IPF compared to male control lung fibroblasts and 215 genes with significantly altered methylation in 
female IPF compared to female control lung fibroblasts. 78 genes overlapped whereas 115 and 137 
were distinct in male and females respectively (Figure 5.11.2). Taken together this suggests that 
biological processes enriched in PFAMs/genes with altered methylation in IPF compared to control 
lung fibroblasts may involve multiple overlapping as well as different genes between males and 
females. 
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IPF males compared to control males 
 
 
IPF females compared to control females 
 
Figure 5.11.2. Induction of apoptosis by extracellular signals enriched in PFAMs containing genes 
with significantly altered methylation in IPF male compared to control male and IPF female 
compared to control female lung fibroblasts. Coloured boxes represent direction of methylation, 
yellow; genes with increased methylation, blue; genes with decreased methylation, green; genes with 
both increased and decreased methylation in male IPF (n=2) compared to male control (n=2) or female 
IPF (n=3) compared to female control (n=4) lung fibroblasts. Boxes with a red border represent 
overlapping genes. Genes which also had significantly altered expression (TNoM ≤1; ≥2FC) are 
annotated with the direction of change shown. M=methylation, E= expression.  
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5.12. Summary 
 Multiple biological processes relevant to fibrosis are enriched in genes with significantly 
altered methylation and/or expression in male compared to female lung fibroblasts. This 
could, in part explain the sex-bias in IPF.  
 
 Some biological processes enriched in PFAMs containing genes with significantly altered 
methylation in IPF compared to control lung fibroblasts were distinct to each sex. These 
included those relating to response to virus, Actinobacterium and circadian rhythm in males 
and ER stress, response to hexose and response to corticosteroids in females.  
 
 83% of biological processes enriched in PFAMs containing genes with significantly altered 
methylation in male IPF compared to male controls were the same biological processes 
enriched in PFAMs containing genes with significantly altered methylation in female IPF 
compared to female control lung fibroblasts. This suggests the majority of biological 
processes overlap.  
 
 Whilst multiple genes with altered methylation in male IPF compared to male controls are 
the same genes with altered methylation in female IPF compared to female control lung 
fibroblasts, suggesting multiple genes overlap between both sexes, multiple genes were 
distinct to both sexes. This suggests that within overlapping enriched biological processes, 
multiple genes have sex-specific differences in methylation.  
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 Effect of DNMT inhibition on methylation in primary human lung 
fibroblasts 
6.1. Overview 
No study to date has examined the effects of DNMT inhibition on global DNA methylation and gene 
expression in IPF or SSc lung fibroblasts. 5-Aza-2'-deoxycytidine (5-Aza), a chemical analogue of 
cytosine, can incorporate itself into DNA and binds to DNMT enzymes which inhibits their activity 
(Christman, 2002). Previous studies suggest 5-Aza treatment could have potential benefits in treating 
a number diseases by reactivating genes silenced by methylation. Indeed, 5-Aza is already used to 
treat a number of diseases including myelodysplastic syndromes (Wijermans et al, 2000). As previously 
shown in Chapter 3, multiple genes have CpGs with altered methylation in IPF and SSc compared with 
control lung fibroblasts. Therefore, using 5-Aza to treat such diseases may be beneficial and warrants 
further investigation. However, the opposing argument is that 5-Aza is non-specific and thus, could 
activate multiple genes which could have adverse effects. Furthermore, for the vast majority of genes, 
it is unknown whether DNA methylation can directly regulate expression, thus demethylation of one 
gene could activate or inhibit multiple genes regulated by it and in turn these genes could do the 
same. Differences in methylation between genders, methylation of genes involved in epigenetic 
regulation (MiRs, HDACs) and other epigenetic mechanisms create a complex network of gene 
regulation on multiple levels. Furthermore, what change in methylation is required to have a biological 
effect and whether this change in methylation is the same for all genes or tissues or across different 
cell lines is unknown. To further try to understand the role of DNA methylation in regulating gene 
expression in human lung fibroblasts, control, IPF and SSc lung fibroblast cell lines were treated with 
5-Aza. Basal methylation was compared to methylation levels after 5-Aza treatment for each cell line. 
The following section will focus on analysing the effects of 5-Aza on CpG methylation and gene 
expression. Furthermore, correlation between changes in methylation and gene expression after 5-
Aza treatment will also be discussed.  
I show that DNMT inhibition with 5-Aza alters the methylation of multiple CpGs and the expression of 
multiple genes in control, IPF and SSc lung fibroblasts. Analysis of individual lung fibroblast cell lines 
show they respond differently in relation to which CpGs/genes have altered methylation/expression 
and to what extent methylation and expression levels change. Furthermore, by correlating 
methylation changes with changes to gene expression I identify multiple genes in lung fibroblasts that 
are potentially directly regulated by methylation, many of which are differentially methylated or 
expressed in IPF and/or SSc compared with control lung fibroblasts. I also show that small changes in 
methylation can have an effect on gene expression 
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6.2. Effect of DNMT inhibition on methylation in primary human lung fibroblasts 
Following 5-Aza treatment, the Illumina Infinium Human Methylation 450k BeadChip microarray 
identified multiple CpG sites with significantly (P<0.05) altered methylation in control (n=6) and IPF 
(n=5) and SSc (n=7) lung fibroblasts. 19421 CpGs corresponding to 10250 genes in control (n=6), 17412 
CpGs corresponding to 9493 genes in IPF (n=5) and 16948 CpGs corresponding to 9926 genes in SSc 
(n=7) lung fibroblasts had significantly (P<0.05) altered methylation after 5-Aza treatment. 937 
biological processes were enriched in genes with significantly altered methylation (P<0.05) after 5-Aza 
treatment in control lung fibroblasts. 77% of these biological processes overlapped with IPF and 67% 
with SSc lung fibroblasts. These included apoptosis, Wnt signalling, cell adhesion and lung 
development, which were previously shown to be enriched in genes with significantly altered 
methylation (Δβ ≥ 0.136; P<0.05) in IPF and/or SSc compared to control lung fibroblasts (Table 6.2.1). 
This suggests that multiple genes associated with biological processes relevant to PF are potentially 
regulated by methylation.  
 
Biological process Control IPF SSc Ref list 
Apoptotic process  276 306 283 594 
Blood coagulation  200 215 202 457 
Cell adhesion  243 268 267 556 
Chromatin modification  119 131 115 224 
Cytoskeleton organization  53 53 58 106 
Gene expression  188 216 171 408 
Lung development  43 49 46 75 
Regulation of transcription, DNA-dependent  775 838 763 1609 
TGFß signalling pathway  40 39 30 65 
Viral reproduction  137 163 133 329 
Wnt receptor signalling pathway  65 65 59 110 
Table 6.2.1. Examples of biological processes which are enriched in genes which have altered 
methylation after 5-Aza treatment in lung fibroblasts. Numbers represent the number of genes with 
significantly altered methylation (P<0.05) after 5-Aza treatment in control (n=6), IPF (n=5) and SSc 
(n=7) lung fibroblasts. The reference list shows the number of genes associated with each biological 
process.  
 
 
Multiple CpG sites in control (n=6) and IPF (n=5) but not SSc (n=7) lung fibroblasts had significant 
(P<0.05) changes in methylation after 5-Aza treatment which were ≥13.6% (Δβ ≥0.136). 284 CpGs (283 
decreased, 1 increased) in control (n=6), 670 CpGs (666 decreased, 5 increased) in IPF (n=5) and 1 CpG 
in SSc (n=7) lung fibroblasts had significantly altered (P<0.05; Δβ ≥0.136) methylation after 5-Aza 
treatment (Figure 6.2.1). 
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Figure 6.2.1. CpGs which had altered methylation after 5-Aza treatment in lung fibroblasts. Scatter plots show all CpGs which had significantly altered (P<0.05) 
methylation in control (n=6), IPF (n=5) and SSc (n=7) after treatment with 5-Aza. β value = methylation (0 = 0%, 1 = 100% methylated). ● P<0.05; Δβ<0.05, ● P<0.05; 
Δβ ≥0.05<0.136 ● P<0.05; Δβ ≥0.136.  
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This data suggested the majority of changes in CpG methylation after 5-Aza treatment were small. 
(<13.6%). However, cluster analysis of the CpGs with a significant change in methylation (Δβ ≥ 0.136; 
P<0.05) in control and IPF lung fibroblast cell lines after 5-Aza treatment identified cell lines which did 
not respond to 5-Aza treatment to the same extent as others (Figure 6.2.2). It is unclear why some 
cell lines responded to 5-Aza more than others, however, failure to efficiently incorporate 5-Aza or 
activation of genes which affected DNMTs or de-methylation genes, such as TETs, could offer a 
feasible explanation. Three control lung fibroblast cell lines (1, 3 and 4) responded to 5-Aza treatment 
and clustered together, separately from their respective basal methylation states. The other three cell 
lines (2, 5 and 6) clustered together with their basal methylation state after 5-Aza treatment, 
suggesting they did not respond to the same extent as the other cell lines after 5-Aza treatment at 
these CpGs.  
 
Similarly, IPF cell lines 1, 2 and 5 responded to 5-Aza and clustered together, separately from their 
respective basal methylation states. IPF cell line 3 responded to 5-Aza, but not to the same extent as 
cell lines 1, 2 and 5. Nonetheless, after treatment, IPF cell line 3 clustered separately from its basal 
methylation state. In contrast, after 5-Aza treatment IPF cell line 4 clustered together with its basal 
methylation state, suggesting it did not respond to the same extent as other cell lines after 5-Aza 
treatment at these CpGs (Figure 6.2.2). 
 
Only 1 CpG in SSc lung fibroblasts had a Δβ ≥ 0.136 change in methylation after 5-Aza treatment. 
Cluster analysis on CpGs which had a significant change in methylation (P<0.05; Δβ ≥ 0.05) showed all 
non-treated cell lines (basal methylation) clustered separately from all treated cell lines. Therefore, 
small changes in methylation occurred after 5-Aza treatment in all cell lines, however, there was 
heterogeneity between samples suggesting the change in methylation at these CpGs was different 
between cell lines (Figure 6.2.2).  
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Figure 6.2.2. Hierarchical clustering based on CpGs with altered methylation in lung fibroblasts after treatment with 5-Aza. Heat-maps shows CpGs with 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) in control (n=6) and IPF (n=5) and (Δβ ≥ 0.05; P<0.05) in SSc (n=7) lung fibroblasts after 5-Aza treatment. 
T=treated, NT=untreated. Light blue represents low methylation, yellow represents high methylation with respect to each CpG.  
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These data suggest different cell lines responded differently to 5-Aza, which could account for the 
relatively low number of CpGs which had significant (P<0.05) changes in methylation ≥13.6% after 5-
Aza treatment in control, IPF and SSc lung fibroblasts. To further investigate to what extent 5-Aza 
treatment had on methylation in lung fibroblasts, each cell line was analysed separately. Basal 
methylation of each CpG on the array (n=324973) in each control (n=6), IPF (n=5) and SSc (n=7) lung 
fibroblast cell line was compared to the methylation of each CpG after 5-Aza treatment.  
 
Results confirmed that some cell lines responded to a greater extent to 5-Aza treatment than others 
(Figure 6.2.3, Figure 6.2.4 and Figure 6.2.5). Cell lines which had multiple CpGs with a Δβ ≥0.136 
change in methylation after 5-Aza treatment were labelled as strong responding cell lines, whereas 
cell lines which had fewer CpGs with a Δβ ≥0.136 change in methylation after 5-Aza treatment were 
labelled as weaker responding cell lines. Control cell lines, 1, 3 and 4 and IPF cell lines 1, 2 and 5 had 
multiple CpGs which had changes (Δβ ≥0.136) in methylation after 5-Aza. As previously shown (Figure 
6.2.1), only 1 CpG in SSc (n=7) lung fibroblasts had a significant change in methylation (P<0.05) which 
was ≥13.6% after 5-Aza treatment. Analysis of each individual SSc cell line identified all as having 
relatively few CpGs with changes (Δβ ≥0.136) in methylation after 5-Aza. However, there were CpGs 
which did have large changes in methylation (≥13.6%) after 5-Aza treatment. Table 6.2.2 summarises 
the number of CpGs which had a Δβ ≥0.136 (13.6%) change in methylation after 5-Aza treatment in 
each cell line.  
 
Cell line Control IPF SSc 
1 12101 8985 582 
2 781 31194 2063 
3 26608 1375 1235 
4 14848 313 458 
5 321 15942 620 
6 704 - 495 
7 - - 596 
Table 6.2.2. CpGs which have a change in methylation after 5-Aza treatment in each cell line. 
Number of CpGs in each control (n=6), IPF (n=5) and SSc (n=7) lung fibroblast cell line which have a 
change Δβ ≥0.136 (13.6%) in methylation after 5-Aza treatment.  
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Figure 6.2.3. CpGs which have altered methylation after 5-Aza treatment in 6 different control lung 
fibroblast cell lines. Scatter plots show the basal methylation compared to the methylation level after 
treatment with 5-Aza. β value = methylation (0 = 0%, 1 = 100% methylated). Δβ value = change in 
methylation after 5-Aza treatment.● Δβ <0.136 (<13.6%) change in basal compared to 5-Aza treated 
methylation, ● Δβ ≥0.136 (≥ 13.6%) change in basal compared to 5-Aza treated methylation.  
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Figure 6.2.4. CpGs which had altered methylation after 5-Aza treatment in 5 different IPF lung 
fibroblast cell lines. Scatter plots show the basal methylation compared to the methylation level after 
treatment with 5-Aza. β value = methylation (0 = 0%, 1 = 100% methylated). Δβ value = change in 
methylation after 5-Aza treatment.● Δβ <0.136 (<13.6%) change in basal compared to 5-Aza treated 
methylation, ● Δβ ≥0.136 (≥ 13.6%) change in basal compared to 5-Aza treated methylation.  
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Figure 6.2.5. CpGs which had altered methylation after 5-Aza treatment in 7 different SSc lung fibroblast cell lines. Scatter plots show the basal methylation 
compared to the methylation level after treatment with 5-Aza. β value = methylation (0 = 0%, 1 = 100% methylated). Δβ value = change in methylation after 5-Aza 
treatment. ● Δβ <0.136 (<13.6%) change in basal compared to 5-Aza treated methylation, ● Δβ ≥0.136 (≥ 13.6%) change in basal compared to 5-Aza treated 
methylation.  
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6.3. Effect of DNMT inhibition on expression in primary human lung fibroblasts 
Basal gene expression was compared with gene expression after 5-Aza treatment in all control (n=6), 
IPF (n=5) and SSc (n=7) lung fibroblast cell lines. The Illumina Infinium HT12v4 expression microarray 
identified 548 genes in control, 2912 genes in IPF and 940 genes in SSc with significantly (P<0.05; 
TNoM ≤1) altered expression after 5-Aza treatment compared with basal expression (Figure 6.3.1). 
Cluster analysis on genes with significantly altered expression (P<0.05; TNoM ≤1) after 5-Aza 
treatment compared with basal expression identified control cell line 5 and SSc cell line 3 as cell lines 
which, after 5-Aza treatment, clustered with non-treated cell lines. This suggests that multiple genes 
in these cell lines were not affected by 5-Aza to the same extent that other cell lines were (Figure 
6.3.1).  
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Figure 6.3.1. Effect of 5-Aza on gene expression. Scatter plots and heat-maps show the effect of 
DNMT inhibition on gene expression in control (n=6), IPF (n=5) and SSc (n=7) lung fibroblasts. Scatter 
plots shows the average expression of genes which had a significant change in expression (P<0.05; 
TNoM≤1) after DNMT inhibition with 5-Aza compared to basal expression. ● TNoM=0, ● TNoM =1. 
Not treated (basal) = NT, treated (5-Aza) = T. Light blue represents low expression, yellow represents 
high expression with respect to each CpG.  
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To determine whether 5-Aza affected gene expression to a greater extent in different lung fibroblast 
cell lines, basal gene expression was compared to gene expression after 5-Aza treatment in each 
individual lung fibroblast cell line. Large changes in gene expression were classified as ≥ 2-fold changes 
(≥ 2FC) in basal gene expression compared to gene expression after 5-Aza treatment.  
Concurrent with data showing multiple CpGs with large changes in methylation after 5-Aza treatment, 
control fibroblast cell lines 1, 3 and 4 and IPF fibroblast cell lines 1, 2 and 5 had the most genes which 
had a ≥2FC in gene expression after 5-Aza treatment compared with basal expression levels (Figure 
6.3.2 and Figure 6.3.3). All SSc lung fibroblast cell lines had a relatively low number of genes with a 
≥2FC in gene expression after 5-Aza treatment. Interestingly however, SSc lung fibroblast cell lines 2 
and 3 (which had the most number of CpGs with altered methylation (Δβ ≥ 0.136), had the least 
number of genes (5 and 3 respectively) with a ≥2FC in gene expression after 5-Aza treatment (Figure 
6.3.4). This may suggest that small changes in methylation can have a big effect on gene expression 
and that large changes in methylation do not necessarily result in large changes in expression. 
Furthermore, small changes in methylation could effect the expression of genes such as master 
transcription factors or other epigenetic regulators such as miRs, which subsequently could have an 
effect on other genes. Table 6.3.1 summarises the number of genes in each cell line which have ≥2FC 
in expression after 5-Aza treatment compared with their basal expression levels.  
 
Cell line Control IPF SSc 
1 250 618 7 
2 9 632 5 
3 496 111 3 
4 656 127 102 
5 0 625 117 
6 115 - 53 
7 - - 151 
Table 6.3.1. Genes which have a change in expression after 5-Aza treatment compared with basal 
expression in each cell line. Number of genes with a ≥2FC in expression in each control (n=6), IPF (n=5) 
and SSc (n=7) lung fibroblast cell line after 5-Aza treatment compared to basal expression.  
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Figure 6.3.2. Genes which have altered expression after 5-Aza treatment in 6 different control lung 
fibroblast cell lines. ● Fold change in expression <2, ● fold change in expression ≥2.  
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Figure 6.3.3. Genes which have altered expression after 5-Aza treatment in 5 different IPF lung 
fibroblast cell lines. ● Fold change in expression <2, ● fold change in expression ≥2.  
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Figure 6.3.4. Genes which had altered expression after 5-Aza treatment in 7 different SSc lung fibroblast cell lines. ● Fold change in expression <2, ● fold change 
in expression ≥2.  
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6.4. Confirmation of 5-Aza expression arrays 
As previously discussed, multiple genes had large changes to their expression after treatment with 5-
Aza. For genes including Matrix metalloproteinase-10 (MMP10), Matrix metalloproteinase-12 
(MMP12) (Figure 6.4.1), changes in expression after 5-Aza treatment were confirmed by qRT-PCR. 
Fold changes in gene expression after treatment with 5-Aza were identified as being much larger by 
qRT-PCR compared with microarray data, however, this was not surprising as qRT-PCR has previously 
been shown to be more sensitive than microarray analysis (Chen et al, 2009). 
 
 
 
Figure 6.4.1. Validation of 5-Aza microarray data using qRT-PCR. MMP10 and MMP12 expression in 
control (n=6), IPF (n=5) and SSc (n=7) lung fibroblasts after 5-Aza treatment. Data presented as the 
geometric mean fold-change relative to basal expression of each cell line ± 95% confidence intervals. 
Each data point represents a different cell line.  
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6.5. Correlation between methylation and gene expression after 5-Aza treatment 
The ß value of methylation and the log2 transformed normalised expression value after 5-Aza 
treatment was compared with basal levels to determine what change in methylation may have an 
effect on gene expression. Although some cell lines responded more to 5-Aza than others, it was 
hypothesised that changes to methylation would still correlate with changes to expression in a linear 
manner. For example, small changes in methylation could result in small changes in expression and 
large changes in methylation with large changes in expression. However, previous studies have shown 
small methylation changes can induce large changes in expression (Sanders et al, 2012, Huang et al, 
2014, Yang et al, 2014). Furthermore, it is unclear whether changes in methylation have a linear 
relationship with changes in expression. The following analysis looked at what change in methylation 
could have an effect on expression.  
 
1392 CpGs corresponding to 801 genes had significant correlation between changes in methylation 
and changes in expression in control, IPF and SSc cell lines. The location of these CpGs, their change 
in methylation and their corresponding genes change in expression after 5-Aza treatment compared 
with basal levels in each control, IPF and SSc cell line is shown in Figure 6.5.1, Figure 6.5.2 and Figure 
6.5.3.  
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Figure 6.5.1. Control lung fibroblasts: the location of 1392 CpGs in which changes to CpG methylation correlate with changes in expression. Scatter plot shows CpGs change 
in methylation (Δβ) and their corresponding genes change in expression (Log2FC) after 5-Aza treatment compared with basal levels in each control lung fibroblast cell line 
(n=6). Each dot represents a different CpG.  
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Figure 6.5.2. IPF lung fibroblasts: the location of 1392 CpGs in which changes to CpG methylation correlate with changes in expression. Scatter plot shows CpGs change in 
methylation (Δβ) and their corresponding genes change in expression (Log2FC) after 5-Aza treatment compared with basal levels in each IPF lung fibroblast cell line (n=5). 
Each dot represents a different CpG.  
203 
 
 
Figure 6.5.3. SSc lung fibroblasts: the location of 1392 CpGs in which changes to CpG methylation correlate with changes in expression. Scatter plot shows CpGs change in 
methylation (Δβ) and their corresponding genes change in expression (Log2FC) after 5-Aza treatment compared with basal levels in each SSc lung fibroblast cell line (n=7). 
Each dot represents a different CpG.  
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Multiple genes including, Mitotic spindle assembly checkpoint protein MAD1 (MAD1L1), Rho guanine 
nucleotide exchange factor 10 (ARHGEF10), Macrophage erythroblast attacher (MAEA) and O-6-
methylguanine-DNA methyltransferase (MGMT) had >10 CpG sites to which changes in methylation 
correlated with changes in expression. Some examples of CpGs/genes which showed correlation 
between changes in methylation and changes in expression are shown in Figure 6.5.4. 
 
 
Figure 6.5.4. CpGs which showed correlation between changes in their methylation with changes to 
their respective genes expression level. Examples of 4 CpGs which have correlation between CpG 
methylation and expression across all cell lines (n=18) after 5-Aza treatment compared with basal 
levels. The change in methylation is shown by the Δß value. The change in expression is shown by the 
log2 fold-change (Log2FC). Shaded areas indicate 95% confidence regions. ● Control (n=6), ● IPF (n=5), 
● SSc (n=7).  
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A number of CpGs appeared to have negligible changes in methylation which correlated with large 
changes to their respective genes expression, particularly evident in SSc cell lines. For example, 
changes in methylation at 9 CREB binding protein (CREBBP) CpGs correlated with changes in CREBBP 
expression. In 2/6 control and 6/7 SSc cell lines, the highest change in methylation across all 9 CpG 
sites was <5%, yet expression of CREBBP was decreased ≥2fold in all cell lines (n=18) after 5-Aza 
treatment compared with basal levels (Figure 6.5.5). Another gene, CMIP, had 2 CpGs to which 
changes in methylation correlated with changes in CMIP expression. All cell lines (n=18) had ≥2fold 
increased expression of CMIP after 5-Aza compared with basal CMIP levels, yet the highest change in 
methylation across both CpGs in 11/18 cell lines was <5%. Changes in methylation at other CpGs not 
covered on the array could be responsible for the observed changes in expression, however, these 
data suggest that small changes in methylation could potentially have a big impact on the expression 
of some genes.  
 
Other genes appeared to require larger changes in methylation to have an effect on expression. For 
example, changes in methylation at 130 MAD1L1 CpGs correlated with changes in MAD1L1 
expression. Methylation changes at 4 CpGs in the MAD1L1 gene which showed the strongest 
correlation with MAD1L1 expression are shown in Figure 6.5.6. 17/18 cell lines had at least 1 CpG with 
a ≥5% change in methylation after 5-Aza treatment compared with basal levels, yet only cell lines 
which had above an 18% change in methylation in at least 1 CpG had a ≥2fold change in expression. 
This suggests for some genes large changes in methylation are required to have an effect on gene 
expression.  
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Figure 6.5.5. CREBBP CpGs which showed correlation between changes in their methylation with 
changes to CREBBP expression. Examples of 4 CREBBP CpGs which have significant correlation (R2=) 
between CpG methylation and CREBBP expression across all cell lines (n=18) after 5-Aza treatment 
compared with basal levels. The change in methylation is shown by the Δß value. The change in 
expression is shown by the log2 fold-change (Log2FC). Shaded areas indicate 95% confidence regions. 
● Control (n=6), ● IPF (n=5), ● SSc (n=7).  
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Figure 6.5.6. MAD1L1 CpGs which showed correlation between changes in their methylation with 
changes to MAD1L1 expression. Examples of 4 MAD1L1 CpGs which have significant correlation (R2=) 
between CpG methylation and MAD1L1 expression across all cell lines (n=18) after 5-Aza treatment 
compared with basal levels. The change in methylation is shown by the Δß value. The change in 
expression is shown by the log2 fold-change (Log2FC). Shaded areas indicate 95% confidence regions. 
● Control (n=6), ● IPF (n=5), ● SSc (n=7).  
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6.6. Effect of DNMT inhibition on TNXB methylation in primary human lung 
fibroblasts 
As previously shown in section 6.2, DNMT inhibition reduced methylation of multiple genes in control, 
IPF and SSc lung fibroblasts. 68, 34 and 36 CpG sites in the TNXB gene had decreased methylation 
(P<0.05) after 5-Aza treatment in control, IPF and SSc respectively (Figure 6.6.1). The highest 
frequency of CpGs with significantly (P<0.05) altered methylation after 5-Aza treatment were located 
in open sea regions in all lung fibroblasts (Figure 6.6.2 and Figure 6.6.3).  
 
 
 
Figure 6.6.1. Distinct and overlapping CpG sites which had decreased methylation in lung fibroblasts 
after 5-Aza treatment. CpGs with significantly decreased (P<0.05) methylation after 5-Aza treatment 
in control (n=6), IPF (n=5) and SSc (n=7) lung fibroblasts. 
 
 
 
Figure 6.6.2. The location of CpG sites which had decreased methylation in lung fibroblasts after 5-
Aza treatment. CpGs with significantly (P<0.05) decreased methylation after 5-Aza treatment in 
control ● (n=6), IPF ▲ (n=5) and SSc ■ (n=7) lung fibroblasts. 
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Figure 6.6.3. The location, number and degree of methylation change of CpG sites which had decreased methylation after 5-Aza treatment. CpG with significantly 
(P<0.05; ≥ 5%) decreased methylation after 5-Aza treatment in control (n=6), IPF (n=5) and SSc (n=7) lung fibroblasts. 
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Three control cell lines and three IPF cell lines had large decreases in methylation in the TNXB gene 
after 5-Aza treatment, whereas little change in methylation was observed after 5-Aza treatment in 
SSc lung fibroblast cell lines (Figure 6.6.4). Large changes in methylation after 5-Aza treatment 
corresponded with large increases in TNXB mRNA expression (Figure 6.6.4). 
 
  
 
Figure 6.6.4. Three representative CpGs which had decreased in methylation after 5-Aza treatment 
in control lung fibroblasts. Three representative CpGs which had decreased in methylation after 5-
Aza treatment in control lung fibroblasts. No significant change was observed in IPF (n=5) or SSc (n=7) 
lung fibroblasts. Each point represents a different lung fibroblast cell line. Bottom right: fold change 
in TNXB mRNA expression relative to the basal average in each fibroblast cell line after 5-Aza 
treatment. 
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6.7. Enrichment and pathway analysis of genes modulated by 5-Aza treatment 
6.7.1. Biological enrichment of strong and weak responding cell lines to 5-Aza 
GO-term enrichment analysis was performed on strong and weak responding cell lines to determine 
if similar biological processes were enriched in genes with varying levels of altered methylation. Strong 
responding cell lines: control 1 and IPF5 identified 867 and 835 biological processes, respectively, 
which were significantly enriched in genes with ≥13.6% changes in methylation after 5-Aza treatment. 
Weak responding cell lines: control 5, IPF4 and SSc7 identified 6, 9 and 85 biological processes, 
respectively, which were significantly enriched in genes with ≥13.6% changes in methylation after 5-
Aza treatment. Whilst the weak responding cell lines had few enriched biological processes, the weak 
responding cell line SSc7, did have multiple biological processes including regulation of transcription, 
cell adhesion, lung development, regulation of histone deacetylation, response to TGFß and apoptosis 
which were significantly enriched in genes with ≥13.6% changes in methylation after 5-Aza treatment. 
Furthermore, the weak responding cell lines had multiple CpGs/genes with ≥5% changes in 
methylation after 5-Aza treatment (control 5: 19152 CpGs/10753 genes, IPF4: 21233 CpGs/11192 
genes, SSc7: 24828 CpGs/12188 genes).  
A strong responding IPF cell line, IPF5 (a cell line that had 15942 CpGs with ≥13.6% changes in 
methylation after 5-Aza treatment), and a weak responding IPF cell line, IPF4 (a cell line which only 
had 313 CpGs with ≥13.6% changes in methylation after 5-Aza treatment) were compared using 
genecodis enrichment analysis. For IPF cell line 5, genes with ≥13.6% changes in methylation after 5-
Aza treatment were analysed, whereas, for IPF cell line 4, genes with ≥5% changes in methylation after 
5-Aza treatment were analysed. 835 and 617 biological processes were identified as being enriched in 
genes with altered methylation after 5-Aza in IPF5 and IPF4, respectively, of which 407 overlapped. 
Furthermore, many of these biological processes were relevant to fibrosis (Table 6.7.1.1). These data 
suggest that cell lines which have a weaker response to 5-Aza still have multiple CpG/genes with 
altered methylation, many of which are associated with biological processes which may be relevant 
to pulmonary fibrosis. 
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IPF5 (strong response to 5-Aza) 
Biological process (BP) Number of 
genes 
Total number of genes 
associated with the BP  
Hypergeometric P 
value 
Regulation of transcription, DNA-
dependent  539 1609 2.53E-49 
Apoptotic process  233 594 1.07e-31 
Cell adhesion  237 556 7.72e-39 
FGFR signaling pathway  37 78 2.19e-07 
Chromatin modification  87 224 2.85e-11 
Actin cytoskeleton organization  59 128 4.07e-11 
ECM organization  34 73 1.38e-06 
Collagen fibril organization  12 32 0.049419 
Lung development  45 75 1.48e-13 
Cellular response to TGFß 
stimulus  10 24 0.042908 
 
IPF4 (weak response to 5-Aza) 
Biological process (BP) Number of 
genes 
Total number of genes 
associated with the BP  
Hypergeometric P 
value 
Regulation of transcription, DNA-
dependent  757 1609 2.36E-70 
Apoptotic process  285 594 3.56e-27 
Cell adhesion  310 556 3.42e-46 
FGFR signaling pathway  40 78 6.89e-05 
Chromatin modification  107 224 5.56e-10 
Actin cytoskeleton organization  73 128 2.82e-11 
ECM organization  46 73 4.47e-09 
Collagen fibril organization  19 32 0.001445 
Lung development  51 75 7.58e-12 
Cellular response to TGFß 
stimulus  15 24 0.003 
 
Table 6.7.1.1. Examples of biological processes enriched in genes with altered methylation after 5- 
Aza treatment in 1 strong and 1 weak responding IPF cell line. Biological processes enriched in genes 
with large changes in methylation (≥13.6%) in 1 strong responding cell line (IPF5) compared to 
biological processes enriched in genes with ≥5% changes in methylation in 1 weak responding cell line 
(IPF4) after 5-Aza treatment. The number of genes associated with each biological process (BP) and 
the total number of genes that belong to each process is shown. The P-value was calculated using the 
hypergeometric distribution and corrected for multiple testing using the Benjamini-Hochberg FDR 
method. A smaller adjusted P-value correlated with greater gene enrichment. 
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Genes (625) had large changes in expression (≥2-fold) after 5-Aza treatment in the strong responding 
cell line, IPF5. Enrichment analysis identified 320 biological processes enriched in these genes, many 
of which were relevant to fibrosis (Table 6.7.1.2). Genes (127) had large changes in expression (≥2-
fold) after 5-Aza treatment in the weak responding cell line, IPF4. Enrichment analysis identified 311 
biological processes enriched in these genes, many of which were relevant to fibrosis (Table 6.7.1.2) 
and 82 of which, overlapped with cell line IPF5. This suggests that smaller changes in methylation 
(<13.6) can still lead to large changes in expression (≥2-fold) and that the genes which have altered 
expression after 5-Aza in both strong and weak responsing cell lines, are associated with many 
biological processes relevant to fibrosis.  
 
IPF cell line 5 (strong response to 5-Aza) 
Biological process (BP) Number of 
genes 
Total number of genes 
associated with the BP  
Hypergeometric P 
value 
Prostaglandin biosynthetic process  3 15 0.016979 
Anti-apoptosis  15 200 7.08e-05 
Signal transduction  56 1176 7.34e-10 
Cell-cell signaling  17 242 4.63e-05 
Response to wounding  7 65 0.001961 
Response to virus  16 144 3.70e-07 
Cytokine-mediated signaling 
pathway  20 181 7.34e-09 
Epithelial cell differentiation  4 42 0.034859 
Type I interferon-mediated signaling  15 75 5.90E-10 
Response to mechanical stimulus  7 51 0.000613 
 
IPF cell line 4 (weak response to 5-Aza) 
Biological process (BP) Number of 
genes 
Total number of genes 
associated with the BP  
Hypergeometric P 
value 
Prostaglandin biosynthetic process  2 15 0.015534 
Anti-apoptosis  4 200 0.030658 
Signal transduction  18 1176 2.30e-05 
Cell-cell signaling  10 242 8.25e-06 
Response to wounding  2 65 0.047935 
Response to virus  3 144 0.045149 
Cytokine-mediated signaling 
pathway  6 181 0.00173 
Epithelial cell differentiation  2 42 0.037966 
Type I interferon-mediated signaling  4 75 0.003268 
Response to mechanical stimulus  2 51 0.045168 
Table 6.7.1.2. Examples of biological processes enriched in genes with altered expression after 5-
Aza treatment in 1 strong and 1 weak responding IPF cell line. Biological processes enriched in genes 
with large changes in expression (≥2-fold) in 1 strong (IPF5) and 1 weak (IPF4) responding cell line after 
5-Aza treatment. The number of genes associated with each biological process and the total number 
of genes that belong to each process is shown. The P-value was calculated using the hypergeometric 
distribution and corrected for multiple testing using the Benjamini-Hochberg FDR method. A smaller 
adjusted P-value correlated with greater gene enrichment. 
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6.7.2. Biological enrichment and pathway analysis of genes which had correlation 
between changes in methylation and changes in expression after 5-Aza treatment 
CpGs (1392) corresponding to 801 genes had significant correlations (R2=≥0.5; P<0.05) between 
changes in methylation and changes in expression, in control, IPF and SSc lung fibroblasts. GO-term 
enrichment analysis identified 251 biological processes enriched in these genes, many of which are 
relevant to fibrosis (Table 6.7.2.1). Furthermore, KEGG enrichment identified 50 pathways, many of 
which have relevance to fibrosis, as being enriched in genes which may be directly regulated by 
methylation (Table 6.7.2.2). 
Biological process (BP) Number of 
genes 
Total number of genes 
associated with the BP  
Hypergeometric P 
value 
ECM organization  12 73 2.87e-05 
Apoptotic process  35 594 0.000103 
Regulation of transcription, DNA-
dependent  68 1609 0.000203 
Cell adhesion  32 556 0.00029 
Wnt receptor signaling pathway  12 110 0.000772 
Response to virus  13 144 0.001927 
Wound healing  8 68 0.006282 
Actin cytoskeleton organization  11 128 0.006915 
Cytoskeleton organization  9 106 0.016346 
Positive regulation of fibroblast 
proliferation  5 39 0.026752 
Table 6.7.2.1. Biological processes enriched in genes which have significant correlation between 
changes in methylation and changes in gene expression after 5-Aza. Biological processes enriched in 
genes with significant correlation (R2=≥0.5; P<0.05) between changes in methylation and changes in 
expression after 5-Aza treatment, in control (n=6), IPF (n=5) and SSc (n=7) lung fibroblasts. The 
number of genes associated with each biological process and the total number of genes that belong 
to each process is shown. The P-value was calculated using the hypergeometric distribution and 
corrected for multiple testing using the Benjamini-Hochberg FDR method. A smaller adjusted P-value 
correlated with greater gene enrichment. 
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KEGG pathway Number of 
genes 
Total number of genes 
associated with the BP  
Hypergeometric P 
value 
p53 signaling pathway 13 67 7.51E-07 
Cell cycle 14 123 0.0001 
Oocyte meiosis 12 110 0.000604 
Pathways in cancer 21 324 0.000703 
Focal adhesion 16 197 0.000744 
Amoebiasis 11 102 0.000785 
ECM-receptor interaction 10 84 0.000922 
Calcium signaling pathway 14 175 0.001462 
Regulation of actin cytoskeleton 15 209 0.002467 
Rheumatoid arthritis 9 84 0.002669 
Dilated cardiomyopathy 9 89 0.003466 
Vibrio cholerae infection 7 53 0.003594 
Ribosome biogenesis in eukaryotes 8 73 0.00408 
MAPK signaling pathway 16 262 0.005983 
TGFß signaling pathway 8 82 0.007816 
Axon guidance 10 128 0.008473 
Small cell lung cancer 8 84 0.008608 
Malaria 6 48 0.008876 
Tight junction 10 130 0.009047 
Amyotrophic lateral sclerosis (ALS) 6 50 0.009395 
PPAR signaling pathway 7 70 0.009956 
Cytokine-cytokine receptor interaction 15 259 0.010144 
Fc gamma R-mediated phagocytosis 8 92 0.010881 
GAG biosynthesis - chondroitin sulfate 4 22 0.011585 
GnRH signaling pathway 8 98 0.014999 
Wnt signaling pathway 10 149 0.018348 
Hypertrophic cardiomyopathy (HCM) 7 82 0.020279 
Complement and coagulation cascades 6 65 0.023526 
Notch signaling pathway 5 46 0.023884 
Hepatitis C 9 133 0.024226 
Gap junction 7 88 0.024609 
Purine metabolism 10 158 0.025048 
Ribosome 7 86 0.025537 
Amino sugar and nucleotide sugar 
metabolism 5 48 0.027037 
Bacterial invasion of epithelial cells 6 70 0.030024 
Adherens junction 6 71 0.031273 
Chronic myeloid leukemia 6 73 0.032186 
Gastric acid secretion 6 72 0.032559 
Base excision repair 4 33 0.032616 
RNA transport 9 145 0.033431 
Melanogenesis 7 98 0.03545 
Pathogenic Escherichia coli infection 5 54 0.036099 
Neurotrophin signaling pathway 8 124 0.036267 
Osteoclast differentiation 8 126 0.038855 
Chagas disease (American 
trypanosomiasis) 7 102 0.038992 
Protein digestion and absorption 6 78 0.039198 
Inositol phosphate metabolism 5 57 0.040367 
Hematopoietic cell lineage 6 83 0.048048 
Cytosolic DNA-sensing pathway 5 60 0.048733 
Ubiquitin mediated proteolysis 8 135 0.049444 
Table 6.7.2.2. KEGG pathways enriched in genes which have significant correlation between changes 
in methylation and changes in gene expression after 5-Aza. KEGG pathways enriched in genes with 
significant correlation between changes in methylation and changes in expression after 5-Aza 
treatment in control (n=6), IPF (n=5) and SSc (n=7) lung fibroblasts. The number of genes associated 
with each biological process (BP) and the total number of genes that belong to each process is shown. 
The P-value was calculated using the hypergeometric distribution and corrected for multiple testing 
using the Benjamini-Hochberg FDR method. A smaller adjusted P-value correlated with greater gene 
enrichment. 
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Using data combined from both GO-term and KEGG enrichment analyses, STRING analysis was used 
to determine how genes potentially directly regulated by methylation could interact with each other 
in specific pathways such as WNT signalling (Table 6.7.2.3) and ECM-interactions (Table 6.7.2.4). 
Furthermore, genes were highlighted which were previously identified as having significantly altered 
methylation (Δβ ≥ 0.136; P<0.05) and/or expression (TNoM ≤1; P<0.05) in IPF compared to control 
lung fibroblasts.  
 
Table 6.7.2.3. The Wnt signalling pathway enriched in genes with a significant correlation between 
changes in methylation and changes in expression after 5-Aza treatment. Genes with significantly 
altered basal methylation and/or expression in IPF (n=5) compared to control (n=6) lung fibroblasts 
are highlighted.  
 
 
Table 6.7.2.4. The ECM-interaction pathway enriched in genes with a significant correlation 
between changes in methylation and changes in expression after 5-Aza . Genes with significantly 
altered basal methylation and/or expression in IPF (n=5) compared to control (n=6) lung fibroblasts 
are highlighted.  
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6.8. Summary 
 Treatment of cell lines with 5-Aza affected methylation at multiple CpG sites and the 
expression of multiple genes in all cell lines. 
 
 Multiple biological processes previously identified as having significantly altered methylation 
in IPF and SSc compared to control lung fibroblasts were identified as being enriched in genes 
with significantly altered methylation (P<0.05) after 5-Aza treatment. 
 
 The extent of methylation and expression changes after 5-Aza treatment varied between cell 
lines. 
 
 Correlation between changes in methylation and changes in expression, after 5-Aza 
treatment, identified multiple novel genes potentially regulated by methylation in lung 
fibroblasts and multiple novel pathways potentially important in pulmonary fibrosis.  
 
 Multiple genes for which changes in methylation and changes in expression correlated after 
5-Aza treatment, had significantly altered basal methylation and/or basal expression in 
IPF/SSc compared to control lung fibroblasts.  
 
 TNXB methylation was significantly reduced in control cell lines after 5-Aza treatment and 
corresponded with increased TNXB expression. The three control fibroblast cell lines with 
large decreases in methylation at multiple CpGs within the TNXB had the largest increases in 
TNXB expression.  
 
 The number of CpGs with a large (≥13.6%) change in methylation after 5-Aza treatment 
correlated with the number of genes with large (≥2FC) changes in expression.   
 
 Small changes in methylation (≤5%) also correlated with large changes (≥2FC) in expression 
in multiple genes, suggesting small changes in methylation may have an effect on the 
expression of multiple genes.  
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 Discussion 
7.1. Overview 
Previous studies have identified multiple genes with altered methylation in lung tissue derived from 
IPF patients compared to non-fibrotic controls (Sanders et al, 2012, Rabinovich et al, 2012, Yang et al, 
2014). Rabinovich et al, used Agilent microarrays to examine global methylation patterns in IPF lung 
tissue and found global methylation was decreased in IPF compared to control lung tissue. 
Interestingly, the pattern of methylation seen in IPF was similar to that which was seen in lung cancer 
tissue, where methylation patterns of 65% of CpG islands overlapped (Rabinovich et al, 2012). Sanders 
et al reported no global difference in methylation between IPF and control lung tissue but did find 
that DNMT3A and DNMT3B had increased expression (Sanders et al, 2012). Both these studies also 
suggested that DNA methylation may influence gene expression although neither study analysed 
genome-wide expression in relation to CpG methylation. Yang et al, used CHARM arrays to analyse 
the methylation of 4.6 million CpG sites and subsequently compared global expression using Agilent 
expression arrays, making this study the most comprehensive study to date looking at CpG 
methylation in IPF lung tissue (Yang et al, 2014). 2130 differentially methylated regions were identified 
in IPF compared to control tissue, of which 738 corresponded to significant changes in gene 
expression. Whilst these studies offer a valuable insight into how methylation differs between IPF and 
control lung tissue and potentially how methylation may affect gene expression, the use of lung tissue, 
which contains multiple cell types, makes it impossible to distinguish cell type-specific changes in 
methylation, as large changes in methylation in one cell type could be masked by large changes in 
methylation in a different cell type. Therefore, examining methylation in lung tissue could mask 
changes in methylation of genes which may be important in pulmonary fibrosis or result in over or 
under estimation of methylation. Furthermore, the use of different lung tissue samples and their 
degree of heterogeneity, different stringency criteria for inclusion/statistical analysis and the use of 
different microarray platforms could all contribute reasons as to why these previous studies had 
different results regarding global methylation.  
 
To date, only one study has examined global DNA methylation in IPF lung fibroblasts (Huang et al, 
2014). This study identified global changes in methylation between IPF and two control lung fibroblast 
groups with 58% of CpGs in IPF lung fibroblasts being hypomethylated (Huang et al, 2014). However, 
a number of limitations were present in this study. For example, Huang et al, utilised the Illumina 
Infinium HumanMethylation 27k BeadChip array which only covers 1-2 CpGs per a gene and is biased 
towards CpG islands. Furthermore 6-10% of probes on the array were non-specific (Chen et al, 2011) 
and control fibroblasts used for analysis were mainly male, whereas IPF fibroblasts were mainly 
female, thus making it impossible to determine if the reported differences in methylation between 
IPF and controls were real or due to differences between males and females. Methylation was also 
compared to gene expression data obtained from other studies, thus the cell lines used to determine 
methylation were not the same cell lines used to determine expression. This makes it difficult to 
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determine whether genes with altered methylation truly have changes in expression, as different 
culture techniques, array platforms, and heterogeneity between fibroblast cell lines all add bias to 
their results.  
 
To my knowledge, this thesis is the first to examine genome-wide methylation in IPF and SSc lung 
fibroblasts and to examine the effects of methylation on gene expression using the same cell cultures. 
Furthermore, it is the first study to characterise gender-specific methylation differences in human lung 
fibroblasts and compare gender differences in methylation in IPF males with control males and IPF 
females with control females.  
 
7.2. Illumina Infinium HumanMethylation 450k BeadChip Array  
The Illumina Infinium HumanMethylation 450k BeadChip microarray is the successor to the previous 
Ilumina methylation array, the Infinium HumanMethylation 27k BeadChip array. The Illumina 450k 
methylation array was chosen for its comprehensive coverage of the human methylome. The Illumina 
450k array interrogates 482421 CpGs representing ~2% of the entire methylome, with an average of 
17 CpGs per a gene, covering CGIs and their flanking shore, shelf and open sea regions, which are 
recognised as playing an increasingly important role in disease and gene regulation (Irizarry et al, 2009, 
Rakyan et al 2011, Rao et al, 2013, Bockmühl et al, 2015). The 450k array represents a significant 
upgrade from the 27k array which is heavily biased towards CGIs and covers far fewer CpGs, although, 
a number of limitations have been discovered (Chen et al, 2013, Price et al, 2013). By definition, the 
Illumina microarrays are biased towards which CpGs they examine as the list of CpGs was compiled 
by a consortium of experts and aimed towards their interests. Furthermore, in 2013 two studies 
identified a number of probes which overlapped with SNPs or were non-specific (Chen et al, 2013, 
Price et al, 2013). Others have also suggested multiple probes on the 450k array are affected by a SNP 
(Liu et al, 2013). There is no general consensus as to whether to remove or leave probes on the array 
which cover a SNP, although many recent studies have removed or have suggested removing them 
(Price et al, 2013, Chen et al, 2013, Fortin et al, 2014). SNPs which cover a CpG site or within a probe 
could be compromised by sample genotype (Dedeurwaerder et al, 2011, Price et al, 2013), thus all 
probes covering a SNP were removed. Non-specific probes can hybridise to multiple different genomic 
regions and could potentially measure multiple sites of methylation. Non-specific probes represented 
approximately 8.6% of all probes on the array (Price et al, 2013), therefore these probes were filtered 
out to avoid potentially inaccurate methylation readings. Normalisation of the array was performed 
by Cambridge Genomic Services (CGS, UK) using the popular R package Lumi (Du et al, 2008). However, 
as the number of researchers using the 450k array increases so does the number of tools being 
developed to help with analysing array data (Dedeurwaeder et al, 2013). Therefore future studies 
should explore the increasing number of tools now available to analysis the 450k array. 
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7.2.1. Criteria for inclusion  
The change in methylation required to have a significant biological effect and whether this change in 
methylation is the same for all genes or different cell lines remains a difficult question to answer. 
There is no universal way to analyse methylation data and different normalisation methods and array 
technologies make it hard to compare data from different studies. For example, Sanders et al, used a 
P<0.05 to avoid missing true positive signals and Huang et al, used a P<0.05 with a 2-fold change, 
whereas, Rabinovich used a FDR of P<0.05. In my studies, an FDR of P<0.05 resulted in very few 
CpGs/genes being detected, likely due to the heterogeneity between IPF samples and effects of sex-
specific differences in methylation in control and IPF lung fibroblasts. Instead, I chose a cut-off 
methylation value of Δβ ≥0.136 (≥13.6% change in methylation) with a P value <0.05. This was based 
on previous studies showing a 13.6% change in methylation could be detected with 95% confidence 
(Bibikova et al, 2009, Lokk, 2012). The β-value, which represents the level of methylation (0= 
unmethylated, 1= 100% methylated), was chosen as it allows easy biological interpretation and is 
recommended for use when an absolute difference in methylation cut-off is applied (Dedeurwaeder 
et al, 2011). 
Several studies have reported that altered methylation of specific genes in IPF corresponds with their 
expression, however, to what extent methylation must change in order to have an effect on gene 
expression is unknown. Sanders et al, showed that genes including DDAH and TP53INP1 had large 
methylation differences (>20%) in IPF compared to control lung tissue. These changes in methylation 
corresponded to altered gene expression (Sanders et al, 2012) however, several studies have shown 
that small changes (<5%) in methylation can also affect individual gene expression. For example, Yang 
et al, showed that 8 CpGs on the CASZ1 gene, had on average a 3.5% change in methylation in IPF 
compared to control type II alveolar epithelial cells which corresponded with increased gene 
expression (Yang et al, 2014). In 2010, Huang et al, showed <5% changes in methylation of the PTGER2 
gene could affect PTGER2 expression and in 2014, showed that an average decrease of 6.9% over 28 
CpGs of the gene CDKN2B resulted in increased expression (Huang et al, 2010, Huang et al, 2014). This 
suggests <13.6% changes in methylation could potentially be important in regulating expression. In 
support of this, small but significant differences in TNXB methylation identified by the 450k array were 
confirmed by bisulfite sequencing. Furthermore, cell lines which had a weak response to 5-Aza with 
relatively few CpGs reaching the 13.6% cut-off, still had multiple genes with large changes (≥2-fold) in 
expression (see Chapter 6). This suggests that small changes in methylation potentially can have an 
effect on gene expression and that a 13.6% cut-off may be too stringent. However, it has been 
reported that the 450k array may not be suitable for the detection of small differences in methylation 
due to technical variability in measurements (Dedeurwaerder et al, 2011). Therefore, to avoid the 
possibility of including a large number of false positives, only genes reaching the 13.6% cut-off were 
included. 
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For gene expression analysis, the TNoM method was applied (see Chapter 2: section 2.6.6) which has 
previously been applied to gene expression data in other IPF studies (Zuo et al, 2002). A TNoM <1 with 
a p value <0.05 was chosen to increase the stringency criteria as few genes reached a FDR <0.05 rate, 
whereas multiple genes reached a non-stringent p value <0.05. Other studies have used a non-
stringent p value <0.05 with ≥2fold-change in gene expression (Huang et al, 2014), however, what 
change in gene expression is sufficient to have a biological effect is unknown. Therefore, to avoid 
missing genes with smaller, but potentially important fold-change in expression, no fold-change 
criteria was applied. One potential limitation of using TNoMs in IPF studies is that IPF fibroblast cell 
lines are notoriously heterogeneous (Martinez et al, 2005, Habiel and Hogaboam, 2014, DePianto et 
al, 2015). Therefore, filtering samples over 1 TNoM may be too stringent, however a large number of 
genes reached this statistical threshold (568 in IPF and 688 in SSc compared to control lung fibroblasts) 
many of which have previously been linked to fibrosis including IL8 (Ziegenhagen et al, 1998), WNT2B 
(Zhou et al, 2014), PPARγ (Lakatos et al, 2007), S100A4 (Tomcik et al, 2014), NOTCH3 (Dees et al, 2011), 
IGFBP7 (Hsu et al, 2011), CCL13 (Yanaba et al, 2010), IL7R (Grigoryev et al, 2008) and TIMP4 (Elias et 
al, 2008), suggesting this approach was a good compromise. 
 
7.3. Genome-wide methylation in IPF and in SSc compared to control lung 
fibroblasts. 
The results from this study identified 7153 CpGs corresponding to 4563 genes in IPF and 8392 CpGs 
corresponding to 5294 genes in SSc which had significantly altered methylation (Δβ ≥ 0.136; P<0.05)  
compared to control lung fibroblasts. In agreement with previous studies examining global DNA 
methylation in lung tissue and lung fibroblasts (Rabinovich et al, 2012, Huang et al, 2014) the majority 
of CpGs (69%) had decreased methylation in IPF. In contrast, Sanders et al, reported no global 
differences in CpG methylation however, the Illumina 27k array they used covered fewer CpGs, was 
heavily biased towards CGIs in promoter regions and did not take into account methylation at other 
genomic regions. Furthermore, they used lung tissue as opposed to lung fibroblasts. As previously 
stated, lung tissue contains multiple cell types which may result in over or under estimation of 
methylation, thus fibroblast-specific changes in methylation were impossible to determine. In 
agreement with previously published data from targeted studies using lung fibroblasts, THY-1, PTGER2 
and P14ARF all had CpG sites with increased methylation in IPF compared to control lung fibroblasts 
(Table 7.3.1), although the increase in methylation did not meet the stringency criteria I chose (Δβ ≥ 
0.136; P<0.05).  
Gene name IPF Δβ P-value 
THY1 0.268 0.11644 
P14ARF 0.02593 0.039913 
PTGER2 0.06889 0.363231 
Table 7.3.1. Comparison of microarray data with genes previously identified as having increased 
methylation in IPF compared to control lung fibroblasts. 
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The majority (67%) of CpGs which had significantly altered methylation (Δβ ≥ 0.136; P<0.05) in SSc had 
increased methylation compared to control lung fibroblasts. Furthermore, 7827 CpGs corresponding 
to 5082 genes had significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc lung 
fibroblasts. These data suggest that global methylation patterns are different between IPF and SSc 
which may reflect outcomes such as disease progression and sex bias.  
Despite global differences in methylation, multiple genes with significantly altered methylation (Δβ ≥ 
0.136; P<0.05) overlapped between IPF and SSc lung fibroblasts. These genes included, interleukins, 
WNTs, collagens, miRs and mucins, all of which have been implicated in the pathogenesis of IPF and/or 
SSc. Furthermore, multiple biological processes and pathways were enriched in genes that had 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF and SSc compared to control lung 
fibroblasts. Many of these pathways including coagulation (Scotton et al, 2009), apoptosis (Ramos et 
al, 2001, Thannickal et al, 2006, Fattman, 2008) and ECM interactions (Pardo et al, 2005, Emblom-
Callahan et al, 2010, Huang et al, 2014), have all previously been linked to IPF. Wnt signalling was also 
an enriched biological process identified in both IPF and SSc lung fibroblasts which has previously been 
associated with the pathogenesis of both IPF and SSc (Chilosi et al, 2003, Konigshoff et al, 2008, Vuga 
et al, 2009, Wei et al, 2012). In support of this finding, a recent study found two genes involved in Wnt 
signalling; DKK1 and SFRP1 have decreased expression as a direct result from promoter 
hypermethylation in SSc fibroblasts (Dees et al, 2013). Pathway analysis is discussed in detail in section 
7.6.  
 
7.4. Distribution of methylation in lung fibroblasts 
Methylation across the genome is typically regarded as bimodal with CpGs having low methylation in 
CpG islands close to gene promoters and high methylation in other genomic areas (Jones, 2012). CpG 
islands within promoter regions are classically reported as being unmethylated to allow transcription 
to occur, however few studies have been able to delineate methylation distribution patterns based 
on the location of CpGs (with respect to CpG islands) and within different genomic regions due to 
limited CpG coverage on previous array platform technology. This has important implications 
particularly when trying to determine relationships between methylation and gene transcription as 
methylation within different genomic regions can act in opposing ways (Wan et al, 2015). Although 
there are several studies looking at genome-wide methylation in a variety of tissues or in a disease 
context, to my knowledge there are no studies which have examined unbiased genome-wide 
distribution of methylation in primary human lung fibroblasts. 
Distribution of methylation in autosomes was bimodal in control, IPF and SSc lung fibroblasts with the 
highest frequency of CpGs having low methylation (0-15%) and high methylation (85-95%) (Section 
3.2, figure 3.2.1). A bimodal pattern of CpG methylation was also observed on the X-chromosome 
with the highest frequency of CpGs having 25-35% methylation. However genome-wide distribution 
of methylation on the X-chromosome in female, but not male lung fibroblasts, showed a partially 
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methylated pattern of methylation which was considered consistent with X-inactivation in females 
(Bell et al, 2011, Johansson et al, 2013, Joo et al, 2014).  
Distribution of CpG methylation in CGIs within 1.5kb of their corresponding gene’s TSS was unimodal 
with the majority of CpGs with low methylation (0-15%) consistent with the dogma that the majority 
of CGIs are unmethylated (Bird et al, 2012). However, CpGs located in CGIs further than 1.5kb from 
their corresponding gene’s TSS had a bimodal distribution of CpG methylation with the highest 
frequencies of CpGs having 10-15% and 85-90% methylation. These CGIs located distal to promoter 
regions, coined ‘orphans’ (Illingworth et al, 2010), have a different distribution pattern of methylation 
compared to CGIs within promoter region. Some studies have identified CpG methylation in gene 
bodies positively correlates with gene expression (Lister et al, 2009, Kulis et al, 2012, Banovich et al, 
2014), thus the dogma that methylation in CGIs inversely correlates to gene expression (Bird et al, 
2002) may not be true for CGIs located in different genomic areas. This also opens up the possibility 
that methylation could both positively and negatively correlate with gene expression based on the 
location of CpG methylation. Indeed, out of the 724 genes in lung fibroblasts which had correlation 
between methylation and expression, 96 had CpGs which both positively and negatively correlated 
with their respective genes expression. 
Distribution of CpG methylation in non-CGIs, which covers shore, shelf and open sea regions were 
analysed individually. North and south shore regions flank CGIs and are located up to 2kb away. Within 
1.5kb of their corresponding gene’s TSS, shore regions had a high frequency of CpGs with low 
methylation, whereas shore regions further than 1.5kb from their gene’s TSS had a higher frequency 
of CpGs with high methylation. North and south shelf regions are located 2-4kb away from CGIs. 
Within and further than 1.5kb of their gene’s corresponding TSS, shelf regions had a high frequency 
of CpGs with high methylation. Open sea regions which are denoted as being located beyond 4kb of a 
CGI had the highest frequency of CpGs with high methylation within and further than 1.5kb from their 
gene’s TSS. Open sea regions within 1.5kb from their genes TSS had a bimodal distribution of CpG 
methylation. The distribution of CpG methylation further than 1.5kb from their gene’s TSS was also 
bimodal but with a greater proportion of CpGs having high methylation compared to low methylation.  
In agreement with other studies examining genome-wide distribution of methylation patterns in other 
cell types, shore regions tended to have a similar methylation pattern to CGIs based on genomic 
regions, whereas the majority of shelf regions had high methylation (Lokk et al, 2014, Zhang et al, 
2015). Also in agreement with these studies, open sea regions had the highest number of CpGs with 
high methylation (Lokk et al, 2014, Zhang et al, 2015), however, a large number of CpGs (~2000) had 
low methylation in open sea regions within 1.5kb of their corresponding gene’s TSS which may play 
an important role in regulating gene expression but have been ignored by array platforms which only 
focus on CGIs.   
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7.4.1. Distribution of CpGs with altered methylation in IPF/SSc compared to control 
lung fibroblasts 
Of the 7153 CpGs with altered methylation in IPF compared to control lung fibroblasts, 985 (14%) 
were located in CGIs, whereas 6168 (86%) were located in non-CGIs. This is consistent with the study 
published in 2014 by Yang et al, which reported the majority of CpGs with altered methylation were 
located distal to CGIs. Interestingly Yang et al, show that the majority of CpGs with altered methylation 
in IPF compared to control lung tissue were located in shore regions, however, they defined shore 
regions as 0-3000bp away from a CGI as opposed to the standard definition of 0-2000bp away and 
thus incorporate CpGs normally defined as being in shelf regions (2000-4000bp away) into their 
analysis. They also identified a large number of differentially methylated regions which are >3000bp 
away from CGIs. This is consistent with our study, although the majority of CpGs with altered 
methylation in IPF occured in open sea regions (at least 4000bp away from a CGI). Barring the obvious 
fact that Yang et al, analysed lung tissue as opposed to lung fibroblasts, these differences may be due 
to the differences in CpG coverage of the arrays. The Illumina 450k is able to analyse ~482,000 CpGs 
(324,973 after applying filtering) whereas Yang et al, were able to analyse 4.6 million, and thus were 
potentially able to determine the distribution of CpG methylation more accurately, albeit in lung 
tissue. Furthermore, Yang et al, did not state what percentage of CpGs were analysed within each 
region, thus making it impossible to determine whether CpGs in different regions were actually over-
represented relative to the number of CpGs studied in each region. Therefore, shore and open sea 
regions may have been represented in a different ratio compared to our study, which could explain 
the discussed differences.  
To try to determine whether different regions were over-represented in CpG with altered 
methylation, the total number of CpGs in each location was divided by the total number of CpGs on 
the array to determine what percentage of CpGs were analysed in each area. In our study 34% of all 
CpGs analysed were in open sea regions compared to 24% in shore regions, 33% in CGIs and 9% in 
shelves. Open sea regions consistently had a higher O/E ratio of CpGs with altered methylation 
(≥13.6%) in IPF compared to control lung fibroblasts. Shore regions had a higher O/E ratio on CpGs 
with increased methylation, but no significant difference in O/E ratios with CpGs with decreased 
methylation. However, whilst this analysis confirmed that altered methylation occurred more 
frequently in open sea regions, it did not take into account that CpGs with low methylation could not 
go lower than 0% methylation, nor CpGs with high methylation, which could not go over 100%. Thus, 
a 13.6% difference was mathematically impossible which would bias results for CpGs within regions 
such as CGIs/shores as they have a high frequency of CpGs with low methylation.  
To draw more accurate comparisons, a greater number of CpGs in lung fibroblasts would need to be 
analysed to fully determine which locations have altered CpG methylation. Nonetheless, this study 
suggests the majority of CpGs with altered methylation in IPF are located in non-CGI areas. 
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Furthermore, even though the Illumina 27k array is heavily biased towards CGIs in promoter regions, 
the majority of CpGs identified by Huang et al, which had altered methylation in IPF compared to 
control lung fibroblasts, were located outside of CGIs (Huang et al, 2014).  
 
7.5. Validation of Illumina microarrays  
TNXB was bisulfite sequenced to validate the methylation microarrays, based on a large number of 
CpGs on the array with significantly altered methylation (Δβ ≥ 0.136; P<0.05) in IPF compared to SSc 
and control lung fibroblasts and a thorough literature search suggesting its potential role in collagen 
deposition, fibril organisation (Elefteriou et al, 2001) and fibrosis (Jing et al, 2011). Bisulfite sequencing 
confirmed similar changes in methylation at multiple CpGs in two different CGIs (1 located in exon 3 
and one located in exon 10), with all having decreased methylation in IPF compared to SSc and control 
lung fibroblasts and showed strong correlation with microarray data (Pearsons r=0.77). Furthermore, 
7 CpGs not on the array also had significantly decreased methylation in IPF compared to control lung 
fibroblasts. The total methylation observed was different between bisulfite and microarray data, 
however, this could potentially be explained by different normalisation methods. One unexpected 
challenge during bisulfite sequencing was designing primers which didn’t overlap CpGs in the dense 
CGI located in exon 3. CpGs should not be included in bisulfite primers to avoid discrimination against 
methylated or unmethylated DNA (Li and Dahiya, 2002). Bisulfite primers should also be longer than 
primers used in regular PCR to ensure specificity and the length of the PCR product should ideally be 
less than 400bp to avoid potential DNA degradation during bisulfite modification (Li and Tollefsbo, 
2011). In this region there were few primer choices which fit all the criteria other than the primers I 
designed (see Chapter 2: section 2.11.1). In future studies, to overcome this problem for other dense 
areas of CpG methylation for which no suitable primers can be made, different techniques such as 
pyrosequencing could be used. 
Gene expression arrays (basal and 5-Aza) were validated using qRT-PCR on multiple genes including, 
IL8, CADM1, EIF1AY, MMP10 and MMP12. These genes were chosen based on previously being 
associated with fibrosis and/or had large changes in expression in IPF and/or SSc compared to control 
lung fibroblasts. qRT-PCR and microarray data showed strong correlation for each gene analysed (IL8: 
r=0.91, CADM1: r=0.74, EIF1AY: r=0.85), validating the microarray’s ability to detect significant 
differences in gene expression. MMP10 and MMP12 were used to validate the 5-Aza expression arrays 
with both showing a strong correlation between qRT-PCR and microarray data, however, the fold-
changes observed by qRT-PCR were far greater than on the microarray. This is most likely due to the 
increased sensitivity of qRT-PCR compared to microarray techniques and is a common observation 
(Chen et al, 2009). TNXB mRNA expression was examined using qRT-PCR as the probe on the array 
was not detected. This may have been due to a faulty probe or a probe which did not have a low 
enough P value for detection during quality control. qRT-PCR showed TNXB was expressed in lung 
fibroblasts and it’s expression was significantly increased in IPF compared to SSc and control lung 
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fibroblasts. IHC in lung tissue samples derived from control, IPF and SSc lungs confirmed increased 
TNX expression in IPF. Furthermore, other members within our group were examining other genes of 
interest and showed similar results, which further validated the methylation and expression arrays.  
 
7.6. Biological interpretation and pathway analysis 
As previously described (see Chapter 4: section 4.1), two different types of enrichment analyses were 
performed; GO-term and PFAM. GO-term analysis is commonly used to identify enriched functional 
groups for a given list of genes and can be performed using a variety of online platforms such as DAVID 
analysis (Huang et al, 2008, Fang and Gough, 2013) or Genecodis (Carmona-Saez et al, 2007, Nogales-
Cadenas et al, 2009, Tabas-Madrid et al, 2012). PFAM domain enrichment analysis uses pre-defined 
protein-level GO annotations to determine if a specific biological process is enriched in given list of 
PFAMs. Furthermore, each biological process is given a level of specificity ranging from highly general 
to highly specific (1=highly general, 2; general, 3; specific, 4; highly specific). For example, the general 
term ‘ECM organisation’ includes PFAMs associated broadly with this ontology, whereas the specific 
term ‘collagen fibril organisation’ only contains PFAM associated with this process.  The main 
difference between GO-term and PFAM enrichment analysis is that GO-term enrichment analysis uses 
ontology annotations relating to genes associated with a specific biological process, whereas PFAM-
domain centric analysis uses ontology annotations relating to the functional units of proteins 
associated with a specific biological process. PFAM enrichment analysis therefore identifies PFAMs 
containing genes associated with a specific biological process. This allows the potential to identify 
genes which share domains which are associated with a specific biological process but have not yet 
themselves been associated with the specific biological process. Thus, PFAM analysis can potentially 
aid in the identification of novel genes involved in biological processes associated with fibrosis. 
Multiple biological processes enriched in genes with significantly altered methylation and/or 
expression were consistent with previous literature and with diseases characterised by fibrosis (Yang 
et al, 2014, Huang et al, 2014). These biological processes included Wnt signalling, ECM organisation, 
apoptosis, gene expression, integrin signalling and EMT. Of the biological processes enriched in PFAMs 
containing genes with significantly altered methylation, 86% were the same in both IPF and SSc. 79% 
of biological processes enriched in PFAMs containing genes with significantly altered expression were 
the same in both IPF and SSc. Furthermore, 66% of biological processes enriched in PFAMs containing 
genes with altered methylation in IPF compared to control lung fibroblasts were the same biological 
processes enriched in PFAMs containing genes with altered expression. Similarly, 63% of biological 
processes enriched in PFAM containing genes with altered methylation in SSc compared to control 
lung fibroblasts were the same biological processes enriched in PFAMs containing genes with altered 
expression. This demonstrates a potential link between methylation and expression and suggests that 
multiple biological processes overlap between IPF and SSc. GO-term enrichment showed similar 
biological processes contain genes with altered methylation in IPF and SSc compared to control lung 
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fibroblasts, but far fewer biological processes were identified containing genes with significantly 
altered expression in IPF and SSc compared to control lung fibroblasts. This is likely due to the fact 
that in PFAM enrichment, the number of PFAMs associated with specific biological process are far less 
than the number of genes and only one gene needs to be associated with a PFAM for it to be linked 
to a biological process. GO-term enrichment requires the number of genes observed in a given list to 
exceed the number of genes expected for a given biological process. For example 38 PFAMs are 
associated with WNT signalling. 14 in IPF and 16 in SSc contained genes with altered expression 
compared to control fibroblasts. In GO-term enrichment, there are 110 genes associated with Wnt 
signalling, however, only 2 in IPF and 3 in SSc had significantly altered expression. Combining these 
two types of enrichment analysis therefore allows one to identify genes which may or may not be 
involved but share similar domains associated with a specific biological process, such as Wnt signalling, 
whilst also allowing one to identify genes which have already been associated with Wnt signalling. 
Although multiple biological processes overlapped between IPF and SSc, 81% of these processes were 
enriched in PFAMs containing genes with altered methylation in IPF compared to SSc lung fibroblasts. 
This data further suggests that multiple biological processes overlap between IPF and SSc but contain 
different genes which have altered methylation in each disease. This may underlie the different 
phenotypes of each disease and could potentially provide insights as to why IPF has a much poorer 
prognosis than SSc. For example, Wnt signalling which has been implicated in both IPF (Königshoff et 
al, 2008) and SSc (Wei et al, 2012) was enriched in genes with altered methylation in both IPF and SSc 
compared to control and in IPF compared to SSc. In IPF, the majority of genes within the WNT pathway 
had decreased methylation compared to control lung fibroblasts, whereas the majority of genes had 
increased methylation in SSc. Furthermore, multiple genes had significantly altered methylation 
between IPF and SSc, the majority of which had decreased methylation in IPF. These data suggest 
genes associated with Wnt signalling have aberrant methylation in both IPF and SSc but multiple 
different genes are affected. Genecodis was used for GO-term enrichment instead of DAVID analysis, 
as the DAVID tool has not been updated since early 2010, however, a major limitation of using GO-
terms is that many do not overlap with well-defined pathway databases such as KEGG (Mao et al, 
2005). Thus, when examining how genes within the Wnt pathway, which had altered 
methylation/expression could potentially interact with each other, both KEGG and GO-term 
enrichment was used. This kind of data analysis could potentially be used in the future to identify 
biomarkers and facilitate drug production targeting specific pathways associated with pulmonary 
fibrotic diseases. Furthermore, pathway analysis could be used to identify transcipriton factors or 
other ‘master’ regulators of gene expression and to identify targets that would benefit groups of 
patients or specific individuals. 
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7.7. Male compared to female methylation 
Despite fundamental differences in male and female biology and with respect to gender-specific 
susceptibility to disease and responses to drugs, it is surprising in this era that many studies do not 
adequately, if at all, analyse data based on gender (Flanagan, 2014). Prior to 2014, there were very 
few studies which had compared methylation patterns between males and females (Sarter et al, 
2005). Since 2014, although there are still very few studies which have compared male and female 
methylation patterns in a tissue-specific or disease context, there is emerging evidence that gender-
specific methylation differences do exist which may play important roles in sex-biased diseases. For 
example, Spiers et al, recently identified gender-specific differences in methylation on multiple 
autosomes during fetal brain development (Spiers et al, 2015). Hall et al, identified chromosome-wide 
and gene-specific differences in methylation in human islets contributed to sex-specific metabolic 
phenotypes (Hall et al, 2014) and Pinto et al, identified gender differences in methylation in familial 
breast cancer (Pinto et al, 2013). Furthermore, it has recently been identified that leukocytes have an 
altered methylation profile in males compared to females (Inoshita et al, 2015) and gender can 
influence saliva methylation on the X chromosome and autosomes, with many sites of methylation 
also associated with diseases such as cancer (Liu et al, 2010). Furthermore, a sex-biased pattern of 
methylation in the human pre-frontal cortex has also recently been shown (Xu et al, 2014).  
These studies all suggest that gender differences in methylation exist in a variety of tissues and could 
potentially be important in disease, particular in those which have a sex-bias such as IPF and SSc. The 
study by Spiers et al, is of particular interest as multiple neurological diseases such as Autism affect 
males more than females (Croen et al, 2002) which could potentially be in part explained by gender 
differences in brain methylation as identified in their study. It is therefore logical and important to 
examine gender differences in methylation for all cell types and tissues and in all sex-bias diseases 
such as IPF and SSc. To my knowledge, there have been no studies which have examined gender 
differences in primary human lung fibroblasts or methylation differences between male and female 
IPF lung fibroblasts.  
One of the main limitations of the only previous study examining methylation in IPF lung fibroblasts 
was that they used mainly male control and female IPF lung fibroblasts (Huang et al, 2014). Thus it is 
hard to delineate whether CpGs had significantly altered methylation in IPF compared to controls or 
whether these CpGs had significantly altered methylation between male and females. For the same 
reason in my studies, it was not possible to analyse male and female differences in SSc lung fibroblasts 
as 6/7 cell lines were female. However, this work represents the first study to examine methylation 
differences between male and female human lung fibroblasts (using IPF and control lung fibroblasts) 
and the first study to compare methylation differences in male controls with male IPF and female 
controls with female IPF lung fibroblasts separately. 
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DNA methylation is known to play an important role in X-inactivation, which occurs to silence genes 
on one of the X-chromosomes in each female cell (Carrel and Willard, 2005). Thus, one would expect 
differences in methylation between male and females on X-linked genes. Indeed, 50% of genes with 
significantly altered methylation between male and female lung fibroblasts were located on the X-
chromosome. The distribution of methylation was bimodal in male lung fibroblasts, whereas female 
lung fibroblasts displayed a partially methylated pattern on the X-chromosome which is consistent 
with X-chromosome inactivation. However, 49% of all genes with significantly altered methylation 
between males and female lung fibroblasts were located on autosomes. Interestingly, the distribution 
of CpGs with significantly altered methylation in male compared to female lung fibroblasts was either 
unimodal or bimodal in male lung fibroblasts (depending of genomic location), whereas in female lung 
fibroblasts the distribution of CpG methylation was always that of a partially methylated pattern. CGIs 
had a higher frequency of CpGs with decreased methylation in male compared to female lung 
fibroblasts, whereas open sea regions had a higher frequency of CpGs with increased methylation in 
male compared to female lung fibroblasts. Shore regions within 1.5kb of their corresponding genes 
TSS had a higher frequency of CpGs with low methylation in male compared to female lung fibroblasts 
whereas CpGs in shelf regions had a higher frequency of CpGs with increased methylation in male 
compared to female lung fibroblasts. This was consistent with the locations of male/female 
differences in methylation in the study by Hall et al, who showed CGIs and shore regions had 
decreased methylation in male compared to female islets, whereas shelf and open had increased 
methylation. This suggests multiple genes in male lung fibroblasts have a distinct methylation pattern 
compared to female lung fibroblasts.  
Functional analyses identified multiple biological processes with relevance to fibrosis, including, Wnt 
signalling, EMT, ECM organisation and response to viruses, which were enriched in genes with 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) in male compared to female lung fibroblasts. 
Many of these biological processes were also enriched in genes with altered methylation in IPF and/or 
SSc compared to control lung fibroblasts, suggesting that genes belonging to these processes have 
disease-specific and gender-specific differences in methylation. This could provide a novel insight as 
to why IPF predominates in males and potentially be used to target drugs specifically designed for use 
in male or female patients, based on their respective gene methylation/expression profiles and 
pathways. 
On the discovery that multiple genes had significantly altered methylation (Δβ ≥ 0.136; P<0.05) in male 
compared to female lung fibroblasts, IPF males were compared to control male lung fibroblasts and 
IPF females were compared to control female lung fibroblasts separately. Although the number of cell 
lines used were small, the analysis did reveal a number of interesting findings. Firstly, the distribution 
of methylation on the Y-chromosome was different in male IPF compared to male control lung 
fibroblasts. Furthermore, multiple Y-linked genes had large fold-changes in expression in male IPF 
compared to male control lung fibroblasts. Although IPF occurs in females and is increasing, aberrant 
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methylation and/or expression of Y-linked genes could play a role in why IPF predominates in males 
as female do not possess the Y-chromosome. Multiple CpGs/genes had significantly altered 
methylation (Δβ ≥ 0.136; P<0.05) in male IPF compared to male control and female IPF compared to 
female control lung fibroblasts, but very few CpGs/genes overlapped. Whilst this is preliminary data, 
it suggests that multiple CpGs/genes have altered methylation in male IPF lung fibroblasts compared 
to male control lung fibroblasts which are distinct from those which have altered methylation in IPF 
female lung fibroblasts compared to female control lung fibroblasts. However, multiple biological 
processes enriched in PFAMs containing genes with significantly altered methylation (Δβ ≥ 0.136; 
P<0.05) in male IPF compared to male control overlapped with enriched biological processes in female 
IPF compared to female control lung fibroblasts. This may explain why there is a sex-bias but similar 
outcomes in IPF. For example methylation and/or expression of specific genes may induce IPF more 
rapidly and increase the risk of developing IPF. Further studies into gender-specific differences in 
methylation in IPF are clearly needed to validate this data.  
Analysing methylation patterns in IPF compared to control lung fibroblasts based on gender could 
provide further insight into the role of methylation in PF and may lead to a more personalised 
medicine approach in the treatment of IPF (and other sex-bias diseases), such as a gender-based drug 
program as opposed to a ‘one drug for all’. Interestingly, several biological processes enriched in 
PFAMs containing genes with significantly altered methylation in male IPF compared to male control 
included those relating to viruses and Actinobacteria. The lung microbiome is an increasingly active 
area of research in IPF (Han et al, 2014) and recently Actinobacteria levels have been shown to be 
decreased in IPF (Molyneaux et al, 2013). Viruses have previously been linked with IPF (Egan et al, 
1997) and it is well known that males and females differ in response to being infected by certain 
viruses (Klein, 2012). Viruses have also been shown to play a role in acute exacerbations in many lung 
diseases including asthma (Busse et al, 2010) and chronic obstructive pulmonary disease (Wedzicha, 
2004). Furthermore, in liver fibrosis, men have a worse virological profile than women and significantly 
more advanced fibrosis (Collazos et al, 2011). Thus, treatment of IPF and/or SSc-PF with vaccines could 
be designed with male/female differences in mind. Circadian rhythm was also enriched in PFAMs 
containing genes with altered methylation in male IPF compared to male control lung fibroblasts but 
not female IPF compared to female control lung fibroblasts. Increasing evidence suggests circadian 
rhythms are important in disease (Maury et al, 2010, Takeda and Maemura, 2011) and gender-
differences have been reported (Wever et al, 1984, Bertossa et al, 2013, Krizo et al, 2014). 
Furthermore, recent evidence suggests they can regulate anti-oxidant pathways to modulate 
pulmonary fibrosis (Pekovic-Vaughan et al, 2014).  
Biological processes enriched in PFAMs containing genes with significantly altered methylation (Δβ ≥ 
0.136; P<0.05) in female IPF compared to female control but not in male IPF compared to male control 
lung fibroblasts included response to hexose, response to corticosteroids and ER stress. 
Corticosteroids have been trialled in IPF studies, however, there is no evidence showing they have a 
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beneficial effect (Richeldi et al, 2003, Atkins et al, 2014). Nonetheless, corticosteroids are currently 
used in the treatment of some IPF patients with acute exacerbations (Atkins et al, 2014). The finding 
that the biological process ‘response to corticosteroids’ is enriched in females but not males could 
potentially explain why corticosteroids have so far failed to treat IPF but may work for a specific 
minority. Response to hexose was also identified as being enriched in female IPF compared to female 
control but not male IPF compared to male controls. Hexose is a monosaccharide and increased levels 
correlate with disease severity in cystic fibrosis (Chace et al, 1983). Cyclophosphamide-induced lung 
fibrosis also causes hexose levels to increase (Vemkatesan et al, 1998), however, there are no studies 
examining the role of hexose in IPF. ER stress has previously been linked to IPF (Tanjore et al, 2012) 
and ER stress can modulate gene expression (Baumeister et al, 2005, Chen et al, 2014). Furthermore, 
methylation of ER-associated genes can regulate their expression (Han et al, 2013) therefore, genes 
with altered methylation could potentially explain how ER stress is initiated or how ER stress activates 
certain genes and contributes to PF potentially specifically in females.  
 
7.8. Moduation of DNA methylation using 5-Aza 
5-Aza is a chemical analogue of cytosine which can be incorporated into DNA, bind to DNMTs 
(inhibiting their activity) and subsequently results in genome-wide demethylation. 5-Aza is already 
used to treat myelodysplastic syndromes (Saunthararajah, 2013) and previous studies have shown 
benefits of 5-Aza treatment in murine models of fibrosis in both IPF (Dakhlallah et al, 2013) and SSc 
(Dees et al, 2009). Furthermore, treatment with 5-Aza can activate the expression of specific genes 
which are hypermethylated in either IPF (Cisneros et al, 2010, Huang et al, 2014)  or SSc (Wang et al, 
2006) suggesting it may be useful in the treatment of PF. 
5-Aza was used in this study to inhibit methylation and subsequently the effects on gene expression 
were measured. Originally, analysis using the average change in methylation and expression after 5-
Aza treatment compared with basal levels in control, IPF and SSc lung fibroblasts identified multiple 
changes in CpG methylation but few were ≥13.6%. Furthermore, very few genes had large changes 
(≥2FC) in expression after treatment with 5-Aza, suggesting that alterations to DNA methylation had 
limited consequences on transcription. Interestingly the loss of methylation in promoter regions, 
islands and shores in other diseases which use 5-Aza as a treatment solution, such as acute myeloid 
leukaemia, show no correlation with changes to gene expression (Lund et al, 2014). However, cluster 
analysis revealed the effects of 5-Aza treatment were different in each cell line (see Chapter 6: section 
6.2, figure 6.2.2). Subsequent analyses showed some cell lines had a large response to 5-Aza, where 
large changes across genome-wide methylation were observed. Other cell lines including all of the SSc 
cell lines had a much weaker response. Reasons behind this observation are unclear, however it has 
been shown that some cell lines are resistant to 5-Aza treatment (Flatau et al, 1984, Qin et al, 2009). 
This might be caused by insufficient incorporation into the DNA (Qin et al, 2009) or through an altered 
DNA damage response pathway (Palli et al, 2008), although the different population doublings 
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between control, IPF and SSc cell lines after treatment with 5-Aza did not correlate with the number 
of CpGs/genes with altered methylation/expression. Deficiency and mutations in deoxycytidine kinase 
(DCK), a gene responsible for converting 5-Aza into its activate form by phosphorylation, have also 
been associated with increased resistance to the effects of 5-Aza (Stegmann et al, 1995) although no 
study has reported mutations or deficiency of this gene in SSc patients.  
The number of CpGs/genes with large changes (≥13.6%) in methylation after 5-Aza treatment 
correlated with an increased number of genes with large changes in expression (≥2FC). However, in 
SSc lung fibroblast cell lines, many genes had large changes in expression without having large changes 
in methylation. This suggested that smaller changes in methylation may potentially have a large effect 
on gene expression. Indeed, when analysing changes to methylation with respect to gene expression 
across all 18 cell lines, small changes in methylation appeared to correlate with large changes in 
expression in multiple genes. However, the Illumina 450K array is unable to accurately measure small 
changes in methylation (Dedeurwaerder et al, 2011), therefore more accurate methods of detecting 
methylation, such as bisulfite sequencing would be required to confirm these results.  
Multiple genes had correlation between methylation and their expression before and after treatment 
with 5-Aza. This suggests many genes are potentially directly regulated by DNA methylation in lung 
fibroblasts. This is consistent with a recent study in IPF lung tissue showing multiple differentially 
methylated regions correlate with changes in gene expression although changes in methylation 
correlated with expression in an inverse manner (Yang et al, 2014). Furthermore, the Illumina 450k 
array only covers 99% of all genes, representing ~2% of the entire human methylome. Thus, one can 
assume that multiple CpGs not covered by the array will have also had changes in methylation after 
5-Aza treatment and may be specifically important in regulating their corresponding gene’s 
expression. To fully understand and elucidate the role methylation has in regulating gene expression 
in lung fibroblasts, the entire methylome would need to be analysed and integrated with other 
epigenetic mechanisms including miRs and histone modifications.  
Whilst multiple genes with altered methylation after 5-Aza treatment correlated with changes to their 
expression, multiple genes had increased or decreased expression after 5-Aza-2'-deoxycytidine 
treatment without having alterations to their methylation. This could be explained also by CpGs not 
covered on the array having an effect on gene expression.  Another plausible explanation for this 
observation is that genes activated or inhibited by 5-Aza treatment could potentially regulate the 
expression of other genes. Recently published data supports this hypothesis in IPF.  Methylation of 
miR-17-92 silences its expression which leads to a number of genes that are associated with 
fibroproliferative responses being upregulated (Dakhlallah et al, 2013). This suggests that other genes 
in IPF lung fibroblasts that are activated or inhibited by demethylation could increase or decrease the 
expression of multiple other genes. Genes may also be activated in response to the damage 5-Aza can 
cause to DNA. It has previously been shown that ataxia telangiectasia pathways (ATM and ATR) are 
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activated upon DNA damage via 5-Aza (Palii et al, 2008) and thus could be responsible for the 
increased expression of genes related to DNA repair, adding further complexity in finding genes whose 
expression levels are directly or indirectly regulated by methylation. 
Although 5-Aza is a demethylation agent, surprisingly, multiple CpGs had increased methylation after 
treatment with 5-Aza, a finding which is rarely, if at all described in any literature on 5-Aza studies. 
The increase in methylation after 5-Aza could potentially be explained by 5-Aza directly or indirectly 
affecting the expression of other genes or signalling pathway which may be able to specifically 
remethylate DNA. However, no obvious genes associated with remethylation (such as DNMTs) were 
identified as having significantly altered mRNA expression after 5-Aza treatment. This is consistent 
with some previous reports showing 5-Aza does not affect the mRNA expression level of some DNMTs 
(Ghoshal et al, 2005, Scheider-Stock et al, 2005). It has been shown that DNMT1 (Ghoshal et al, 2005) 
and DNMT3b (Scheider-Stock et al, 2005) mRNA expression is not affected by 5-Aza and only DNMT1 
is rapidly degraded in mammalian cells by 5-Aza, thus other DNMTs may still be able to function 
(Ghoshal et al, 2005). Furthermore, 5-Aza can induce histone acetylation (Takebayashi et al, 2001, 
Yang et al, 2010) and modify histone methylation by increasing lys-4 and increasing or decreasing lys-
9 depending on the concentration of 5-Aza used (Kondo et al, 2003, Coombes et al, 2003). Increasing 
evidence shows DNA methylation and histone lysine methylation are highly inter-related (Rose and 
Klose, 2014) and can influence each other’s state (Cedar and Bergman, 2009, Rose and Klose, 2014). 
Genes marked with specific histone modifications on histone H3 dimethylation on lysine 4 (H3K4me2) 
and histone H3 trimethylated on lysine 27 (H3K27me3) can gain histone marks which target CGIs for 
DNA methylation (Ohm et al, 2007). This could potentially explain why multiple genes had increased 
methylation after 5-Aza or again, why multiple genes had altered expression without any observations 
in changes to their DNA methylation after 5-Aza treatment. 
Another potentially interesting explanation as to why 5-Aza increased CpG methylation in lung 
fibroblasts at multiple CpGs, relates to the effects of 5-Aza on the activation of EBV. 5-Aza can activate 
the EBV genome (Ben-Sasson and Klein, 1981, Masucci et al, 1989), a virus which has previously been 
associated with IPF (Lok et al, 2001, Kelly et al, 2002). Recently in immortalised oral keratinocytes, EBV 
infection resulted in increased DNA methylation at 10676 CpGs (Birdwell et al, 2014). The patient data 
for the control IPF and SSc lung fibroblasts did not include EBV status, however, EBV can infect lung 
fibroblasts (Adachi et al, 2001) and is one of the most common human viruses in the world. Thus it is 
likely these cells line were infected with EBV and could explain why multiple CpGs had increased 
methylation after 5-Aza treatment. These observations regarding EBV activation by 5-Aza and its 
ability to increase methylation could have important clinical implications in IPF and SSc, such as 5-Aza 
treatment having a different effect on methylation in a non-EBV infected patient compared to an EBV 
infected patient. Future studies could examine methylation in EBV infected compared to non-EBV 
infected IPF or SSc individuals, which may provide a link between epigenetic and environmental 
factors associated with these diseases. Furthermore, this could be extremely interesting as males and 
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females have an altered response and predisposition to viruses and bacteria (Klein, 2012, Giefing-Kröll 
et al, 2015). The mechanisms of how 5-Aza works are also not fully understood, therefore future 
studies may shed more information on how and to what extent methylation changes with 5-Aza 
treatment.  
 
7.8.1. Limitations of 5-Aza 
The exact in vivo mechanisms of 5-Aza drugs remain poorly understood, although 5-Aza-2'-
deoxycytidine is known to inhibit cell proliferation (Karpf et al, 2001). Enzymatic de-amination of 5-
Azacytidine and 5-Aza-2'-deoxycytidine causes increased cytotoxicity (Vesely et al, 1969) although 5-
Aza-2'-deoxycytidine is 10 times more cytotoxic to cultured cells than 5-Azacytidine (Flatau et al, 
1984). The cytotoxicity of 5-Aza-2'-deoxycytidine and its unknown in vivo mechanisms represent a 
major concern when trying to analyse the effects of reducing methylation on gene expression. Low 
concentrations of 5-Aza (1µm) were used to limit toxicity. Other less toxic DNMT inhibitors could be 
used in future studies such as 1-(β-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one (Zebularine) which 
has been shown to be able to reactivate epigenetically silenced genes (Cheng et al, 2003). Zebularine 
inhibits DNMTs and cytidine deaminase which is essential for deamination of cytidine nucleosides 
(Marquez et al, 1980). Another de-methylating drug called Hydralazine, which is a non-nucleoside 
analogue, can inhibit DNMTs and subsequently reduce methylation without altering DNMT expression 
(Cruz-Hernandez et al, 2011). It has been shown that hydralazine can reduce kidney fibrosis by 
reducing methylation of the RAS protein activator like 1 (RASL1) gene via activation of Tet 
methylcytosine dioxygenase 3 (TET3) (Tampe et al, 2015). Hydralazine has also been shown to reduce 
cardiac fibrosis (Qi et al, 2011) and fibrosis in stable ILD patients (Lupi-Herrera et al, 1985). However, 
it remains unknown whether hydralazine could be beneficial in IPF/SSc-PF, and there are reports of 
hydralazine causing autoimmunity and frequently causing deleterious effects in patients with 
pulmonary hypertension (Packer et al, 1982).  
As previously discussed, multiple genes had increased expression after 5-Aza treatment. This makes 
5-Aza's application in in vivo models somewhat limited as 5-Aza could inadvertently activate multiple 
genes which could then activate other genes and cause disease. Nonetheless, the use of 5-Aza does 
provide an insight into which genes can be activated by reducing methylation, which could play a role 
in the pathogenesis or IPF and other fibrotic diseases. 
 
7.9. The role of TNXB in pulmonary fibrosis 
Previous studies have identified deficiency of TNXB as a pathological cause of EDS which is 
characterised by hyper-mobility and hyper-extensible joints (Zweers et al, 2003). TNXB knockout mice 
also show reduced collagen density resulting in a 30% reduction in collagen content in skin (Mao et al, 
2002). Tenascin-X has also been shown to increase collagen fibril formation in vitro (Egging et al, 2007) 
and bind to fibril-associated type XII and XIV collagens (Lethias et al, 2006), both of which have been 
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shown to be upregulated after bleomycin-induced pulmonary fibrosis (Tzortzaki et al, 2003). 
Furthermore, increased TNXB is associated with fibrous tumours including mesothelioma (Yuan et al, 
2009) whereas TNXB knockout rats are protected from cardiac fibrosis, mediated by an increase in 
PPARγ and a decrease in TGFß (Jing et al, 2011). Whilst tenascin C has been studied in IPF (Estany et 
al, 2014) and SSc (Brissett et al, 2012, Inoue et al, 2013), no studies prior to this thesis, have examined 
the role of TNX In pulmonary fibrosis. Furthermore, how TNXB expression is regulated is poorly 
understood, although, hypomethylation of a CpG island located in exon 3 in muscle corresponds with 
increased TNXB expression (Rakyan et al, 2004), suggesting a potential regulatory role of methylation 
on TNXB expression.  
The Illumina 450k array identified multiple CpGs with significantly altered methylation in IPF and SSc 
compared to control and IPF compared to SSc lung fibroblasts. Therefore, based on the array data 
combined with the previous TNXB literature, the role of TNXB in pulmonary fibrosis was examined. 
The microarray identified 27 CpG sites in IPF (10 increased and 17 decreased) and 41 CpG sites in SSc 
(38 increased and 3 decreased) as having a significant change in methylation compared to control 
fibroblasts. The majority of CpGs with increased methylation in IPF lung fibroblasts were located in 
north shelf and open sea regions, whereas the majority of CpGs with increased methylation in SSc 
lung fibroblasts were located in island and open sea regions. The majority of CpGs with decreased 
methylation in IPF lung fibroblasts were located in open sea and south shelf regions, whereas in SSc 
lung fibroblasts only 3 CpGs had decreased methylation (1 in the north shore, 1 in the south shelf and 
1 in open sea). As previously mentioned, CGIs with increased methylation have been strongly linked 
with decreased gene expression in many diseases including IPF (Sanders et al, 2008, Sanders et al, 
2012, Rabinovich et al, 2012, Cisneros et al, 2010) and SSc (Wang et al, 2006), however, the role of 
shore/shelf and open sea CpG methylation remains poorly understood in disease (Irizzary et al, 2008).  
The microarray covered 3 CpG islands in the TNXB gene (one in exon 3, one in intron 6 and one in exon 
10). Although data from the microarray in this study suggested the majority of CpGs in IPF lung 
fibroblasts had reduced methylation in open sea regions, previously published data has shown 
hypomethylation of a CGI in exon 3 correlated with high TNXB expression in muscle tissue compared 
to other tissues (Rakyan et al, 2004). Our microarray data also identified 1 CpG with significantly 
decreased methylation (13.6%) and multiple other CpG sites in IPF lung fibroblasts, with a small but 
significant decrease in methylation (P<0.05 <0.136) in this CpG island. Furthmore, open sea regions 
are sparsely populated with CpGs, whereas CGIs have a high frequency of CpGs close together. 
Therefore, in order to maximise the number of CpGs sequenced to validate the microarray data, a 
349bp region located in the exon 3 CGI was bisulfite sequenced. This region covered 7 of the CpGs 
identified on the microarray, 6 of which had significantly decreased methylation in IPF compared to 
control lung fibroblasts. 
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Changes in methylation between control, IPF and SSc lung fibroblasts for all 7 CpGs using bisulfite 
sequencing were comparable with the microarray data (Pearson r=0.77). The total percentage of 
methylation however did vary between microarray and bisulfite sequencing. This is most likely to be 
due to differences in normalising data to different background controls, although the efficiency of the 
bisulfite conversion could also have an impact on results. Poor bisulfite conversion could reduce the 
accuracy of the results by underestimating total methylation. However, both methods showed 
consistent differences in methylation of 7 CpGs between control, IPF and SSc lung fibroblasts. 
Furthermore, bisulfite sequencing of a 440bp region in the CpG island located in exon 10 of the TNXB 
gene identified 7 CpGs with significantly decreased methylation in IPF compared to control, 5 of which 
were also significantly decreased in IPF compared with SSc lung fibroblasts.  
For unknown reasons there was no data regarding TNXB expression on the expression microarray, 
perhaps explained by the probe not working or not being detected. Therefore, the expression of TNXB 
in lung fibroblasts was examined by qRT-PCR and the expression of TNX, in lung tissue, by IHC to 
determine whether altered TNXB methylation correlated with expression in control, IPF and SSc lung 
fibroblasts. qRT-PCR analysis demonstrated TNXB was increased in IPF compared to control and SSc 
lung fibroblasts, whereas there was no significant difference in TNXB expression between SSc and 
control lung fibroblasts. The increase in TNX expression in IPF, but not SSc, was confirmed by IHC 
staining of lung tissue sections.  
These data support a role for methylation in regulating TNXB expression. The observation that the 
majority of CpGs had decreased methylation in IPF and increased methylation in SSc compared to 
control lung fibroblasts, suggests the location of the methylated CpG sites may be of fundamental 
importance. However, whether small changes in methylation at one or multiple CpG sites within 
specific regions or just one CpG site with a change in methylation can have an effect on gene 
expression is currently unknown. In order to elucidate what change in methylation could have an 
effect on TNXB expression, TNXB methylation and expression were analysed in control, IPF and SSc 
lung fibroblasts after treatment with 5-Aza.  
 
7.9.1. 5-Aza treatment and its effects on TNXB expression in control, IPF and SSc 
lung fibroblasts 
Microarray analysis identified 68, 34 and 36 CpG sites in control, IPF and SSc lung fibroblasts, 
respectively, which had significantly decreased (P<0.05) methylation after 5-Aza treatment (see 
section 6.6). qRT-PCR analysis of TNXB expression identified control lung fibroblast cell lines had 
significantly increased gene expression after 5-Aza treatment in contrast to IPF and SSc lung fibroblasts 
which had no change in expression. Three out of six control lung fibroblast cell lines had large increases 
in expression (>5FC) which correlated with large changes in TNXB methylation (≥13.6) after 5-Aza 
treatment. These control cell lines were the 3 cell lines identified as ‘strong responders’ which had a 
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greater number of CpGs with altered methylation after 5-Aza treatment compared to the other cell 
lines. Furthermore, treatment with 5-Aza brought the average methylation of TNXB in control lung 
fibroblasts down to similar levels of basal TNXB methylation in IPF lung fibroblasts. Interestingly, three 
IPF cell lines had large changes (≥13.6%) in TNXB methylation after 5-Aza treatment but did not have 
any change in TNXB expression, whereas no SSc lung fibroblast cell line had large changes (≥13.6%) in 
TNXB methylation or changes in TNXB expression after 5-Aza treatment. These data potentially 
suggests that large changes (≥13.6) in TNXB methylation are required to have an effect on TNXB 
expression and that once the threshold has been met, further demethylation has little or no effect on 
TNXB expression. However, as previously discussed, multiple genes had large changes (≥2FC) in 
expression in cell lines which had relatively few CpGs with large changes (≥13.6) in methylation. 
Therefore, activation of any negative regulators or other regulatory mechanisms of TNXB could mask 
the effects of small changes in TNXB methylation on TNXB expression. Thus, whilst data in this study 
suggests large changes in methylation are required to have an effect on TNXB expression, one cannot 
rule out entirely that small changes in TNXB methylation may also have an effect on TNXB expression.  
 
7.9.2. siRNA knockdown of TNXB in IPF lung fibroblasts and its effects on collagen 
gel contration 
The mechano-properties of the ECM and its ability to modulate cell responses has previously been 
implicated in the pathogenesis of IPF and other fibrotic diseases (Liu et al, 2010, Marinkovic et al, 
2013, Zhou et al, 2013). Fibroblasts in contact with stiff matrices can respond differently to fibroblasts 
in contact with softer matrices in a number of ways, including proliferation rate, survival rate, collagen 
synthesis and gene expression (Marinkovic et al, 2013, Zhou et al, 2013). Expression of TGFß, a 
profibrotic cytokine which has strongly been associated with IPF (Johnston et al, 1990, Khalil et al, 
1991, Laurent et al, 2008) can be modulated by matrix stiffness (Wipff et al, 2007, Tatler and Gisli, 
2012). Subsequently, TGFß can regulate the expression of other genes such as PPARγ (Wei et al, 2010) 
and COX2 (Keerthisingam et al, 2001) which may have anti-fibrotic effects in lung fibrosis. 
Pathway analysis using Cytoscape 3.2.1, Genecodis 3 and KEGG pathways, identified biological 
processes and/or pathways including cytoskeletal organisation, focal adhesion and ECM interactions 
as being in enriched in genes including TNXB. Alterations to these processes can affect cell contractility 
(Parsons, 2010). Therefore, it was hypothesised that altered methylation and subsequent expression 
of TNXB, may play an important role in tissue contractility. Collagen gel assays were used to measure 
fibroblast-mediated collagen gel contraction in control and IPF lung fibroblasts and siRNA targeting 
TNXB was used to assess the effects of TNXB knockdown on collagen gel contraction in IPF lung 
fibroblasts. Measuring the effects of knocking down a gene using siRNA is often difficult due to siRNA 
off-targeting effects, where siRNA binds to unintended mRNA  targets (Jackson and Linsley, 2010) and 
toxic phenotypes being induced, via high levels of siRNA (Fedorov et al, 2006). These adverse effects 
of siRNA were reduced by using INTERFERin (Polyplus, USA), a transfection reagent which allows a 
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much lower concentration of siRNA to be used, thus reducing off-target effects and toxicity. Results 
identified that IPF lung fibroblasts contracted collagen gels to a greater extent than control lung 
fibroblasts. This could be explained by increased/decreased expression of genes involved in regulating 
cell contraction (as identified by enrichment analyses) and/or differences in ECM remodelling. 
Knockdown of TNXB resulted in decreased collagen gel contraction, suggesting TNXB is important in 
regulating the ability of fibroblasts to contract collagen. However, knockdown of TNXB did not have a 
significant effect on TGFß or PPARγ which is in contrast to a previous study, which concluded TNXB 
could initiate myocardial fibrosis via upregulation of TGFß and downregulation of PPARγ (Jing et al, 
2011).  
 
7.10. Summary and conclusions 
To my knowledge, this thesis represents the largest and most detailed report of DNA methylation and 
its role in fibrotic lung fibroblasts and extends beyond the only other study examining methylation in 
IPF lung fibroblasts (Huang et al, 2014) by interrogating more CpG sites, different locations of CpG 
methylation and comparing methylation with expression using the same cell cultures. Furthermore, 
the data presented in this thesis are the first to examine gender-differences in methylation in lung 
fibroblasts, compare male IPF with female IPF methylation and compare global methylation in two 
diseases characterised by pulmonary fibrosis; IPF and SSc.  
In agreement with previous studies examining DNA methylation in IPF lung tissue (Rabinovich et al, 
2012, Sanders et al, 2012, Yang et al, 2014) and IPF lung fibroblasts (Huang et al, 2014), data presented 
in this thesis provide further evidence that altered DNA methylation in lung fibroblasts plays an 
important role in pulmonary fibrosis. CpGs/genes were predominately hypomethylated in IPF but 
conversely, hypermethylated in SSc, compared to control lung fibroblasts. Many of these genes 
overlapped between IPF and SSc, although, fewer CpGs overlapped. This suggests, for genes which 
overlap, different CpGs have altered methylation in IPF/SSc. Furthermore, multiple genes were 
distinct to each disease and multiple CpGs/genes had altered methylation and/or expression in IPF 
compared to SSc lung fibroblasts. This suggests IPF and SSc have distinct methylation and expression 
profiles which could, in part, explain differences in disease prevalence, progression and 
manifestations.  
Consistent with recent IPF studies (Huang et al, 2014, Yang et al, 2014), the majority of CpGs with 
altered methylation in IPF compared to control lung fibroblasts were located outside of CGIs. (Huang 
et al, 2014, Yang et al, 2014). This was also true for SSc lung fibroblasts. In other cell types and diseases, 
emerging data suggests that non-CGI methylation plays an important regulatory role (Jones, 2012), 
therefore interrogating CpGs outside of CGIs is important in future methylation studies. The 
distribution of CpG methylation in control, IPF and SSc lung fibroblasts was bimodal on autosomes. 
On the X-chromosome the bimodal pattern of methylation was clear but there were more CpGs with 
a partially methylated. Further analysis identified the X-chromosome had a bimodal pattern of 
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methylation in male lung fibroblasts, whereas a partially methylated pattern was observed in female 
lung fibroblasts, most likely caused by the effects of methylation on X-chromosome inactivation (Sharp 
et al, 2011). Further distribution analysis identified that different genomic locations had specific 
patterns of methylation suggesting the location of CpG methylation may be important in determining 
whether a CpG plays an important role in regulating gene expression.  
Multiple genes were also identified as having significantly altered expression (TNoM ≤1; P<0.05) in 
IPF/SSc compared to control lung fibroblasts and correlation analysis identified strong associations 
between methylation and expression in multiple genes, suggesting methylation plays an important 
role in both IPF and SSc. Many of these genes have previously been linked to PF whereas others 
identified, including TNXB, were novel to pulmonary fibrosis, suggesting multiple genes in lung 
fibroblasts can be regulated by methylation and may be relevant to pulmonary fibrosis. 
The data in this thesis represents the first evidence suggesting that TNX plays an important role in IPF. 
Multiple CpGs within the TNXB gene had significantly decreased methylation in IPF compared to SSc 
and control lung fibroblasts, which correlated with increased TNXB expression in IPF lung fibroblasts 
and lung tissue. Furthermore, treatment of control cell lines with 5-Aza resulted in large decreases 
(≥13.6%) in TNXB methylation which correlated with large increases (≥2FC) in TNXB expression, 
suggesting that methylation plays an important role in TNXB regulation. Pathway and enrichment 
analysis identified TNXB as playing an important role in cytoskeletal organisation, focal adhesions and 
ECM interactions, all of which are important in regulating cell contractility (Tomasek et al, 1992). 
Subsequent analysis identified IPF fibroblasts could contract collagen gels to a greater extent than 
control lung fibroblasts and that knockdown of TNXB in IPF fibroblasts significantly reduced collagen 
gel contraction. Therefore, increased TNX expression via hypomethylation of the TNXB gene, may 
contribute to the pathogenesis of IPF through altered regulation of ECM deposition and increased 
tissue contractility. 
Multiple CpGs/genes also had significant differences in methylation and expression in male compared 
to female lung fibroblasts, irrespective of where they were derived from. The majority of CpGs/genes 
on autosomes (49%), the X-chromosome (50%) and the Y-chromosome (1%) had decreased 
methylation in male compared to female lung fibroblasts. Multiple CpGs/genes had significantly 
altered methylation in male IPF compared to male control and female IPF compared to female control 
lung fibroblasts, however, very few CpGs/genes overlapped, suggesting IPF males have a difference 
pattern of methylation compared to IPF females. Interestingly, enrichment analysis identified similar 
biological processes enriched in genes with altered methylation in both sexes, suggesting different 
genes belonging to the same biological processes are affected. Specific biological processes, including 
those relating to viruses, were only found in male lung fibroblasts. Viral infections have previously 
been linked to IPF (Egan et al, 1995), although it is unclear whether viruses play a major role in IPF 
(Wootton et al, 2011). This data could potentially explain, in part, why IPF predominates in males. 
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In summary, data presented in this thesis suggests multiple genes are potentially directly regulated by 
methylation in lung fibroblasts. Multiple CpGs/genes have significantly altered methylation and/or 
significantly altered expression in IPF/SSc compared to control lung fibroblasts many of which are 
associated with biological processes/pathways relevant to fibrosis. Multiple genes also overlap 
between IPF and SSc, although the majority are distinct to each disease suggesting different 
methylation profiles in each disease. Functional analyses on one gene, TNXB, suggested increased TNX 
expression via hypomethylation contributes to the pathogenesis of IPF by regulating tissue 
contractility and could distinguish IPF from other diseases characterised by pulmonary fibrosis, such 
as SSc. Treatment of fibroblasts with 5-Aza altered methylation at multiple CpGs and the expression 
of multiple genes confirming the importance of methylation in regulating gene expression. For 
multiple genes, large changes in methylation (≥13.6%) correlated with large changes in gene 
expression (≥2FC). However, in SSc lung fibroblasts, small changes in methylation (<13.6) were 
associated with large changes in gene expression (≥2FC), potentially suggesting that some genes might 
be sensitive to small changes in methylation. Furthermore, chromosome-wide and gene-specific sex 
differences in methylation and expression were identified in lung fibroblasts, suggesting a potential 
role for gender-differences in methylation in sex-biased diseases such as IPF and SSc. 
 
7.11. Future work 
7.11.1. Future methylation and expression analysis 
The Illumina Infinium HumanMethylation 450 BeadChip array identified multiple CpGs/genes with 
altered methylation in IPF/SSc compared to control lung fibroblasts and represents a significant 
upgrade on the only other previous study examining methylation in IPF lung fibroblasts (Huang et al, 
2014). However, the 450k array still only covers approximately 2% of the entire human methylome. 
Therefore, 98% of the human lung fibroblast methylome remains to be determined. CpGs not covered 
by the Illumina 450k array could potentially play important roles in IPF/SSc. Being able to analyse 
methylation of each CpG in a gene, particular those genes identified in this thesis with large changes 
in expression, but with no changes in methylation after 5-Aza treatment, would be of particular 
interest, as they may be directly regulated by methylation. To extend the current understanding on 
the role of methylation on gene expression in human lung fibroblasts and potentially reveal more 
novel genes potentially regulated by methylation, more CpGs would need to be analysed. This could 
be done by performing whole genome bisulfite sequencing or by using arrays which cover millions of 
CpGs such as the comprehensive high-throughput arrays for relative methylation (CHARM) arrays 
previously used to study DNA methylation in lung tissue (Yang et al, 2014).  
 
7.11.2. Comparisons with other fibrotic diseases and analysis of other cell types 
Comparing methylation of IPF with another fibrotic disease, SSc, gave a valuable insight into which 
CpGs/genes overlapped between both diseases and which were specific to each disease. Future 
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studies could extend this analysis by examining more fibrotic lung fibroblast cell lines and compare 
IPF with other fibrotic diseases, particular those which are idiopathic. This analysis could potentially 
reveal more overlapping pathways and biological processes affected by altered methylation and/or 
expression in idiopathic fibroses. Whilst fibroblasts are key effector cells in pulmonary fibrosis, altered 
methylation and expression of genes in other cell types, including myofibroblasts, alveolar epithelial 
cells, macrophages and neutrophils, could also be important. Three studies have examined 
methylation in lung tissue (Sanders et al, 2012, Rabinovich et al, 2012, Yang et al, 2014) which contains 
all these cell types. However, it is impossible to determine any cell-specific changes in methylation 
from this data. Future studies should therefore focus on examining methylation in other specific cell 
types, which could elucidate more genes whose expression is regulated by methylation. Furthermore, 
IPF is characterized by areas of fibrosis and normal lung, with fibrotic foci believed to represent areas 
of active fibrosis. The heterogeneity often associated with IPF could be in part explained by fibroblasts 
coming from both fibrotic and normal regions of IPF lung. Using a laser capture system, future studies 
could analyse fibroblasts derived from only fibrotic foci, thus reducing potentially heterogeneity by 
providing a ‘pure’ sample of fibrotic lung fibroblasts to analyse. Data could then be compared from 
multiple different cell types to generate a greater understanding of the role of DNA methylation in 
pulmonary fibrosis.  
 
7.11.3. Male and female methylation/expression differences 
To my knowledge, this is the first study to analyse gender-differences in methylation in primary human 
lung fibroblasts and compare gender-differences in IPF lung fibroblasts. This study identified multiple 
CpGs/genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) and/or expression (TNoM ≤1; 
P<0.05) in male compared to female lung fibroblasts irrespective of where they were derived. 
Furthermore, analysis of male IPF compared to male control and female IPF compared to female 
control lung fibroblasts identified multiple CpGs distinct to each sex which had significantly altered 
methylation. This is extremely interesting as recently, other studies have identified gender-differences 
in methylation in other cell types (Liu et al, 2010, Hall et al, 2014, Inoshita et al, 2015) and diseases 
(Pinto et al, 2013). Furthermore, sex-specific differences in methylation during brain development can 
affect multiple genes, leading to the speculation that a number of neurological diseases with a sex-
bias maybe linked to altered methylation (Spiers et al, 2015). Therefore the identification of gender 
differences in methylation in IPF lung fibroblasts, could, in part, explain why IPF predominates in 
males. However, the number of cell lines analysed in this study were small (male: n=4, female: n=7). 
To confirm gender-difference in methylation in IPF, future studies could examine fibroblasts from a 
larger cohort of patients and/or other cell types to determine the full extent and role of gender-
difference in methylation in IPF. Due to the lack of male SSc lung fibroblast cell lines (n=1), gender-
differences in methylation, in SSc, were not examined. However, SSc is also a sex-biased disease that 
predominates in females. Therefore, it would be of interest to study gender-differences in methylation 
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in SSc lung fibroblasts and/or other cell types to determine whether gender-differences in methylation 
exist in other diseases in which pulmonary fibrosis often occurs.   
 
7.11.4. Pathway analysis and data visualisation 
STRING 10.0 (Szklarczyk et al, 2015), Cytoscape (Shannon et al, 2003), DC:GO PFAM enrichment (Fang 
and Gough, 2013) and Genecodis 3 GO-term and KEGG enrichment analyses (Carmona-Saez et al, 
2007, Nogales-Cadenas et al, 2009, Tabas-Madrid et al, 2012) were all used to analyse methylation 
and gene expression data. GO-term enrichment enabled the identification of biological processes 
significantly enriched in genes with significantly altered methylation (Δβ ≥ 0.136; P<0.05) and/or 
expression (TNoM ≤1; P<0.05) in IPF/SSc compared to control lung fibroblasts. PFAM enrichment 
enabled the identification of biological processes enriched in PFAMs belonging to genes with 
significantly altered methylation (Δβ ≥ 0.136; P<0.05) and/or expression (TNoM ≤1; P<0.05) in IPF/SSc 
compared to control lung fibroblasts. Thus, with this combined approach, genes either previously 
linked to a biological process or genes which shared domains previously linked to a biological process, 
but not necessarily directly associated with that biological process, could be identified. This enabled 
the discovery of novel genes potentially regulated by methylation and involved in biological processes 
potentially relevant to fibrosis. Future studies could further analyse specific genes or groups of genes 
associated with specific biological processes/pathways of interest, to determine their role in IPF/SSc 
and whether methylation plays an important role in their regulation.  
STRING 10.0 was used to identify potential protein-protein interactions between genes with altered 
methylation and/or expression and helped visualise how these genes could potentially interact with 
each other. The KEGG plugin for Cytoscape was used in combination with GO-term and KEGG pathway 
enrichment analyses to map genes with significantly altered methylation and/or expression onto 
known KEGG pathways, thus, allowing further visualisation of how genes in a pathway may interact. 
However, GO-terms do not match well with KEGG pathways (Mao et al, 2005) and KEGG pathways are 
not always updated with the latest findings in research. Furthermore, the KEGG plugin for Cytoscape 
required extensive modifications to work as intended. Future analysis should therefore aim to build 
on these pathways by manually adding data to specific points in a given pathway using Cytoscape, or 
with other pathway analysis options, such as IPA (Ingenuity, USA) or Pathway Studio (Ariadne 
Genomics, USA), both of which can be used to manually create pathways.  
Data was visualised using the R (v3.2.0) statistical program and a number of scripts were developed 
to analyse data. These provided valuable insights into how CpG methylation was distributed within 
different genomic locations and in relation to CGIs, how different cell lines clustered, and which 
CpGs/genes had significant correlations between methylation and gene expression. Furthermore, 
analysis using R helped identify how 5-Aza affected different cells lines to varying extents. Future 
studies could use or adapt these scripts to any given dataset and extend their capability, such as 
displaying specific genes or groups of genes associated with different pathways/biological processes 
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directly on graphs. This could potentially reveal in more detail the extent of altered methylation 
and/or expression in fibrotic lung fibroblasts.  
 
7.11.5. The role of TNXB in pulmonary fibrosis 
In this thesis, I identified multiple CpG sites within the TNXB gene as having decreased methylation in 
IPF compared to SSc and control lung fibroblasts, which correlated with increased TNXB expression in 
IPF lung fibroblasts. Furthermore, treatment of control lung fibroblasts with 5-Aza caused large 
decreases (≥13.6%) in TNXB methylation which correlated with large increases (≥2FC) in TNXB 
expression, thus suggesting that methylation plays an important role in TNXB regulation. However, it 
remains unknown which CpGs are important for regulating TNXB. It would therefore be of interest to 
examine more CpGs within the TNXB to determine the specific region/s which are responsible for 
regulating TNXB expression. For example, there are potentially important Specificity 1 (SP1) and 
Specificity 3 (SP3) binding sites within the TNXB promoter region, which may be important in 
regulating TNXB expression (Wijesuriya et al, 2002). Interestingly, methylation of CpGs adjacent to 
SP1 binding sites can affect SP1 binding (Zhu et al, 2003). Although no changes in methylation between 
control, IPF and SSc lung fibroblasts were found covering SP1/SP3 binding sites in the TNXB promoter, 
altered methylation of CpGs in IPF compared to control lung fibroblasts which surrounded SP1 binding 
sites, were identified in the exon 10 CGI. Therefore, future studies could examine whether SP1/SP3 
binding sites in this, or other regions, are affected by methylation in TNXB and whether changes to 
methylation at these regions can alter SP1/SP3 binding and subsequently, modulate TNXB expression.  
Pathway and enrichment analyses identified biological processes/pathways associated with cell 
contraction as being enriched in genes including TNXB. Using a model of cell-mediated collagen gel 
contraction, I showed that IPF fibroblasts contracted collagen to a greater extent compared to control 
lung fibroblasts and that siRNA knockdown of TNXB reduced collagen gel contraction. However, the 
exact role of TNXB in pulmonary fibrosis and how it affects contraction remains unknown. A recent 
study in epithelial cells identified the fibrinogen-like (FBG) domain of TNXB can interact with latent 
TGFß (Alcaraz et al, 2014). Integrin α 11 (ITGA11) was essential for TNXB FBG-mediated activation of 
TGFß to occur (Alcaraz et al, 2014). It has previously been shown that multiple integrins can interact 
with latent TGFß causing the release of active TGFß, however their role in IPF is yet to be fully 
determined (Tatler and Jenkins, 2012). It would therefore be of interest to study whether ITGA11 
and/or other integrins can interact with TNXB in lung fibroblasts and whether this interaction is 
important for latent TGFß activation and matrix contraction. 
Increased TGFß can cause EMT (Xu et al, 2009) which has previously been implicated in ILDs including 
IPF and may contribute to the increased generation of fibroblasts and myofibroblasts (Kage and Borok, 
2012). Interestingly, epithelial cells seeded onto the FBG-domain of TNXB undergo EMT, whereas the 
EMT response is much weaker when epithelial cells are seeded onto the full length of TNXB, explained 
by an FNIII-repeat region acting negatively on the FBG-domain (Alcaraz et al, 2014). Methylation can 
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regulate alternative splicing, the process by which multiple transcripts of the same gene are produced. 
In theory, altered TNXB methylation could result in aberrant alternative splicing which could produce 
increased transcripts of TNXB lacking the FNIII-repeat region. Therefore, future studies could compare 
the relative expression of different TNXB transcripts in IPF and control lung fibroblasts and determine 
their importance in PF.  
 
7.11.6. Determine the role of other epigenetic mechanisms in IPF lung fibroblasts 
DNA methylation is one of three main epigenetic mechanisms which can regulate gene expression, 
the other two being histone modifications and microRNAs (miRs). MiRs have been extensively studied 
in IPF with evidence indicating multiple miRs are dysregulated (Hagood, 2014, Pandit and Milosevic, 
2015). Furthermore, methylation can regulate microRNA expression in IPF (Dakhlallah et al, 2013) 
thus, different epigenetic mechanisms can interact with each other to regulate gene expression. 
Histone modifications have also been shown to affect the expression of individual genes (Coward et 
al, 2010, Sanders et al, 2011, Hagood et al, 2014) and can affect methylation of genes associated with 
IPF (Sanders et al, 2011). However, there are no genome-wide studies examining the effects of altered 
histone modifications in IPF. It would therefore be of interest to study other epigenetic mechanisms 
including miRs and histone modifications in parallel with DNA methylation to determine how different 
epigenetic mechanisms interact with each other and together, contribute to altered gene expression 
in IPF and other diseases characterised by PF. 
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Appendices 
Appendice A. 
Genes with both positive and negative correlation between methylation and expression. 
Symbol Name Symbol Name 
ACVRL1 activin A receptor type 
II-like 1 
MGMT O-6-methylguanine-DNA 
methyltransferase 
ADAM15 ADAM metallopeptidase 
domain 15 
MYOM2 myomesin (M-protein) 2, 
165kDa 
ADAMTS2 ADAM metallopeptidase 
with thrombospondin 
type 1 motif, 2 
NETO2 neuropilin (NRP) and 
tolloid (TLL)-like 2 
ALDH3A1 aldehyde 
dehydrogenase 3 family, 
memberA1 
NLGN4Y neuroligin 4, Y-linked 
ANO1 anoctamin 1, calcium 
activated chloride 
channel 
NPTX1 neuronal pentraxin I 
C13orf15 chromosome 13 open 
reading frame 15 
PAX8 paired box 8 
C1orf159 chromosome 1 open 
reading frame 159 
PGM3 phosphoglucomutase 3 
CA12 carbonic anhydrase XII PLA2G5 phospholipase A2, group 
V 
CDH13 cadherin 13, H-cadherin 
(heart) 
PLAG1 pleiomorphic adenoma 
gene 1 
CHST15 carbohydrate (N-
acetylgalactosamine 4-
sulfate 6-O) 
sulfotransferase 15 
PLAGL1 pleiomorphic adenoma 
gene-like 1 
CLEC14A C-type lectin domain 
family 14, member A 
PPP3CA protein phosphatase 3 
(formerly 2B), catalytic 
subunit, alpha isoform 
CPNE8 copine VIII PRKY protein kinase, Y-linked 
CRIPAK cysteine-rich PAK1 
inhibitor 
RAMP1 receptor (G protein-
coupled) activity 
modifying protein 1 
DLL1 delta-like 1 (Drosophila) RPS4Y1 ribosomal protein S4, Y-
linked 1 
EIF1AY eukaryotic translation 
initiation factor 1A, Y-
linked 
SAMD14 sterile alpha motif 
domain containing 14 
FAM13A family with sequence 
similarity 13, member A 
SASH1 SAM and SH3 domain 
containing 1 
FST follistatin SPON2 spondin 2, extracellular 
matrix protein 
GPER G protein-coupled 
estrogen receptor 1 
STX18 syntaxin 18 
GSTT1 glutathione S-
transferase theta 1 
TANC1 tetratricopeptide repeat, 
ankyrin repeat and 
coiled-coil containing 1 
ICMT isoprenylcysteine 
carboxyl 
methyltransferase 
TNFAIP8L3 tumor necrosis factor, 
alpha-induced protein 8-
like 3 
IL16 interleukin 16 
(lymphocyte 
chemoattractant factor) 
TRIM56 tripartite motif-
containing 56 
MACF1 microtubule-actin 
crosslinking factor 1 
ZFHX4 zinc finger homeobox 4 
MAPRE1 microtubule-associated 
protein, RP/EB family, 
member 1 
ZFY zinc finger protein, Y-
linked 
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Appendice B.  
Differentially methylated genes in fibrotic compared to control lung fibroblasts involved in the Wnt 
signalling pathway as determined by GO-term and KEGG enrichment. 
Symbol Name Symbol Name 
APC Adenomatous polyposis coli MCC Mutated in colorectal cancers 
ARL6 ADP-ribosylation factor-like 6 MITF Microphthalmia-associated 
transcription factor 
AXIN2 Axin 2 NDRG2 NDRG family member 2 
BAMBI Hypothetical LOC729590; BMP and activin 
membrane-bound inhibitor homolog 
(Xenopus laevis) 
NFATC1 Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 
1 
BCL9 B-cell CLL/lymphoma 9 NFATC2 Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 
2 
BRD7 Bromodomain containing 7; bromodomain 
containing 7 pseudogene 2 
NKD2 Naked cuticle homolog 2 
(Drosophila) 
BTRC Beta-transducin repeat containing NXN Nucleoredoxin 
C1orf187 Chromosome 1 open reading frame 187 PLCB1 Phospholipase C, beta 1 
(phosphoinositide-specific) 
CACYBP Similar to calcyclin binding protein; 
calcyclin binding protein 
PLCB2 Phospholipase C, beta 2 
CALCOCO1 Calcium binding and coiled-coil domain 1 PLCB3 Phospholipase C, beta 3 
(phosphatidylinositol-specific) 
CAMK2A Calcium/calmodulin-dependent protein 
kinase II alpha 
PPP2R5A Protein phosphatase 2, regulatory 
subunit B', alpha isoform 
CAMK2B Calcium/calmodulin-dependent protein 
kinase II beta 
PPP2R5C Protein phosphatase 2, regulatory 
subunit B', gamma isoform 
CAMK2G Calcium/calmodulin-dependent protein 
kinase II gamma 
PPP3CA Protein phosphatase 3 (formerly 
2B), catalytic subunit, alpha isoform 
CCDC88C Coiled-coil domain containing 88C PRICKLE1 Prickle homolog 1 (Drosophila) 
CCND3 Cyclin D3 PRICKLE2 Prickle homolog 2 (Drosophila) 
CCNY Cyclin Y PRKCA Protein kinase C, alpha 
CD44 CD44 molecule (Indian blood group) PRKCB Protein kinase C, beta 
CDK14 PFTAIRE protein kinase 1 PRKCG Protein kinase C, gamma 
CELSR2 Cadherin, EGF LAG seven-pass G-type 
receptor 2 (flamingo homolog, Drosophila) 
RNF146 Ring finger protein 146 
CPZ Carboxypeptidase Z RSPO2 R-spondin 2 homolog (Xenopus 
laevis) 
CREBBP CREB binding protein SENP2 SUMO1/sentrin/SMT3 specific 
peptidase 2 
CSNK1A1L Casein kinase 1, alpha 1-like SFRP1 Secreted frizzled-related protein 1 
CSNK1D Casein kinase 1, delta SFRP2 Secreted frizzled-related protein 2 
CSNK1G1 Casein kinase 1, gamma 1 SFRP5 Secreted frizzled-related protein 5 
CSNK1G3 Casein kinase 1, gamma 3 SIAH1 Seven in absentia homolog 1 
(Drosophila) 
CSNK2A1 Casein kinase 2, alpha 1 polypeptide 
pseudogene; casein kinase 2, alpha 1 
polypeptide 
SKP1 S-phase kinase-associated protein 1 
CTBP2 C-terminal binding protein 2 SMAD2 SMAD family member 2 
CTNNB1 Catenin (cadherin-associated protein), 
beta 1, 88kda 
SMAD3 SMAD family member 3 
CTNNBIP1 Catenin, beta interacting protein 1 SOST Sclerosteosis 
CUL1 Cullin 1 SOSTDC1 Sclerostin domain containing 1 
CXXC4 CXXC finger 4 SOX17 SRY (sex determining region Y)-box 
17 
CYLD Cylindromatosis (turban tumor syndrome) TBL1XR1 Transducin (beta)-like 1 X-linked 
receptor 1 
DAAM2 Dishevelled associated activator of 
morphogenesis 2 
TBL1Y Transducin (beta)-like 1Y-linked 
DACT1 Dapper, antagonist of beta-catenin, 
homolog 1 (Xenopus laevis) 
TCF7L1 Transcription factor 7-like 1 (T-cell 
specific, HMG-box) 
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DKK4 Dickkopf homolog 4 (Xenopus laevis) TCF7L2 Transcription factor 7-like 2 (T-cell 
specific, HMG-box) 
DRD2 Dopamine receptor D2 TLE2 Transducin-like enhancer of split 2 
(E(sp1) homolog, Drosophila) 
FAM123B Family with sequence similarity 123B TLE3 Transducin-like enhancer of split 3 
(E(sp1) homolog, Drosophila) 
FBXW11 F-box and WD repeat domain containing 
11 
TNIK TRAF2 and NCK interacting kinase 
FBXW4 F-box and WD repeat domain containing 4 TNKS Tankyrase, TRF1-interacting ankyrin-
related ADP-ribose polymerase 
FOSL1 FOS-like antigen 1 VANGL2 Vang-like 2 (van gogh, Drosophila) 
FZD1 Frizzled homolog 1 (Drosophila) WIF1 WNT inhibitory factor 1 
FZD10 Frizzled homolog 10 (Drosophila) WISP1 WNT1 inducible signaling pathway 
protein 1 
FZD5 Frizzled homolog 5 (Drosophila) WNT10A Wingless-type MMTV integration 
site family, member 10A 
FZD6 Frizzled homolog 6 (Drosophila) WNT10B Wingless-type MMTV integration 
site family, member 10B 
FZD7 Frizzled homolog 7 (Drosophila) WNT11 Wingless-type MMTV integration 
site family, member 11 
FZD9 Frizzled homolog 9 (Drosophila) WNT16 Wingless-type MMTV integration 
site family, member 16 
GPC4 Glypican 4 WNT3 Wingless-type MMTV integration 
site family, member 3 
GRK5 G protein-coupled receptor kinase 5 WNT4 Wingless-type MMTV integration 
site family, member 4 
GRK6 G protein-coupled receptor kinase 6 WNT5A Wingless-type MMTV integration 
site family, member 5A 
GSK3A Glycogen synthase kinase 3 alpha WNT6 Wingless-type MMTV integration 
site family, member 6 
JUN Jun oncogene WNT7A Wingless-type MMTV integration 
site family, member 7A 
KREMEN2 Kringle containing transmembrane protein 
2 
WNT7B Wingless-type MMTV integration 
site family, member 7B 
LEF1 Lymphoid enhancer-binding factor 1 WNT8A Wingless-type MMTV integration 
site family, member 8A 
LRP5 Low density lipoprotein receptor-related 
protein 5 
WNT8B Wingless-type MMTV integration 
site family, member 8B 
LRRFIP2 Leucine rich repeat (in FLII) interacting 
protein 2 
WNT9A Wingless-type MMTV integration 
site family, member 9A 
MAPK10 Mitogen-activated protein kinase 10   
 
